<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>R Notebook</title>

<script>// Pandoc 2.9 adds attributes on both header and div. We remove the former (to
// be compatible with the behavior of Pandoc < 2.8).
document.addEventListener('DOMContentLoaded', function(e) {
  var hs = document.querySelectorAll("div.section[class*='level'] > :first-child");
  var i, h, a;
  for (i = 0; i < hs.length; i++) {
    h = hs[i];
    if (!/^h[1-6]$/i.test(h.tagName)) continue;  // it should be a header h1-h6
    a = h.attributes;
    while (a.length > 0) h.removeAttribute(a[0].name);
  }
});
</script>
<script>/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
</script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<style type="text/css">html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,details,figcaption,figure,footer,header,hgroup,main,menu,nav,section,summary{display:block}audio,canvas,progress,video{display:inline-block;vertical-align:baseline}audio:not([controls]){display:none;height:0}[hidden],template{display:none}a{background-color:transparent}a:active,a:hover{outline:0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:700}dfn{font-style:italic}h1{margin:.67em 0;font-size:2em}mark{color:#000;background:#ff0}small{font-size:80%}sub,sup{position:relative;font-size:75%;line-height:0;vertical-align:baseline}sup{top:-.5em}sub{bottom:-.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:1em 40px}hr{height:0;-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}pre{overflow:auto}code,kbd,pre,samp{font-family:monospace,monospace;font-size:1em}button,input,optgroup,select,textarea{margin:0;font:inherit;color:inherit}button{overflow:visible}button,select{text-transform:none}button,html input[type=button],input[type=reset],input[type=submit]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}button::-moz-focus-inner,input::-moz-focus-inner{padding:0;border:0}input{line-height:normal}input[type=checkbox],input[type=radio]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box;padding:0}input[type=number]::-webkit-inner-spin-button,input[type=number]::-webkit-outer-spin-button{height:auto}input[type=search]{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box;-webkit-appearance:textfield}input[type=search]::-webkit-search-cancel-button,input[type=search]::-webkit-search-decoration{-webkit-appearance:none}fieldset{padding:.35em .625em .75em;margin:0 2px;border:1px solid silver}legend{padding:0;border:0}textarea{overflow:auto}optgroup{font-weight:700}table{border-spacing:0;border-collapse:collapse}td,th{padding:0}@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}abbr[title]:after{content:" (" attr(title) ")"}a[href^="javascript:"]:after,a[href^="#"]:after{content:""}blockquote,pre{border:1px solid #999;page-break-inside:avoid}thead{display:table-header-group}img,tr{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.navbar{display:none}.btn>.caret,.dropup>.btn>.caret{border-top-color:#000!important}.label{border:1px solid #000}.table{border-collapse:collapse!important}.table td,.table th{background-color:#fff!important}.table-bordered td,.table-bordered th{border:1px solid #ddd!important}}@font-face{font-family:'Glyphicons Halflings';src:url(data:application/vnd.ms-fontobject;base64,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);src:url(data:application/vnd.ms-fontobject;base64,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) format('embedded-opentype'),url(data:font/woff;base64,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) format('woff'),url(data:font/ttf;base64,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) format('truetype'),url(data:image/svg+xml;base64,<?xml version="1.0" standalone="no"?>
<!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd" >
<svg xmlns="http://www.w3.org/2000/svg">
<metadata></metadata>
<defs>
<font id="glyphicons_halflingsregular" horiz-adv-x="1200" >
<font-face units-per-em="1200" ascent="960" descent="-240" />
<missing-glyph horiz-adv-x="500" />
<glyph horiz-adv-x="0" />
<glyph horiz-adv-x="400" />
<glyph unicode=" " />
<glyph unicode="*" d="M600 1100q15 0 34 -1.5t30 -3.5l11 -1q10 -2 17.5 -10.5t7.5 -18.5v-224l158 158q7 7 18 8t19 -6l106 -106q7 -8 6 -19t-8 -18l-158 -158h224q10 0 18.5 -7.5t10.5 -17.5q6 -41 6 -75q0 -15 -1.5 -34t-3.5 -30l-1 -11q-2 -10 -10.5 -17.5t-18.5 -7.5h-224l158 -158 q7 -7 8 -18t-6 -19l-106 -106q-8 -7 -19 -6t-18 8l-158 158v-224q0 -10 -7.5 -18.5t-17.5 -10.5q-41 -6 -75 -6q-15 0 -34 1.5t-30 3.5l-11 1q-10 2 -17.5 10.5t-7.5 18.5v224l-158 -158q-7 -7 -18 -8t-19 6l-106 106q-7 8 -6 19t8 18l158 158h-224q-10 0 -18.5 7.5 t-10.5 17.5q-6 41 -6 75q0 15 1.5 34t3.5 30l1 11q2 10 10.5 17.5t18.5 7.5h224l-158 158q-7 7 -8 18t6 19l106 106q8 7 19 6t18 -8l158 -158v224q0 10 7.5 18.5t17.5 10.5q41 6 75 6z" />
<glyph unicode="+" d="M450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-350h350q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-350v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v350h-350q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5 h350v350q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xa0;" />
<glyph unicode="&#xa5;" d="M825 1100h250q10 0 12.5 -5t-5.5 -13l-364 -364q-6 -6 -11 -18h268q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-100h275q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-125v-174q0 -11 -7.5 -18.5t-18.5 -7.5h-148q-11 0 -18.5 7.5t-7.5 18.5v174 h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h125v100h-275q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h118q-5 12 -11 18l-364 364q-8 8 -5.5 13t12.5 5h250q25 0 43 -18l164 -164q8 -8 18 -8t18 8l164 164q18 18 43 18z" />
<glyph unicode="&#x2000;" horiz-adv-x="650" />
<glyph unicode="&#x2001;" horiz-adv-x="1300" />
<glyph unicode="&#x2002;" horiz-adv-x="650" />
<glyph unicode="&#x2003;" horiz-adv-x="1300" />
<glyph unicode="&#x2004;" horiz-adv-x="433" />
<glyph unicode="&#x2005;" horiz-adv-x="325" />
<glyph unicode="&#x2006;" horiz-adv-x="216" />
<glyph unicode="&#x2007;" horiz-adv-x="216" />
<glyph unicode="&#x2008;" horiz-adv-x="162" />
<glyph unicode="&#x2009;" horiz-adv-x="260" />
<glyph unicode="&#x200a;" horiz-adv-x="72" />
<glyph unicode="&#x202f;" horiz-adv-x="260" />
<glyph unicode="&#x205f;" horiz-adv-x="325" />
<glyph unicode="&#x20ac;" d="M744 1198q242 0 354 -189q60 -104 66 -209h-181q0 45 -17.5 82.5t-43.5 61.5t-58 40.5t-60.5 24t-51.5 7.5q-19 0 -40.5 -5.5t-49.5 -20.5t-53 -38t-49 -62.5t-39 -89.5h379l-100 -100h-300q-6 -50 -6 -100h406l-100 -100h-300q9 -74 33 -132t52.5 -91t61.5 -54.5t59 -29 t47 -7.5q22 0 50.5 7.5t60.5 24.5t58 41t43.5 61t17.5 80h174q-30 -171 -128 -278q-107 -117 -274 -117q-206 0 -324 158q-36 48 -69 133t-45 204h-217l100 100h112q1 47 6 100h-218l100 100h134q20 87 51 153.5t62 103.5q117 141 297 141z" />
<glyph unicode="&#x20bd;" d="M428 1200h350q67 0 120 -13t86 -31t57 -49.5t35 -56.5t17 -64.5t6.5 -60.5t0.5 -57v-16.5v-16.5q0 -36 -0.5 -57t-6.5 -61t-17 -65t-35 -57t-57 -50.5t-86 -31.5t-120 -13h-178l-2 -100h288q10 0 13 -6t-3 -14l-120 -160q-6 -8 -18 -14t-22 -6h-138v-175q0 -11 -5.5 -18 t-15.5 -7h-149q-10 0 -17.5 7.5t-7.5 17.5v175h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v100h-267q-10 0 -13 6t3 14l120 160q6 8 18 14t22 6h117v475q0 10 7.5 17.5t17.5 7.5zM600 1000v-300h203q64 0 86.5 33t22.5 119q0 84 -22.5 116t-86.5 32h-203z" />
<glyph unicode="&#x2212;" d="M250 700h800q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#x231b;" d="M1000 1200v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-50v-100q0 -91 -49.5 -165.5t-130.5 -109.5q81 -35 130.5 -109.5t49.5 -165.5v-150h50q21 0 35.5 -14.5t14.5 -35.5v-150h-800v150q0 21 14.5 35.5t35.5 14.5h50v150q0 91 49.5 165.5t130.5 109.5q-81 35 -130.5 109.5 t-49.5 165.5v100h-50q-21 0 -35.5 14.5t-14.5 35.5v150h800zM400 1000v-100q0 -60 32.5 -109.5t87.5 -73.5q28 -12 44 -37t16 -55t-16 -55t-44 -37q-55 -24 -87.5 -73.5t-32.5 -109.5v-150h400v150q0 60 -32.5 109.5t-87.5 73.5q-28 12 -44 37t-16 55t16 55t44 37 q55 24 87.5 73.5t32.5 109.5v100h-400z" />
<glyph unicode="&#x25fc;" horiz-adv-x="500" d="M0 0z" />
<glyph unicode="&#x2601;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -206.5q0 -121 -85 -207.5t-205 -86.5h-750q-79 0 -135.5 57t-56.5 137q0 69 42.5 122.5t108.5 67.5q-2 12 -2 37q0 153 108 260.5t260 107.5z" />
<glyph unicode="&#x26fa;" d="M774 1193.5q16 -9.5 20.5 -27t-5.5 -33.5l-136 -187l467 -746h30q20 0 35 -18.5t15 -39.5v-42h-1200v42q0 21 15 39.5t35 18.5h30l468 746l-135 183q-10 16 -5.5 34t20.5 28t34 5.5t28 -20.5l111 -148l112 150q9 16 27 20.5t34 -5zM600 200h377l-182 112l-195 534v-646z " />
<glyph unicode="&#x2709;" d="M25 1100h1150q10 0 12.5 -5t-5.5 -13l-564 -567q-8 -8 -18 -8t-18 8l-564 567q-8 8 -5.5 13t12.5 5zM18 882l264 -264q8 -8 8 -18t-8 -18l-264 -264q-8 -8 -13 -5.5t-5 12.5v550q0 10 5 12.5t13 -5.5zM918 618l264 264q8 8 13 5.5t5 -12.5v-550q0 -10 -5 -12.5t-13 5.5 l-264 264q-8 8 -8 18t8 18zM818 482l364 -364q8 -8 5.5 -13t-12.5 -5h-1150q-10 0 -12.5 5t5.5 13l364 364q8 8 18 8t18 -8l164 -164q8 -8 18 -8t18 8l164 164q8 8 18 8t18 -8z" />
<glyph unicode="&#x270f;" d="M1011 1210q19 0 33 -13l153 -153q13 -14 13 -33t-13 -33l-99 -92l-214 214l95 96q13 14 32 14zM1013 800l-615 -614l-214 214l614 614zM317 96l-333 -112l110 335z" />
<glyph unicode="&#xe001;" d="M700 650v-550h250q21 0 35.5 -14.5t14.5 -35.5v-50h-800v50q0 21 14.5 35.5t35.5 14.5h250v550l-500 550h1200z" />
<glyph unicode="&#xe002;" d="M368 1017l645 163q39 15 63 0t24 -49v-831q0 -55 -41.5 -95.5t-111.5 -63.5q-79 -25 -147 -4.5t-86 75t25.5 111.5t122.5 82q72 24 138 8v521l-600 -155v-606q0 -42 -44 -90t-109 -69q-79 -26 -147 -5.5t-86 75.5t25.5 111.5t122.5 82.5q72 24 138 7v639q0 38 14.5 59 t53.5 34z" />
<glyph unicode="&#xe003;" d="M500 1191q100 0 191 -39t156.5 -104.5t104.5 -156.5t39 -191l-1 -2l1 -5q0 -141 -78 -262l275 -274q23 -26 22.5 -44.5t-22.5 -42.5l-59 -58q-26 -20 -46.5 -20t-39.5 20l-275 274q-119 -77 -261 -77l-5 1l-2 -1q-100 0 -191 39t-156.5 104.5t-104.5 156.5t-39 191 t39 191t104.5 156.5t156.5 104.5t191 39zM500 1022q-88 0 -162 -43t-117 -117t-43 -162t43 -162t117 -117t162 -43t162 43t117 117t43 162t-43 162t-117 117t-162 43z" />
<glyph unicode="&#xe005;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104z" />
<glyph unicode="&#xe006;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429z" />
<glyph unicode="&#xe007;" d="M407 800l131 353q7 19 17.5 19t17.5 -19l129 -353h421q21 0 24 -8.5t-14 -20.5l-342 -249l130 -401q7 -20 -0.5 -25.5t-24.5 6.5l-343 246l-342 -247q-17 -12 -24.5 -6.5t-0.5 25.5l130 400l-347 251q-17 12 -14 20.5t23 8.5h429zM477 700h-240l197 -142l-74 -226 l193 139l195 -140l-74 229l192 140h-234l-78 211z" />
<glyph unicode="&#xe008;" d="M600 1200q124 0 212 -88t88 -212v-250q0 -46 -31 -98t-69 -52v-75q0 -10 6 -21.5t15 -17.5l358 -230q9 -5 15 -16.5t6 -21.5v-93q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v93q0 10 6 21.5t15 16.5l358 230q9 6 15 17.5t6 21.5v75q-38 0 -69 52 t-31 98v250q0 124 88 212t212 88z" />
<glyph unicode="&#xe009;" d="M25 1100h1150q10 0 17.5 -7.5t7.5 -17.5v-1050q0 -10 -7.5 -17.5t-17.5 -7.5h-1150q-10 0 -17.5 7.5t-7.5 17.5v1050q0 10 7.5 17.5t17.5 7.5zM100 1000v-100h100v100h-100zM875 1000h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5t17.5 -7.5h550 q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM1000 1000v-100h100v100h-100zM100 800v-100h100v100h-100zM1000 800v-100h100v100h-100zM100 600v-100h100v100h-100zM1000 600v-100h100v100h-100zM875 500h-550q-10 0 -17.5 -7.5t-7.5 -17.5v-350q0 -10 7.5 -17.5 t17.5 -7.5h550q10 0 17.5 7.5t7.5 17.5v350q0 10 -7.5 17.5t-17.5 7.5zM100 400v-100h100v100h-100zM1000 400v-100h100v100h-100zM100 200v-100h100v100h-100zM1000 200v-100h100v100h-100z" />
<glyph unicode="&#xe010;" d="M50 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM50 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM650 500h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe011;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM850 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 700h200q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h200 q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM850 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5 t35.5 14.5z" />
<glyph unicode="&#xe012;" d="M50 1100h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 1100h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200 q0 21 14.5 35.5t35.5 14.5zM50 700h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 700h700q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-700 q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM50 300h200q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5zM450 300h700q21 0 35.5 -14.5t14.5 -35.5v-200 q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe013;" d="M465 477l571 571q8 8 18 8t17 -8l177 -177q8 -7 8 -17t-8 -18l-783 -784q-7 -8 -17.5 -8t-17.5 8l-384 384q-8 8 -8 18t8 17l177 177q7 8 17 8t18 -8l171 -171q7 -7 18 -7t18 7z" />
<glyph unicode="&#xe014;" d="M904 1083l178 -179q8 -8 8 -18.5t-8 -17.5l-267 -268l267 -268q8 -7 8 -17.5t-8 -18.5l-178 -178q-8 -8 -18.5 -8t-17.5 8l-268 267l-268 -267q-7 -8 -17.5 -8t-18.5 8l-178 178q-8 8 -8 18.5t8 17.5l267 268l-267 268q-8 7 -8 17.5t8 18.5l178 178q8 8 18.5 8t17.5 -8 l268 -267l268 268q7 7 17.5 7t18.5 -7z" />
<glyph unicode="&#xe015;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM425 900h150q10 0 17.5 -7.5t7.5 -17.5v-75h75q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5 t-17.5 -7.5h-75v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-75q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v75q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe016;" d="M507 1177q98 0 187.5 -38.5t154.5 -103.5t103.5 -154.5t38.5 -187.5q0 -141 -78 -262l300 -299q8 -8 8 -18.5t-8 -18.5l-109 -108q-7 -8 -17.5 -8t-18.5 8l-300 299q-119 -77 -261 -77q-98 0 -188 38.5t-154.5 103t-103 154.5t-38.5 188t38.5 187.5t103 154.5 t154.5 103.5t188 38.5zM506.5 1023q-89.5 0 -165.5 -44t-120 -120.5t-44 -166t44 -165.5t120 -120t165.5 -44t166 44t120.5 120t44 165.5t-44 166t-120.5 120.5t-166 44zM325 800h350q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-350q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe017;" d="M550 1200h100q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM800 975v166q167 -62 272 -209.5t105 -331.5q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5 t-184.5 123t-123 184.5t-45.5 224q0 184 105 331.5t272 209.5v-166q-103 -55 -165 -155t-62 -220q0 -116 57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5q0 120 -62 220t-165 155z" />
<glyph unicode="&#xe018;" d="M1025 1200h150q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM725 800h150q10 0 17.5 -7.5t7.5 -17.5v-750q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v750 q0 10 7.5 17.5t17.5 7.5zM425 500h150q10 0 17.5 -7.5t7.5 -17.5v-450q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v450q0 10 7.5 17.5t17.5 7.5zM125 300h150q10 0 17.5 -7.5t7.5 -17.5v-250q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5 v250q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe019;" d="M600 1174q33 0 74 -5l38 -152l5 -1q49 -14 94 -39l5 -2l134 80q61 -48 104 -105l-80 -134l3 -5q25 -44 39 -93l1 -6l152 -38q5 -43 5 -73q0 -34 -5 -74l-152 -38l-1 -6q-15 -49 -39 -93l-3 -5l80 -134q-48 -61 -104 -105l-134 81l-5 -3q-44 -25 -94 -39l-5 -2l-38 -151 q-43 -5 -74 -5q-33 0 -74 5l-38 151l-5 2q-49 14 -94 39l-5 3l-134 -81q-60 48 -104 105l80 134l-3 5q-25 45 -38 93l-2 6l-151 38q-6 42 -6 74q0 33 6 73l151 38l2 6q13 48 38 93l3 5l-80 134q47 61 105 105l133 -80l5 2q45 25 94 39l5 1l38 152q43 5 74 5zM600 815 q-89 0 -152 -63t-63 -151.5t63 -151.5t152 -63t152 63t63 151.5t-63 151.5t-152 63z" />
<glyph unicode="&#xe020;" d="M500 1300h300q41 0 70.5 -29.5t29.5 -70.5v-100h275q10 0 17.5 -7.5t7.5 -17.5v-75h-1100v75q0 10 7.5 17.5t17.5 7.5h275v100q0 41 29.5 70.5t70.5 29.5zM500 1200v-100h300v100h-300zM1100 900v-800q0 -41 -29.5 -70.5t-70.5 -29.5h-700q-41 0 -70.5 29.5t-29.5 70.5 v800h900zM300 800v-700h100v700h-100zM500 800v-700h100v700h-100zM700 800v-700h100v700h-100zM900 800v-700h100v700h-100z" />
<glyph unicode="&#xe021;" d="M18 618l620 608q8 7 18.5 7t17.5 -7l608 -608q8 -8 5.5 -13t-12.5 -5h-175v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v375h-300v-375q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v575h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe022;" d="M600 1200v-400q0 -41 29.5 -70.5t70.5 -29.5h300v-650q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5h450zM1000 800h-250q-21 0 -35.5 14.5t-14.5 35.5v250z" />
<glyph unicode="&#xe023;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h50q10 0 17.5 -7.5t7.5 -17.5v-275h175q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe024;" d="M1300 0h-538l-41 400h-242l-41 -400h-538l431 1200h209l-21 -300h162l-20 300h208zM515 800l-27 -300h224l-27 300h-170z" />
<glyph unicode="&#xe025;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-450h191q20 0 25.5 -11.5t-7.5 -27.5l-327 -400q-13 -16 -32 -16t-32 16l-327 400q-13 16 -7.5 27.5t25.5 11.5h191v450q0 21 14.5 35.5t35.5 14.5zM1125 400h50q10 0 17.5 -7.5t7.5 -17.5v-350q0 -10 -7.5 -17.5t-17.5 -7.5 h-1050q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h50q10 0 17.5 -7.5t7.5 -17.5v-175h900v175q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe026;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM525 900h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -275q-13 -16 -32 -16t-32 16l-223 275q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z " />
<glyph unicode="&#xe027;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM632 914l223 -275q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5l223 275q13 16 32 16 t32 -16z" />
<glyph unicode="&#xe028;" d="M225 1200h750q10 0 19.5 -7t12.5 -17l186 -652q7 -24 7 -49v-425q0 -12 -4 -27t-9 -17q-12 -6 -37 -6h-1100q-12 0 -27 4t-17 8q-6 13 -6 38l1 425q0 25 7 49l185 652q3 10 12.5 17t19.5 7zM878 1000h-556q-10 0 -19 -7t-11 -18l-87 -450q-2 -11 4 -18t16 -7h150 q10 0 19.5 -7t11.5 -17l38 -152q2 -10 11.5 -17t19.5 -7h250q10 0 19.5 7t11.5 17l38 152q2 10 11.5 17t19.5 7h150q10 0 16 7t4 18l-87 450q-2 11 -11 18t-19 7z" />
<glyph unicode="&#xe029;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM540 820l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe030;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-362q0 -10 -7.5 -17.5t-17.5 -7.5h-362q-11 0 -13 5.5t5 12.5l133 133q-109 76 -238 76q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5h150q0 -117 -45.5 -224 t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117z" />
<glyph unicode="&#xe031;" d="M947 1060l135 135q7 7 12.5 5t5.5 -13v-361q0 -11 -7.5 -18.5t-18.5 -7.5h-361q-11 0 -13 5.5t5 12.5l134 134q-110 75 -239 75q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5h-150q0 117 45.5 224t123 184.5t184.5 123t224 45.5q192 0 347 -117zM1027 600h150 q0 -117 -45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5q-192 0 -348 118l-134 -134q-7 -8 -12.5 -5.5t-5.5 12.5v360q0 11 7.5 18.5t18.5 7.5h360q10 0 12.5 -5.5t-5.5 -12.5l-133 -133q110 -76 240 -76q116 0 214.5 57t155.5 155.5t57 214.5z" />
<glyph unicode="&#xe032;" d="M125 1200h1050q10 0 17.5 -7.5t7.5 -17.5v-1150q0 -10 -7.5 -17.5t-17.5 -7.5h-1050q-10 0 -17.5 7.5t-7.5 17.5v1150q0 10 7.5 17.5t17.5 7.5zM1075 1000h-850q-10 0 -17.5 -7.5t-7.5 -17.5v-850q0 -10 7.5 -17.5t17.5 -7.5h850q10 0 17.5 7.5t7.5 17.5v850 q0 10 -7.5 17.5t-17.5 7.5zM325 900h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 900h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 700h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 700h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 500h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 500h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5zM325 300h50q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM525 300h450q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-450q-10 0 -17.5 7.5t-7.5 17.5v50 q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe033;" d="M900 800v200q0 83 -58.5 141.5t-141.5 58.5h-300q-82 0 -141 -59t-59 -141v-200h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h900q41 0 70.5 29.5t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5h-100zM400 800v150q0 21 15 35.5t35 14.5h200 q20 0 35 -14.5t15 -35.5v-150h-300z" />
<glyph unicode="&#xe034;" d="M125 1100h50q10 0 17.5 -7.5t7.5 -17.5v-1075h-100v1075q0 10 7.5 17.5t17.5 7.5zM1075 1052q4 0 9 -2q16 -6 16 -23v-421q0 -6 -3 -12q-33 -59 -66.5 -99t-65.5 -58t-56.5 -24.5t-52.5 -6.5q-26 0 -57.5 6.5t-52.5 13.5t-60 21q-41 15 -63 22.5t-57.5 15t-65.5 7.5 q-85 0 -160 -57q-7 -5 -15 -5q-6 0 -11 3q-14 7 -14 22v438q22 55 82 98.5t119 46.5q23 2 43 0.5t43 -7t32.5 -8.5t38 -13t32.5 -11q41 -14 63.5 -21t57 -14t63.5 -7q103 0 183 87q7 8 18 8z" />
<glyph unicode="&#xe035;" d="M600 1175q116 0 227 -49.5t192.5 -131t131 -192.5t49.5 -227v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v300q0 127 -70.5 231.5t-184.5 161.5t-245 57t-245 -57t-184.5 -161.5t-70.5 -231.5v-300q0 -10 -7.5 -17.5t-17.5 -7.5h-50 q-10 0 -17.5 7.5t-7.5 17.5v300q0 116 49.5 227t131 192.5t192.5 131t227 49.5zM220 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460q0 8 6 14t14 6zM820 500h160q8 0 14 -6t6 -14v-460q0 -8 -6 -14t-14 -6h-160q-8 0 -14 6t-6 14v460 q0 8 6 14t14 6z" />
<glyph unicode="&#xe036;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM900 668l120 120q7 7 17 7t17 -7l34 -34q7 -7 7 -17t-7 -17l-120 -120l120 -120q7 -7 7 -17 t-7 -17l-34 -34q-7 -7 -17 -7t-17 7l-120 119l-120 -119q-7 -7 -17 -7t-17 7l-34 34q-7 7 -7 17t7 17l119 120l-119 120q-7 7 -7 17t7 17l34 34q7 8 17 8t17 -8z" />
<glyph unicode="&#xe037;" d="M321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6 l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238q-6 8 -4.5 18t9.5 17l29 22q7 5 15 5z" />
<glyph unicode="&#xe038;" d="M967 1004h3q11 -1 17 -10q135 -179 135 -396q0 -105 -34 -206.5t-98 -185.5q-7 -9 -17 -10h-3q-9 0 -16 6l-42 34q-8 6 -9 16t5 18q111 150 111 328q0 90 -29.5 176t-84.5 157q-6 9 -5 19t10 16l42 33q7 5 15 5zM321 814l258 172q9 6 15 2.5t6 -13.5v-750q0 -10 -6 -13.5 t-15 2.5l-258 172q-21 14 -46 14h-250q-10 0 -17.5 7.5t-7.5 17.5v350q0 10 7.5 17.5t17.5 7.5h250q25 0 46 14zM766 900h4q10 -1 16 -10q96 -129 96 -290q0 -154 -90 -281q-6 -9 -17 -10l-3 -1q-9 0 -16 6l-29 23q-7 7 -8.5 16.5t4.5 17.5q72 103 72 229q0 132 -78 238 q-6 8 -4.5 18.5t9.5 16.5l29 22q7 5 15 5z" />
<glyph unicode="&#xe039;" d="M500 900h100v-100h-100v-100h-400v-100h-100v600h500v-300zM1200 700h-200v-100h200v-200h-300v300h-200v300h-100v200h600v-500zM100 1100v-300h300v300h-300zM800 1100v-300h300v300h-300zM300 900h-100v100h100v-100zM1000 900h-100v100h100v-100zM300 500h200v-500 h-500v500h200v100h100v-100zM800 300h200v-100h-100v-100h-200v100h-100v100h100v200h-200v100h300v-300zM100 400v-300h300v300h-300zM300 200h-100v100h100v-100zM1200 200h-100v100h100v-100zM700 0h-100v100h100v-100zM1200 0h-300v100h300v-100z" />
<glyph unicode="&#xe040;" d="M100 200h-100v1000h100v-1000zM300 200h-100v1000h100v-1000zM700 200h-200v1000h200v-1000zM900 200h-100v1000h100v-1000zM1200 200h-200v1000h200v-1000zM400 0h-300v100h300v-100zM600 0h-100v91h100v-91zM800 0h-100v91h100v-91zM1100 0h-200v91h200v-91z" />
<glyph unicode="&#xe041;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe042;" d="M500 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-682 682l1 475q0 10 7.5 17.5t17.5 7.5h474zM800 1200l682 -682q8 -8 8 -18t-8 -18l-464 -464q-8 -8 -18 -8t-18 8l-56 56l424 426l-700 700h150zM319.5 1024.5q-29.5 29.5 -71 29.5t-71 -29.5 t-29.5 -71.5t29.5 -71.5t71 -29.5t71 29.5t29.5 71.5t-29.5 71.5z" />
<glyph unicode="&#xe043;" d="M300 1200h825q75 0 75 -75v-900q0 -25 -18 -43l-64 -64q-8 -8 -13 -5.5t-5 12.5v950q0 10 -7.5 17.5t-17.5 7.5h-700q-25 0 -43 -18l-64 -64q-8 -8 -5.5 -13t12.5 -5h700q10 0 17.5 -7.5t7.5 -17.5v-950q0 -10 -7.5 -17.5t-17.5 -7.5h-850q-10 0 -17.5 7.5t-7.5 17.5v975 q0 25 18 43l139 139q18 18 43 18z" />
<glyph unicode="&#xe044;" d="M250 1200h800q21 0 35.5 -14.5t14.5 -35.5v-1150l-450 444l-450 -445v1151q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe045;" d="M822 1200h-444q-11 0 -19 -7.5t-9 -17.5l-78 -301q-7 -24 7 -45l57 -108q6 -9 17.5 -15t21.5 -6h450q10 0 21.5 6t17.5 15l62 108q14 21 7 45l-83 301q-1 10 -9 17.5t-19 7.5zM1175 800h-150q-10 0 -21 -6.5t-15 -15.5l-78 -156q-4 -9 -15 -15.5t-21 -6.5h-550 q-10 0 -21 6.5t-15 15.5l-78 156q-4 9 -15 15.5t-21 6.5h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-650q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h750q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5 t7.5 17.5v650q0 10 -7.5 17.5t-17.5 7.5zM850 200h-500q-10 0 -19.5 -7t-11.5 -17l-38 -152q-2 -10 3.5 -17t15.5 -7h600q10 0 15.5 7t3.5 17l-38 152q-2 10 -11.5 17t-19.5 7z" />
<glyph unicode="&#xe046;" d="M500 1100h200q56 0 102.5 -20.5t72.5 -50t44 -59t25 -50.5l6 -20h150q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5h150q2 8 6.5 21.5t24 48t45 61t72 48t102.5 21.5zM900 800v-100 h100v100h-100zM600 730q-95 0 -162.5 -67.5t-67.5 -162.5t67.5 -162.5t162.5 -67.5t162.5 67.5t67.5 162.5t-67.5 162.5t-162.5 67.5zM600 603q43 0 73 -30t30 -73t-30 -73t-73 -30t-73 30t-30 73t30 73t73 30z" />
<glyph unicode="&#xe047;" d="M681 1199l385 -998q20 -50 60 -92q18 -19 36.5 -29.5t27.5 -11.5l10 -2v-66h-417v66q53 0 75 43.5t5 88.5l-82 222h-391q-58 -145 -92 -234q-11 -34 -6.5 -57t25.5 -37t46 -20t55 -6v-66h-365v66q56 24 84 52q12 12 25 30.5t20 31.5l7 13l399 1006h93zM416 521h340 l-162 457z" />
<glyph unicode="&#xe048;" d="M753 641q5 -1 14.5 -4.5t36 -15.5t50.5 -26.5t53.5 -40t50.5 -54.5t35.5 -70t14.5 -87q0 -67 -27.5 -125.5t-71.5 -97.5t-98.5 -66.5t-108.5 -40.5t-102 -13h-500v89q41 7 70.5 32.5t29.5 65.5v827q0 24 -0.5 34t-3.5 24t-8.5 19.5t-17 13.5t-28 12.5t-42.5 11.5v71 l471 -1q57 0 115.5 -20.5t108 -57t80.5 -94t31 -124.5q0 -51 -15.5 -96.5t-38 -74.5t-45 -50.5t-38.5 -30.5zM400 700h139q78 0 130.5 48.5t52.5 122.5q0 41 -8.5 70.5t-29.5 55.5t-62.5 39.5t-103.5 13.5h-118v-350zM400 200h216q80 0 121 50.5t41 130.5q0 90 -62.5 154.5 t-156.5 64.5h-159v-400z" />
<glyph unicode="&#xe049;" d="M877 1200l2 -57q-83 -19 -116 -45.5t-40 -66.5l-132 -839q-9 -49 13 -69t96 -26v-97h-500v97q186 16 200 98l173 832q3 17 3 30t-1.5 22.5t-9 17.5t-13.5 12.5t-21.5 10t-26 8.5t-33.5 10q-13 3 -19 5v57h425z" />
<glyph unicode="&#xe050;" d="M1300 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM175 1000h-75v-800h75l-125 -167l-125 167h75v800h-75l125 167z" />
<glyph unicode="&#xe051;" d="M1100 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-650q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v650h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM1167 50l-167 -125v75h-800v-75l-167 125l167 125v-75h800v75z" />
<glyph unicode="&#xe052;" d="M50 1100h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe053;" d="M250 1100h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM250 500h700q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-700q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe054;" d="M500 950v100q0 21 14.5 35.5t35.5 14.5h600q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5zM100 650v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000 q-21 0 -35.5 14.5t-14.5 35.5zM300 350v100q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5zM0 50v100q0 21 14.5 35.5t35.5 14.5h1100q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5z" />
<glyph unicode="&#xe055;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 800h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 500h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h1100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe056;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 1100h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 800h800q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 500h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 500h800q21 0 35.5 -14.5t14.5 -35.5v-100 q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM350 200h800 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe057;" d="M400 0h-100v1100h100v-1100zM550 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM267 550l-167 -125v75h-200v100h200v75zM550 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM550 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe058;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM900 0h-100v1100h100v-1100zM50 800h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM1100 600h200v-100h-200v-75l-167 125l167 125v-75zM50 500h300q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5zM50 200h600 q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-600q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe059;" d="M75 1000h750q31 0 53 -22t22 -53v-650q0 -31 -22 -53t-53 -22h-750q-31 0 -53 22t-22 53v650q0 31 22 53t53 22zM1200 300l-300 300l300 300v-600z" />
<glyph unicode="&#xe060;" d="M44 1100h1112q18 0 31 -13t13 -31v-1012q0 -18 -13 -31t-31 -13h-1112q-18 0 -31 13t-13 31v1012q0 18 13 31t31 13zM100 1000v-737l247 182l298 -131l-74 156l293 318l236 -288v500h-1000zM342 884q56 0 95 -39t39 -94.5t-39 -95t-95 -39.5t-95 39.5t-39 95t39 94.5 t95 39z" />
<glyph unicode="&#xe062;" d="M648 1169q117 0 216 -60t156.5 -161t57.5 -218q0 -115 -70 -258q-69 -109 -158 -225.5t-143 -179.5l-54 -62q-9 8 -25.5 24.5t-63.5 67.5t-91 103t-98.5 128t-95.5 148q-60 132 -60 249q0 88 34 169.5t91.5 142t137 96.5t166.5 36zM652.5 974q-91.5 0 -156.5 -65 t-65 -157t65 -156.5t156.5 -64.5t156.5 64.5t65 156.5t-65 157t-156.5 65z" />
<glyph unicode="&#xe063;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 173v854q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57z" />
<glyph unicode="&#xe064;" d="M554 1295q21 -72 57.5 -143.5t76 -130t83 -118t82.5 -117t70 -116t49.5 -126t18.5 -136.5q0 -71 -25.5 -135t-68.5 -111t-99 -82t-118.5 -54t-125.5 -23q-84 5 -161.5 34t-139.5 78.5t-99 125t-37 164.5q0 69 18 136.5t49.5 126.5t69.5 116.5t81.5 117.5t83.5 119 t76.5 131t58.5 143zM344 710q-23 -33 -43.5 -70.5t-40.5 -102.5t-17 -123q1 -37 14.5 -69.5t30 -52t41 -37t38.5 -24.5t33 -15q21 -7 32 -1t13 22l6 34q2 10 -2.5 22t-13.5 19q-5 4 -14 12t-29.5 40.5t-32.5 73.5q-26 89 6 271q2 11 -6 11q-8 1 -15 -10z" />
<glyph unicode="&#xe065;" d="M1000 1013l108 115q2 1 5 2t13 2t20.5 -1t25 -9.5t28.5 -21.5q22 -22 27 -43t0 -32l-6 -10l-108 -115zM350 1100h400q50 0 105 -13l-187 -187h-368q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v182l200 200v-332 q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM1009 803l-362 -362l-161 -50l55 170l355 355z" />
<glyph unicode="&#xe066;" d="M350 1100h361q-164 -146 -216 -200h-195q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5l200 153v-103q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M824 1073l339 -301q8 -7 8 -17.5t-8 -17.5l-340 -306q-7 -6 -12.5 -4t-6.5 11v203q-26 1 -54.5 0t-78.5 -7.5t-92 -17.5t-86 -35t-70 -57q10 59 33 108t51.5 81.5t65 58.5t68.5 40.5t67 24.5t56 13.5t40 4.5v210q1 10 6.5 12.5t13.5 -4.5z" />
<glyph unicode="&#xe067;" d="M350 1100h350q60 0 127 -23l-178 -177h-349q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v69l200 200v-219q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5z M643 639l395 395q7 7 17.5 7t17.5 -7l101 -101q7 -7 7 -17.5t-7 -17.5l-531 -532q-7 -7 -17.5 -7t-17.5 7l-248 248q-7 7 -7 17.5t7 17.5l101 101q7 7 17.5 7t17.5 -7l111 -111q8 -7 18 -7t18 7z" />
<glyph unicode="&#xe068;" d="M318 918l264 264q8 8 18 8t18 -8l260 -264q7 -8 4.5 -13t-12.5 -5h-170v-200h200v173q0 10 5 12t13 -5l264 -260q8 -7 8 -17.5t-8 -17.5l-264 -265q-8 -7 -13 -5t-5 12v173h-200v-200h170q10 0 12.5 -5t-4.5 -13l-260 -264q-8 -8 -18 -8t-18 8l-264 264q-8 8 -5.5 13 t12.5 5h175v200h-200v-173q0 -10 -5 -12t-13 5l-264 265q-8 7 -8 17.5t8 17.5l264 260q8 7 13 5t5 -12v-173h200v200h-175q-10 0 -12.5 5t5.5 13z" />
<glyph unicode="&#xe069;" d="M250 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe070;" d="M50 1100h100q21 0 35.5 -14.5t14.5 -35.5v-438l464 453q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5 t-14.5 35.5v1000q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe071;" d="M1200 1050v-1000q0 -21 -10.5 -25t-25.5 10l-464 453v-438q0 -21 -10.5 -25t-25.5 10l-492 480q-15 14 -15 35t15 35l492 480q15 14 25.5 10t10.5 -25v-438l464 453q15 14 25.5 10t10.5 -25z" />
<glyph unicode="&#xe072;" d="M243 1074l814 -498q18 -11 18 -26t-18 -26l-814 -498q-18 -11 -30.5 -4t-12.5 28v1000q0 21 12.5 28t30.5 -4z" />
<glyph unicode="&#xe073;" d="M250 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM650 1000h200q21 0 35.5 -14.5t14.5 -35.5v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v800 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe074;" d="M1100 950v-800q0 -21 -14.5 -35.5t-35.5 -14.5h-800q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5h800q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe075;" d="M500 612v438q0 21 10.5 25t25.5 -10l492 -480q15 -14 15 -35t-15 -35l-492 -480q-15 -14 -25.5 -10t-10.5 25v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10z" />
<glyph unicode="&#xe076;" d="M1048 1102l100 1q20 0 35 -14.5t15 -35.5l5 -1000q0 -21 -14.5 -35.5t-35.5 -14.5l-100 -1q-21 0 -35.5 14.5t-14.5 35.5l-2 437l-463 -454q-14 -15 -24.5 -10.5t-10.5 25.5l-2 437l-462 -455q-15 -14 -25.5 -9.5t-10.5 24.5l-5 1000q0 21 10.5 25.5t25.5 -10.5l466 -450 l-2 438q0 20 10.5 24.5t25.5 -9.5l466 -451l-2 438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe077;" d="M850 1100h100q21 0 35.5 -14.5t14.5 -35.5v-1000q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v438l-464 -453q-15 -14 -25.5 -10t-10.5 25v1000q0 21 10.5 25t25.5 -10l464 -453v438q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe078;" d="M686 1081l501 -540q15 -15 10.5 -26t-26.5 -11h-1042q-22 0 -26.5 11t10.5 26l501 540q15 15 36 15t36 -15zM150 400h1000q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe079;" d="M885 900l-352 -353l352 -353l-197 -198l-552 552l552 550z" />
<glyph unicode="&#xe080;" d="M1064 547l-551 -551l-198 198l353 353l-353 353l198 198z" />
<glyph unicode="&#xe081;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM650 900h-100q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-150 q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5h150v-150q0 -21 14.5 -35.5t35.5 -14.5h100q21 0 35.5 14.5t14.5 35.5v150h150q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-150v150q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe082;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM850 700h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5 t35.5 -14.5h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5z" />
<glyph unicode="&#xe083;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM741.5 913q-12.5 0 -21.5 -9l-120 -120l-120 120q-9 9 -21.5 9 t-21.5 -9l-141 -141q-9 -9 -9 -21.5t9 -21.5l120 -120l-120 -120q-9 -9 -9 -21.5t9 -21.5l141 -141q9 -9 21.5 -9t21.5 9l120 120l120 -120q9 -9 21.5 -9t21.5 9l141 141q9 9 9 21.5t-9 21.5l-120 120l120 120q9 9 9 21.5t-9 21.5l-141 141q-9 9 -21.5 9z" />
<glyph unicode="&#xe084;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM546 623l-84 85q-7 7 -17.5 7t-18.5 -7l-139 -139q-7 -8 -7 -18t7 -18 l242 -241q7 -8 17.5 -8t17.5 8l375 375q7 7 7 17.5t-7 18.5l-139 139q-7 7 -17.5 7t-17.5 -7z" />
<glyph unicode="&#xe085;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM588 941q-29 0 -59 -5.5t-63 -20.5t-58 -38.5t-41.5 -63t-16.5 -89.5 q0 -25 20 -25h131q30 -5 35 11q6 20 20.5 28t45.5 8q20 0 31.5 -10.5t11.5 -28.5q0 -23 -7 -34t-26 -18q-1 0 -13.5 -4t-19.5 -7.5t-20 -10.5t-22 -17t-18.5 -24t-15.5 -35t-8 -46q-1 -8 5.5 -16.5t20.5 -8.5h173q7 0 22 8t35 28t37.5 48t29.5 74t12 100q0 47 -17 83 t-42.5 57t-59.5 34.5t-64 18t-59 4.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe086;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM675 1000h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5 t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5zM675 700h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h75v-200h-75q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h350q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5 t-17.5 7.5h-75v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe087;" d="M525 1200h150q10 0 17.5 -7.5t7.5 -17.5v-194q103 -27 178.5 -102.5t102.5 -178.5h194q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-194q-27 -103 -102.5 -178.5t-178.5 -102.5v-194q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v194 q-103 27 -178.5 102.5t-102.5 178.5h-194q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h194q27 103 102.5 178.5t178.5 102.5v194q0 10 7.5 17.5t17.5 7.5zM700 893v-168q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v168q-68 -23 -119 -74 t-74 -119h168q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-168q23 -68 74 -119t119 -74v168q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-168q68 23 119 74t74 119h-168q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h168 q-23 68 -74 119t-119 74z" />
<glyph unicode="&#xe088;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM759 823l64 -64q7 -7 7 -17.5t-7 -17.5l-124 -124l124 -124q7 -7 7 -17.5t-7 -17.5l-64 -64q-7 -7 -17.5 -7t-17.5 7l-124 124l-124 -124q-7 -7 -17.5 -7t-17.5 7l-64 64 q-7 7 -7 17.5t7 17.5l124 124l-124 124q-7 7 -7 17.5t7 17.5l64 64q7 7 17.5 7t17.5 -7l124 -124l124 124q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe089;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5t57 -214.5 t155.5 -155.5t214.5 -57t214.5 57t155.5 155.5t57 214.5t-57 214.5t-155.5 155.5t-214.5 57zM782 788l106 -106q7 -7 7 -17.5t-7 -17.5l-320 -321q-8 -7 -18 -7t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l197 197q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe090;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM600 1027q-116 0 -214.5 -57t-155.5 -155.5t-57 -214.5q0 -120 65 -225 l587 587q-105 65 -225 65zM965 819l-584 -584q104 -62 219 -62q116 0 214.5 57t155.5 155.5t57 214.5q0 115 -62 219z" />
<glyph unicode="&#xe091;" d="M39 582l522 427q16 13 27.5 8t11.5 -26v-291h550q21 0 35.5 -14.5t14.5 -35.5v-200q0 -21 -14.5 -35.5t-35.5 -14.5h-550v-291q0 -21 -11.5 -26t-27.5 8l-522 427q-16 13 -16 32t16 32z" />
<glyph unicode="&#xe092;" d="M639 1009l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291h-550q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h550v291q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe093;" d="M682 1161l427 -522q13 -16 8 -27.5t-26 -11.5h-291v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v550h-291q-21 0 -26 11.5t8 27.5l427 522q13 16 32 16t32 -16z" />
<glyph unicode="&#xe094;" d="M550 1200h200q21 0 35.5 -14.5t14.5 -35.5v-550h291q21 0 26 -11.5t-8 -27.5l-427 -522q-13 -16 -32 -16t-32 16l-427 522q-13 16 -8 27.5t26 11.5h291v550q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe095;" d="M639 1109l522 -427q16 -13 16 -32t-16 -32l-522 -427q-16 -13 -27.5 -8t-11.5 26v291q-94 -2 -182 -20t-170.5 -52t-147 -92.5t-100.5 -135.5q5 105 27 193.5t67.5 167t113 135t167 91.5t225.5 42v262q0 21 11.5 26t27.5 -8z" />
<glyph unicode="&#xe096;" d="M850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5zM350 0h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249 q8 7 18 7t18 -7l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5z" />
<glyph unicode="&#xe097;" d="M1014 1120l106 -106q7 -8 7 -18t-7 -18l-249 -249l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l249 249q8 7 18 7t18 -7zM250 600h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-249 -249q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l249 249l-94 94q-14 14 -10 24.5t25 10.5z" />
<glyph unicode="&#xe101;" d="M600 1177q117 0 224 -45.5t184.5 -123t123 -184.5t45.5 -224t-45.5 -224t-123 -184.5t-184.5 -123t-224 -45.5t-224 45.5t-184.5 123t-123 184.5t-45.5 224t45.5 224t123 184.5t184.5 123t224 45.5zM704 900h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5 t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM675 400h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe102;" d="M260 1200q9 0 19 -2t15 -4l5 -2q22 -10 44 -23l196 -118q21 -13 36 -24q29 -21 37 -12q11 13 49 35l196 118q22 13 45 23q17 7 38 7q23 0 47 -16.5t37 -33.5l13 -16q14 -21 18 -45l25 -123l8 -44q1 -9 8.5 -14.5t17.5 -5.5h61q10 0 17.5 -7.5t7.5 -17.5v-50 q0 -10 -7.5 -17.5t-17.5 -7.5h-50q-10 0 -17.5 -7.5t-7.5 -17.5v-175h-400v300h-200v-300h-400v175q0 10 -7.5 17.5t-17.5 7.5h-50q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5h61q11 0 18 3t7 8q0 4 9 52l25 128q5 25 19 45q2 3 5 7t13.5 15t21.5 19.5t26.5 15.5 t29.5 7zM915 1079l-166 -162q-7 -7 -5 -12t12 -5h219q10 0 15 7t2 17l-51 149q-3 10 -11 12t-15 -6zM463 917l-177 157q-8 7 -16 5t-11 -12l-51 -143q-3 -10 2 -17t15 -7h231q11 0 12.5 5t-5.5 12zM500 0h-375q-10 0 -17.5 7.5t-7.5 17.5v375h400v-400zM1100 400v-375 q0 -10 -7.5 -17.5t-17.5 -7.5h-375v400h400z" />
<glyph unicode="&#xe103;" d="M1165 1190q8 3 21 -6.5t13 -17.5q-2 -178 -24.5 -323.5t-55.5 -245.5t-87 -174.5t-102.5 -118.5t-118 -68.5t-118.5 -33t-120 -4.5t-105 9.5t-90 16.5q-61 12 -78 11q-4 1 -12.5 0t-34 -14.5t-52.5 -40.5l-153 -153q-26 -24 -37 -14.5t-11 43.5q0 64 42 102q8 8 50.5 45 t66.5 58q19 17 35 47t13 61q-9 55 -10 102.5t7 111t37 130t78 129.5q39 51 80 88t89.5 63.5t94.5 45t113.5 36t129 31t157.5 37t182 47.5zM1116 1098q-8 9 -22.5 -3t-45.5 -50q-38 -47 -119 -103.5t-142 -89.5l-62 -33q-56 -30 -102 -57t-104 -68t-102.5 -80.5t-85.5 -91 t-64 -104.5q-24 -56 -31 -86t2 -32t31.5 17.5t55.5 59.5q25 30 94 75.5t125.5 77.5t147.5 81q70 37 118.5 69t102 79.5t99 111t86.5 148.5q22 50 24 60t-6 19z" />
<glyph unicode="&#xe104;" d="M653 1231q-39 -67 -54.5 -131t-10.5 -114.5t24.5 -96.5t47.5 -80t63.5 -62.5t68.5 -46.5t65 -30q-4 7 -17.5 35t-18.5 39.5t-17 39.5t-17 43t-13 42t-9.5 44.5t-2 42t4 43t13.5 39t23 38.5q96 -42 165 -107.5t105 -138t52 -156t13 -159t-19 -149.5q-13 -55 -44 -106.5 t-68 -87t-78.5 -64.5t-72.5 -45t-53 -22q-72 -22 -127 -11q-31 6 -13 19q6 3 17 7q13 5 32.5 21t41 44t38.5 63.5t21.5 81.5t-6.5 94.5t-50 107t-104 115.5q10 -104 -0.5 -189t-37 -140.5t-65 -93t-84 -52t-93.5 -11t-95 24.5q-80 36 -131.5 114t-53.5 171q-2 23 0 49.5 t4.5 52.5t13.5 56t27.5 60t46 64.5t69.5 68.5q-8 -53 -5 -102.5t17.5 -90t34 -68.5t44.5 -39t49 -2q31 13 38.5 36t-4.5 55t-29 64.5t-36 75t-26 75.5q-15 85 2 161.5t53.5 128.5t85.5 92.5t93.5 61t81.5 25.5z" />
<glyph unicode="&#xe105;" d="M600 1094q82 0 160.5 -22.5t140 -59t116.5 -82.5t94.5 -95t68 -95t42.5 -82.5t14 -57.5t-14 -57.5t-43 -82.5t-68.5 -95t-94.5 -95t-116.5 -82.5t-140 -59t-159.5 -22.5t-159.5 22.5t-140 59t-116.5 82.5t-94.5 95t-68.5 95t-43 82.5t-14 57.5t14 57.5t42.5 82.5t68 95 t94.5 95t116.5 82.5t140 59t160.5 22.5zM888 829q-15 15 -18 12t5 -22q25 -57 25 -119q0 -124 -88 -212t-212 -88t-212 88t-88 212q0 59 23 114q8 19 4.5 22t-17.5 -12q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q22 -36 47 -71t70 -82t92.5 -81t113 -58.5t133.5 -24.5 t133.5 24t113 58.5t92.5 81.5t70 81.5t47 70.5q11 18 9 42.5t-14 41.5q-90 117 -163 189zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l35 34q14 15 12.5 33.5t-16.5 33.5q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe106;" d="M592 0h-148l31 120q-91 20 -175.5 68.5t-143.5 106.5t-103.5 119t-66.5 110t-22 76q0 21 14 57.5t42.5 82.5t68 95t94.5 95t116.5 82.5t140 59t160.5 22.5q61 0 126 -15l32 121h148zM944 770l47 181q108 -85 176.5 -192t68.5 -159q0 -26 -19.5 -71t-59.5 -102t-93 -112 t-129 -104.5t-158 -75.5l46 173q77 49 136 117t97 131q11 18 9 42.5t-14 41.5q-54 70 -107 130zM310 824q-70 -69 -160 -184q-13 -16 -15 -40.5t9 -42.5q18 -30 39 -60t57 -70.5t74 -73t90 -61t105 -41.5l41 154q-107 18 -178.5 101.5t-71.5 193.5q0 59 23 114q8 19 4.5 22 t-17.5 -12zM448 727l-35 -36q-15 -15 -19.5 -38.5t4.5 -41.5q37 -68 93 -116q16 -13 38.5 -11t36.5 17l12 11l22 86l-3 4q-44 44 -89 117q-11 18 -28 20t-32 -12z" />
<glyph unicode="&#xe107;" d="M-90 100l642 1066q20 31 48 28.5t48 -35.5l642 -1056q21 -32 7.5 -67.5t-50.5 -35.5h-1294q-37 0 -50.5 34t7.5 66zM155 200h345v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h345l-445 723zM496 700h208q20 0 32 -14.5t8 -34.5l-58 -252 q-4 -20 -21.5 -34.5t-37.5 -14.5h-54q-20 0 -37.5 14.5t-21.5 34.5l-58 252q-4 20 8 34.5t32 14.5z" />
<glyph unicode="&#xe108;" d="M650 1200q62 0 106 -44t44 -106v-339l363 -325q15 -14 26 -38.5t11 -44.5v-41q0 -20 -12 -26.5t-29 5.5l-359 249v-263q100 -93 100 -113v-64q0 -21 -13 -29t-32 1l-205 128l-205 -128q-19 -9 -32 -1t-13 29v64q0 20 100 113v263l-359 -249q-17 -12 -29 -5.5t-12 26.5v41 q0 20 11 44.5t26 38.5l363 325v339q0 62 44 106t106 44z" />
<glyph unicode="&#xe109;" d="M850 1200h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-150h-1100v150q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5h100q21 0 35.5 -14.5t14.5 -35.5v-50h500v50q0 21 14.5 35.5t35.5 14.5zM1100 800v-750q0 -21 -14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v750h1100zM100 600v-100h100v100h-100zM300 600v-100h100v100h-100zM500 600v-100h100v100h-100zM700 600v-100h100v100h-100zM900 600v-100h100v100h-100zM100 400v-100h100v100h-100zM300 400v-100h100v100h-100zM500 400 v-100h100v100h-100zM700 400v-100h100v100h-100zM900 400v-100h100v100h-100zM100 200v-100h100v100h-100zM300 200v-100h100v100h-100zM500 200v-100h100v100h-100zM700 200v-100h100v100h-100zM900 200v-100h100v100h-100z" />
<glyph unicode="&#xe110;" d="M1135 1165l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-159l-600 -600h-291q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h209l600 600h241v150q0 21 10.5 25t24.5 -10zM522 819l-141 -141l-122 122h-209q-21 0 -35.5 14.5 t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h291zM1135 565l249 -230q15 -14 15 -35t-15 -35l-249 -230q-14 -14 -24.5 -10t-10.5 25v150h-241l-181 181l141 141l122 -122h159v150q0 21 10.5 25t24.5 -10z" />
<glyph unicode="&#xe111;" d="M100 1100h1000q41 0 70.5 -29.5t29.5 -70.5v-600q0 -41 -29.5 -70.5t-70.5 -29.5h-596l-304 -300v300h-100q-41 0 -70.5 29.5t-29.5 70.5v600q0 41 29.5 70.5t70.5 29.5z" />
<glyph unicode="&#xe112;" d="M150 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM850 1200h200q21 0 35.5 -14.5t14.5 -35.5v-250h-300v250q0 21 14.5 35.5t35.5 14.5zM1100 800v-300q0 -41 -3 -77.5t-15 -89.5t-32 -96t-58 -89t-89 -77t-129 -51t-174 -20t-174 20 t-129 51t-89 77t-58 89t-32 96t-15 89.5t-3 77.5v300h300v-250v-27v-42.5t1.5 -41t5 -38t10 -35t16.5 -30t25.5 -24.5t35 -19t46.5 -12t60 -4t60 4.5t46.5 12.5t35 19.5t25 25.5t17 30.5t10 35t5 38t2 40.5t-0.5 42v25v250h300z" />
<glyph unicode="&#xe113;" d="M1100 411l-198 -199l-353 353l-353 -353l-197 199l551 551z" />
<glyph unicode="&#xe114;" d="M1101 789l-550 -551l-551 551l198 199l353 -353l353 353z" />
<glyph unicode="&#xe115;" d="M404 1000h746q21 0 35.5 -14.5t14.5 -35.5v-551h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v401h-381zM135 984l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-400h385l215 -200h-750q-21 0 -35.5 14.5 t-14.5 35.5v550h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe116;" d="M56 1200h94q17 0 31 -11t18 -27l38 -162h896q24 0 39 -18.5t10 -42.5l-100 -475q-5 -21 -27 -42.5t-55 -21.5h-633l48 -200h535q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-50q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-300v-50 q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v50h-31q-18 0 -32.5 10t-20.5 19l-5 10l-201 961h-54q-20 0 -35 14.5t-15 35.5t15 35.5t35 14.5z" />
<glyph unicode="&#xe117;" d="M1200 1000v-100h-1200v100h200q0 41 29.5 70.5t70.5 29.5h300q41 0 70.5 -29.5t29.5 -70.5h500zM0 800h1200v-800h-1200v800z" />
<glyph unicode="&#xe118;" d="M200 800l-200 -400v600h200q0 41 29.5 70.5t70.5 29.5h300q42 0 71 -29.5t29 -70.5h500v-200h-1000zM1500 700l-300 -700h-1200l300 700h1200z" />
<glyph unicode="&#xe119;" d="M635 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-601h150q21 0 25 -10.5t-10 -24.5l-230 -249q-14 -15 -35 -15t-35 15l-230 249q-14 14 -10 24.5t25 10.5h150v601h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe120;" d="M936 864l249 -229q14 -15 14 -35.5t-14 -35.5l-249 -229q-15 -15 -25.5 -10.5t-10.5 24.5v151h-600v-151q0 -20 -10.5 -24.5t-25.5 10.5l-249 229q-14 15 -14 35.5t14 35.5l249 229q15 15 25.5 10.5t10.5 -25.5v-149h600v149q0 21 10.5 25.5t25.5 -10.5z" />
<glyph unicode="&#xe121;" d="M1169 400l-172 732q-5 23 -23 45.5t-38 22.5h-672q-20 0 -38 -20t-23 -41l-172 -739h1138zM1100 300h-1000q-41 0 -70.5 -29.5t-29.5 -70.5v-100q0 -41 29.5 -70.5t70.5 -29.5h1000q41 0 70.5 29.5t29.5 70.5v100q0 41 -29.5 70.5t-70.5 29.5zM800 100v100h100v-100h-100 zM1000 100v100h100v-100h-100z" />
<glyph unicode="&#xe122;" d="M1150 1100q21 0 35.5 -14.5t14.5 -35.5v-850q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v850q0 21 14.5 35.5t35.5 14.5zM1000 200l-675 200h-38l47 -276q3 -16 -5.5 -20t-29.5 -4h-7h-84q-20 0 -34.5 14t-18.5 35q-55 337 -55 351v250v6q0 16 1 23.5t6.5 14 t17.5 6.5h200l675 250v-850zM0 750v-250q-4 0 -11 0.5t-24 6t-30 15t-24 30t-11 48.5v50q0 26 10.5 46t25 30t29 16t25.5 7z" />
<glyph unicode="&#xe123;" d="M553 1200h94q20 0 29 -10.5t3 -29.5l-18 -37q83 -19 144 -82.5t76 -140.5l63 -327l118 -173h17q19 0 33 -14.5t14 -35t-13 -40.5t-31 -27q-8 -4 -23 -9.5t-65 -19.5t-103 -25t-132.5 -20t-158.5 -9q-57 0 -115 5t-104 12t-88.5 15.5t-73.5 17.5t-54.5 16t-35.5 12l-11 4 q-18 8 -31 28t-13 40.5t14 35t33 14.5h17l118 173l63 327q15 77 76 140t144 83l-18 32q-6 19 3.5 32t28.5 13zM498 110q50 -6 102 -6q53 0 102 6q-12 -49 -39.5 -79.5t-62.5 -30.5t-63 30.5t-39 79.5z" />
<glyph unicode="&#xe124;" d="M800 946l224 78l-78 -224l234 -45l-180 -155l180 -155l-234 -45l78 -224l-224 78l-45 -234l-155 180l-155 -180l-45 234l-224 -78l78 224l-234 45l180 155l-180 155l234 45l-78 224l224 -78l45 234l155 -180l155 180z" />
<glyph unicode="&#xe125;" d="M650 1200h50q40 0 70 -40.5t30 -84.5v-150l-28 -125h328q40 0 70 -40.5t30 -84.5v-100q0 -45 -29 -74l-238 -344q-16 -24 -38 -40.5t-45 -16.5h-250q-7 0 -42 25t-66 50l-31 25h-61q-45 0 -72.5 18t-27.5 57v400q0 36 20 63l145 196l96 198q13 28 37.5 48t51.5 20z M650 1100l-100 -212l-150 -213v-375h100l136 -100h214l250 375v125h-450l50 225v175h-50zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe126;" d="M600 1100h250q23 0 45 -16.5t38 -40.5l238 -344q29 -29 29 -74v-100q0 -44 -30 -84.5t-70 -40.5h-328q28 -118 28 -125v-150q0 -44 -30 -84.5t-70 -40.5h-50q-27 0 -51.5 20t-37.5 48l-96 198l-145 196q-20 27 -20 63v400q0 39 27.5 57t72.5 18h61q124 100 139 100z M50 1000h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM636 1000l-136 -100h-100v-375l150 -213l100 -212h50v175l-50 225h450v125l-250 375h-214z" />
<glyph unicode="&#xe127;" d="M356 873l363 230q31 16 53 -6l110 -112q13 -13 13.5 -32t-11.5 -34l-84 -121h302q84 0 138 -38t54 -110t-55 -111t-139 -39h-106l-131 -339q-6 -21 -19.5 -41t-28.5 -20h-342q-7 0 -90 81t-83 94v525q0 17 14 35.5t28 28.5zM400 792v-503l100 -89h293l131 339 q6 21 19.5 41t28.5 20h203q21 0 30.5 25t0.5 50t-31 25h-456h-7h-6h-5.5t-6 0.5t-5 1.5t-5 2t-4 2.5t-4 4t-2.5 4.5q-12 25 5 47l146 183l-86 83zM50 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v500 q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe128;" d="M475 1103l366 -230q2 -1 6 -3.5t14 -10.5t18 -16.5t14.5 -20t6.5 -22.5v-525q0 -13 -86 -94t-93 -81h-342q-15 0 -28.5 20t-19.5 41l-131 339h-106q-85 0 -139.5 39t-54.5 111t54 110t138 38h302l-85 121q-11 15 -10.5 34t13.5 32l110 112q22 22 53 6zM370 945l146 -183 q17 -22 5 -47q-2 -2 -3.5 -4.5t-4 -4t-4 -2.5t-5 -2t-5 -1.5t-6 -0.5h-6h-6.5h-6h-475v-100h221q15 0 29 -20t20 -41l130 -339h294l106 89v503l-342 236zM1050 800h100q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5 v500q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe129;" d="M550 1294q72 0 111 -55t39 -139v-106l339 -131q21 -6 41 -19.5t20 -28.5v-342q0 -7 -81 -90t-94 -83h-525q-17 0 -35.5 14t-28.5 28l-9 14l-230 363q-16 31 6 53l112 110q13 13 32 13.5t34 -11.5l121 -84v302q0 84 38 138t110 54zM600 972v203q0 21 -25 30.5t-50 0.5 t-25 -31v-456v-7v-6v-5.5t-0.5 -6t-1.5 -5t-2 -5t-2.5 -4t-4 -4t-4.5 -2.5q-25 -12 -47 5l-183 146l-83 -86l236 -339h503l89 100v293l-339 131q-21 6 -41 19.5t-20 28.5zM450 200h500q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-500 q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe130;" d="M350 1100h500q21 0 35.5 14.5t14.5 35.5v100q0 21 -14.5 35.5t-35.5 14.5h-500q-21 0 -35.5 -14.5t-14.5 -35.5v-100q0 -21 14.5 -35.5t35.5 -14.5zM600 306v-106q0 -84 -39 -139t-111 -55t-110 54t-38 138v302l-121 -84q-15 -12 -34 -11.5t-32 13.5l-112 110 q-22 22 -6 53l230 363q1 2 3.5 6t10.5 13.5t16.5 17t20 13.5t22.5 6h525q13 0 94 -83t81 -90v-342q0 -15 -20 -28.5t-41 -19.5zM308 900l-236 -339l83 -86l183 146q22 17 47 5q2 -1 4.5 -2.5t4 -4t2.5 -4t2 -5t1.5 -5t0.5 -6v-5.5v-6v-7v-456q0 -22 25 -31t50 0.5t25 30.5 v203q0 15 20 28.5t41 19.5l339 131v293l-89 100h-503z" />
<glyph unicode="&#xe131;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM914 632l-275 223q-16 13 -27.5 8t-11.5 -26v-137h-275 q-10 0 -17.5 -7.5t-7.5 -17.5v-150q0 -10 7.5 -17.5t17.5 -7.5h275v-137q0 -21 11.5 -26t27.5 8l275 223q16 13 16 32t-16 32z" />
<glyph unicode="&#xe132;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM561 855l-275 -223q-16 -13 -16 -32t16 -32l275 -223q16 -13 27.5 -8 t11.5 26v137h275q10 0 17.5 7.5t7.5 17.5v150q0 10 -7.5 17.5t-17.5 7.5h-275v137q0 21 -11.5 26t-27.5 -8z" />
<glyph unicode="&#xe133;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM855 639l-223 275q-13 16 -32 16t-32 -16l-223 -275q-13 -16 -8 -27.5 t26 -11.5h137v-275q0 -10 7.5 -17.5t17.5 -7.5h150q10 0 17.5 7.5t7.5 17.5v275h137q21 0 26 11.5t-8 27.5z" />
<glyph unicode="&#xe134;" d="M600 1178q118 0 225 -45.5t184.5 -123t123 -184.5t45.5 -225t-45.5 -225t-123 -184.5t-184.5 -123t-225 -45.5t-225 45.5t-184.5 123t-123 184.5t-45.5 225t45.5 225t123 184.5t184.5 123t225 45.5zM675 900h-150q-10 0 -17.5 -7.5t-7.5 -17.5v-275h-137q-21 0 -26 -11.5 t8 -27.5l223 -275q13 -16 32 -16t32 16l223 275q13 16 8 27.5t-26 11.5h-137v275q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe135;" d="M600 1176q116 0 222.5 -46t184 -123.5t123.5 -184t46 -222.5t-46 -222.5t-123.5 -184t-184 -123.5t-222.5 -46t-222.5 46t-184 123.5t-123.5 184t-46 222.5t46 222.5t123.5 184t184 123.5t222.5 46zM627 1101q-15 -12 -36.5 -20.5t-35.5 -12t-43 -8t-39 -6.5 q-15 -3 -45.5 0t-45.5 -2q-20 -7 -51.5 -26.5t-34.5 -34.5q-3 -11 6.5 -22.5t8.5 -18.5q-3 -34 -27.5 -91t-29.5 -79q-9 -34 5 -93t8 -87q0 -9 17 -44.5t16 -59.5q12 0 23 -5t23.5 -15t19.5 -14q16 -8 33 -15t40.5 -15t34.5 -12q21 -9 52.5 -32t60 -38t57.5 -11 q7 -15 -3 -34t-22.5 -40t-9.5 -38q13 -21 23 -34.5t27.5 -27.5t36.5 -18q0 -7 -3.5 -16t-3.5 -14t5 -17q104 -2 221 112q30 29 46.5 47t34.5 49t21 63q-13 8 -37 8.5t-36 7.5q-15 7 -49.5 15t-51.5 19q-18 0 -41 -0.5t-43 -1.5t-42 -6.5t-38 -16.5q-51 -35 -66 -12 q-4 1 -3.5 25.5t0.5 25.5q-6 13 -26.5 17.5t-24.5 6.5q1 15 -0.5 30.5t-7 28t-18.5 11.5t-31 -21q-23 -25 -42 4q-19 28 -8 58q6 16 22 22q6 -1 26 -1.5t33.5 -4t19.5 -13.5q7 -12 18 -24t21.5 -20.5t20 -15t15.5 -10.5l5 -3q2 12 7.5 30.5t8 34.5t-0.5 32q-3 18 3.5 29 t18 22.5t15.5 24.5q6 14 10.5 35t8 31t15.5 22.5t34 22.5q-6 18 10 36q8 0 24 -1.5t24.5 -1.5t20 4.5t20.5 15.5q-10 23 -31 42.5t-37.5 29.5t-49 27t-43.5 23q0 1 2 8t3 11.5t1.5 10.5t-1 9.5t-4.5 4.5q31 -13 58.5 -14.5t38.5 2.5l12 5q5 28 -9.5 46t-36.5 24t-50 15 t-41 20q-18 -4 -37 0zM613 994q0 -17 8 -42t17 -45t9 -23q-8 1 -39.5 5.5t-52.5 10t-37 16.5q3 11 16 29.5t16 25.5q10 -10 19 -10t14 6t13.5 14.5t16.5 12.5z" />
<glyph unicode="&#xe136;" d="M756 1157q164 92 306 -9l-259 -138l145 -232l251 126q6 -89 -34 -156.5t-117 -110.5q-60 -34 -127 -39.5t-126 16.5l-596 -596q-15 -16 -36.5 -16t-36.5 16l-111 110q-15 15 -15 36.5t15 37.5l600 599q-34 101 5.5 201.5t135.5 154.5z" />
<glyph unicode="&#xe137;" horiz-adv-x="1220" d="M100 1196h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 1096h-200v-100h200v100zM100 796h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 696h-500v-100h500v100zM100 396h1000q41 0 70.5 -29.5t29.5 -70.5v-100q0 -41 -29.5 -70.5t-70.5 -29.5h-1000q-41 0 -70.5 29.5t-29.5 70.5v100q0 41 29.5 70.5t70.5 29.5zM1100 296h-300v-100h300v100z " />
<glyph unicode="&#xe138;" d="M150 1200h900q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM700 500v-300l-200 -200v500l-350 500h900z" />
<glyph unicode="&#xe139;" d="M500 1200h200q41 0 70.5 -29.5t29.5 -70.5v-100h300q41 0 70.5 -29.5t29.5 -70.5v-400h-500v100h-200v-100h-500v400q0 41 29.5 70.5t70.5 29.5h300v100q0 41 29.5 70.5t70.5 29.5zM500 1100v-100h200v100h-200zM1200 400v-200q0 -41 -29.5 -70.5t-70.5 -29.5h-1000 q-41 0 -70.5 29.5t-29.5 70.5v200h1200z" />
<glyph unicode="&#xe140;" d="M50 1200h300q21 0 25 -10.5t-10 -24.5l-94 -94l199 -199q7 -8 7 -18t-7 -18l-106 -106q-8 -7 -18 -7t-18 7l-199 199l-94 -94q-14 -14 -24.5 -10t-10.5 25v300q0 21 14.5 35.5t35.5 14.5zM850 1200h300q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -10.5 -25t-24.5 10l-94 94 l-199 -199q-8 -7 -18 -7t-18 7l-106 106q-7 8 -7 18t7 18l199 199l-94 94q-14 14 -10 24.5t25 10.5zM364 470l106 -106q7 -8 7 -18t-7 -18l-199 -199l94 -94q14 -14 10 -24.5t-25 -10.5h-300q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 10.5 25t24.5 -10l94 -94l199 199 q8 7 18 7t18 -7zM1071 271l94 94q14 14 24.5 10t10.5 -25v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -25 10.5t10 24.5l94 94l-199 199q-7 8 -7 18t7 18l106 106q8 7 18 7t18 -7z" />
<glyph unicode="&#xe141;" d="M596 1192q121 0 231.5 -47.5t190 -127t127 -190t47.5 -231.5t-47.5 -231.5t-127 -190.5t-190 -127t-231.5 -47t-231.5 47t-190.5 127t-127 190.5t-47 231.5t47 231.5t127 190t190.5 127t231.5 47.5zM596 1010q-112 0 -207.5 -55.5t-151 -151t-55.5 -207.5t55.5 -207.5 t151 -151t207.5 -55.5t207.5 55.5t151 151t55.5 207.5t-55.5 207.5t-151 151t-207.5 55.5zM454.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38.5 -16.5t-38.5 16.5t-16 39t16 38.5t38.5 16zM754.5 905q22.5 0 38.5 -16t16 -38.5t-16 -39t-38 -16.5q-14 0 -29 10l-55 -145 q17 -23 17 -51q0 -36 -25.5 -61.5t-61.5 -25.5t-61.5 25.5t-25.5 61.5q0 32 20.5 56.5t51.5 29.5l122 126l1 1q-9 14 -9 28q0 23 16 39t38.5 16zM345.5 709q22.5 0 38.5 -16t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16zM854.5 709q22.5 0 38.5 -16 t16 -38.5t-16 -38.5t-38.5 -16t-38.5 16t-16 38.5t16 38.5t38.5 16z" />
<glyph unicode="&#xe142;" d="M546 173l469 470q91 91 99 192q7 98 -52 175.5t-154 94.5q-22 4 -47 4q-34 0 -66.5 -10t-56.5 -23t-55.5 -38t-48 -41.5t-48.5 -47.5q-376 -375 -391 -390q-30 -27 -45 -41.5t-37.5 -41t-32 -46.5t-16 -47.5t-1.5 -56.5q9 -62 53.5 -95t99.5 -33q74 0 125 51l548 548 q36 36 20 75q-7 16 -21.5 26t-32.5 10q-26 0 -50 -23q-13 -12 -39 -38l-341 -338q-15 -15 -35.5 -15.5t-34.5 13.5t-14 34.5t14 34.5q327 333 361 367q35 35 67.5 51.5t78.5 16.5q14 0 29 -1q44 -8 74.5 -35.5t43.5 -68.5q14 -47 2 -96.5t-47 -84.5q-12 -11 -32 -32 t-79.5 -81t-114.5 -115t-124.5 -123.5t-123 -119.5t-96.5 -89t-57 -45q-56 -27 -120 -27q-70 0 -129 32t-93 89q-48 78 -35 173t81 163l511 511q71 72 111 96q91 55 198 55q80 0 152 -33q78 -36 129.5 -103t66.5 -154q17 -93 -11 -183.5t-94 -156.5l-482 -476 q-15 -15 -36 -16t-37 14t-17.5 34t14.5 35z" />
<glyph unicode="&#xe143;" d="M649 949q48 68 109.5 104t121.5 38.5t118.5 -20t102.5 -64t71 -100.5t27 -123q0 -57 -33.5 -117.5t-94 -124.5t-126.5 -127.5t-150 -152.5t-146 -174q-62 85 -145.5 174t-150 152.5t-126.5 127.5t-93.5 124.5t-33.5 117.5q0 64 28 123t73 100.5t104 64t119 20 t120.5 -38.5t104.5 -104zM896 972q-33 0 -64.5 -19t-56.5 -46t-47.5 -53.5t-43.5 -45.5t-37.5 -19t-36 19t-40 45.5t-43 53.5t-54 46t-65.5 19q-67 0 -122.5 -55.5t-55.5 -132.5q0 -23 13.5 -51t46 -65t57.5 -63t76 -75l22 -22q15 -14 44 -44t50.5 -51t46 -44t41 -35t23 -12 t23.5 12t42.5 36t46 44t52.5 52t44 43q4 4 12 13q43 41 63.5 62t52 55t46 55t26 46t11.5 44q0 79 -53 133.5t-120 54.5z" />
<glyph unicode="&#xe144;" d="M776.5 1214q93.5 0 159.5 -66l141 -141q66 -66 66 -160q0 -42 -28 -95.5t-62 -87.5l-29 -29q-31 53 -77 99l-18 18l95 95l-247 248l-389 -389l212 -212l-105 -106l-19 18l-141 141q-66 66 -66 159t66 159l283 283q65 66 158.5 66zM600 706l105 105q10 -8 19 -17l141 -141 q66 -66 66 -159t-66 -159l-283 -283q-66 -66 -159 -66t-159 66l-141 141q-66 66 -66 159.5t66 159.5l55 55q29 -55 75 -102l18 -17l-95 -95l247 -248l389 389z" />
<glyph unicode="&#xe145;" d="M603 1200q85 0 162 -15t127 -38t79 -48t29 -46v-953q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-41 0 -70.5 29.5t-29.5 70.5v953q0 21 30 46.5t81 48t129 37.5t163 15zM300 1000v-700h600v700h-600zM600 254q-43 0 -73.5 -30.5t-30.5 -73.5t30.5 -73.5t73.5 -30.5t73.5 30.5 t30.5 73.5t-30.5 73.5t-73.5 30.5z" />
<glyph unicode="&#xe146;" d="M902 1185l283 -282q15 -15 15 -36t-14.5 -35.5t-35.5 -14.5t-35 15l-36 35l-279 -267v-300l-212 210l-308 -307l-280 -203l203 280l307 308l-210 212h300l267 279l-35 36q-15 14 -15 35t14.5 35.5t35.5 14.5t35 -15z" />
<glyph unicode="&#xe148;" d="M700 1248v-78q38 -5 72.5 -14.5t75.5 -31.5t71 -53.5t52 -84t24 -118.5h-159q-4 36 -10.5 59t-21 45t-40 35.5t-64.5 20.5v-307l64 -13q34 -7 64 -16.5t70 -32t67.5 -52.5t47.5 -80t20 -112q0 -139 -89 -224t-244 -97v-77h-100v79q-150 16 -237 103q-40 40 -52.5 93.5 t-15.5 139.5h139q5 -77 48.5 -126t117.5 -65v335l-27 8q-46 14 -79 26.5t-72 36t-63 52t-40 72.5t-16 98q0 70 25 126t67.5 92t94.5 57t110 27v77h100zM600 754v274q-29 -4 -50 -11t-42 -21.5t-31.5 -41.5t-10.5 -65q0 -29 7 -50.5t16.5 -34t28.5 -22.5t31.5 -14t37.5 -10 q9 -3 13 -4zM700 547v-310q22 2 42.5 6.5t45 15.5t41.5 27t29 42t12 59.5t-12.5 59.5t-38 44.5t-53 31t-66.5 24.5z" />
<glyph unicode="&#xe149;" d="M561 1197q84 0 160.5 -40t123.5 -109.5t47 -147.5h-153q0 40 -19.5 71.5t-49.5 48.5t-59.5 26t-55.5 9q-37 0 -79 -14.5t-62 -35.5q-41 -44 -41 -101q0 -26 13.5 -63t26.5 -61t37 -66q6 -9 9 -14h241v-100h-197q8 -50 -2.5 -115t-31.5 -95q-45 -62 -99 -112 q34 10 83 17.5t71 7.5q32 1 102 -16t104 -17q83 0 136 30l50 -147q-31 -19 -58 -30.5t-55 -15.5t-42 -4.5t-46 -0.5q-23 0 -76 17t-111 32.5t-96 11.5q-39 -3 -82 -16t-67 -25l-23 -11l-55 145q4 3 16 11t15.5 10.5t13 9t15.5 12t14.5 14t17.5 18.5q48 55 54 126.5 t-30 142.5h-221v100h166q-23 47 -44 104q-7 20 -12 41.5t-6 55.5t6 66.5t29.5 70.5t58.5 71q97 88 263 88z" />
<glyph unicode="&#xe150;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM935 1184l230 -249q14 -14 10 -24.5t-25 -10.5h-150v-900h-200v900h-150q-21 0 -25 10.5t10 24.5l230 249q14 15 35 15t35 -15z" />
<glyph unicode="&#xe151;" d="M1000 700h-100v100h-100v-100h-100v500h300v-500zM400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM801 1100v-200h100v200h-100zM1000 350l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150z " />
<glyph unicode="&#xe152;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 1050l-200 -250h200v-100h-300v150l200 250h-200v100h300v-150zM1000 0h-100v100h-100v-100h-100v500h300v-500zM801 400v-200h100v200h-100z " />
<glyph unicode="&#xe153;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1000 700h-100v400h-100v100h200v-500zM1100 0h-100v100h-200v400h300v-500zM901 400v-200h100v200h-100z" />
<glyph unicode="&#xe154;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1100 700h-100v100h-200v400h300v-500zM901 1100v-200h100v200h-100zM1000 0h-100v400h-100v100h200v-500z" />
<glyph unicode="&#xe155;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM900 1000h-200v200h200v-200zM1000 700h-300v200h300v-200zM1100 400h-400v200h400v-200zM1200 100h-500v200h500v-200z" />
<glyph unicode="&#xe156;" d="M400 300h150q21 0 25 -11t-10 -25l-230 -250q-14 -15 -35 -15t-35 15l-230 250q-14 14 -10 25t25 11h150v900h200v-900zM1200 1000h-500v200h500v-200zM1100 700h-400v200h400v-200zM1000 400h-300v200h300v-200zM900 100h-200v200h200v-200z" />
<glyph unicode="&#xe157;" d="M350 1100h400q162 0 256 -93.5t94 -256.5v-400q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5z" />
<glyph unicode="&#xe158;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-163 0 -256.5 92.5t-93.5 257.5v400q0 163 94 256.5t256 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM440 770l253 -190q17 -12 17 -30t-17 -30l-253 -190q-16 -12 -28 -6.5t-12 26.5v400q0 21 12 26.5t28 -6.5z" />
<glyph unicode="&#xe159;" d="M350 1100h400q163 0 256.5 -94t93.5 -256v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 163 92.5 256.5t257.5 93.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM350 700h400q21 0 26.5 -12t-6.5 -28l-190 -253q-12 -17 -30 -17t-30 17l-190 253q-12 16 -6.5 28t26.5 12z" />
<glyph unicode="&#xe160;" d="M350 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -163 -92.5 -256.5t-257.5 -93.5h-400q-163 0 -256.5 94t-93.5 256v400q0 165 92.5 257.5t257.5 92.5zM800 900h-500q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5 v500q0 41 -29.5 70.5t-70.5 29.5zM580 693l190 -253q12 -16 6.5 -28t-26.5 -12h-400q-21 0 -26.5 12t6.5 28l190 253q12 17 30 17t30 -17z" />
<glyph unicode="&#xe161;" d="M550 1100h400q165 0 257.5 -92.5t92.5 -257.5v-400q0 -165 -92.5 -257.5t-257.5 -92.5h-400q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h450q41 0 70.5 29.5t29.5 70.5v500q0 41 -29.5 70.5t-70.5 29.5h-450q-21 0 -35.5 14.5t-14.5 35.5v100 q0 21 14.5 35.5t35.5 14.5zM338 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe162;" d="M793 1182l9 -9q8 -10 5 -27q-3 -11 -79 -225.5t-78 -221.5l300 1q24 0 32.5 -17.5t-5.5 -35.5q-1 0 -133.5 -155t-267 -312.5t-138.5 -162.5q-12 -15 -26 -15h-9l-9 8q-9 11 -4 32q2 9 42 123.5t79 224.5l39 110h-302q-23 0 -31 19q-10 21 6 41q75 86 209.5 237.5 t228 257t98.5 111.5q9 16 25 16h9z" />
<glyph unicode="&#xe163;" d="M350 1100h400q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-450q-41 0 -70.5 -29.5t-29.5 -70.5v-500q0 -41 29.5 -70.5t70.5 -29.5h450q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400 q0 165 92.5 257.5t257.5 92.5zM938 867l324 -284q16 -14 16 -33t-16 -33l-324 -284q-16 -14 -27 -9t-11 26v150h-250q-21 0 -35.5 14.5t-14.5 35.5v200q0 21 14.5 35.5t35.5 14.5h250v150q0 21 11 26t27 -9z" />
<glyph unicode="&#xe164;" d="M750 1200h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -10.5 -25t-24.5 10l-109 109l-312 -312q-15 -15 -35.5 -15t-35.5 15l-141 141q-15 15 -15 35.5t15 35.5l312 312l-109 109q-14 14 -10 24.5t25 10.5zM456 900h-156q-41 0 -70.5 -29.5t-29.5 -70.5v-500 q0 -41 29.5 -70.5t70.5 -29.5h500q41 0 70.5 29.5t29.5 70.5v148l200 200v-298q0 -165 -93.5 -257.5t-256.5 -92.5h-400q-165 0 -257.5 92.5t-92.5 257.5v400q0 165 92.5 257.5t257.5 92.5h300z" />
<glyph unicode="&#xe165;" d="M600 1186q119 0 227.5 -46.5t187 -125t125 -187t46.5 -227.5t-46.5 -227.5t-125 -187t-187 -125t-227.5 -46.5t-227.5 46.5t-187 125t-125 187t-46.5 227.5t46.5 227.5t125 187t187 125t227.5 46.5zM600 1022q-115 0 -212 -56.5t-153.5 -153.5t-56.5 -212t56.5 -212 t153.5 -153.5t212 -56.5t212 56.5t153.5 153.5t56.5 212t-56.5 212t-153.5 153.5t-212 56.5zM600 794q80 0 137 -57t57 -137t-57 -137t-137 -57t-137 57t-57 137t57 137t137 57z" />
<glyph unicode="&#xe166;" d="M450 1200h200q21 0 35.5 -14.5t14.5 -35.5v-350h245q20 0 25 -11t-9 -26l-383 -426q-14 -15 -33.5 -15t-32.5 15l-379 426q-13 15 -8.5 26t25.5 11h250v350q0 21 14.5 35.5t35.5 14.5zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe167;" d="M583 1182l378 -435q14 -15 9 -31t-26 -16h-244v-250q0 -20 -17 -35t-39 -15h-200q-20 0 -32 14.5t-12 35.5v250h-250q-20 0 -25.5 16.5t8.5 31.5l383 431q14 16 33.5 17t33.5 -14zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5z M900 200v-50h100v50h-100z" />
<glyph unicode="&#xe168;" d="M396 723l369 369q7 7 17.5 7t17.5 -7l139 -139q7 -8 7 -18.5t-7 -17.5l-525 -525q-7 -8 -17.5 -8t-17.5 8l-292 291q-7 8 -7 18t7 18l139 139q8 7 18.5 7t17.5 -7zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50 h-100z" />
<glyph unicode="&#xe169;" d="M135 1023l142 142q14 14 35 14t35 -14l77 -77l-212 -212l-77 76q-14 15 -14 36t14 35zM655 855l210 210q14 14 24.5 10t10.5 -25l-2 -599q-1 -20 -15.5 -35t-35.5 -15l-597 -1q-21 0 -25 10.5t10 24.5l208 208l-154 155l212 212zM50 300h1000q21 0 35.5 -14.5t14.5 -35.5 v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe170;" d="M350 1200l599 -2q20 -1 35 -15.5t15 -35.5l1 -597q0 -21 -10.5 -25t-24.5 10l-208 208l-155 -154l-212 212l155 154l-210 210q-14 14 -10 24.5t25 10.5zM524 512l-76 -77q-15 -14 -36 -14t-35 14l-142 142q-14 14 -14 35t14 35l77 77zM50 300h1000q21 0 35.5 -14.5 t14.5 -35.5v-250h-1100v250q0 21 14.5 35.5t35.5 14.5zM900 200v-50h100v50h-100z" />
<glyph unicode="&#xe171;" d="M1200 103l-483 276l-314 -399v423h-399l1196 796v-1096zM483 424v-230l683 953z" />
<glyph unicode="&#xe172;" d="M1100 1000v-850q0 -21 -14.5 -35.5t-35.5 -14.5h-150v400h-700v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200z" />
<glyph unicode="&#xe173;" d="M1100 1000l-2 -149l-299 -299l-95 95q-9 9 -21.5 9t-21.5 -9l-149 -147h-312v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1132 638l106 -106q7 -7 7 -17.5t-7 -17.5l-420 -421q-8 -7 -18 -7 t-18 7l-202 203q-8 7 -8 17.5t8 17.5l106 106q7 8 17.5 8t17.5 -8l79 -79l297 297q7 7 17.5 7t17.5 -7z" />
<glyph unicode="&#xe174;" d="M1100 1000v-269l-103 -103l-134 134q-15 15 -33.5 16.5t-34.5 -12.5l-266 -266h-329v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM1202 572l70 -70q15 -15 15 -35.5t-15 -35.5l-131 -131 l131 -131q15 -15 15 -35.5t-15 -35.5l-70 -70q-15 -15 -35.5 -15t-35.5 15l-131 131l-131 -131q-15 -15 -35.5 -15t-35.5 15l-70 70q-15 15 -15 35.5t15 35.5l131 131l-131 131q-15 15 -15 35.5t15 35.5l70 70q15 15 35.5 15t35.5 -15l131 -131l131 131q15 15 35.5 15 t35.5 -15z" />
<glyph unicode="&#xe175;" d="M1100 1000v-300h-350q-21 0 -35.5 -14.5t-14.5 -35.5v-150h-500v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM850 600h100q21 0 35.5 -14.5t14.5 -35.5v-250h150q21 0 25 -10.5t-10 -24.5 l-230 -230q-14 -14 -35 -14t-35 14l-230 230q-14 14 -10 24.5t25 10.5h150v250q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe176;" d="M1100 1000v-400l-165 165q-14 15 -35 15t-35 -15l-263 -265h-402v-400h-150q-21 0 -35.5 14.5t-14.5 35.5v1000q0 20 14.5 35t35.5 15h250v-300h500v300h100zM700 1000h-100v200h100v-200zM935 565l230 -229q14 -15 10 -25.5t-25 -10.5h-150v-250q0 -20 -14.5 -35 t-35.5 -15h-100q-21 0 -35.5 15t-14.5 35v250h-150q-21 0 -25 10.5t10 25.5l230 229q14 15 35 15t35 -15z" />
<glyph unicode="&#xe177;" d="M50 1100h1100q21 0 35.5 -14.5t14.5 -35.5v-150h-1200v150q0 21 14.5 35.5t35.5 14.5zM1200 800v-550q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v550h1200zM100 500v-200h400v200h-400z" />
<glyph unicode="&#xe178;" d="M935 1165l248 -230q14 -14 14 -35t-14 -35l-248 -230q-14 -14 -24.5 -10t-10.5 25v150h-400v200h400v150q0 21 10.5 25t24.5 -10zM200 800h-50q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v-200zM400 800h-100v200h100v-200zM18 435l247 230 q14 14 24.5 10t10.5 -25v-150h400v-200h-400v-150q0 -21 -10.5 -25t-24.5 10l-247 230q-15 14 -15 35t15 35zM900 300h-100v200h100v-200zM1000 500h51q20 0 34.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-34.5 -14.5h-51v200z" />
<glyph unicode="&#xe179;" d="M862 1073l276 116q25 18 43.5 8t18.5 -41v-1106q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v397q-4 1 -11 5t-24 17.5t-30 29t-24 42t-11 56.5v359q0 31 18.5 65t43.5 52zM550 1200q22 0 34.5 -12.5t14.5 -24.5l1 -13v-450q0 -28 -10.5 -59.5 t-25 -56t-29 -45t-25.5 -31.5l-10 -11v-447q0 -21 -14.5 -35.5t-35.5 -14.5h-200q-21 0 -35.5 14.5t-14.5 35.5v447q-4 4 -11 11.5t-24 30.5t-30 46t-24 55t-11 60v450q0 2 0.5 5.5t4 12t8.5 15t14.5 12t22.5 5.5q20 0 32.5 -12.5t14.5 -24.5l3 -13v-350h100v350v5.5t2.5 12 t7 15t15 12t25.5 5.5q23 0 35.5 -12.5t13.5 -24.5l1 -13v-350h100v350q0 2 0.5 5.5t3 12t7 15t15 12t24.5 5.5z" />
<glyph unicode="&#xe180;" d="M1200 1100v-56q-4 0 -11 -0.5t-24 -3t-30 -7.5t-24 -15t-11 -24v-888q0 -22 25 -34.5t50 -13.5l25 -2v-56h-400v56q75 0 87.5 6.5t12.5 43.5v394h-500v-394q0 -37 12.5 -43.5t87.5 -6.5v-56h-400v56q4 0 11 0.5t24 3t30 7.5t24 15t11 24v888q0 22 -25 34.5t-50 13.5 l-25 2v56h400v-56q-75 0 -87.5 -6.5t-12.5 -43.5v-394h500v394q0 37 -12.5 43.5t-87.5 6.5v56h400z" />
<glyph unicode="&#xe181;" d="M675 1000h375q21 0 35.5 -14.5t14.5 -35.5v-150h-105l-295 -98v98l-200 200h-400l100 100h375zM100 900h300q41 0 70.5 -29.5t29.5 -70.5v-500q0 -41 -29.5 -70.5t-70.5 -29.5h-300q-41 0 -70.5 29.5t-29.5 70.5v500q0 41 29.5 70.5t70.5 29.5zM100 800v-200h300v200 h-300zM1100 535l-400 -133v163l400 133v-163zM100 500v-200h300v200h-300zM1100 398v-248q0 -21 -14.5 -35.5t-35.5 -14.5h-375l-100 -100h-375l-100 100h400l200 200h105z" />
<glyph unicode="&#xe182;" d="M17 1007l162 162q17 17 40 14t37 -22l139 -194q14 -20 11 -44.5t-20 -41.5l-119 -118q102 -142 228 -268t267 -227l119 118q17 17 42.5 19t44.5 -12l192 -136q19 -14 22.5 -37.5t-13.5 -40.5l-163 -162q-3 -1 -9.5 -1t-29.5 2t-47.5 6t-62.5 14.5t-77.5 26.5t-90 42.5 t-101.5 60t-111 83t-119 108.5q-74 74 -133.5 150.5t-94.5 138.5t-60 119.5t-34.5 100t-15 74.5t-4.5 48z" />
<glyph unicode="&#xe183;" d="M600 1100q92 0 175 -10.5t141.5 -27t108.5 -36.5t81.5 -40t53.5 -37t31 -27l9 -10v-200q0 -21 -14.5 -33t-34.5 -9l-202 34q-20 3 -34.5 20t-14.5 38v146q-141 24 -300 24t-300 -24v-146q0 -21 -14.5 -38t-34.5 -20l-202 -34q-20 -3 -34.5 9t-14.5 33v200q3 4 9.5 10.5 t31 26t54 37.5t80.5 39.5t109 37.5t141 26.5t175 10.5zM600 795q56 0 97 -9.5t60 -23.5t30 -28t12 -24l1 -10v-50l365 -303q14 -15 24.5 -40t10.5 -45v-212q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v212q0 20 10.5 45t24.5 40l365 303v50 q0 4 1 10.5t12 23t30 29t60 22.5t97 10z" />
<glyph unicode="&#xe184;" d="M1100 700l-200 -200h-600l-200 200v500h200v-200h200v200h200v-200h200v200h200v-500zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5 t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe185;" d="M700 1100h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-1000h300v1000q0 41 -29.5 70.5t-70.5 29.5zM1100 800h-100q-41 0 -70.5 -29.5t-29.5 -70.5v-700h300v700q0 41 -29.5 70.5t-70.5 29.5zM400 0h-300v400q0 41 29.5 70.5t70.5 29.5h100q41 0 70.5 -29.5t29.5 -70.5v-400z " />
<glyph unicode="&#xe186;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe187;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 300h-100v200h-100v-200h-100v500h100v-200h100v200h100v-500zM900 700v-300l-100 -100h-200v500h200z M700 700v-300h100v300h-100z" />
<glyph unicode="&#xe188;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-300h200v-100h-300v500h300v-100zM900 700h-200v-300h200v-100h-300v500h300v-100z" />
<glyph unicode="&#xe189;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 400l-300 150l300 150v-300zM900 550l-300 -150v300z" />
<glyph unicode="&#xe190;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM900 300h-700v500h700v-500zM800 700h-130q-38 0 -66.5 -43t-28.5 -108t27 -107t68 -42h130v300zM300 700v-300 h130q41 0 68 42t27 107t-28.5 108t-66.5 43h-130z" />
<glyph unicode="&#xe191;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 700h-200v-100h200v-300h-300v100h200v100h-200v300h300v-100zM900 300h-100v400h-100v100h200v-500z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe192;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM300 700h200v-400h-300v500h100v-100zM900 300h-100v400h-100v100h200v-500zM300 600v-200h100v200h-100z M700 300h-100v100h100v-100z" />
<glyph unicode="&#xe193;" d="M200 1100h700q124 0 212 -88t88 -212v-500q0 -124 -88 -212t-212 -88h-700q-124 0 -212 88t-88 212v500q0 124 88 212t212 88zM100 900v-700h900v700h-900zM500 500l-199 -200h-100v50l199 200v150h-200v100h300v-300zM900 300h-100v400h-100v100h200v-500zM701 300h-100 v100h100v-100z" />
<glyph unicode="&#xe194;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700h-300v-200h300v-100h-300l-100 100v200l100 100h300v-100z" />
<glyph unicode="&#xe195;" d="M600 1191q120 0 229.5 -47t188.5 -126t126 -188.5t47 -229.5t-47 -229.5t-126 -188.5t-188.5 -126t-229.5 -47t-229.5 47t-188.5 126t-126 188.5t-47 229.5t47 229.5t126 188.5t188.5 126t229.5 47zM600 1021q-114 0 -211 -56.5t-153.5 -153.5t-56.5 -211t56.5 -211 t153.5 -153.5t211 -56.5t211 56.5t153.5 153.5t56.5 211t-56.5 211t-153.5 153.5t-211 56.5zM800 700v-100l-50 -50l100 -100v-50h-100l-100 100h-150v-100h-100v400h300zM500 700v-100h200v100h-200z" />
<glyph unicode="&#xe197;" d="M503 1089q110 0 200.5 -59.5t134.5 -156.5q44 14 90 14q120 0 205 -86.5t85 -207t-85 -207t-205 -86.5h-128v250q0 21 -14.5 35.5t-35.5 14.5h-300q-21 0 -35.5 -14.5t-14.5 -35.5v-250h-222q-80 0 -136 57.5t-56 136.5q0 69 43 122.5t108 67.5q-2 19 -2 37q0 100 49 185 t134 134t185 49zM525 500h150q10 0 17.5 -7.5t7.5 -17.5v-275h137q21 0 26 -11.5t-8 -27.5l-223 -244q-13 -16 -32 -16t-32 16l-223 244q-13 16 -8 27.5t26 11.5h137v275q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe198;" d="M502 1089q110 0 201 -59.5t135 -156.5q43 15 89 15q121 0 206 -86.5t86 -206.5q0 -99 -60 -181t-150 -110l-378 360q-13 16 -31.5 16t-31.5 -16l-381 -365h-9q-79 0 -135.5 57.5t-56.5 136.5q0 69 43 122.5t108 67.5q-2 19 -2 38q0 100 49 184.5t133.5 134t184.5 49.5z M632 467l223 -228q13 -16 8 -27.5t-26 -11.5h-137v-275q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v275h-137q-21 0 -26 11.5t8 27.5q199 204 223 228q19 19 31.5 19t32.5 -19z" />
<glyph unicode="&#xe199;" d="M700 100v100h400l-270 300h170l-270 300h170l-300 333l-300 -333h170l-270 -300h170l-270 -300h400v-100h-50q-21 0 -35.5 -14.5t-14.5 -35.5v-50h400v50q0 21 -14.5 35.5t-35.5 14.5h-50z" />
<glyph unicode="&#xe200;" d="M600 1179q94 0 167.5 -56.5t99.5 -145.5q89 -6 150.5 -71.5t61.5 -155.5q0 -61 -29.5 -112.5t-79.5 -82.5q9 -29 9 -55q0 -74 -52.5 -126.5t-126.5 -52.5q-55 0 -100 30v-251q21 0 35.5 -14.5t14.5 -35.5v-50h-300v50q0 21 14.5 35.5t35.5 14.5v251q-45 -30 -100 -30 q-74 0 -126.5 52.5t-52.5 126.5q0 18 4 38q-47 21 -75.5 65t-28.5 97q0 74 52.5 126.5t126.5 52.5q5 0 23 -2q0 2 -1 10t-1 13q0 116 81.5 197.5t197.5 81.5z" />
<glyph unicode="&#xe201;" d="M1010 1010q111 -111 150.5 -260.5t0 -299t-150.5 -260.5q-83 -83 -191.5 -126.5t-218.5 -43.5t-218.5 43.5t-191.5 126.5q-111 111 -150.5 260.5t0 299t150.5 260.5q83 83 191.5 126.5t218.5 43.5t218.5 -43.5t191.5 -126.5zM476 1065q-4 0 -8 -1q-121 -34 -209.5 -122.5 t-122.5 -209.5q-4 -12 2.5 -23t18.5 -14l36 -9q3 -1 7 -1q23 0 29 22q27 96 98 166q70 71 166 98q11 3 17.5 13.5t3.5 22.5l-9 35q-3 13 -14 19q-7 4 -15 4zM512 920q-4 0 -9 -2q-80 -24 -138.5 -82.5t-82.5 -138.5q-4 -13 2 -24t19 -14l34 -9q4 -1 8 -1q22 0 28 21 q18 58 58.5 98.5t97.5 58.5q12 3 18 13.5t3 21.5l-9 35q-3 12 -14 19q-7 4 -15 4zM719.5 719.5q-49.5 49.5 -119.5 49.5t-119.5 -49.5t-49.5 -119.5t49.5 -119.5t119.5 -49.5t119.5 49.5t49.5 119.5t-49.5 119.5zM855 551q-22 0 -28 -21q-18 -58 -58.5 -98.5t-98.5 -57.5 q-11 -4 -17 -14.5t-3 -21.5l9 -35q3 -12 14 -19q7 -4 15 -4q4 0 9 2q80 24 138.5 82.5t82.5 138.5q4 13 -2.5 24t-18.5 14l-34 9q-4 1 -8 1zM1000 515q-23 0 -29 -22q-27 -96 -98 -166q-70 -71 -166 -98q-11 -3 -17.5 -13.5t-3.5 -22.5l9 -35q3 -13 14 -19q7 -4 15 -4 q4 0 8 1q121 34 209.5 122.5t122.5 209.5q4 12 -2.5 23t-18.5 14l-36 9q-3 1 -7 1z" />
<glyph unicode="&#xe202;" d="M700 800h300v-380h-180v200h-340v-200h-380v755q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM700 300h162l-212 -212l-212 212h162v200h100v-200zM520 0h-395q-10 0 -17.5 7.5t-7.5 17.5v395zM1000 220v-195q0 -10 -7.5 -17.5t-17.5 -7.5h-195z" />
<glyph unicode="&#xe203;" d="M700 800h300v-520l-350 350l-550 -550v1095q0 10 7.5 17.5t17.5 7.5h575v-400zM1000 900h-200v200zM862 200h-162v-200h-100v200h-162l212 212zM480 0h-355q-10 0 -17.5 7.5t-7.5 17.5v55h380v-80zM1000 80v-55q0 -10 -7.5 -17.5t-17.5 -7.5h-155v80h180z" />
<glyph unicode="&#xe204;" d="M1162 800h-162v-200h100l100 -100h-300v300h-162l212 212zM200 800h200q27 0 40 -2t29.5 -10.5t23.5 -30t7 -57.5h300v-100h-600l-200 -350v450h100q0 36 7 57.5t23.5 30t29.5 10.5t40 2zM800 400h240l-240 -400h-800l300 500h500v-100z" />
<glyph unicode="&#xe205;" d="M650 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM1000 850v150q41 0 70.5 -29.5t29.5 -70.5v-800 q0 -41 -29.5 -70.5t-70.5 -29.5h-600q-1 0 -20 4l246 246l-326 326v324q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM412 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe206;" d="M450 1100h100q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-300q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h50v50q0 21 14.5 35.5t35.5 14.5zM800 850v150q41 0 70.5 -29.5t29.5 -70.5v-500 h-200v-300h200q0 -36 -7 -57.5t-23.5 -30t-29.5 -10.5t-40 -2h-600q-41 0 -70.5 29.5t-29.5 70.5v800q0 41 29.5 70.5t70.5 29.5v-150q0 -62 44 -106t106 -44h300q62 0 106 44t44 106zM1212 250l-212 -212v162h-200v100h200v162z" />
<glyph unicode="&#xe209;" d="M658 1197l637 -1104q23 -38 7 -65.5t-60 -27.5h-1276q-44 0 -60 27.5t7 65.5l637 1104q22 39 54 39t54 -39zM704 800h-208q-20 0 -32 -14.5t-8 -34.5l58 -302q4 -20 21.5 -34.5t37.5 -14.5h54q20 0 37.5 14.5t21.5 34.5l58 302q4 20 -8 34.5t-32 14.5zM500 300v-100h200 v100h-200z" />
<glyph unicode="&#xe210;" d="M425 1100h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM825 800h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM25 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5zM425 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 500h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5 v150q0 10 7.5 17.5t17.5 7.5zM25 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM425 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5 t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM825 200h250q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-250q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe211;" d="M700 1200h100v-200h-100v-100h350q62 0 86.5 -39.5t-3.5 -94.5l-66 -132q-41 -83 -81 -134h-772q-40 51 -81 134l-66 132q-28 55 -3.5 94.5t86.5 39.5h350v100h-100v200h100v100h200v-100zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-12l137 -100 h-950l138 100h-13q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe212;" d="M600 1300q40 0 68.5 -29.5t28.5 -70.5h-194q0 41 28.5 70.5t68.5 29.5zM443 1100h314q18 -37 18 -75q0 -8 -3 -25h328q41 0 44.5 -16.5t-30.5 -38.5l-175 -145h-678l-178 145q-34 22 -29 38.5t46 16.5h328q-3 17 -3 25q0 38 18 75zM250 700h700q21 0 35.5 -14.5 t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-150v-200l275 -200h-950l275 200v200h-150q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe213;" d="M600 1181q75 0 128 -53t53 -128t-53 -128t-128 -53t-128 53t-53 128t53 128t128 53zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13 l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe214;" d="M600 1300q47 0 92.5 -53.5t71 -123t25.5 -123.5q0 -78 -55.5 -133.5t-133.5 -55.5t-133.5 55.5t-55.5 133.5q0 62 34 143l144 -143l111 111l-163 163q34 26 63 26zM602 798h46q34 0 55.5 -28.5t21.5 -86.5q0 -76 39 -183h-324q39 107 39 183q0 58 21.5 86.5t56.5 28.5h45 zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe215;" d="M600 1200l300 -161v-139h-300q0 -57 18.5 -108t50 -91.5t63 -72t70 -67.5t57.5 -61h-530q-60 83 -90.5 177.5t-30.5 178.5t33 164.5t87.5 139.5t126 96.5t145.5 41.5v-98zM250 400h700q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-13l138 -100h-950l137 100 h-12q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5zM50 100h1100q21 0 35.5 -14.5t14.5 -35.5v-50h-1200v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe216;" d="M600 1300q41 0 70.5 -29.5t29.5 -70.5v-78q46 -26 73 -72t27 -100v-50h-400v50q0 54 27 100t73 72v78q0 41 29.5 70.5t70.5 29.5zM400 800h400q54 0 100 -27t72 -73h-172v-100h200v-100h-200v-100h200v-100h-200v-100h200q0 -83 -58.5 -141.5t-141.5 -58.5h-400 q-83 0 -141.5 58.5t-58.5 141.5v400q0 83 58.5 141.5t141.5 58.5z" />
<glyph unicode="&#xe218;" d="M150 1100h900q21 0 35.5 -14.5t14.5 -35.5v-500q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v500q0 21 14.5 35.5t35.5 14.5zM125 400h950q10 0 17.5 -7.5t7.5 -17.5v-50q0 -10 -7.5 -17.5t-17.5 -7.5h-283l224 -224q13 -13 13 -31.5t-13 -32 t-31.5 -13.5t-31.5 13l-88 88h-524l-87 -88q-13 -13 -32 -13t-32 13.5t-13 32t13 31.5l224 224h-289q-10 0 -17.5 7.5t-7.5 17.5v50q0 10 7.5 17.5t17.5 7.5zM541 300l-100 -100h324l-100 100h-124z" />
<glyph unicode="&#xe219;" d="M200 1100h800q83 0 141.5 -58.5t58.5 -141.5v-200h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100q0 41 -29.5 70.5t-70.5 29.5h-250q-41 0 -70.5 -29.5t-29.5 -70.5h-100v200q0 83 58.5 141.5t141.5 58.5zM100 600h1000q41 0 70.5 -29.5 t29.5 -70.5v-300h-1200v300q0 41 29.5 70.5t70.5 29.5zM300 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200zM1100 100v-50q0 -21 -14.5 -35.5t-35.5 -14.5h-100q-21 0 -35.5 14.5t-14.5 35.5v50h200z" />
<glyph unicode="&#xe221;" d="M480 1165l682 -683q31 -31 31 -75.5t-31 -75.5l-131 -131h-481l-517 518q-32 31 -32 75.5t32 75.5l295 296q31 31 75.5 31t76.5 -31zM108 794l342 -342l303 304l-341 341zM250 100h800q21 0 35.5 -14.5t14.5 -35.5v-50h-900v50q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe223;" d="M1057 647l-189 506q-8 19 -27.5 33t-40.5 14h-400q-21 0 -40.5 -14t-27.5 -33l-189 -506q-8 -19 1.5 -33t30.5 -14h625v-150q0 -21 14.5 -35.5t35.5 -14.5t35.5 14.5t14.5 35.5v150h125q21 0 30.5 14t1.5 33zM897 0h-595v50q0 21 14.5 35.5t35.5 14.5h50v50 q0 21 14.5 35.5t35.5 14.5h48v300h200v-300h47q21 0 35.5 -14.5t14.5 -35.5v-50h50q21 0 35.5 -14.5t14.5 -35.5v-50z" />
<glyph unicode="&#xe224;" d="M900 800h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-375v591l-300 300v84q0 10 7.5 17.5t17.5 7.5h375v-400zM1200 900h-200v200zM400 600h300v-575q0 -10 -7.5 -17.5t-17.5 -7.5h-650q-10 0 -17.5 7.5t-7.5 17.5v950q0 10 7.5 17.5t17.5 7.5h375v-400zM700 700h-200v200z " />
<glyph unicode="&#xe225;" d="M484 1095h195q75 0 146 -32.5t124 -86t89.5 -122.5t48.5 -142q18 -14 35 -20q31 -10 64.5 6.5t43.5 48.5q10 34 -15 71q-19 27 -9 43q5 8 12.5 11t19 -1t23.5 -16q41 -44 39 -105q-3 -63 -46 -106.5t-104 -43.5h-62q-7 -55 -35 -117t-56 -100l-39 -234q-3 -20 -20 -34.5 t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l12 70q-49 -14 -91 -14h-195q-24 0 -65 8l-11 -64q-3 -20 -20 -34.5t-38 -14.5h-100q-21 0 -33 14.5t-9 34.5l26 157q-84 74 -128 175l-159 53q-19 7 -33 26t-14 40v50q0 21 14.5 35.5t35.5 14.5h124q11 87 56 166l-111 95 q-16 14 -12.5 23.5t24.5 9.5h203q116 101 250 101zM675 1000h-250q-10 0 -17.5 -7.5t-7.5 -17.5v-50q0 -10 7.5 -17.5t17.5 -7.5h250q10 0 17.5 7.5t7.5 17.5v50q0 10 -7.5 17.5t-17.5 7.5z" />
<glyph unicode="&#xe226;" d="M641 900l423 247q19 8 42 2.5t37 -21.5l32 -38q14 -15 12.5 -36t-17.5 -34l-139 -120h-390zM50 1100h106q67 0 103 -17t66 -71l102 -212h823q21 0 35.5 -14.5t14.5 -35.5v-50q0 -21 -14 -40t-33 -26l-737 -132q-23 -4 -40 6t-26 25q-42 67 -100 67h-300q-62 0 -106 44 t-44 106v200q0 62 44 106t106 44zM173 928h-80q-19 0 -28 -14t-9 -35v-56q0 -51 42 -51h134q16 0 21.5 8t5.5 24q0 11 -16 45t-27 51q-18 28 -43 28zM550 727q-32 0 -54.5 -22.5t-22.5 -54.5t22.5 -54.5t54.5 -22.5t54.5 22.5t22.5 54.5t-22.5 54.5t-54.5 22.5zM130 389 l152 130q18 19 34 24t31 -3.5t24.5 -17.5t25.5 -28q28 -35 50.5 -51t48.5 -13l63 5l48 -179q13 -61 -3.5 -97.5t-67.5 -79.5l-80 -69q-47 -40 -109 -35.5t-103 51.5l-130 151q-40 47 -35.5 109.5t51.5 102.5zM380 377l-102 -88q-31 -27 2 -65l37 -43q13 -15 27.5 -19.5 t31.5 6.5l61 53q19 16 14 49q-2 20 -12 56t-17 45q-11 12 -19 14t-23 -8z" />
<glyph unicode="&#xe227;" d="M625 1200h150q10 0 17.5 -7.5t7.5 -17.5v-109q79 -33 131 -87.5t53 -128.5q1 -46 -15 -84.5t-39 -61t-46 -38t-39 -21.5l-17 -6q6 0 15 -1.5t35 -9t50 -17.5t53 -30t50 -45t35.5 -64t14.5 -84q0 -59 -11.5 -105.5t-28.5 -76.5t-44 -51t-49.5 -31.5t-54.5 -16t-49.5 -6.5 t-43.5 -1v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-100v-75q0 -10 -7.5 -17.5t-17.5 -7.5h-150q-10 0 -17.5 7.5t-7.5 17.5v75h-175q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5h75v600h-75q-10 0 -17.5 7.5t-7.5 17.5v150 q0 10 7.5 17.5t17.5 7.5h175v75q0 10 7.5 17.5t17.5 7.5h150q10 0 17.5 -7.5t7.5 -17.5v-75h100v75q0 10 7.5 17.5t17.5 7.5zM400 900v-200h263q28 0 48.5 10.5t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-263zM400 500v-200h363q28 0 48.5 10.5 t30 25t15 29t5.5 25.5l1 10q0 4 -0.5 11t-6 24t-15 30t-30 24t-48.5 11h-363z" />
<glyph unicode="&#xe230;" d="M212 1198h780q86 0 147 -61t61 -147v-416q0 -51 -18 -142.5t-36 -157.5l-18 -66q-29 -87 -93.5 -146.5t-146.5 -59.5h-572q-82 0 -147 59t-93 147q-8 28 -20 73t-32 143.5t-20 149.5v416q0 86 61 147t147 61zM600 1045q-70 0 -132.5 -11.5t-105.5 -30.5t-78.5 -41.5 t-57 -45t-36 -41t-20.5 -30.5l-6 -12l156 -243h560l156 243q-2 5 -6 12.5t-20 29.5t-36.5 42t-57 44.5t-79 42t-105 29.5t-132.5 12zM762 703h-157l195 261z" />
<glyph unicode="&#xe231;" d="M475 1300h150q103 0 189 -86t86 -189v-500q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe232;" d="M475 1300h96q0 -150 89.5 -239.5t239.5 -89.5v-446q0 -41 -42 -83t-83 -42h-450q-41 0 -83 42t-42 83v500q0 103 86 189t189 86zM700 300v-225q0 -21 -27 -48t-48 -27h-150q-21 0 -48 27t-27 48v225h300z" />
<glyph unicode="&#xe233;" d="M1294 767l-638 -283l-378 170l-78 -60v-224l100 -150v-199l-150 148l-150 -149v200l100 150v250q0 4 -0.5 10.5t0 9.5t1 8t3 8t6.5 6l47 40l-147 65l642 283zM1000 380l-350 -166l-350 166v147l350 -165l350 165v-147z" />
<glyph unicode="&#xe234;" d="M250 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM650 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM1050 800q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe235;" d="M550 1100q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 700q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44zM550 300q62 0 106 -44t44 -106t-44 -106t-106 -44t-106 44t-44 106t44 106t106 44z" />
<glyph unicode="&#xe236;" d="M125 1100h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5zM125 700h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5 t17.5 7.5zM125 300h950q10 0 17.5 -7.5t7.5 -17.5v-150q0 -10 -7.5 -17.5t-17.5 -7.5h-950q-10 0 -17.5 7.5t-7.5 17.5v150q0 10 7.5 17.5t17.5 7.5z" />
<glyph unicode="&#xe237;" d="M350 1200h500q162 0 256 -93.5t94 -256.5v-500q0 -165 -93.5 -257.5t-256.5 -92.5h-500q-165 0 -257.5 92.5t-92.5 257.5v500q0 165 92.5 257.5t257.5 92.5zM900 1000h-600q-41 0 -70.5 -29.5t-29.5 -70.5v-600q0 -41 29.5 -70.5t70.5 -29.5h600q41 0 70.5 29.5 t29.5 70.5v600q0 41 -29.5 70.5t-70.5 29.5zM350 900h500q21 0 35.5 -14.5t14.5 -35.5v-300q0 -21 -14.5 -35.5t-35.5 -14.5h-500q-21 0 -35.5 14.5t-14.5 35.5v300q0 21 14.5 35.5t35.5 14.5zM400 800v-200h400v200h-400z" />
<glyph unicode="&#xe238;" d="M150 1100h1000q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5t-35.5 -14.5h-50v-200h50q21 0 35.5 -14.5t14.5 -35.5t-14.5 -35.5 t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5h50v200h-50q-21 0 -35.5 14.5t-14.5 35.5t14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe239;" d="M650 1187q87 -67 118.5 -156t0 -178t-118.5 -155q-87 66 -118.5 155t0 178t118.5 156zM300 800q124 0 212 -88t88 -212q-124 0 -212 88t-88 212zM1000 800q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM300 500q124 0 212 -88t88 -212q-124 0 -212 88t-88 212z M1000 500q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM700 199v-144q0 -21 -14.5 -35.5t-35.5 -14.5t-35.5 14.5t-14.5 35.5v142q40 -4 43 -4q17 0 57 6z" />
<glyph unicode="&#xe240;" d="M745 878l69 19q25 6 45 -12l298 -295q11 -11 15 -26.5t-2 -30.5q-5 -14 -18 -23.5t-28 -9.5h-8q1 0 1 -13q0 -29 -2 -56t-8.5 -62t-20 -63t-33 -53t-51 -39t-72.5 -14h-146q-184 0 -184 288q0 24 10 47q-20 4 -62 4t-63 -4q11 -24 11 -47q0 -288 -184 -288h-142 q-48 0 -84.5 21t-56 51t-32 71.5t-16 75t-3.5 68.5q0 13 2 13h-7q-15 0 -27.5 9.5t-18.5 23.5q-6 15 -2 30.5t15 25.5l298 296q20 18 46 11l76 -19q20 -5 30.5 -22.5t5.5 -37.5t-22.5 -31t-37.5 -5l-51 12l-182 -193h891l-182 193l-44 -12q-20 -5 -37.5 6t-22.5 31t6 37.5 t31 22.5z" />
<glyph unicode="&#xe241;" d="M1200 900h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-200v-850q0 -22 25 -34.5t50 -13.5l25 -2v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v850h-200q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h1000v-300zM500 450h-25q0 15 -4 24.5t-9 14.5t-17 7.5t-20 3t-25 0.5h-100v-425q0 -11 12.5 -17.5t25.5 -7.5h12v-50h-200v50q50 0 50 25v425h-100q-17 0 -25 -0.5t-20 -3t-17 -7.5t-9 -14.5t-4 -24.5h-25v150h500v-150z" />
<glyph unicode="&#xe242;" d="M1000 300v50q-25 0 -55 32q-14 14 -25 31t-16 27l-4 11l-289 747h-69l-300 -754q-18 -35 -39 -56q-9 -9 -24.5 -18.5t-26.5 -14.5l-11 -5v-50h273v50q-49 0 -78.5 21.5t-11.5 67.5l69 176h293l61 -166q13 -34 -3.5 -66.5t-55.5 -32.5v-50h312zM412 691l134 342l121 -342 h-255zM1100 150v-100q0 -21 -14.5 -35.5t-35.5 -14.5h-1000q-21 0 -35.5 14.5t-14.5 35.5v100q0 21 14.5 35.5t35.5 14.5h1000q21 0 35.5 -14.5t14.5 -35.5z" />
<glyph unicode="&#xe243;" d="M50 1200h1100q21 0 35.5 -14.5t14.5 -35.5v-1100q0 -21 -14.5 -35.5t-35.5 -14.5h-1100q-21 0 -35.5 14.5t-14.5 35.5v1100q0 21 14.5 35.5t35.5 14.5zM611 1118h-70q-13 0 -18 -12l-299 -753q-17 -32 -35 -51q-18 -18 -56 -34q-12 -5 -12 -18v-50q0 -8 5.5 -14t14.5 -6 h273q8 0 14 6t6 14v50q0 8 -6 14t-14 6q-55 0 -71 23q-10 14 0 39l63 163h266l57 -153q11 -31 -6 -55q-12 -17 -36 -17q-8 0 -14 -6t-6 -14v-50q0 -8 6 -14t14 -6h313q8 0 14 6t6 14v50q0 7 -5.5 13t-13.5 7q-17 0 -42 25q-25 27 -40 63h-1l-288 748q-5 12 -19 12zM639 611 h-197l103 264z" />
<glyph unicode="&#xe244;" d="M1200 1100h-1200v100h1200v-100zM50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 1000h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM700 900v-300h300v300h-300z" />
<glyph unicode="&#xe245;" d="M50 1200h400q21 0 35.5 -14.5t14.5 -35.5v-900q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v900q0 21 14.5 35.5t35.5 14.5zM650 700h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400 q0 21 14.5 35.5t35.5 14.5zM700 600v-300h300v300h-300zM1200 0h-1200v100h1200v-100z" />
<glyph unicode="&#xe246;" d="M50 1000h400q21 0 35.5 -14.5t14.5 -35.5v-350h100v150q0 21 14.5 35.5t35.5 14.5h400q21 0 35.5 -14.5t14.5 -35.5v-150h100v-100h-100v-150q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v150h-100v-350q0 -21 -14.5 -35.5t-35.5 -14.5h-400 q-21 0 -35.5 14.5t-14.5 35.5v800q0 21 14.5 35.5t35.5 14.5zM700 700v-300h300v300h-300z" />
<glyph unicode="&#xe247;" d="M100 0h-100v1200h100v-1200zM250 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM300 1000v-300h300v300h-300zM250 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe248;" d="M600 1100h150q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-100h450q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h350v100h-150q-21 0 -35.5 14.5 t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5h150v100h100v-100zM400 1000v-300h300v300h-300z" />
<glyph unicode="&#xe249;" d="M1200 0h-100v1200h100v-1200zM550 1100h400q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-400q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM600 1000v-300h300v300h-300zM50 500h900q21 0 35.5 -14.5t14.5 -35.5v-400 q0 -21 -14.5 -35.5t-35.5 -14.5h-900q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5z" />
<glyph unicode="&#xe250;" d="M865 565l-494 -494q-23 -23 -41 -23q-14 0 -22 13.5t-8 38.5v1000q0 25 8 38.5t22 13.5q18 0 41 -23l494 -494q14 -14 14 -35t-14 -35z" />
<glyph unicode="&#xe251;" d="M335 635l494 494q29 29 50 20.5t21 -49.5v-1000q0 -41 -21 -49.5t-50 20.5l-494 494q-14 14 -14 35t14 35z" />
<glyph unicode="&#xe252;" d="M100 900h1000q41 0 49.5 -21t-20.5 -50l-494 -494q-14 -14 -35 -14t-35 14l-494 494q-29 29 -20.5 50t49.5 21z" />
<glyph unicode="&#xe253;" d="M635 865l494 -494q29 -29 20.5 -50t-49.5 -21h-1000q-41 0 -49.5 21t20.5 50l494 494q14 14 35 14t35 -14z" />
<glyph unicode="&#xe254;" d="M700 741v-182l-692 -323v221l413 193l-413 193v221zM1200 0h-800v200h800v-200z" />
<glyph unicode="&#xe255;" d="M1200 900h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300zM0 700h50q0 21 4 37t9.5 26.5t18 17.5t22 11t28.5 5.5t31 2t37 0.5h100v-550q0 -22 -25 -34.5t-50 -13.5l-25 -2v-100h400v100q-4 0 -11 0.5t-24 3t-30 7t-24 15t-11 24.5v550h100q25 0 37 -0.5t31 -2 t28.5 -5.5t22 -11t18 -17.5t9.5 -26.5t4 -37h50v300h-800v-300z" />
<glyph unicode="&#xe256;" d="M800 700h-50q0 21 -4 37t-9.5 26.5t-18 17.5t-22 11t-28.5 5.5t-31 2t-37 0.5h-100v-550q0 -22 25 -34.5t50 -14.5l25 -1v-100h-400v100q4 0 11 0.5t24 3t30 7t24 15t11 24.5v550h-100q-25 0 -37 -0.5t-31 -2t-28.5 -5.5t-22 -11t-18 -17.5t-9.5 -26.5t-4 -37h-50v300 h800v-300zM1100 200h-200v-100h200v-100h-300v300h200v100h-200v100h300v-300z" />
<glyph unicode="&#xe257;" d="M701 1098h160q16 0 21 -11t-7 -23l-464 -464l464 -464q12 -12 7 -23t-21 -11h-160q-13 0 -23 9l-471 471q-7 8 -7 18t7 18l471 471q10 9 23 9z" />
<glyph unicode="&#xe258;" d="M339 1098h160q13 0 23 -9l471 -471q7 -8 7 -18t-7 -18l-471 -471q-10 -9 -23 -9h-160q-16 0 -21 11t7 23l464 464l-464 464q-12 12 -7 23t21 11z" />
<glyph unicode="&#xe259;" d="M1087 882q11 -5 11 -21v-160q0 -13 -9 -23l-471 -471q-8 -7 -18 -7t-18 7l-471 471q-9 10 -9 23v160q0 16 11 21t23 -7l464 -464l464 464q12 12 23 7z" />
<glyph unicode="&#xe260;" d="M618 993l471 -471q9 -10 9 -23v-160q0 -16 -11 -21t-23 7l-464 464l-464 -464q-12 -12 -23 -7t-11 21v160q0 13 9 23l471 471q8 7 18 7t18 -7z" />
<glyph unicode="&#xf8ff;" d="M1000 1200q0 -124 -88 -212t-212 -88q0 124 88 212t212 88zM450 1000h100q21 0 40 -14t26 -33l79 -194q5 1 16 3q34 6 54 9.5t60 7t65.5 1t61 -10t56.5 -23t42.5 -42t29 -64t5 -92t-19.5 -121.5q-1 -7 -3 -19.5t-11 -50t-20.5 -73t-32.5 -81.5t-46.5 -83t-64 -70 t-82.5 -50q-13 -5 -42 -5t-65.5 2.5t-47.5 2.5q-14 0 -49.5 -3.5t-63 -3.5t-43.5 7q-57 25 -104.5 78.5t-75 111.5t-46.5 112t-26 90l-7 35q-15 63 -18 115t4.5 88.5t26 64t39.5 43.5t52 25.5t58.5 13t62.5 2t59.5 -4.5t55.5 -8l-147 192q-12 18 -5.5 30t27.5 12z" />
<glyph unicode="&#x1f511;" d="M250 1200h600q21 0 35.5 -14.5t14.5 -35.5v-400q0 -21 -14.5 -35.5t-35.5 -14.5h-150v-500l-255 -178q-19 -9 -32 -1t-13 29v650h-150q-21 0 -35.5 14.5t-14.5 35.5v400q0 21 14.5 35.5t35.5 14.5zM400 1100v-100h300v100h-300z" />
<glyph unicode="&#x1f6aa;" d="M250 1200h750q39 0 69.5 -40.5t30.5 -84.5v-933l-700 -117v950l600 125h-700v-1000h-100v1025q0 23 15.5 49t34.5 26zM500 525v-100l100 20v100z" />
</font>
</defs></svg> ) format('svg')}.glyphicon{position:relative;top:1px;display:inline-block;font-family:'Glyphicons Halflings';font-style:normal;font-weight:400;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.glyphicon-asterisk:before{content:"\2a"}.glyphicon-plus:before{content:"\2b"}.glyphicon-eur:before,.glyphicon-euro:before{content:"\20ac"}.glyphicon-minus:before{content:"\2212"}.glyphicon-cloud:before{content:"\2601"}.glyphicon-envelope:before{content:"\2709"}.glyphicon-pencil:before{content:"\270f"}.glyphicon-glass:before{content:"\e001"}.glyphicon-music:before{content:"\e002"}.glyphicon-search:before{content:"\e003"}.glyphicon-heart:before{content:"\e005"}.glyphicon-star:before{content:"\e006"}.glyphicon-star-empty:before{content:"\e007"}.glyphicon-user:before{content:"\e008"}.glyphicon-film:before{content:"\e009"}.glyphicon-th-large:before{content:"\e010"}.glyphicon-th:before{content:"\e011"}.glyphicon-th-list:before{content:"\e012"}.glyphicon-ok:before{content:"\e013"}.glyphicon-remove:before{content:"\e014"}.glyphicon-zoom-in:before{content:"\e015"}.glyphicon-zoom-out:before{content:"\e016"}.glyphicon-off:before{content:"\e017"}.glyphicon-signal:before{content:"\e018"}.glyphicon-cog:before{content:"\e019"}.glyphicon-trash:before{content:"\e020"}.glyphicon-home:before{content:"\e021"}.glyphicon-file:before{content:"\e022"}.glyphicon-time:before{content:"\e023"}.glyphicon-road:before{content:"\e024"}.glyphicon-download-alt:before{content:"\e025"}.glyphicon-download:before{content:"\e026"}.glyphicon-upload:before{content:"\e027"}.glyphicon-inbox:before{content:"\e028"}.glyphicon-play-circle:before{content:"\e029"}.glyphicon-repeat:before{content:"\e030"}.glyphicon-refresh:before{content:"\e031"}.glyphicon-list-alt:before{content:"\e032"}.glyphicon-lock:before{content:"\e033"}.glyphicon-flag:before{content:"\e034"}.glyphicon-headphones:before{content:"\e035"}.glyphicon-volume-off:before{content:"\e036"}.glyphicon-volume-down:before{content:"\e037"}.glyphicon-volume-up:before{content:"\e038"}.glyphicon-qrcode:before{content:"\e039"}.glyphicon-barcode:before{content:"\e040"}.glyphicon-tag:before{content:"\e041"}.glyphicon-tags:before{content:"\e042"}.glyphicon-book:before{content:"\e043"}.glyphicon-bookmark:before{content:"\e044"}.glyphicon-print:before{content:"\e045"}.glyphicon-camera:before{content:"\e046"}.glyphicon-font:before{content:"\e047"}.glyphicon-bold:before{content:"\e048"}.glyphicon-italic:before{content:"\e049"}.glyphicon-text-height:before{content:"\e050"}.glyphicon-text-width:before{content:"\e051"}.glyphicon-align-left:before{content:"\e052"}.glyphicon-align-center:before{content:"\e053"}.glyphicon-align-right:before{content:"\e054"}.glyphicon-align-justify:before{content:"\e055"}.glyphicon-list:before{content:"\e056"}.glyphicon-indent-left:before{content:"\e057"}.glyphicon-indent-right:before{content:"\e058"}.glyphicon-facetime-video:before{content:"\e059"}.glyphicon-picture:before{content:"\e060"}.glyphicon-map-marker:before{content:"\e062"}.glyphicon-adjust:before{content:"\e063"}.glyphicon-tint:before{content:"\e064"}.glyphicon-edit:before{content:"\e065"}.glyphicon-share:before{content:"\e066"}.glyphicon-check:before{content:"\e067"}.glyphicon-move:before{content:"\e068"}.glyphicon-step-backward:before{content:"\e069"}.glyphicon-fast-backward:before{content:"\e070"}.glyphicon-backward:before{content:"\e071"}.glyphicon-play:before{content:"\e072"}.glyphicon-pause:before{content:"\e073"}.glyphicon-stop:before{content:"\e074"}.glyphicon-forward:before{content:"\e075"}.glyphicon-fast-forward:before{content:"\e076"}.glyphicon-step-forward:before{content:"\e077"}.glyphicon-eject:before{content:"\e078"}.glyphicon-chevron-left:before{content:"\e079"}.glyphicon-chevron-right:before{content:"\e080"}.glyphicon-plus-sign:before{content:"\e081"}.glyphicon-minus-sign:before{content:"\e082"}.glyphicon-remove-sign:before{content:"\e083"}.glyphicon-ok-sign:before{content:"\e084"}.glyphicon-question-sign:before{content:"\e085"}.glyphicon-info-sign:before{content:"\e086"}.glyphicon-screenshot:before{content:"\e087"}.glyphicon-remove-circle:before{content:"\e088"}.glyphicon-ok-circle:before{content:"\e089"}.glyphicon-ban-circle:before{content:"\e090"}.glyphicon-arrow-left:before{content:"\e091"}.glyphicon-arrow-right:before{content:"\e092"}.glyphicon-arrow-up:before{content:"\e093"}.glyphicon-arrow-down:before{content:"\e094"}.glyphicon-share-alt:before{content:"\e095"}.glyphicon-resize-full:before{content:"\e096"}.glyphicon-resize-small:before{content:"\e097"}.glyphicon-exclamation-sign:before{content:"\e101"}.glyphicon-gift:before{content:"\e102"}.glyphicon-leaf:before{content:"\e103"}.glyphicon-fire:before{content:"\e104"}.glyphicon-eye-open:before{content:"\e105"}.glyphicon-eye-close:before{content:"\e106"}.glyphicon-warning-sign:before{content:"\e107"}.glyphicon-plane:before{content:"\e108"}.glyphicon-calendar:before{content:"\e109"}.glyphicon-random:before{content:"\e110"}.glyphicon-comment:before{content:"\e111"}.glyphicon-magnet:before{content:"\e112"}.glyphicon-chevron-up:before{content:"\e113"}.glyphicon-chevron-down:before{content:"\e114"}.glyphicon-retweet:before{content:"\e115"}.glyphicon-shopping-cart:before{content:"\e116"}.glyphicon-folder-close:before{content:"\e117"}.glyphicon-folder-open:before{content:"\e118"}.glyphicon-resize-vertical:before{content:"\e119"}.glyphicon-resize-horizontal:before{content:"\e120"}.glyphicon-hdd:before{content:"\e121"}.glyphicon-bullhorn:before{content:"\e122"}.glyphicon-bell:before{content:"\e123"}.glyphicon-certificate:before{content:"\e124"}.glyphicon-thumbs-up:before{content:"\e125"}.glyphicon-thumbs-down:before{content:"\e126"}.glyphicon-hand-right:before{content:"\e127"}.glyphicon-hand-left:before{content:"\e128"}.glyphicon-hand-up:before{content:"\e129"}.glyphicon-hand-down:before{content:"\e130"}.glyphicon-circle-arrow-right:before{content:"\e131"}.glyphicon-circle-arrow-left:before{content:"\e132"}.glyphicon-circle-arrow-up:before{content:"\e133"}.glyphicon-circle-arrow-down:before{content:"\e134"}.glyphicon-globe:before{content:"\e135"}.glyphicon-wrench:before{content:"\e136"}.glyphicon-tasks:before{content:"\e137"}.glyphicon-filter:before{content:"\e138"}.glyphicon-briefcase:before{content:"\e139"}.glyphicon-fullscreen:before{content:"\e140"}.glyphicon-dashboard:before{content:"\e141"}.glyphicon-paperclip:before{content:"\e142"}.glyphicon-heart-empty:before{content:"\e143"}.glyphicon-link:before{content:"\e144"}.glyphicon-phone:before{content:"\e145"}.glyphicon-pushpin:before{content:"\e146"}.glyphicon-usd:before{content:"\e148"}.glyphicon-gbp:before{content:"\e149"}.glyphicon-sort:before{content:"\e150"}.glyphicon-sort-by-alphabet:before{content:"\e151"}.glyphicon-sort-by-alphabet-alt:before{content:"\e152"}.glyphicon-sort-by-order:before{content:"\e153"}.glyphicon-sort-by-order-alt:before{content:"\e154"}.glyphicon-sort-by-attributes:before{content:"\e155"}.glyphicon-sort-by-attributes-alt:before{content:"\e156"}.glyphicon-unchecked:before{content:"\e157"}.glyphicon-expand:before{content:"\e158"}.glyphicon-collapse-down:before{content:"\e159"}.glyphicon-collapse-up:before{content:"\e160"}.glyphicon-log-in:before{content:"\e161"}.glyphicon-flash:before{content:"\e162"}.glyphicon-log-out:before{content:"\e163"}.glyphicon-new-window:before{content:"\e164"}.glyphicon-record:before{content:"\e165"}.glyphicon-save:before{content:"\e166"}.glyphicon-open:before{content:"\e167"}.glyphicon-saved:before{content:"\e168"}.glyphicon-import:before{content:"\e169"}.glyphicon-export:before{content:"\e170"}.glyphicon-send:before{content:"\e171"}.glyphicon-floppy-disk:before{content:"\e172"}.glyphicon-floppy-saved:before{content:"\e173"}.glyphicon-floppy-remove:before{content:"\e174"}.glyphicon-floppy-save:before{content:"\e175"}.glyphicon-floppy-open:before{content:"\e176"}.glyphicon-credit-card:before{content:"\e177"}.glyphicon-transfer:before{content:"\e178"}.glyphicon-cutlery:before{content:"\e179"}.glyphicon-header:before{content:"\e180"}.glyphicon-compressed:before{content:"\e181"}.glyphicon-earphone:before{content:"\e182"}.glyphicon-phone-alt:before{content:"\e183"}.glyphicon-tower:before{content:"\e184"}.glyphicon-stats:before{content:"\e185"}.glyphicon-sd-video:before{content:"\e186"}.glyphicon-hd-video:before{content:"\e187"}.glyphicon-subtitles:before{content:"\e188"}.glyphicon-sound-stereo:before{content:"\e189"}.glyphicon-sound-dolby:before{content:"\e190"}.glyphicon-sound-5-1:before{content:"\e191"}.glyphicon-sound-6-1:before{content:"\e192"}.glyphicon-sound-7-1:before{content:"\e193"}.glyphicon-copyright-mark:before{content:"\e194"}.glyphicon-registration-mark:before{content:"\e195"}.glyphicon-cloud-download:before{content:"\e197"}.glyphicon-cloud-upload:before{content:"\e198"}.glyphicon-tree-conifer:before{content:"\e199"}.glyphicon-tree-deciduous:before{content:"\e200"}.glyphicon-cd:before{content:"\e201"}.glyphicon-save-file:before{content:"\e202"}.glyphicon-open-file:before{content:"\e203"}.glyphicon-level-up:before{content:"\e204"}.glyphicon-copy:before{content:"\e205"}.glyphicon-paste:before{content:"\e206"}.glyphicon-alert:before{content:"\e209"}.glyphicon-equalizer:before{content:"\e210"}.glyphicon-king:before{content:"\e211"}.glyphicon-queen:before{content:"\e212"}.glyphicon-pawn:before{content:"\e213"}.glyphicon-bishop:before{content:"\e214"}.glyphicon-knight:before{content:"\e215"}.glyphicon-baby-formula:before{content:"\e216"}.glyphicon-tent:before{content:"\26fa"}.glyphicon-blackboard:before{content:"\e218"}.glyphicon-bed:before{content:"\e219"}.glyphicon-apple:before{content:"\f8ff"}.glyphicon-erase:before{content:"\e221"}.glyphicon-hourglass:before{content:"\231b"}.glyphicon-lamp:before{content:"\e223"}.glyphicon-duplicate:before{content:"\e224"}.glyphicon-piggy-bank:before{content:"\e225"}.glyphicon-scissors:before{content:"\e226"}.glyphicon-bitcoin:before{content:"\e227"}.glyphicon-btc:before{content:"\e227"}.glyphicon-xbt:before{content:"\e227"}.glyphicon-yen:before{content:"\00a5"}.glyphicon-jpy:before{content:"\00a5"}.glyphicon-ruble:before{content:"\20bd"}.glyphicon-rub:before{content:"\20bd"}.glyphicon-scale:before{content:"\e230"}.glyphicon-ice-lolly:before{content:"\e231"}.glyphicon-ice-lolly-tasted:before{content:"\e232"}.glyphicon-education:before{content:"\e233"}.glyphicon-option-horizontal:before{content:"\e234"}.glyphicon-option-vertical:before{content:"\e235"}.glyphicon-menu-hamburger:before{content:"\e236"}.glyphicon-modal-window:before{content:"\e237"}.glyphicon-oil:before{content:"\e238"}.glyphicon-grain:before{content:"\e239"}.glyphicon-sunglasses:before{content:"\e240"}.glyphicon-text-size:before{content:"\e241"}.glyphicon-text-color:before{content:"\e242"}.glyphicon-text-background:before{content:"\e243"}.glyphicon-object-align-top:before{content:"\e244"}.glyphicon-object-align-bottom:before{content:"\e245"}.glyphicon-object-align-horizontal:before{content:"\e246"}.glyphicon-object-align-left:before{content:"\e247"}.glyphicon-object-align-vertical:before{content:"\e248"}.glyphicon-object-align-right:before{content:"\e249"}.glyphicon-triangle-right:before{content:"\e250"}.glyphicon-triangle-left:before{content:"\e251"}.glyphicon-triangle-bottom:before{content:"\e252"}.glyphicon-triangle-top:before{content:"\e253"}.glyphicon-console:before{content:"\e254"}.glyphicon-superscript:before{content:"\e255"}.glyphicon-subscript:before{content:"\e256"}.glyphicon-menu-left:before{content:"\e257"}.glyphicon-menu-right:before{content:"\e258"}.glyphicon-menu-down:before{content:"\e259"}.glyphicon-menu-up:before{content:"\e260"}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:rgba(0,0,0,0)}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}button,input,select,textarea{font-family:inherit;font-size:inherit;line-height:inherit}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}figure{margin:0}img{vertical-align:middle}.carousel-inner>.item>a>img,.carousel-inner>.item>img,.img-responsive,.thumbnail a>img,.thumbnail>img{display:block;max-width:100%;height:auto}.img-rounded{border-radius:6px}.img-thumbnail{display:inline-block;max-width:100%;height:auto;padding:4px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:all .2s ease-in-out;-o-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.img-circle{border-radius:50%}hr{margin-top:20px;margin-bottom:20px;border:0;border-top:1px solid #eee}.sr-only{position:absolute;width:1px;height:1px;padding:0;margin:-1px;overflow:hidden;clip:rect(0,0,0,0);border:0}.sr-only-focusable:active,.sr-only-focusable:focus{position:static;width:auto;height:auto;margin:0;overflow:visible;clip:auto}[role=button]{cursor:pointer}.h1,.h2,.h3,.h4,.h5,.h6,h1,h2,h3,h4,h5,h6{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-weight:400;line-height:1;color:#777}.h1,.h2,.h3,h1,h2,h3{margin-top:20px;margin-bottom:10px}.h1 .small,.h1 small,.h2 .small,.h2 small,.h3 .small,.h3 small,h1 .small,h1 small,h2 .small,h2 small,h3 .small,h3 small{font-size:65%}.h4,.h5,.h6,h4,h5,h6{margin-top:10px;margin-bottom:10px}.h4 .small,.h4 small,.h5 .small,.h5 small,.h6 .small,.h6 small,h4 .small,h4 small,h5 .small,h5 small,h6 .small,h6 small{font-size:75%}.h1,h1{font-size:36px}.h2,h2{font-size:30px}.h3,h3{font-size:24px}.h4,h4{font-size:18px}.h5,h5{font-size:14px}.h6,h6{font-size:12px}p{margin:0 0 10px}.lead{margin-bottom:20px;font-size:16px;font-weight:300;line-height:1.4}@media (min-width:768px){.lead{font-size:21px}}.small,small{font-size:85%}.mark,mark{padding:.2em;background-color:#fcf8e3}.text-left{text-align:left}.text-right{text-align:right}.text-center{text-align:center}.text-justify{text-align:justify}.text-nowrap{white-space:nowrap}.text-lowercase{text-transform:lowercase}.text-uppercase{text-transform:uppercase}.text-capitalize{text-transform:capitalize}.text-muted{color:#777}.text-primary{color:#337ab7}a.text-primary:focus,a.text-primary:hover{color:#286090}.text-success{color:#3c763d}a.text-success:focus,a.text-success:hover{color:#2b542c}.text-info{color:#31708f}a.text-info:focus,a.text-info:hover{color:#245269}.text-warning{color:#8a6d3b}a.text-warning:focus,a.text-warning:hover{color:#66512c}.text-danger{color:#a94442}a.text-danger:focus,a.text-danger:hover{color:#843534}.bg-primary{color:#fff;background-color:#337ab7}a.bg-primary:focus,a.bg-primary:hover{background-color:#286090}.bg-success{background-color:#dff0d8}a.bg-success:focus,a.bg-success:hover{background-color:#c1e2b3}.bg-info{background-color:#d9edf7}a.bg-info:focus,a.bg-info:hover{background-color:#afd9ee}.bg-warning{background-color:#fcf8e3}a.bg-warning:focus,a.bg-warning:hover{background-color:#f7ecb5}.bg-danger{background-color:#f2dede}a.bg-danger:focus,a.bg-danger:hover{background-color:#e4b9b9}.page-header{padding-bottom:9px;margin:40px 0 20px;border-bottom:1px solid #eee}ol,ul{margin-top:0;margin-bottom:10px}ol ol,ol ul,ul ol,ul ul{margin-bottom:0}.list-unstyled{padding-left:0;list-style:none}.list-inline{padding-left:0;margin-left:-5px;list-style:none}.list-inline>li{display:inline-block;padding-right:5px;padding-left:5px}dl{margin-top:0;margin-bottom:20px}dd,dt{line-height:1.42857143}dt{font-weight:700}dd{margin-left:0}@media (min-width:768px){.dl-horizontal dt{float:left;width:160px;overflow:hidden;clear:left;text-align:right;text-overflow:ellipsis;white-space:nowrap}.dl-horizontal dd{margin-left:180px}}abbr[data-original-title],abbr[title]{cursor:help;border-bottom:1px dotted #777}.initialism{font-size:90%;text-transform:uppercase}blockquote{padding:10px 20px;margin:0 0 20px;font-size:17.5px;border-left:5px solid #eee}blockquote ol:last-child,blockquote p:last-child,blockquote ul:last-child{margin-bottom:0}blockquote .small,blockquote footer,blockquote small{display:block;font-size:80%;line-height:1.42857143;color:#777}blockquote .small:before,blockquote footer:before,blockquote small:before{content:'\2014 \00A0'}.blockquote-reverse,blockquote.pull-right{padding-right:15px;padding-left:0;text-align:right;border-right:5px solid #eee;border-left:0}.blockquote-reverse .small:before,.blockquote-reverse footer:before,.blockquote-reverse small:before,blockquote.pull-right .small:before,blockquote.pull-right footer:before,blockquote.pull-right small:before{content:''}.blockquote-reverse .small:after,.blockquote-reverse footer:after,.blockquote-reverse small:after,blockquote.pull-right .small:after,blockquote.pull-right footer:after,blockquote.pull-right small:after{content:'\00A0 \2014'}address{margin-bottom:20px;font-style:normal;line-height:1.42857143}code,kbd,pre,samp{font-family:monospace}code{padding:2px 4px;font-size:90%;color:#c7254e;background-color:#f9f2f4;border-radius:4px}kbd{padding:2px 4px;font-size:90%;color:#fff;background-color:#333;border-radius:3px;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.25);box-shadow:inset 0 -1px 0 rgba(0,0,0,.25)}kbd kbd{padding:0;font-size:100%;font-weight:700;-webkit-box-shadow:none;box-shadow:none}pre{display:block;padding:9.5px;margin:0 0 10px;font-size:13px;line-height:1.42857143;color:#333;word-break:break-all;word-wrap:break-word;background-color:#f5f5f5;border:1px solid #ccc;border-radius:4px}pre code{padding:0;font-size:inherit;color:inherit;white-space:pre-wrap;background-color:transparent;border-radius:0}.pre-scrollable{max-height:340px;overflow-y:scroll}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9,.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9,.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9,.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-1,.col-xs-10,.col-xs-11,.col-xs-12,.col-xs-2,.col-xs-3,.col-xs-4,.col-xs-5,.col-xs-6,.col-xs-7,.col-xs-8,.col-xs-9{float:left}.col-xs-12{width:100%}.col-xs-11{width:91.66666667%}.col-xs-10{width:83.33333333%}.col-xs-9{width:75%}.col-xs-8{width:66.66666667%}.col-xs-7{width:58.33333333%}.col-xs-6{width:50%}.col-xs-5{width:41.66666667%}.col-xs-4{width:33.33333333%}.col-xs-3{width:25%}.col-xs-2{width:16.66666667%}.col-xs-1{width:8.33333333%}.col-xs-pull-12{right:100%}.col-xs-pull-11{right:91.66666667%}.col-xs-pull-10{right:83.33333333%}.col-xs-pull-9{right:75%}.col-xs-pull-8{right:66.66666667%}.col-xs-pull-7{right:58.33333333%}.col-xs-pull-6{right:50%}.col-xs-pull-5{right:41.66666667%}.col-xs-pull-4{right:33.33333333%}.col-xs-pull-3{right:25%}.col-xs-pull-2{right:16.66666667%}.col-xs-pull-1{right:8.33333333%}.col-xs-pull-0{right:auto}.col-xs-push-12{left:100%}.col-xs-push-11{left:91.66666667%}.col-xs-push-10{left:83.33333333%}.col-xs-push-9{left:75%}.col-xs-push-8{left:66.66666667%}.col-xs-push-7{left:58.33333333%}.col-xs-push-6{left:50%}.col-xs-push-5{left:41.66666667%}.col-xs-push-4{left:33.33333333%}.col-xs-push-3{left:25%}.col-xs-push-2{left:16.66666667%}.col-xs-push-1{left:8.33333333%}.col-xs-push-0{left:auto}.col-xs-offset-12{margin-left:100%}.col-xs-offset-11{margin-left:91.66666667%}.col-xs-offset-10{margin-left:83.33333333%}.col-xs-offset-9{margin-left:75%}.col-xs-offset-8{margin-left:66.66666667%}.col-xs-offset-7{margin-left:58.33333333%}.col-xs-offset-6{margin-left:50%}.col-xs-offset-5{margin-left:41.66666667%}.col-xs-offset-4{margin-left:33.33333333%}.col-xs-offset-3{margin-left:25%}.col-xs-offset-2{margin-left:16.66666667%}.col-xs-offset-1{margin-left:8.33333333%}.col-xs-offset-0{margin-left:0}@media (min-width:768px){.col-sm-1,.col-sm-10,.col-sm-11,.col-sm-12,.col-sm-2,.col-sm-3,.col-sm-4,.col-sm-5,.col-sm-6,.col-sm-7,.col-sm-8,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-11{width:91.66666667%}.col-sm-10{width:83.33333333%}.col-sm-9{width:75%}.col-sm-8{width:66.66666667%}.col-sm-7{width:58.33333333%}.col-sm-6{width:50%}.col-sm-5{width:41.66666667%}.col-sm-4{width:33.33333333%}.col-sm-3{width:25%}.col-sm-2{width:16.66666667%}.col-sm-1{width:8.33333333%}.col-sm-pull-12{right:100%}.col-sm-pull-11{right:91.66666667%}.col-sm-pull-10{right:83.33333333%}.col-sm-pull-9{right:75%}.col-sm-pull-8{right:66.66666667%}.col-sm-pull-7{right:58.33333333%}.col-sm-pull-6{right:50%}.col-sm-pull-5{right:41.66666667%}.col-sm-pull-4{right:33.33333333%}.col-sm-pull-3{right:25%}.col-sm-pull-2{right:16.66666667%}.col-sm-pull-1{right:8.33333333%}.col-sm-pull-0{right:auto}.col-sm-push-12{left:100%}.col-sm-push-11{left:91.66666667%}.col-sm-push-10{left:83.33333333%}.col-sm-push-9{left:75%}.col-sm-push-8{left:66.66666667%}.col-sm-push-7{left:58.33333333%}.col-sm-push-6{left:50%}.col-sm-push-5{left:41.66666667%}.col-sm-push-4{left:33.33333333%}.col-sm-push-3{left:25%}.col-sm-push-2{left:16.66666667%}.col-sm-push-1{left:8.33333333%}.col-sm-push-0{left:auto}.col-sm-offset-12{margin-left:100%}.col-sm-offset-11{margin-left:91.66666667%}.col-sm-offset-10{margin-left:83.33333333%}.col-sm-offset-9{margin-left:75%}.col-sm-offset-8{margin-left:66.66666667%}.col-sm-offset-7{margin-left:58.33333333%}.col-sm-offset-6{margin-left:50%}.col-sm-offset-5{margin-left:41.66666667%}.col-sm-offset-4{margin-left:33.33333333%}.col-sm-offset-3{margin-left:25%}.col-sm-offset-2{margin-left:16.66666667%}.col-sm-offset-1{margin-left:8.33333333%}.col-sm-offset-0{margin-left:0}}@media (min-width:992px){.col-md-1,.col-md-10,.col-md-11,.col-md-12,.col-md-2,.col-md-3,.col-md-4,.col-md-5,.col-md-6,.col-md-7,.col-md-8,.col-md-9{float:left}.col-md-12{width:100%}.col-md-11{width:91.66666667%}.col-md-10{width:83.33333333%}.col-md-9{width:75%}.col-md-8{width:66.66666667%}.col-md-7{width:58.33333333%}.col-md-6{width:50%}.col-md-5{width:41.66666667%}.col-md-4{width:33.33333333%}.col-md-3{width:25%}.col-md-2{width:16.66666667%}.col-md-1{width:8.33333333%}.col-md-pull-12{right:100%}.col-md-pull-11{right:91.66666667%}.col-md-pull-10{right:83.33333333%}.col-md-pull-9{right:75%}.col-md-pull-8{right:66.66666667%}.col-md-pull-7{right:58.33333333%}.col-md-pull-6{right:50%}.col-md-pull-5{right:41.66666667%}.col-md-pull-4{right:33.33333333%}.col-md-pull-3{right:25%}.col-md-pull-2{right:16.66666667%}.col-md-pull-1{right:8.33333333%}.col-md-pull-0{right:auto}.col-md-push-12{left:100%}.col-md-push-11{left:91.66666667%}.col-md-push-10{left:83.33333333%}.col-md-push-9{left:75%}.col-md-push-8{left:66.66666667%}.col-md-push-7{left:58.33333333%}.col-md-push-6{left:50%}.col-md-push-5{left:41.66666667%}.col-md-push-4{left:33.33333333%}.col-md-push-3{left:25%}.col-md-push-2{left:16.66666667%}.col-md-push-1{left:8.33333333%}.col-md-push-0{left:auto}.col-md-offset-12{margin-left:100%}.col-md-offset-11{margin-left:91.66666667%}.col-md-offset-10{margin-left:83.33333333%}.col-md-offset-9{margin-left:75%}.col-md-offset-8{margin-left:66.66666667%}.col-md-offset-7{margin-left:58.33333333%}.col-md-offset-6{margin-left:50%}.col-md-offset-5{margin-left:41.66666667%}.col-md-offset-4{margin-left:33.33333333%}.col-md-offset-3{margin-left:25%}.col-md-offset-2{margin-left:16.66666667%}.col-md-offset-1{margin-left:8.33333333%}.col-md-offset-0{margin-left:0}}@media (min-width:1200px){.col-lg-1,.col-lg-10,.col-lg-11,.col-lg-12,.col-lg-2,.col-lg-3,.col-lg-4,.col-lg-5,.col-lg-6,.col-lg-7,.col-lg-8,.col-lg-9{float:left}.col-lg-12{width:100%}.col-lg-11{width:91.66666667%}.col-lg-10{width:83.33333333%}.col-lg-9{width:75%}.col-lg-8{width:66.66666667%}.col-lg-7{width:58.33333333%}.col-lg-6{width:50%}.col-lg-5{width:41.66666667%}.col-lg-4{width:33.33333333%}.col-lg-3{width:25%}.col-lg-2{width:16.66666667%}.col-lg-1{width:8.33333333%}.col-lg-pull-12{right:100%}.col-lg-pull-11{right:91.66666667%}.col-lg-pull-10{right:83.33333333%}.col-lg-pull-9{right:75%}.col-lg-pull-8{right:66.66666667%}.col-lg-pull-7{right:58.33333333%}.col-lg-pull-6{right:50%}.col-lg-pull-5{right:41.66666667%}.col-lg-pull-4{right:33.33333333%}.col-lg-pull-3{right:25%}.col-lg-pull-2{right:16.66666667%}.col-lg-pull-1{right:8.33333333%}.col-lg-pull-0{right:auto}.col-lg-push-12{left:100%}.col-lg-push-11{left:91.66666667%}.col-lg-push-10{left:83.33333333%}.col-lg-push-9{left:75%}.col-lg-push-8{left:66.66666667%}.col-lg-push-7{left:58.33333333%}.col-lg-push-6{left:50%}.col-lg-push-5{left:41.66666667%}.col-lg-push-4{left:33.33333333%}.col-lg-push-3{left:25%}.col-lg-push-2{left:16.66666667%}.col-lg-push-1{left:8.33333333%}.col-lg-push-0{left:auto}.col-lg-offset-12{margin-left:100%}.col-lg-offset-11{margin-left:91.66666667%}.col-lg-offset-10{margin-left:83.33333333%}.col-lg-offset-9{margin-left:75%}.col-lg-offset-8{margin-left:66.66666667%}.col-lg-offset-7{margin-left:58.33333333%}.col-lg-offset-6{margin-left:50%}.col-lg-offset-5{margin-left:41.66666667%}.col-lg-offset-4{margin-left:33.33333333%}.col-lg-offset-3{margin-left:25%}.col-lg-offset-2{margin-left:16.66666667%}.col-lg-offset-1{margin-left:8.33333333%}.col-lg-offset-0{margin-left:0}}table{background-color:transparent}caption{padding-top:8px;padding-bottom:8px;color:#777;text-align:left}th{}.table{width:100%;max-width:100%;margin-bottom:20px}.table>tbody>tr>td,.table>tbody>tr>th,.table>tfoot>tr>td,.table>tfoot>tr>th,.table>thead>tr>td,.table>thead>tr>th{padding:8px;line-height:1.42857143;vertical-align:top;border-top:1px solid #ddd}.table>thead>tr>th{vertical-align:bottom;border-bottom:2px solid #ddd}.table>caption+thead>tr:first-child>td,.table>caption+thead>tr:first-child>th,.table>colgroup+thead>tr:first-child>td,.table>colgroup+thead>tr:first-child>th,.table>thead:first-child>tr:first-child>td,.table>thead:first-child>tr:first-child>th{border-top:0}.table>tbody+tbody{border-top:2px solid #ddd}.table .table{background-color:#fff}.table-condensed>tbody>tr>td,.table-condensed>tbody>tr>th,.table-condensed>tfoot>tr>td,.table-condensed>tfoot>tr>th,.table-condensed>thead>tr>td,.table-condensed>thead>tr>th{padding:5px}.table-bordered{border:1px solid #ddd}.table-bordered>tbody>tr>td,.table-bordered>tbody>tr>th,.table-bordered>tfoot>tr>td,.table-bordered>tfoot>tr>th,.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border:1px solid #ddd}.table-bordered>thead>tr>td,.table-bordered>thead>tr>th{border-bottom-width:2px}.table-striped>tbody>tr:nth-of-type(odd){background-color:#f9f9f9}.table-hover>tbody>tr:hover{background-color:#f5f5f5}table col[class*=col-]{position:static;display:table-column;float:none}table td[class*=col-],table th[class*=col-]{position:static;display:table-cell;float:none}.table>tbody>tr.active>td,.table>tbody>tr.active>th,.table>tbody>tr>td.active,.table>tbody>tr>th.active,.table>tfoot>tr.active>td,.table>tfoot>tr.active>th,.table>tfoot>tr>td.active,.table>tfoot>tr>th.active,.table>thead>tr.active>td,.table>thead>tr.active>th,.table>thead>tr>td.active,.table>thead>tr>th.active{background-color:#f5f5f5}.table-hover>tbody>tr.active:hover>td,.table-hover>tbody>tr.active:hover>th,.table-hover>tbody>tr:hover>.active,.table-hover>tbody>tr>td.active:hover,.table-hover>tbody>tr>th.active:hover{background-color:#e8e8e8}.table>tbody>tr.success>td,.table>tbody>tr.success>th,.table>tbody>tr>td.success,.table>tbody>tr>th.success,.table>tfoot>tr.success>td,.table>tfoot>tr.success>th,.table>tfoot>tr>td.success,.table>tfoot>tr>th.success,.table>thead>tr.success>td,.table>thead>tr.success>th,.table>thead>tr>td.success,.table>thead>tr>th.success{background-color:#dff0d8}.table-hover>tbody>tr.success:hover>td,.table-hover>tbody>tr.success:hover>th,.table-hover>tbody>tr:hover>.success,.table-hover>tbody>tr>td.success:hover,.table-hover>tbody>tr>th.success:hover{background-color:#d0e9c6}.table>tbody>tr.info>td,.table>tbody>tr.info>th,.table>tbody>tr>td.info,.table>tbody>tr>th.info,.table>tfoot>tr.info>td,.table>tfoot>tr.info>th,.table>tfoot>tr>td.info,.table>tfoot>tr>th.info,.table>thead>tr.info>td,.table>thead>tr.info>th,.table>thead>tr>td.info,.table>thead>tr>th.info{background-color:#d9edf7}.table-hover>tbody>tr.info:hover>td,.table-hover>tbody>tr.info:hover>th,.table-hover>tbody>tr:hover>.info,.table-hover>tbody>tr>td.info:hover,.table-hover>tbody>tr>th.info:hover{background-color:#c4e3f3}.table>tbody>tr.warning>td,.table>tbody>tr.warning>th,.table>tbody>tr>td.warning,.table>tbody>tr>th.warning,.table>tfoot>tr.warning>td,.table>tfoot>tr.warning>th,.table>tfoot>tr>td.warning,.table>tfoot>tr>th.warning,.table>thead>tr.warning>td,.table>thead>tr.warning>th,.table>thead>tr>td.warning,.table>thead>tr>th.warning{background-color:#fcf8e3}.table-hover>tbody>tr.warning:hover>td,.table-hover>tbody>tr.warning:hover>th,.table-hover>tbody>tr:hover>.warning,.table-hover>tbody>tr>td.warning:hover,.table-hover>tbody>tr>th.warning:hover{background-color:#faf2cc}.table>tbody>tr.danger>td,.table>tbody>tr.danger>th,.table>tbody>tr>td.danger,.table>tbody>tr>th.danger,.table>tfoot>tr.danger>td,.table>tfoot>tr.danger>th,.table>tfoot>tr>td.danger,.table>tfoot>tr>th.danger,.table>thead>tr.danger>td,.table>thead>tr.danger>th,.table>thead>tr>td.danger,.table>thead>tr>th.danger{background-color:#f2dede}.table-hover>tbody>tr.danger:hover>td,.table-hover>tbody>tr.danger:hover>th,.table-hover>tbody>tr:hover>.danger,.table-hover>tbody>tr>td.danger:hover,.table-hover>tbody>tr>th.danger:hover{background-color:#ebcccc}.table-responsive{min-height:.01%;overflow-x:auto}@media screen and (max-width:767px){.table-responsive{width:100%;margin-bottom:15px;overflow-y:hidden;-ms-overflow-style:-ms-autohiding-scrollbar;border:1px solid #ddd}.table-responsive>.table{margin-bottom:0}.table-responsive>.table>tbody>tr>td,.table-responsive>.table>tbody>tr>th,.table-responsive>.table>tfoot>tr>td,.table-responsive>.table>tfoot>tr>th,.table-responsive>.table>thead>tr>td,.table-responsive>.table>thead>tr>th{white-space:nowrap}.table-responsive>.table-bordered{border:0}.table-responsive>.table-bordered>tbody>tr>td:first-child,.table-responsive>.table-bordered>tbody>tr>th:first-child,.table-responsive>.table-bordered>tfoot>tr>td:first-child,.table-responsive>.table-bordered>tfoot>tr>th:first-child,.table-responsive>.table-bordered>thead>tr>td:first-child,.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.table-responsive>.table-bordered>tbody>tr>td:last-child,.table-responsive>.table-bordered>tbody>tr>th:last-child,.table-responsive>.table-bordered>tfoot>tr>td:last-child,.table-responsive>.table-bordered>tfoot>tr>th:last-child,.table-responsive>.table-bordered>thead>tr>td:last-child,.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.table-responsive>.table-bordered>tbody>tr:last-child>td,.table-responsive>.table-bordered>tbody>tr:last-child>th,.table-responsive>.table-bordered>tfoot>tr:last-child>td,.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}}fieldset{min-width:0;padding:0;margin:0;border:0}legend{display:block;width:100%;padding:0;margin-bottom:20px;font-size:21px;line-height:inherit;color:#333;border:0;border-bottom:1px solid #e5e5e5}label{display:inline-block;max-width:100%;margin-bottom:5px;font-weight:700}input[type=search]{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}input[type=checkbox],input[type=radio]{margin:4px 0 0;margin-top:1px\9;line-height:normal}input[type=file]{display:block}input[type=range]{display:block;width:100%}select[multiple],select[size]{height:auto}input[type=file]:focus,input[type=checkbox]:focus,input[type=radio]:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}output{display:block;padding-top:7px;font-size:14px;line-height:1.42857143;color:#555}.form-control{display:block;width:100%;height:34px;padding:6px 12px;font-size:14px;line-height:1.42857143;color:#555;background-color:#fff;background-image:none;border:1px solid #ccc;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075);-webkit-transition:border-color ease-in-out .15s,-webkit-box-shadow ease-in-out .15s;-o-transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s;transition:border-color ease-in-out .15s,box-shadow ease-in-out .15s}.form-control:focus{border-color:#66afe9;outline:0;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6);box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 8px rgba(102,175,233,.6)}.form-control::-moz-placeholder{color:#999;opacity:1}.form-control:-ms-input-placeholder{color:#999}.form-control::-webkit-input-placeholder{color:#999}.form-control[disabled],.form-control[readonly],fieldset[disabled] .form-control{background-color:#eee;opacity:1}.form-control[disabled],fieldset[disabled] .form-control{cursor:not-allowed}textarea.form-control{height:auto}input[type=search]{-webkit-appearance:none}@media screen and (-webkit-min-device-pixel-ratio:0){input[type=date].form-control,input[type=time].form-control,input[type=datetime-local].form-control,input[type=month].form-control{line-height:34px}.input-group-sm input[type=date],.input-group-sm input[type=time],.input-group-sm input[type=datetime-local],.input-group-sm input[type=month],input[type=date].input-sm,input[type=time].input-sm,input[type=datetime-local].input-sm,input[type=month].input-sm{line-height:30px}.input-group-lg input[type=date],.input-group-lg input[type=time],.input-group-lg input[type=datetime-local],.input-group-lg input[type=month],input[type=date].input-lg,input[type=time].input-lg,input[type=datetime-local].input-lg,input[type=month].input-lg{line-height:46px}}.form-group{margin-bottom:15px}.checkbox,.radio{position:relative;display:block;margin-top:10px;margin-bottom:10px}.checkbox label,.radio label{min-height:20px;padding-left:20px;margin-bottom:0;font-weight:400;cursor:pointer}.checkbox input[type=checkbox],.checkbox-inline input[type=checkbox],.radio input[type=radio],.radio-inline input[type=radio]{position:absolute;margin-top:4px\9;margin-left:-20px}.checkbox+.checkbox,.radio+.radio{margin-top:-5px}.checkbox-inline,.radio-inline{position:relative;display:inline-block;padding-left:20px;margin-bottom:0;font-weight:400;vertical-align:middle;cursor:pointer}.checkbox-inline+.checkbox-inline,.radio-inline+.radio-inline{margin-top:0;margin-left:10px}fieldset[disabled] input[type=checkbox],fieldset[disabled] input[type=radio],input[type=checkbox].disabled,input[type=checkbox][disabled],input[type=radio].disabled,input[type=radio][disabled]{cursor:not-allowed}.checkbox-inline.disabled,.radio-inline.disabled,fieldset[disabled] .checkbox-inline,fieldset[disabled] .radio-inline{cursor:not-allowed}.checkbox.disabled label,.radio.disabled label,fieldset[disabled] .checkbox label,fieldset[disabled] .radio label{cursor:not-allowed}.form-control-static{min-height:34px;padding-top:7px;padding-bottom:7px;margin-bottom:0}.form-control-static.input-lg,.form-control-static.input-sm{padding-right:0;padding-left:0}.input-sm{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-sm{height:30px;line-height:30px}select[multiple].input-sm,textarea.input-sm{height:auto}.form-group-sm .form-control{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.form-group-sm select.form-control{height:30px;line-height:30px}.form-group-sm select[multiple].form-control,.form-group-sm textarea.form-control{height:auto}.form-group-sm .form-control-static{height:30px;min-height:32px;padding:6px 10px;font-size:12px;line-height:1.5}.input-lg{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-lg{height:46px;line-height:46px}select[multiple].input-lg,textarea.input-lg{height:auto}.form-group-lg .form-control{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.form-group-lg select.form-control{height:46px;line-height:46px}.form-group-lg select[multiple].form-control,.form-group-lg textarea.form-control{height:auto}.form-group-lg .form-control-static{height:46px;min-height:38px;padding:11px 16px;font-size:18px;line-height:1.3333333}.has-feedback{position:relative}.has-feedback .form-control{padding-right:42.5px}.form-control-feedback{position:absolute;top:0;right:0;z-index:2;display:block;width:34px;height:34px;line-height:34px;text-align:center;pointer-events:none}.form-group-lg .form-control+.form-control-feedback,.input-group-lg+.form-control-feedback,.input-lg+.form-control-feedback{width:46px;height:46px;line-height:46px}.form-group-sm .form-control+.form-control-feedback,.input-group-sm+.form-control-feedback,.input-sm+.form-control-feedback{width:30px;height:30px;line-height:30px}.has-success .checkbox,.has-success .checkbox-inline,.has-success .control-label,.has-success .help-block,.has-success .radio,.has-success .radio-inline,.has-success.checkbox label,.has-success.checkbox-inline label,.has-success.radio label,.has-success.radio-inline label{color:#3c763d}.has-success .form-control{border-color:#3c763d;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-success .form-control:focus{border-color:#2b542c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #67b168}.has-success .input-group-addon{color:#3c763d;background-color:#dff0d8;border-color:#3c763d}.has-success .form-control-feedback{color:#3c763d}.has-warning .checkbox,.has-warning .checkbox-inline,.has-warning .control-label,.has-warning .help-block,.has-warning .radio,.has-warning .radio-inline,.has-warning.checkbox label,.has-warning.checkbox-inline label,.has-warning.radio label,.has-warning.radio-inline label{color:#8a6d3b}.has-warning .form-control{border-color:#8a6d3b;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-warning .form-control:focus{border-color:#66512c;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #c0a16b}.has-warning .input-group-addon{color:#8a6d3b;background-color:#fcf8e3;border-color:#8a6d3b}.has-warning .form-control-feedback{color:#8a6d3b}.has-error .checkbox,.has-error .checkbox-inline,.has-error .control-label,.has-error .help-block,.has-error .radio,.has-error .radio-inline,.has-error.checkbox label,.has-error.checkbox-inline label,.has-error.radio label,.has-error.radio-inline label{color:#a94442}.has-error .form-control{border-color:#a94442;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075);box-shadow:inset 0 1px 1px rgba(0,0,0,.075)}.has-error .form-control:focus{border-color:#843534;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483;box-shadow:inset 0 1px 1px rgba(0,0,0,.075),0 0 6px #ce8483}.has-error .input-group-addon{color:#a94442;background-color:#f2dede;border-color:#a94442}.has-error .form-control-feedback{color:#a94442}.has-feedback label~.form-control-feedback{top:25px}.has-feedback label.sr-only~.form-control-feedback{top:0}.help-block{display:block;margin-top:5px;margin-bottom:10px;color:#737373}@media (min-width:768px){.form-inline .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.form-inline .form-control{display:inline-block;width:auto;vertical-align:middle}.form-inline .form-control-static{display:inline-block}.form-inline .input-group{display:inline-table;vertical-align:middle}.form-inline .input-group .form-control,.form-inline .input-group .input-group-addon,.form-inline .input-group .input-group-btn{width:auto}.form-inline .input-group>.form-control{width:100%}.form-inline .control-label{margin-bottom:0;vertical-align:middle}.form-inline .checkbox,.form-inline .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.form-inline .checkbox label,.form-inline .radio label{padding-left:0}.form-inline .checkbox input[type=checkbox],.form-inline .radio input[type=radio]{position:relative;margin-left:0}.form-inline .has-feedback .form-control-feedback{top:0}}.form-horizontal .checkbox,.form-horizontal .checkbox-inline,.form-horizontal .radio,.form-horizontal .radio-inline{padding-top:7px;margin-top:0;margin-bottom:0}.form-horizontal .checkbox,.form-horizontal .radio{min-height:27px}.form-horizontal .form-group{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.form-horizontal .control-label{padding-top:7px;margin-bottom:0;text-align:right}}.form-horizontal .has-feedback .form-control-feedback{right:15px}@media (min-width:768px){.form-horizontal .form-group-lg .control-label{padding-top:14.33px;font-size:18px}}@media (min-width:768px){.form-horizontal .form-group-sm .control-label{padding-top:6px;font-size:12px}}.btn{display:inline-block;padding:6px 12px;margin-bottom:0;font-size:14px;font-weight:400;line-height:1.42857143;text-align:center;white-space:nowrap;vertical-align:middle;-ms-touch-action:manipulation;touch-action:manipulation;cursor:pointer;-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;background-image:none;border:1px solid transparent;border-radius:4px}.btn.active.focus,.btn.active:focus,.btn.focus,.btn:active.focus,.btn:active:focus,.btn:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}.btn.focus,.btn:focus,.btn:hover{color:#333;text-decoration:none}.btn.active,.btn:active{background-image:none;outline:0;-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn.disabled,.btn[disabled],fieldset[disabled] .btn{cursor:not-allowed;filter:alpha(opacity=65);-webkit-box-shadow:none;box-shadow:none;opacity:.65}a.btn.disabled,fieldset[disabled] a.btn{pointer-events:none}.btn-default{color:#333;background-color:#fff;border-color:#ccc}.btn-default.focus,.btn-default:focus{color:#333;background-color:#e6e6e6;border-color:#8c8c8c}.btn-default:hover{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{color:#333;background-color:#e6e6e6;border-color:#adadad}.btn-default.active.focus,.btn-default.active:focus,.btn-default.active:hover,.btn-default:active.focus,.btn-default:active:focus,.btn-default:active:hover,.open>.dropdown-toggle.btn-default.focus,.open>.dropdown-toggle.btn-default:focus,.open>.dropdown-toggle.btn-default:hover{color:#333;background-color:#d4d4d4;border-color:#8c8c8c}.btn-default.active,.btn-default:active,.open>.dropdown-toggle.btn-default{background-image:none}.btn-default.disabled,.btn-default.disabled.active,.btn-default.disabled.focus,.btn-default.disabled:active,.btn-default.disabled:focus,.btn-default.disabled:hover,.btn-default[disabled],.btn-default[disabled].active,.btn-default[disabled].focus,.btn-default[disabled]:active,.btn-default[disabled]:focus,.btn-default[disabled]:hover,fieldset[disabled] .btn-default,fieldset[disabled] .btn-default.active,fieldset[disabled] .btn-default.focus,fieldset[disabled] .btn-default:active,fieldset[disabled] .btn-default:focus,fieldset[disabled] .btn-default:hover{background-color:#fff;border-color:#ccc}.btn-default .badge{color:#fff;background-color:#333}.btn-primary{color:#fff;background-color:#337ab7;border-color:#2e6da4}.btn-primary.focus,.btn-primary:focus{color:#fff;background-color:#286090;border-color:#122b40}.btn-primary:hover{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{color:#fff;background-color:#286090;border-color:#204d74}.btn-primary.active.focus,.btn-primary.active:focus,.btn-primary.active:hover,.btn-primary:active.focus,.btn-primary:active:focus,.btn-primary:active:hover,.open>.dropdown-toggle.btn-primary.focus,.open>.dropdown-toggle.btn-primary:focus,.open>.dropdown-toggle.btn-primary:hover{color:#fff;background-color:#204d74;border-color:#122b40}.btn-primary.active,.btn-primary:active,.open>.dropdown-toggle.btn-primary{background-image:none}.btn-primary.disabled,.btn-primary.disabled.active,.btn-primary.disabled.focus,.btn-primary.disabled:active,.btn-primary.disabled:focus,.btn-primary.disabled:hover,.btn-primary[disabled],.btn-primary[disabled].active,.btn-primary[disabled].focus,.btn-primary[disabled]:active,.btn-primary[disabled]:focus,.btn-primary[disabled]:hover,fieldset[disabled] .btn-primary,fieldset[disabled] .btn-primary.active,fieldset[disabled] .btn-primary.focus,fieldset[disabled] .btn-primary:active,fieldset[disabled] .btn-primary:focus,fieldset[disabled] .btn-primary:hover{background-color:#337ab7;border-color:#2e6da4}.btn-primary .badge{color:#337ab7;background-color:#fff}.btn-success{color:#fff;background-color:#5cb85c;border-color:#4cae4c}.btn-success.focus,.btn-success:focus{color:#fff;background-color:#449d44;border-color:#255625}.btn-success:hover{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{color:#fff;background-color:#449d44;border-color:#398439}.btn-success.active.focus,.btn-success.active:focus,.btn-success.active:hover,.btn-success:active.focus,.btn-success:active:focus,.btn-success:active:hover,.open>.dropdown-toggle.btn-success.focus,.open>.dropdown-toggle.btn-success:focus,.open>.dropdown-toggle.btn-success:hover{color:#fff;background-color:#398439;border-color:#255625}.btn-success.active,.btn-success:active,.open>.dropdown-toggle.btn-success{background-image:none}.btn-success.disabled,.btn-success.disabled.active,.btn-success.disabled.focus,.btn-success.disabled:active,.btn-success.disabled:focus,.btn-success.disabled:hover,.btn-success[disabled],.btn-success[disabled].active,.btn-success[disabled].focus,.btn-success[disabled]:active,.btn-success[disabled]:focus,.btn-success[disabled]:hover,fieldset[disabled] .btn-success,fieldset[disabled] .btn-success.active,fieldset[disabled] .btn-success.focus,fieldset[disabled] .btn-success:active,fieldset[disabled] .btn-success:focus,fieldset[disabled] .btn-success:hover{background-color:#5cb85c;border-color:#4cae4c}.btn-success .badge{color:#5cb85c;background-color:#fff}.btn-info{color:#fff;background-color:#5bc0de;border-color:#46b8da}.btn-info.focus,.btn-info:focus{color:#fff;background-color:#31b0d5;border-color:#1b6d85}.btn-info:hover{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{color:#fff;background-color:#31b0d5;border-color:#269abc}.btn-info.active.focus,.btn-info.active:focus,.btn-info.active:hover,.btn-info:active.focus,.btn-info:active:focus,.btn-info:active:hover,.open>.dropdown-toggle.btn-info.focus,.open>.dropdown-toggle.btn-info:focus,.open>.dropdown-toggle.btn-info:hover{color:#fff;background-color:#269abc;border-color:#1b6d85}.btn-info.active,.btn-info:active,.open>.dropdown-toggle.btn-info{background-image:none}.btn-info.disabled,.btn-info.disabled.active,.btn-info.disabled.focus,.btn-info.disabled:active,.btn-info.disabled:focus,.btn-info.disabled:hover,.btn-info[disabled],.btn-info[disabled].active,.btn-info[disabled].focus,.btn-info[disabled]:active,.btn-info[disabled]:focus,.btn-info[disabled]:hover,fieldset[disabled] .btn-info,fieldset[disabled] .btn-info.active,fieldset[disabled] .btn-info.focus,fieldset[disabled] .btn-info:active,fieldset[disabled] .btn-info:focus,fieldset[disabled] .btn-info:hover{background-color:#5bc0de;border-color:#46b8da}.btn-info .badge{color:#5bc0de;background-color:#fff}.btn-warning{color:#fff;background-color:#f0ad4e;border-color:#eea236}.btn-warning.focus,.btn-warning:focus{color:#fff;background-color:#ec971f;border-color:#985f0d}.btn-warning:hover{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{color:#fff;background-color:#ec971f;border-color:#d58512}.btn-warning.active.focus,.btn-warning.active:focus,.btn-warning.active:hover,.btn-warning:active.focus,.btn-warning:active:focus,.btn-warning:active:hover,.open>.dropdown-toggle.btn-warning.focus,.open>.dropdown-toggle.btn-warning:focus,.open>.dropdown-toggle.btn-warning:hover{color:#fff;background-color:#d58512;border-color:#985f0d}.btn-warning.active,.btn-warning:active,.open>.dropdown-toggle.btn-warning{background-image:none}.btn-warning.disabled,.btn-warning.disabled.active,.btn-warning.disabled.focus,.btn-warning.disabled:active,.btn-warning.disabled:focus,.btn-warning.disabled:hover,.btn-warning[disabled],.btn-warning[disabled].active,.btn-warning[disabled].focus,.btn-warning[disabled]:active,.btn-warning[disabled]:focus,.btn-warning[disabled]:hover,fieldset[disabled] .btn-warning,fieldset[disabled] .btn-warning.active,fieldset[disabled] .btn-warning.focus,fieldset[disabled] .btn-warning:active,fieldset[disabled] .btn-warning:focus,fieldset[disabled] .btn-warning:hover{background-color:#f0ad4e;border-color:#eea236}.btn-warning .badge{color:#f0ad4e;background-color:#fff}.btn-danger{color:#fff;background-color:#d9534f;border-color:#d43f3a}.btn-danger.focus,.btn-danger:focus{color:#fff;background-color:#c9302c;border-color:#761c19}.btn-danger:hover{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{color:#fff;background-color:#c9302c;border-color:#ac2925}.btn-danger.active.focus,.btn-danger.active:focus,.btn-danger.active:hover,.btn-danger:active.focus,.btn-danger:active:focus,.btn-danger:active:hover,.open>.dropdown-toggle.btn-danger.focus,.open>.dropdown-toggle.btn-danger:focus,.open>.dropdown-toggle.btn-danger:hover{color:#fff;background-color:#ac2925;border-color:#761c19}.btn-danger.active,.btn-danger:active,.open>.dropdown-toggle.btn-danger{background-image:none}.btn-danger.disabled,.btn-danger.disabled.active,.btn-danger.disabled.focus,.btn-danger.disabled:active,.btn-danger.disabled:focus,.btn-danger.disabled:hover,.btn-danger[disabled],.btn-danger[disabled].active,.btn-danger[disabled].focus,.btn-danger[disabled]:active,.btn-danger[disabled]:focus,.btn-danger[disabled]:hover,fieldset[disabled] .btn-danger,fieldset[disabled] .btn-danger.active,fieldset[disabled] .btn-danger.focus,fieldset[disabled] .btn-danger:active,fieldset[disabled] .btn-danger:focus,fieldset[disabled] .btn-danger:hover{background-color:#d9534f;border-color:#d43f3a}.btn-danger .badge{color:#d9534f;background-color:#fff}.btn-link{font-weight:400;color:#337ab7;border-radius:0}.btn-link,.btn-link.active,.btn-link:active,.btn-link[disabled],fieldset[disabled] .btn-link{background-color:transparent;-webkit-box-shadow:none;box-shadow:none}.btn-link,.btn-link:active,.btn-link:focus,.btn-link:hover{border-color:transparent}.btn-link:focus,.btn-link:hover{color:#23527c;text-decoration:underline;background-color:transparent}.btn-link[disabled]:focus,.btn-link[disabled]:hover,fieldset[disabled] .btn-link:focus,fieldset[disabled] .btn-link:hover{color:#777;text-decoration:none}.btn-group-lg>.btn,.btn-lg{padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}.btn-group-sm>.btn,.btn-sm{padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}.btn-group-xs>.btn,.btn-xs{padding:1px 5px;font-size:12px;line-height:1.5;border-radius:3px}.btn-block{display:block;width:100%}.btn-block+.btn-block{margin-top:5px}input[type=button].btn-block,input[type=reset].btn-block,input[type=submit].btn-block{width:100%}.fade{opacity:0;-webkit-transition:opacity .15s linear;-o-transition:opacity .15s linear;transition:opacity .15s linear}.fade.in{opacity:1}.collapse{display:none}.collapse.in{display:block}tr.collapse.in{display:table-row}tbody.collapse.in{display:table-row-group}.collapsing{position:relative;height:0;overflow:hidden;-webkit-transition-timing-function:ease;-o-transition-timing-function:ease;transition-timing-function:ease;-webkit-transition-duration:.35s;-o-transition-duration:.35s;transition-duration:.35s;-webkit-transition-property:height,visibility;-o-transition-property:height,visibility;transition-property:height,visibility}.caret{display:inline-block;width:0;height:0;margin-left:2px;vertical-align:middle;border-top:4px dashed;border-top:4px solid\9;border-right:4px solid transparent;border-left:4px solid transparent}.dropdown,.dropup{position:relative}.dropdown-toggle:focus{outline:0}.dropdown-menu{position:absolute;top:100%;left:0;z-index:1000;display:none;float:left;min-width:160px;padding:5px 0;margin:2px 0 0;font-size:14px;text-align:left;list-style:none;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.15);border-radius:4px;-webkit-box-shadow:0 6px 12px rgba(0,0,0,.175);box-shadow:0 6px 12px rgba(0,0,0,.175)}.dropdown-menu.pull-right{right:0;left:auto}.dropdown-menu .divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.dropdown-menu>li>a{display:block;padding:3px 20px;clear:both;font-weight:400;line-height:1.42857143;color:#333;white-space:nowrap}.dropdown-menu>li>a:focus,.dropdown-menu>li>a:hover{color:#262626;text-decoration:none;background-color:#f5f5f5}.dropdown-menu>.active>a,.dropdown-menu>.active>a:focus,.dropdown-menu>.active>a:hover{color:#fff;text-decoration:none;background-color:#337ab7;outline:0}.dropdown-menu>.disabled>a,.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{color:#777}.dropdown-menu>.disabled>a:focus,.dropdown-menu>.disabled>a:hover{text-decoration:none;cursor:not-allowed;background-color:transparent;background-image:none;filter:progid:DXImageTransform.Microsoft.gradient(enabled=false)}.open>.dropdown-menu{display:block}.open>a{outline:0}.dropdown-menu-right{right:0;left:auto}.dropdown-menu-left{right:auto;left:0}.dropdown-header{display:block;padding:3px 20px;font-size:12px;line-height:1.42857143;color:#777;white-space:nowrap}.dropdown-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:990}.pull-right>.dropdown-menu{right:0;left:auto}.dropup .caret,.navbar-fixed-bottom .dropdown .caret{content:"";border-top:0;border-bottom:4px dashed;border-bottom:4px solid\9}.dropup .dropdown-menu,.navbar-fixed-bottom .dropdown .dropdown-menu{top:auto;bottom:100%;margin-bottom:2px}@media (min-width:768px){.navbar-right .dropdown-menu{right:0;left:auto}.navbar-right .dropdown-menu-left{right:auto;left:0}}.btn-group,.btn-group-vertical{position:relative;display:inline-block;vertical-align:middle}.btn-group-vertical>.btn,.btn-group>.btn{position:relative;float:left}.btn-group-vertical>.btn.active,.btn-group-vertical>.btn:active,.btn-group-vertical>.btn:focus,.btn-group-vertical>.btn:hover,.btn-group>.btn.active,.btn-group>.btn:active,.btn-group>.btn:focus,.btn-group>.btn:hover{z-index:2}.btn-group .btn+.btn,.btn-group .btn+.btn-group,.btn-group .btn-group+.btn,.btn-group .btn-group+.btn-group{margin-left:-1px}.btn-toolbar{margin-left:-5px}.btn-toolbar .btn,.btn-toolbar .btn-group,.btn-toolbar .input-group{float:left}.btn-toolbar>.btn,.btn-toolbar>.btn-group,.btn-toolbar>.input-group{margin-left:5px}.btn-group>.btn:not(:first-child):not(:last-child):not(.dropdown-toggle){border-radius:0}.btn-group>.btn:first-child{margin-left:0}.btn-group>.btn:first-child:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn:last-child:not(:first-child),.btn-group>.dropdown-toggle:not(:first-child){border-top-left-radius:0;border-bottom-left-radius:0}.btn-group>.btn-group{float:left}.btn-group>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-top-right-radius:0;border-bottom-right-radius:0}.btn-group>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-bottom-left-radius:0}.btn-group .dropdown-toggle:active,.btn-group.open .dropdown-toggle{outline:0}.btn-group>.btn+.dropdown-toggle{padding-right:8px;padding-left:8px}.btn-group>.btn-lg+.dropdown-toggle{padding-right:12px;padding-left:12px}.btn-group.open .dropdown-toggle{-webkit-box-shadow:inset 0 3px 5px rgba(0,0,0,.125);box-shadow:inset 0 3px 5px rgba(0,0,0,.125)}.btn-group.open .dropdown-toggle.btn-link{-webkit-box-shadow:none;box-shadow:none}.btn .caret{margin-left:0}.btn-lg .caret{border-width:5px 5px 0;border-bottom-width:0}.dropup .btn-lg .caret{border-width:0 5px 5px}.btn-group-vertical>.btn,.btn-group-vertical>.btn-group,.btn-group-vertical>.btn-group>.btn{display:block;float:none;width:100%;max-width:100%}.btn-group-vertical>.btn-group>.btn{float:none}.btn-group-vertical>.btn+.btn,.btn-group-vertical>.btn+.btn-group,.btn-group-vertical>.btn-group+.btn,.btn-group-vertical>.btn-group+.btn-group{margin-top:-1px;margin-left:0}.btn-group-vertical>.btn:not(:first-child):not(:last-child){border-radius:0}.btn-group-vertical>.btn:first-child:not(:last-child){border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn:last-child:not(:first-child){border-top-left-radius:0;border-top-right-radius:0;border-bottom-left-radius:4px}.btn-group-vertical>.btn-group:not(:first-child):not(:last-child)>.btn{border-radius:0}.btn-group-vertical>.btn-group:first-child:not(:last-child)>.btn:last-child,.btn-group-vertical>.btn-group:first-child:not(:last-child)>.dropdown-toggle{border-bottom-right-radius:0;border-bottom-left-radius:0}.btn-group-vertical>.btn-group:last-child:not(:first-child)>.btn:first-child{border-top-left-radius:0;border-top-right-radius:0}.btn-group-justified{display:table;width:100%;table-layout:fixed;border-collapse:separate}.btn-group-justified>.btn,.btn-group-justified>.btn-group{display:table-cell;float:none;width:1%}.btn-group-justified>.btn-group .btn{width:100%}.btn-group-justified>.btn-group .dropdown-menu{left:auto}[data-toggle=buttons]>.btn input[type=checkbox],[data-toggle=buttons]>.btn input[type=radio],[data-toggle=buttons]>.btn-group>.btn input[type=checkbox],[data-toggle=buttons]>.btn-group>.btn input[type=radio]{position:absolute;clip:rect(0,0,0,0);pointer-events:none}.input-group{position:relative;display:table;border-collapse:separate}.input-group[class*=col-]{float:none;padding-right:0;padding-left:0}.input-group .form-control{position:relative;z-index:2;float:left;width:100%;margin-bottom:0}.input-group-lg>.form-control,.input-group-lg>.input-group-addon,.input-group-lg>.input-group-btn>.btn{height:46px;padding:10px 16px;font-size:18px;line-height:1.3333333;border-radius:6px}select.input-group-lg>.form-control,select.input-group-lg>.input-group-addon,select.input-group-lg>.input-group-btn>.btn{height:46px;line-height:46px}select[multiple].input-group-lg>.form-control,select[multiple].input-group-lg>.input-group-addon,select[multiple].input-group-lg>.input-group-btn>.btn,textarea.input-group-lg>.form-control,textarea.input-group-lg>.input-group-addon,textarea.input-group-lg>.input-group-btn>.btn{height:auto}.input-group-sm>.form-control,.input-group-sm>.input-group-addon,.input-group-sm>.input-group-btn>.btn{height:30px;padding:5px 10px;font-size:12px;line-height:1.5;border-radius:3px}select.input-group-sm>.form-control,select.input-group-sm>.input-group-addon,select.input-group-sm>.input-group-btn>.btn{height:30px;line-height:30px}select[multiple].input-group-sm>.form-control,select[multiple].input-group-sm>.input-group-addon,select[multiple].input-group-sm>.input-group-btn>.btn,textarea.input-group-sm>.form-control,textarea.input-group-sm>.input-group-addon,textarea.input-group-sm>.input-group-btn>.btn{height:auto}.input-group .form-control,.input-group-addon,.input-group-btn{display:table-cell}.input-group .form-control:not(:first-child):not(:last-child),.input-group-addon:not(:first-child):not(:last-child),.input-group-btn:not(:first-child):not(:last-child){border-radius:0}.input-group-addon,.input-group-btn{width:1%;white-space:nowrap;vertical-align:middle}.input-group-addon{padding:6px 12px;font-size:14px;font-weight:400;line-height:1;color:#555;text-align:center;background-color:#eee;border:1px solid #ccc;border-radius:4px}.input-group-addon.input-sm{padding:5px 10px;font-size:12px;border-radius:3px}.input-group-addon.input-lg{padding:10px 16px;font-size:18px;border-radius:6px}.input-group-addon input[type=checkbox],.input-group-addon input[type=radio]{margin-top:0}.input-group .form-control:first-child,.input-group-addon:first-child,.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group>.btn,.input-group-btn:first-child>.dropdown-toggle,.input-group-btn:last-child>.btn-group:not(:last-child)>.btn,.input-group-btn:last-child>.btn:not(:last-child):not(.dropdown-toggle){border-top-right-radius:0;border-bottom-right-radius:0}.input-group-addon:first-child{border-right:0}.input-group .form-control:last-child,.input-group-addon:last-child,.input-group-btn:first-child>.btn-group:not(:first-child)>.btn,.input-group-btn:first-child>.btn:not(:first-child),.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group>.btn,.input-group-btn:last-child>.dropdown-toggle{border-top-left-radius:0;border-bottom-left-radius:0}.input-group-addon:last-child{border-left:0}.input-group-btn{position:relative;font-size:0;white-space:nowrap}.input-group-btn>.btn{position:relative}.input-group-btn>.btn+.btn{margin-left:-1px}.input-group-btn>.btn:active,.input-group-btn>.btn:focus,.input-group-btn>.btn:hover{z-index:2}.input-group-btn:first-child>.btn,.input-group-btn:first-child>.btn-group{margin-right:-1px}.input-group-btn:last-child>.btn,.input-group-btn:last-child>.btn-group{z-index:2;margin-left:-1px}.nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.nav>li.disabled>a{color:#777}.nav>li.disabled>a:focus,.nav>li.disabled>a:hover{color:#777;text-decoration:none;cursor:not-allowed;background-color:transparent}.nav .open>a,.nav .open>a:focus,.nav .open>a:hover{background-color:#eee;border-color:#337ab7}.nav .nav-divider{height:1px;margin:9px 0;overflow:hidden;background-color:#e5e5e5}.nav>li>a>img{max-width:none}.nav-tabs{border-bottom:1px solid #ddd}.nav-tabs>li{float:left;margin-bottom:-1px}.nav-tabs>li>a{margin-right:2px;line-height:1.42857143;border:1px solid transparent;border-radius:4px 4px 0 0}.nav-tabs>li>a:hover{border-color:#eee #eee #ddd}.nav-tabs>li.active>a,.nav-tabs>li.active>a:focus,.nav-tabs>li.active>a:hover{color:#555;cursor:default;background-color:#fff;border:1px solid #ddd;border-bottom-color:transparent}.nav-tabs.nav-justified{width:100%;border-bottom:0}.nav-tabs.nav-justified>li{float:none}.nav-tabs.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-tabs.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-tabs.nav-justified>li{display:table-cell;width:1%}.nav-tabs.nav-justified>li>a{margin-bottom:0}}.nav-tabs.nav-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs.nav-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs.nav-justified>.active>a,.nav-tabs.nav-justified>.active>a:focus,.nav-tabs.nav-justified>.active>a:hover{border-bottom-color:#fff}}.nav-pills>li{float:left}.nav-pills>li>a{border-radius:4px}.nav-pills>li+li{margin-left:2px}.nav-pills>li.active>a,.nav-pills>li.active>a:focus,.nav-pills>li.active>a:hover{color:#fff;background-color:#337ab7}.nav-stacked>li{float:none}.nav-stacked>li+li{margin-top:2px;margin-left:0}.nav-justified{width:100%}.nav-justified>li{float:none}.nav-justified>li>a{margin-bottom:5px;text-align:center}.nav-justified>.dropdown .dropdown-menu{top:auto;left:auto}@media (min-width:768px){.nav-justified>li{display:table-cell;width:1%}.nav-justified>li>a{margin-bottom:0}}.nav-tabs-justified{border-bottom:0}.nav-tabs-justified>li>a{margin-right:0;border-radius:4px}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border:1px solid #ddd}@media (min-width:768px){.nav-tabs-justified>li>a{border-bottom:1px solid #ddd;border-radius:4px 4px 0 0}.nav-tabs-justified>.active>a,.nav-tabs-justified>.active>a:focus,.nav-tabs-justified>.active>a:hover{border-bottom-color:#fff}}.tab-content>.tab-pane{display:none}.tab-content>.active{display:block}.nav-tabs .dropdown-menu{margin-top:-1px;border-top-left-radius:0;border-top-right-radius:0}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.in{overflow-y:auto}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}.navbar-collapse.in{overflow-y:visible}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse,.navbar-static-top .navbar-collapse{padding-right:0;padding-left:0}}.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:340px}@media (max-device-width:480px) and (orientation:landscape){.navbar-fixed-bottom .navbar-collapse,.navbar-fixed-top .navbar-collapse{max-height:200px}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header,.container>.navbar-collapse,.container>.navbar-header{margin-right:0;margin-left:0}}.navbar-static-top{z-index:1000;border-width:0 0 1px}@media (min-width:768px){.navbar-static-top{border-radius:0}}.navbar-fixed-bottom,.navbar-fixed-top{position:fixed;right:0;left:0;z-index:1030}@media (min-width:768px){.navbar-fixed-bottom,.navbar-fixed-top{border-radius:0}}.navbar-fixed-top{top:0;border-width:0 0 1px}.navbar-fixed-bottom{bottom:0;margin-bottom:0;border-width:1px 0 0}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}.navbar-brand>img{display:block}@media (min-width:768px){.navbar>.container .navbar-brand,.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-toggle{position:relative;float:right;padding:9px 10px;margin-top:8px;margin-right:15px;margin-bottom:8px;background-color:transparent;background-image:none;border:1px solid transparent;border-radius:4px}.navbar-toggle:focus{outline:0}.navbar-toggle .icon-bar{display:block;width:22px;height:2px;border-radius:1px}.navbar-toggle .icon-bar+.icon-bar{margin-top:4px}@media (min-width:768px){.navbar-toggle{display:none}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (max-width:767px){.navbar-nav .open .dropdown-menu{position:static;float:none;width:auto;margin-top:0;background-color:transparent;border:0;-webkit-box-shadow:none;box-shadow:none}.navbar-nav .open .dropdown-menu .dropdown-header,.navbar-nav .open .dropdown-menu>li>a{padding:5px 15px 5px 25px}.navbar-nav .open .dropdown-menu>li>a{line-height:20px}.navbar-nav .open .dropdown-menu>li>a:focus,.navbar-nav .open .dropdown-menu>li>a:hover{background-image:none}}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}}.navbar-form{padding:10px 15px;margin-top:8px;margin-right:-15px;margin-bottom:8px;margin-left:-15px;border-top:1px solid transparent;border-bottom:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1),0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-form .form-group{display:inline-block;margin-bottom:0;vertical-align:middle}.navbar-form .form-control{display:inline-block;width:auto;vertical-align:middle}.navbar-form .form-control-static{display:inline-block}.navbar-form .input-group{display:inline-table;vertical-align:middle}.navbar-form .input-group .form-control,.navbar-form .input-group .input-group-addon,.navbar-form .input-group .input-group-btn{width:auto}.navbar-form .input-group>.form-control{width:100%}.navbar-form .control-label{margin-bottom:0;vertical-align:middle}.navbar-form .checkbox,.navbar-form .radio{display:inline-block;margin-top:0;margin-bottom:0;vertical-align:middle}.navbar-form .checkbox label,.navbar-form .radio label{padding-left:0}.navbar-form .checkbox input[type=checkbox],.navbar-form .radio input[type=radio]{position:relative;margin-left:0}.navbar-form .has-feedback .form-control-feedback{top:0}}@media (max-width:767px){.navbar-form .form-group{margin-bottom:5px}.navbar-form .form-group:last-child{margin-bottom:0}}@media (min-width:768px){.navbar-form{width:auto;padding-top:0;padding-bottom:0;margin-right:0;margin-left:0;border:0;-webkit-box-shadow:none;box-shadow:none}}.navbar-nav>li>.dropdown-menu{margin-top:0;border-top-left-radius:0;border-top-right-radius:0}.navbar-fixed-bottom .navbar-nav>li>.dropdown-menu{margin-bottom:0;border-top-left-radius:4px;border-top-right-radius:4px;border-bottom-right-radius:0;border-bottom-left-radius:0}.navbar-btn{margin-top:8px;margin-bottom:8px}.navbar-btn.btn-sm{margin-top:10px;margin-bottom:10px}.navbar-btn.btn-xs{margin-top:14px;margin-bottom:14px}.navbar-text{margin-top:15px;margin-bottom:15px}@media (min-width:768px){.navbar-text{float:left;margin-right:15px;margin-left:15px}}@media (min-width:768px){.navbar-left{float:left!important}.navbar-right{float:right!important;margin-right:-15px}.navbar-right~.navbar-right{margin-right:0}}.navbar-default{background-color:#f8f8f8;border-color:#e7e7e7}.navbar-default .navbar-brand{color:#777}.navbar-default .navbar-brand:focus,.navbar-default .navbar-brand:hover{color:#5e5e5e;background-color:transparent}.navbar-default .navbar-text{color:#777}.navbar-default .navbar-nav>li>a{color:#777}.navbar-default .navbar-nav>li>a:focus,.navbar-default .navbar-nav>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav>.active>a,.navbar-default .navbar-nav>.active>a:focus,.navbar-default .navbar-nav>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav>.disabled>a,.navbar-default .navbar-nav>.disabled>a:focus,.navbar-default .navbar-nav>.disabled>a:hover{color:#ccc;background-color:transparent}.navbar-default .navbar-toggle{border-color:#ddd}.navbar-default .navbar-toggle:focus,.navbar-default .navbar-toggle:hover{background-color:#ddd}.navbar-default .navbar-toggle .icon-bar{background-color:#888}.navbar-default .navbar-collapse,.navbar-default .navbar-form{border-color:#e7e7e7}.navbar-default .navbar-nav>.open>a,.navbar-default .navbar-nav>.open>a:focus,.navbar-default .navbar-nav>.open>a:hover{color:#555;background-color:#e7e7e7}@media (max-width:767px){.navbar-default .navbar-nav .open .dropdown-menu>li>a{color:#777}.navbar-default .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>li>a:hover{color:#333;background-color:transparent}.navbar-default .navbar-nav .open .dropdown-menu>.active>a,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.active>a:hover{color:#555;background-color:#e7e7e7}.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-default .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#ccc;background-color:transparent}}.navbar-default .navbar-link{color:#777}.navbar-default .navbar-link:hover{color:#333}.navbar-default .btn-link{color:#777}.navbar-default .btn-link:focus,.navbar-default .btn-link:hover{color:#333}.navbar-default .btn-link[disabled]:focus,.navbar-default .btn-link[disabled]:hover,fieldset[disabled] .navbar-default .btn-link:focus,fieldset[disabled] .navbar-default .btn-link:hover{color:#ccc}.navbar-inverse{background-color:#222;border-color:#080808}.navbar-inverse .navbar-brand{color:#9d9d9d}.navbar-inverse .navbar-brand:focus,.navbar-inverse .navbar-brand:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-text{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav>li>a:focus,.navbar-inverse .navbar-nav>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav>.active>a,.navbar-inverse .navbar-nav>.active>a:focus,.navbar-inverse .navbar-nav>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav>.disabled>a,.navbar-inverse .navbar-nav>.disabled>a:focus,.navbar-inverse .navbar-nav>.disabled>a:hover{color:#444;background-color:transparent}.navbar-inverse .navbar-toggle{border-color:#333}.navbar-inverse .navbar-toggle:focus,.navbar-inverse .navbar-toggle:hover{background-color:#333}.navbar-inverse .navbar-toggle .icon-bar{background-color:#fff}.navbar-inverse .navbar-collapse,.navbar-inverse .navbar-form{border-color:#101010}.navbar-inverse .navbar-nav>.open>a,.navbar-inverse .navbar-nav>.open>a:focus,.navbar-inverse .navbar-nav>.open>a:hover{color:#fff;background-color:#080808}@media (max-width:767px){.navbar-inverse .navbar-nav .open .dropdown-menu>.dropdown-header{border-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu .divider{background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a{color:#9d9d9d}.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>li>a:hover{color:#fff;background-color:transparent}.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.active>a:hover{color:#fff;background-color:#080808}.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:focus,.navbar-inverse .navbar-nav .open .dropdown-menu>.disabled>a:hover{color:#444;background-color:transparent}}.navbar-inverse .navbar-link{color:#9d9d9d}.navbar-inverse .navbar-link:hover{color:#fff}.navbar-inverse .btn-link{color:#9d9d9d}.navbar-inverse .btn-link:focus,.navbar-inverse .btn-link:hover{color:#fff}.navbar-inverse .btn-link[disabled]:focus,.navbar-inverse .btn-link[disabled]:hover,fieldset[disabled] .navbar-inverse .btn-link:focus,fieldset[disabled] .navbar-inverse .btn-link:hover{color:#444}.breadcrumb{padding:8px 15px;margin-bottom:20px;list-style:none;background-color:#f5f5f5;border-radius:4px}.breadcrumb>li{display:inline-block}.breadcrumb>li+li:before{padding:0 5px;color:#ccc;content:"/\00a0"}.breadcrumb>.active{color:#777}.pagination{display:inline-block;padding-left:0;margin:20px 0;border-radius:4px}.pagination>li{display:inline}.pagination>li>a,.pagination>li>span{position:relative;float:left;padding:6px 12px;margin-left:-1px;line-height:1.42857143;color:#337ab7;text-decoration:none;background-color:#fff;border:1px solid #ddd}.pagination>li:first-child>a,.pagination>li:first-child>span{margin-left:0;border-top-left-radius:4px;border-bottom-left-radius:4px}.pagination>li:last-child>a,.pagination>li:last-child>span{border-top-right-radius:4px;border-bottom-right-radius:4px}.pagination>li>a:focus,.pagination>li>a:hover,.pagination>li>span:focus,.pagination>li>span:hover{z-index:3;color:#23527c;background-color:#eee;border-color:#ddd}.pagination>.active>a,.pagination>.active>a:focus,.pagination>.active>a:hover,.pagination>.active>span,.pagination>.active>span:focus,.pagination>.active>span:hover{z-index:2;color:#fff;cursor:default;background-color:#337ab7;border-color:#337ab7}.pagination>.disabled>a,.pagination>.disabled>a:focus,.pagination>.disabled>a:hover,.pagination>.disabled>span,.pagination>.disabled>span:focus,.pagination>.disabled>span:hover{color:#777;cursor:not-allowed;background-color:#fff;border-color:#ddd}.pagination-lg>li>a,.pagination-lg>li>span{padding:10px 16px;font-size:18px;line-height:1.3333333}.pagination-lg>li:first-child>a,.pagination-lg>li:first-child>span{border-top-left-radius:6px;border-bottom-left-radius:6px}.pagination-lg>li:last-child>a,.pagination-lg>li:last-child>span{border-top-right-radius:6px;border-bottom-right-radius:6px}.pagination-sm>li>a,.pagination-sm>li>span{padding:5px 10px;font-size:12px;line-height:1.5}.pagination-sm>li:first-child>a,.pagination-sm>li:first-child>span{border-top-left-radius:3px;border-bottom-left-radius:3px}.pagination-sm>li:last-child>a,.pagination-sm>li:last-child>span{border-top-right-radius:3px;border-bottom-right-radius:3px}.pager{padding-left:0;margin:20px 0;text-align:center;list-style:none}.pager li{display:inline}.pager li>a,.pager li>span{display:inline-block;padding:5px 14px;background-color:#fff;border:1px solid #ddd;border-radius:15px}.pager li>a:focus,.pager li>a:hover{text-decoration:none;background-color:#eee}.pager .next>a,.pager .next>span{float:right}.pager .previous>a,.pager .previous>span{float:left}.pager .disabled>a,.pager .disabled>a:focus,.pager .disabled>a:hover,.pager .disabled>span{color:#777;cursor:not-allowed;background-color:#fff}.label{display:inline;padding:.2em .6em .3em;font-size:75%;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:baseline;border-radius:.25em}a.label:focus,a.label:hover{color:#fff;text-decoration:none;cursor:pointer}.label:empty{display:none}.btn .label{position:relative;top:-1px}.label-default{background-color:#777}.label-default[href]:focus,.label-default[href]:hover{background-color:#5e5e5e}.label-primary{background-color:#337ab7}.label-primary[href]:focus,.label-primary[href]:hover{background-color:#286090}.label-success{background-color:#5cb85c}.label-success[href]:focus,.label-success[href]:hover{background-color:#449d44}.label-info{background-color:#5bc0de}.label-info[href]:focus,.label-info[href]:hover{background-color:#31b0d5}.label-warning{background-color:#f0ad4e}.label-warning[href]:focus,.label-warning[href]:hover{background-color:#ec971f}.label-danger{background-color:#d9534f}.label-danger[href]:focus,.label-danger[href]:hover{background-color:#c9302c}.badge{display:inline-block;min-width:10px;padding:3px 7px;font-size:12px;font-weight:700;line-height:1;color:#fff;text-align:center;white-space:nowrap;vertical-align:middle;background-color:#777;border-radius:10px}.badge:empty{display:none}.btn .badge{position:relative;top:-1px}.btn-group-xs>.btn .badge,.btn-xs .badge{top:0;padding:1px 5px}a.badge:focus,a.badge:hover{color:#fff;text-decoration:none;cursor:pointer}.list-group-item.active>.badge,.nav-pills>.active>a>.badge{color:#337ab7;background-color:#fff}.list-group-item>.badge{float:right}.list-group-item>.badge+.badge{margin-right:5px}.nav-pills>li>a>.badge{margin-left:3px}.jumbotron{padding-top:30px;padding-bottom:30px;margin-bottom:30px;color:inherit;background-color:#eee}.jumbotron .h1,.jumbotron h1{color:inherit}.jumbotron p{margin-bottom:15px;font-size:21px;font-weight:200}.jumbotron>hr{border-top-color:#d5d5d5}.container .jumbotron,.container-fluid .jumbotron{border-radius:6px}.jumbotron .container{max-width:100%}@media screen and (min-width:768px){.jumbotron{padding-top:48px;padding-bottom:48px}.container .jumbotron,.container-fluid .jumbotron{padding-right:60px;padding-left:60px}.jumbotron .h1,.jumbotron h1{font-size:63px}}.thumbnail{display:block;padding:4px;margin-bottom:20px;line-height:1.42857143;background-color:#fff;border:1px solid #ddd;border-radius:4px;-webkit-transition:border .2s ease-in-out;-o-transition:border .2s ease-in-out;transition:border .2s ease-in-out}.thumbnail a>img,.thumbnail>img{margin-right:auto;margin-left:auto}a.thumbnail.active,a.thumbnail:focus,a.thumbnail:hover{border-color:#337ab7}.thumbnail .caption{padding:9px;color:#333}.alert{padding:15px;margin-bottom:20px;border:1px solid transparent;border-radius:4px}.alert h4{margin-top:0;color:inherit}.alert .alert-link{font-weight:700}.alert>p,.alert>ul{margin-bottom:0}.alert>p+p{margin-top:5px}.alert-dismissable,.alert-dismissible{padding-right:35px}.alert-dismissable .close,.alert-dismissible .close{position:relative;top:-2px;right:-21px;color:inherit}.alert-success{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.alert-success hr{border-top-color:#c9e2b3}.alert-success .alert-link{color:#2b542c}.alert-info{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.alert-info hr{border-top-color:#a6e1ec}.alert-info .alert-link{color:#245269}.alert-warning{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.alert-warning hr{border-top-color:#f7e1b5}.alert-warning .alert-link{color:#66512c}.alert-danger{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.alert-danger hr{border-top-color:#e4b9c0}.alert-danger .alert-link{color:#843534}@-webkit-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@-o-keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}@keyframes progress-bar-stripes{from{background-position:40px 0}to{background-position:0 0}}.progress{height:20px;margin-bottom:20px;overflow:hidden;background-color:#f5f5f5;border-radius:4px;-webkit-box-shadow:inset 0 1px 2px rgba(0,0,0,.1);box-shadow:inset 0 1px 2px rgba(0,0,0,.1)}.progress-bar{float:left;width:0;height:100%;font-size:12px;line-height:20px;color:#fff;text-align:center;background-color:#337ab7;-webkit-box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);box-shadow:inset 0 -1px 0 rgba(0,0,0,.15);-webkit-transition:width .6s ease;-o-transition:width .6s ease;transition:width .6s ease}.progress-bar-striped,.progress-striped .progress-bar{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);-webkit-background-size:40px 40px;background-size:40px 40px}.progress-bar.active,.progress.active .progress-bar{-webkit-animation:progress-bar-stripes 2s linear infinite;-o-animation:progress-bar-stripes 2s linear infinite;animation:progress-bar-stripes 2s linear infinite}.progress-bar-success{background-color:#5cb85c}.progress-striped .progress-bar-success{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-info{background-color:#5bc0de}.progress-striped .progress-bar-info{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-warning{background-color:#f0ad4e}.progress-striped .progress-bar-warning{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.progress-bar-danger{background-color:#d9534f}.progress-striped .progress-bar-danger{background-image:-webkit-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:-o-linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent);background-image:linear-gradient(45deg,rgba(255,255,255,.15) 25%,transparent 25%,transparent 50%,rgba(255,255,255,.15) 50%,rgba(255,255,255,.15) 75%,transparent 75%,transparent)}.media{margin-top:15px}.media:first-child{margin-top:0}.media,.media-body{overflow:hidden;zoom:1}.media-body{width:10000px}.media-object{display:block}.media-object.img-thumbnail{max-width:none}.media-right,.media>.pull-right{padding-left:10px}.media-left,.media>.pull-left{padding-right:10px}.media-body,.media-left,.media-right{display:table-cell;vertical-align:top}.media-middle{vertical-align:middle}.media-bottom{vertical-align:bottom}.media-heading{margin-top:0;margin-bottom:5px}.media-list{padding-left:0;list-style:none}.list-group{padding-left:0;margin-bottom:20px}.list-group-item{position:relative;display:block;padding:10px 15px;margin-bottom:-1px;background-color:#fff;border:1px solid #ddd}.list-group-item:first-child{border-top-left-radius:4px;border-top-right-radius:4px}.list-group-item:last-child{margin-bottom:0;border-bottom-right-radius:4px;border-bottom-left-radius:4px}a.list-group-item,button.list-group-item{color:#555}a.list-group-item .list-group-item-heading,button.list-group-item .list-group-item-heading{color:#333}a.list-group-item:focus,a.list-group-item:hover,button.list-group-item:focus,button.list-group-item:hover{color:#555;text-decoration:none;background-color:#f5f5f5}button.list-group-item{width:100%;text-align:left}.list-group-item.disabled,.list-group-item.disabled:focus,.list-group-item.disabled:hover{color:#777;cursor:not-allowed;background-color:#eee}.list-group-item.disabled .list-group-item-heading,.list-group-item.disabled:focus .list-group-item-heading,.list-group-item.disabled:hover .list-group-item-heading{color:inherit}.list-group-item.disabled .list-group-item-text,.list-group-item.disabled:focus .list-group-item-text,.list-group-item.disabled:hover .list-group-item-text{color:#777}.list-group-item.active,.list-group-item.active:focus,.list-group-item.active:hover{z-index:2;color:#fff;background-color:#337ab7;border-color:#337ab7}.list-group-item.active .list-group-item-heading,.list-group-item.active .list-group-item-heading>.small,.list-group-item.active .list-group-item-heading>small,.list-group-item.active:focus .list-group-item-heading,.list-group-item.active:focus .list-group-item-heading>.small,.list-group-item.active:focus .list-group-item-heading>small,.list-group-item.active:hover .list-group-item-heading,.list-group-item.active:hover .list-group-item-heading>.small,.list-group-item.active:hover .list-group-item-heading>small{color:inherit}.list-group-item.active .list-group-item-text,.list-group-item.active:focus .list-group-item-text,.list-group-item.active:hover .list-group-item-text{color:#c7ddef}.list-group-item-success{color:#3c763d;background-color:#dff0d8}a.list-group-item-success,button.list-group-item-success{color:#3c763d}a.list-group-item-success .list-group-item-heading,button.list-group-item-success .list-group-item-heading{color:inherit}a.list-group-item-success:focus,a.list-group-item-success:hover,button.list-group-item-success:focus,button.list-group-item-success:hover{color:#3c763d;background-color:#d0e9c6}a.list-group-item-success.active,a.list-group-item-success.active:focus,a.list-group-item-success.active:hover,button.list-group-item-success.active,button.list-group-item-success.active:focus,button.list-group-item-success.active:hover{color:#fff;background-color:#3c763d;border-color:#3c763d}.list-group-item-info{color:#31708f;background-color:#d9edf7}a.list-group-item-info,button.list-group-item-info{color:#31708f}a.list-group-item-info .list-group-item-heading,button.list-group-item-info .list-group-item-heading{color:inherit}a.list-group-item-info:focus,a.list-group-item-info:hover,button.list-group-item-info:focus,button.list-group-item-info:hover{color:#31708f;background-color:#c4e3f3}a.list-group-item-info.active,a.list-group-item-info.active:focus,a.list-group-item-info.active:hover,button.list-group-item-info.active,button.list-group-item-info.active:focus,button.list-group-item-info.active:hover{color:#fff;background-color:#31708f;border-color:#31708f}.list-group-item-warning{color:#8a6d3b;background-color:#fcf8e3}a.list-group-item-warning,button.list-group-item-warning{color:#8a6d3b}a.list-group-item-warning .list-group-item-heading,button.list-group-item-warning .list-group-item-heading{color:inherit}a.list-group-item-warning:focus,a.list-group-item-warning:hover,button.list-group-item-warning:focus,button.list-group-item-warning:hover{color:#8a6d3b;background-color:#faf2cc}a.list-group-item-warning.active,a.list-group-item-warning.active:focus,a.list-group-item-warning.active:hover,button.list-group-item-warning.active,button.list-group-item-warning.active:focus,button.list-group-item-warning.active:hover{color:#fff;background-color:#8a6d3b;border-color:#8a6d3b}.list-group-item-danger{color:#a94442;background-color:#f2dede}a.list-group-item-danger,button.list-group-item-danger{color:#a94442}a.list-group-item-danger .list-group-item-heading,button.list-group-item-danger .list-group-item-heading{color:inherit}a.list-group-item-danger:focus,a.list-group-item-danger:hover,button.list-group-item-danger:focus,button.list-group-item-danger:hover{color:#a94442;background-color:#ebcccc}a.list-group-item-danger.active,a.list-group-item-danger.active:focus,a.list-group-item-danger.active:hover,button.list-group-item-danger.active,button.list-group-item-danger.active:focus,button.list-group-item-danger.active:hover{color:#fff;background-color:#a94442;border-color:#a94442}.list-group-item-heading{margin-top:0;margin-bottom:5px}.list-group-item-text{margin-bottom:0;line-height:1.3}.panel{margin-bottom:20px;background-color:#fff;border:1px solid transparent;border-radius:4px;-webkit-box-shadow:0 1px 1px rgba(0,0,0,.05);box-shadow:0 1px 1px rgba(0,0,0,.05)}.panel-body{padding:15px}.panel-heading{padding:10px 15px;border-bottom:1px solid transparent;border-top-left-radius:3px;border-top-right-radius:3px}.panel-heading>.dropdown .dropdown-toggle{color:inherit}.panel-title{margin-top:0;margin-bottom:0;font-size:16px;color:inherit}.panel-title>.small,.panel-title>.small>a,.panel-title>a,.panel-title>small,.panel-title>small>a{color:inherit}.panel-footer{padding:10px 15px;background-color:#f5f5f5;border-top:1px solid #ddd;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.list-group,.panel>.panel-collapse>.list-group{margin-bottom:0}.panel>.list-group .list-group-item,.panel>.panel-collapse>.list-group .list-group-item{border-width:1px 0;border-radius:0}.panel>.list-group:first-child .list-group-item:first-child,.panel>.panel-collapse>.list-group:first-child .list-group-item:first-child{border-top:0;border-top-left-radius:3px;border-top-right-radius:3px}.panel>.list-group:last-child .list-group-item:last-child,.panel>.panel-collapse>.list-group:last-child .list-group-item:last-child{border-bottom:0;border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.panel-heading+.panel-collapse>.list-group .list-group-item:first-child{border-top-left-radius:0;border-top-right-radius:0}.panel-heading+.list-group .list-group-item:first-child{border-top-width:0}.list-group+.panel-footer{border-top-width:0}.panel>.panel-collapse>.table,.panel>.table,.panel>.table-responsive>.table{margin-bottom:0}.panel>.panel-collapse>.table caption,.panel>.table caption,.panel>.table-responsive>.table caption{padding-right:15px;padding-left:15px}.panel>.table-responsive:first-child>.table:first-child,.panel>.table:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child,.panel>.table:first-child>thead:first-child>tr:first-child{border-top-left-radius:3px;border-top-right-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:first-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:first-child,.panel>.table:first-child>thead:first-child>tr:first-child td:first-child,.panel>.table:first-child>thead:first-child>tr:first-child th:first-child{border-top-left-radius:3px}.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table-responsive:first-child>.table:first-child>thead:first-child>tr:first-child th:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child td:last-child,.panel>.table:first-child>tbody:first-child>tr:first-child th:last-child,.panel>.table:first-child>thead:first-child>tr:first-child td:last-child,.panel>.table:first-child>thead:first-child>tr:first-child th:last-child{border-top-right-radius:3px}.panel>.table-responsive:last-child>.table:last-child,.panel>.table:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child{border-bottom-right-radius:3px;border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:first-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:first-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:first-child{border-bottom-left-radius:3px}.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table-responsive:last-child>.table:last-child>tfoot:last-child>tr:last-child th:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child td:last-child,.panel>.table:last-child>tbody:last-child>tr:last-child th:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child td:last-child,.panel>.table:last-child>tfoot:last-child>tr:last-child th:last-child{border-bottom-right-radius:3px}.panel>.panel-body+.table,.panel>.panel-body+.table-responsive,.panel>.table+.panel-body,.panel>.table-responsive+.panel-body{border-top:1px solid #ddd}.panel>.table>tbody:first-child>tr:first-child td,.panel>.table>tbody:first-child>tr:first-child th{border-top:0}.panel>.table-bordered,.panel>.table-responsive>.table-bordered{border:0}.panel>.table-bordered>tbody>tr>td:first-child,.panel>.table-bordered>tbody>tr>th:first-child,.panel>.table-bordered>tfoot>tr>td:first-child,.panel>.table-bordered>tfoot>tr>th:first-child,.panel>.table-bordered>thead>tr>td:first-child,.panel>.table-bordered>thead>tr>th:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:first-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:first-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:first-child,.panel>.table-responsive>.table-bordered>thead>tr>td:first-child,.panel>.table-responsive>.table-bordered>thead>tr>th:first-child{border-left:0}.panel>.table-bordered>tbody>tr>td:last-child,.panel>.table-bordered>tbody>tr>th:last-child,.panel>.table-bordered>tfoot>tr>td:last-child,.panel>.table-bordered>tfoot>tr>th:last-child,.panel>.table-bordered>thead>tr>td:last-child,.panel>.table-bordered>thead>tr>th:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>td:last-child,.panel>.table-responsive>.table-bordered>tbody>tr>th:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>td:last-child,.panel>.table-responsive>.table-bordered>tfoot>tr>th:last-child,.panel>.table-responsive>.table-bordered>thead>tr>td:last-child,.panel>.table-responsive>.table-bordered>thead>tr>th:last-child{border-right:0}.panel>.table-bordered>tbody>tr:first-child>td,.panel>.table-bordered>tbody>tr:first-child>th,.panel>.table-bordered>thead>tr:first-child>td,.panel>.table-bordered>thead>tr:first-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:first-child>th,.panel>.table-responsive>.table-bordered>thead>tr:first-child>td,.panel>.table-responsive>.table-bordered>thead>tr:first-child>th{border-bottom:0}.panel>.table-bordered>tbody>tr:last-child>td,.panel>.table-bordered>tbody>tr:last-child>th,.panel>.table-bordered>tfoot>tr:last-child>td,.panel>.table-bordered>tfoot>tr:last-child>th,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>td,.panel>.table-responsive>.table-bordered>tbody>tr:last-child>th,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>td,.panel>.table-responsive>.table-bordered>tfoot>tr:last-child>th{border-bottom:0}.panel>.table-responsive{margin-bottom:0;border:0}.panel-group{margin-bottom:20px}.panel-group .panel{margin-bottom:0;border-radius:4px}.panel-group .panel+.panel{margin-top:5px}.panel-group .panel-heading{border-bottom:0}.panel-group .panel-heading+.panel-collapse>.list-group,.panel-group .panel-heading+.panel-collapse>.panel-body{border-top:1px solid #ddd}.panel-group .panel-footer{border-top:0}.panel-group .panel-footer+.panel-collapse .panel-body{border-bottom:1px solid #ddd}.panel-default{border-color:#ddd}.panel-default>.panel-heading{color:#333;background-color:#f5f5f5;border-color:#ddd}.panel-default>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ddd}.panel-default>.panel-heading .badge{color:#f5f5f5;background-color:#333}.panel-default>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ddd}.panel-primary{border-color:#337ab7}.panel-primary>.panel-heading{color:#fff;background-color:#337ab7;border-color:#337ab7}.panel-primary>.panel-heading+.panel-collapse>.panel-body{border-top-color:#337ab7}.panel-primary>.panel-heading .badge{color:#337ab7;background-color:#fff}.panel-primary>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#337ab7}.panel-success{border-color:#d6e9c6}.panel-success>.panel-heading{color:#3c763d;background-color:#dff0d8;border-color:#d6e9c6}.panel-success>.panel-heading+.panel-collapse>.panel-body{border-top-color:#d6e9c6}.panel-success>.panel-heading .badge{color:#dff0d8;background-color:#3c763d}.panel-success>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#d6e9c6}.panel-info{border-color:#bce8f1}.panel-info>.panel-heading{color:#31708f;background-color:#d9edf7;border-color:#bce8f1}.panel-info>.panel-heading+.panel-collapse>.panel-body{border-top-color:#bce8f1}.panel-info>.panel-heading .badge{color:#d9edf7;background-color:#31708f}.panel-info>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#bce8f1}.panel-warning{border-color:#faebcc}.panel-warning>.panel-heading{color:#8a6d3b;background-color:#fcf8e3;border-color:#faebcc}.panel-warning>.panel-heading+.panel-collapse>.panel-body{border-top-color:#faebcc}.panel-warning>.panel-heading .badge{color:#fcf8e3;background-color:#8a6d3b}.panel-warning>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#faebcc}.panel-danger{border-color:#ebccd1}.panel-danger>.panel-heading{color:#a94442;background-color:#f2dede;border-color:#ebccd1}.panel-danger>.panel-heading+.panel-collapse>.panel-body{border-top-color:#ebccd1}.panel-danger>.panel-heading .badge{color:#f2dede;background-color:#a94442}.panel-danger>.panel-footer+.panel-collapse>.panel-body{border-bottom-color:#ebccd1}.embed-responsive{position:relative;display:block;height:0;padding:0;overflow:hidden}.embed-responsive .embed-responsive-item,.embed-responsive embed,.embed-responsive iframe,.embed-responsive object,.embed-responsive video{position:absolute;top:0;bottom:0;left:0;width:100%;height:100%;border:0}.embed-responsive-16by9{padding-bottom:56.25%}.embed-responsive-4by3{padding-bottom:75%}.well{min-height:20px;padding:19px;margin-bottom:20px;background-color:#f5f5f5;border:1px solid #e3e3e3;border-radius:4px;-webkit-box-shadow:inset 0 1px 1px rgba(0,0,0,.05);box-shadow:inset 0 1px 1px rgba(0,0,0,.05)}.well blockquote{border-color:#ddd;border-color:rgba(0,0,0,.15)}.well-lg{padding:24px;border-radius:6px}.well-sm{padding:9px;border-radius:3px}.close{float:right;font-size:21px;font-weight:700;line-height:1;color:#000;text-shadow:0 1px 0 #fff;filter:alpha(opacity=20);opacity:.2}.close:focus,.close:hover{color:#000;text-decoration:none;cursor:pointer;filter:alpha(opacity=50);opacity:.5}button.close{-webkit-appearance:none;padding:0;cursor:pointer;background:0 0;border:0}.modal-open{overflow:hidden}.modal{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1050;display:none;overflow:hidden;-webkit-overflow-scrolling:touch;outline:0}.modal.fade .modal-dialog{-webkit-transition:-webkit-transform .3s ease-out;-o-transition:-o-transform .3s ease-out;transition:transform .3s ease-out;-webkit-transform:translate(0,-25%);-ms-transform:translate(0,-25%);-o-transform:translate(0,-25%);transform:translate(0,-25%)}.modal.in .modal-dialog{-webkit-transform:translate(0,0);-ms-transform:translate(0,0);-o-transform:translate(0,0);transform:translate(0,0)}.modal-open .modal{overflow-x:hidden;overflow-y:auto}.modal-dialog{position:relative;width:auto;margin:10px}.modal-content{position:relative;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #999;border:1px solid rgba(0,0,0,.2);border-radius:6px;outline:0;-webkit-box-shadow:0 3px 9px rgba(0,0,0,.5);box-shadow:0 3px 9px rgba(0,0,0,.5)}.modal-backdrop{position:fixed;top:0;right:0;bottom:0;left:0;z-index:1040;background-color:#000}.modal-backdrop.fade{filter:alpha(opacity=0);opacity:0}.modal-backdrop.in{filter:alpha(opacity=50);opacity:.5}.modal-header{min-height:16.43px;padding:15px;border-bottom:1px solid #e5e5e5}.modal-header .close{margin-top:-2px}.modal-title{margin:0;line-height:1.42857143}.modal-body{position:relative;padding:15px}.modal-footer{padding:15px;text-align:right;border-top:1px solid #e5e5e5}.modal-footer .btn+.btn{margin-bottom:0;margin-left:5px}.modal-footer .btn-group .btn+.btn{margin-left:-1px}.modal-footer .btn-block+.btn-block{margin-left:0}.modal-scrollbar-measure{position:absolute;top:-9999px;width:50px;height:50px;overflow:scroll}@media (min-width:768px){.modal-dialog{width:600px;margin:30px auto}.modal-content{-webkit-box-shadow:0 5px 15px rgba(0,0,0,.5);box-shadow:0 5px 15px rgba(0,0,0,.5)}.modal-sm{width:300px}}@media (min-width:992px){.modal-lg{width:900px}}.tooltip{position:absolute;z-index:1070;display:block;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:12px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;filter:alpha(opacity=0);opacity:0;line-break:auto}.tooltip.in{filter:alpha(opacity=90);opacity:.9}.tooltip.top{padding:5px 0;margin-top:-3px}.tooltip.right{padding:0 5px;margin-left:3px}.tooltip.bottom{padding:5px 0;margin-top:3px}.tooltip.left{padding:0 5px;margin-left:-3px}.tooltip-inner{max-width:200px;padding:3px 8px;color:#fff;text-align:center;background-color:#000;border-radius:4px}.tooltip-arrow{position:absolute;width:0;height:0;border-color:transparent;border-style:solid}.tooltip.top .tooltip-arrow{bottom:0;left:50%;margin-left:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-left .tooltip-arrow{right:5px;bottom:0;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.top-right .tooltip-arrow{bottom:0;left:5px;margin-bottom:-5px;border-width:5px 5px 0;border-top-color:#000}.tooltip.right .tooltip-arrow{top:50%;left:0;margin-top:-5px;border-width:5px 5px 5px 0;border-right-color:#000}.tooltip.left .tooltip-arrow{top:50%;right:0;margin-top:-5px;border-width:5px 0 5px 5px;border-left-color:#000}.tooltip.bottom .tooltip-arrow{top:0;left:50%;margin-left:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-left .tooltip-arrow{top:0;right:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.tooltip.bottom-right .tooltip-arrow{top:0;left:5px;margin-top:-5px;border-width:0 5px 5px;border-bottom-color:#000}.popover{position:absolute;top:0;left:0;z-index:1060;display:none;max-width:276px;padding:1px;font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;font-style:normal;font-weight:400;line-height:1.42857143;text-align:left;text-align:start;text-decoration:none;text-shadow:none;text-transform:none;letter-spacing:normal;word-break:normal;word-spacing:normal;word-wrap:normal;white-space:normal;background-color:#fff;-webkit-background-clip:padding-box;background-clip:padding-box;border:1px solid #ccc;border:1px solid rgba(0,0,0,.2);border-radius:6px;-webkit-box-shadow:0 5px 10px rgba(0,0,0,.2);box-shadow:0 5px 10px rgba(0,0,0,.2);line-break:auto}.popover.top{margin-top:-10px}.popover.right{margin-left:10px}.popover.bottom{margin-top:10px}.popover.left{margin-left:-10px}.popover-title{padding:8px 14px;margin:0;font-size:14px;background-color:#f7f7f7;border-bottom:1px solid #ebebeb;border-radius:5px 5px 0 0}.popover-content{padding:9px 14px}.popover>.arrow,.popover>.arrow:after{position:absolute;display:block;width:0;height:0;border-color:transparent;border-style:solid}.popover>.arrow{border-width:11px}.popover>.arrow:after{content:"";border-width:10px}.popover.top>.arrow{bottom:-11px;left:50%;margin-left:-11px;border-top-color:#999;border-top-color:rgba(0,0,0,.25);border-bottom-width:0}.popover.top>.arrow:after{bottom:1px;margin-left:-10px;content:" ";border-top-color:#fff;border-bottom-width:0}.popover.right>.arrow{top:50%;left:-11px;margin-top:-11px;border-right-color:#999;border-right-color:rgba(0,0,0,.25);border-left-width:0}.popover.right>.arrow:after{bottom:-10px;left:1px;content:" ";border-right-color:#fff;border-left-width:0}.popover.bottom>.arrow{top:-11px;left:50%;margin-left:-11px;border-top-width:0;border-bottom-color:#999;border-bottom-color:rgba(0,0,0,.25)}.popover.bottom>.arrow:after{top:1px;margin-left:-10px;content:" ";border-top-width:0;border-bottom-color:#fff}.popover.left>.arrow{top:50%;right:-11px;margin-top:-11px;border-right-width:0;border-left-color:#999;border-left-color:rgba(0,0,0,.25)}.popover.left>.arrow:after{right:1px;bottom:-10px;content:" ";border-right-width:0;border-left-color:#fff}.carousel{position:relative}.carousel-inner{position:relative;width:100%;overflow:hidden}.carousel-inner>.item{position:relative;display:none;-webkit-transition:.6s ease-in-out left;-o-transition:.6s ease-in-out left;transition:.6s ease-in-out left}.carousel-inner>.item>a>img,.carousel-inner>.item>img{line-height:1}@media all and (transform-3d),(-webkit-transform-3d){.carousel-inner>.item{-webkit-transition:-webkit-transform .6s ease-in-out;-o-transition:-o-transform .6s ease-in-out;transition:transform .6s ease-in-out;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-perspective:1000px;perspective:1000px}.carousel-inner>.item.active.right,.carousel-inner>.item.next{left:0;-webkit-transform:translate3d(100%,0,0);transform:translate3d(100%,0,0)}.carousel-inner>.item.active.left,.carousel-inner>.item.prev{left:0;-webkit-transform:translate3d(-100%,0,0);transform:translate3d(-100%,0,0)}.carousel-inner>.item.active,.carousel-inner>.item.next.left,.carousel-inner>.item.prev.right{left:0;-webkit-transform:translate3d(0,0,0);transform:translate3d(0,0,0)}}.carousel-inner>.active,.carousel-inner>.next,.carousel-inner>.prev{display:block}.carousel-inner>.active{left:0}.carousel-inner>.next,.carousel-inner>.prev{position:absolute;top:0;width:100%}.carousel-inner>.next{left:100%}.carousel-inner>.prev{left:-100%}.carousel-inner>.next.left,.carousel-inner>.prev.right{left:0}.carousel-inner>.active.left{left:-100%}.carousel-inner>.active.right{left:100%}.carousel-control{position:absolute;top:0;bottom:0;left:0;width:15%;font-size:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6);filter:alpha(opacity=50);opacity:.5}.carousel-control.left{background-image:-webkit-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.5)),to(rgba(0,0,0,.0001)));background-image:linear-gradient(to right,rgba(0,0,0,.5) 0,rgba(0,0,0,.0001) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#80000000', endColorstr='#00000000', GradientType=1);background-repeat:repeat-x}.carousel-control.right{right:0;left:auto;background-image:-webkit-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-o-linear-gradient(left,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);background-image:-webkit-gradient(linear,left top,right top,from(rgba(0,0,0,.0001)),to(rgba(0,0,0,.5)));background-image:linear-gradient(to right,rgba(0,0,0,.0001) 0,rgba(0,0,0,.5) 100%);filter:progid:DXImageTransform.Microsoft.gradient(startColorstr='#00000000', endColorstr='#80000000', GradientType=1);background-repeat:repeat-x}.carousel-control:focus,.carousel-control:hover{color:#fff;text-decoration:none;filter:alpha(opacity=90);outline:0;opacity:.9}.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{position:absolute;top:50%;z-index:5;display:inline-block;margin-top:-10px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{left:50%;margin-left:-10px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{right:50%;margin-right:-10px}.carousel-control .icon-next,.carousel-control .icon-prev{width:20px;height:20px;font-family:serif;line-height:1}.carousel-control .icon-prev:before{content:'\2039'}.carousel-control .icon-next:before{content:'\203a'}.carousel-indicators{position:absolute;bottom:10px;left:50%;z-index:15;width:60%;padding-left:0;margin-left:-30%;text-align:center;list-style:none}.carousel-indicators li{display:inline-block;width:10px;height:10px;margin:1px;text-indent:-999px;cursor:pointer;background-color:#000\9;background-color:rgba(0,0,0,0);border:1px solid #fff;border-radius:10px}.carousel-indicators .active{width:12px;height:12px;margin:0;background-color:#fff}.carousel-caption{position:absolute;right:15%;bottom:20px;left:15%;z-index:10;padding-top:20px;padding-bottom:20px;color:#fff;text-align:center;text-shadow:0 1px 2px rgba(0,0,0,.6)}.carousel-caption .btn{text-shadow:none}@media screen and (min-width:768px){.carousel-control .glyphicon-chevron-left,.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next,.carousel-control .icon-prev{width:30px;height:30px;margin-top:-15px;font-size:30px}.carousel-control .glyphicon-chevron-left,.carousel-control .icon-prev{margin-left:-15px}.carousel-control .glyphicon-chevron-right,.carousel-control .icon-next{margin-right:-15px}.carousel-caption{right:20%;left:20%;padding-bottom:30px}.carousel-indicators{bottom:20px}}.btn-group-vertical>.btn-group:after,.btn-group-vertical>.btn-group:before,.btn-toolbar:after,.btn-toolbar:before,.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.dl-horizontal dd:after,.dl-horizontal dd:before,.form-horizontal .form-group:after,.form-horizontal .form-group:before,.modal-footer:after,.modal-footer:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.pager:after,.pager:before,.panel-body:after,.panel-body:before,.row:after,.row:before{display:table;content:" "}.btn-group-vertical>.btn-group:after,.btn-toolbar:after,.clearfix:after,.container-fluid:after,.container:after,.dl-horizontal dd:after,.form-horizontal .form-group:after,.modal-footer:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.pager:after,.panel-body:after,.row:after{clear:both}.center-block{display:block;margin-right:auto;margin-left:auto}.pull-right{float:right!important}.pull-left{float:left!important}.hide{display:none!important}.show{display:block!important}.invisible{visibility:hidden}.text-hide{font:0/0 a;color:transparent;text-shadow:none;background-color:transparent;border:0}.hidden{display:none!important}.affix{position:fixed}@-ms-viewport{width:device-width}.visible-lg,.visible-md,.visible-sm,.visible-xs{display:none!important}.visible-lg-block,.visible-lg-inline,.visible-lg-inline-block,.visible-md-block,.visible-md-inline,.visible-md-inline-block,.visible-sm-block,.visible-sm-inline,.visible-sm-inline-block,.visible-xs-block,.visible-xs-inline,.visible-xs-inline-block{display:none!important}@media (max-width:767px){.visible-xs{display:block!important}table.visible-xs{display:table!important}tr.visible-xs{display:table-row!important}td.visible-xs,th.visible-xs{display:table-cell!important}}@media (max-width:767px){.visible-xs-block{display:block!important}}@media (max-width:767px){.visible-xs-inline{display:inline!important}}@media (max-width:767px){.visible-xs-inline-block{display:inline-block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm{display:block!important}table.visible-sm{display:table!important}tr.visible-sm{display:table-row!important}td.visible-sm,th.visible-sm{display:table-cell!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-block{display:block!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline{display:inline!important}}@media (min-width:768px) and (max-width:991px){.visible-sm-inline-block{display:inline-block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md{display:block!important}table.visible-md{display:table!important}tr.visible-md{display:table-row!important}td.visible-md,th.visible-md{display:table-cell!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-block{display:block!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline{display:inline!important}}@media (min-width:992px) and (max-width:1199px){.visible-md-inline-block{display:inline-block!important}}@media (min-width:1200px){.visible-lg{display:block!important}table.visible-lg{display:table!important}tr.visible-lg{display:table-row!important}td.visible-lg,th.visible-lg{display:table-cell!important}}@media (min-width:1200px){.visible-lg-block{display:block!important}}@media (min-width:1200px){.visible-lg-inline{display:inline!important}}@media (min-width:1200px){.visible-lg-inline-block{display:inline-block!important}}@media (max-width:767px){.hidden-xs{display:none!important}}@media (min-width:768px) and (max-width:991px){.hidden-sm{display:none!important}}@media (min-width:992px) and (max-width:1199px){.hidden-md{display:none!important}}@media (min-width:1200px){.hidden-lg{display:none!important}}.visible-print{display:none!important}@media print{.visible-print{display:block!important}table.visible-print{display:table!important}tr.visible-print{display:table-row!important}td.visible-print,th.visible-print{display:table-cell!important}}.visible-print-block{display:none!important}@media print{.visible-print-block{display:block!important}}.visible-print-inline{display:none!important}@media print{.visible-print-inline{display:inline!important}}.visible-print-inline-block{display:none!important}@media print{.visible-print-inline-block{display:inline-block!important}}@media print{.hidden-print{display:none!important}}
</style>
<script>/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);</script>
<script>/**
* @preserve HTML5 Shiv 3.7.2 | @afarkas @jdalton @jon_neal @rem | MIT/GPL2 Licensed
*/
// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a,b){function c(a,b){var c=a.createElement("p"),d=a.getElementsByTagName("head")[0]||a.documentElement;return c.innerHTML="x<style>"+b+"</style>",d.insertBefore(c.lastChild,d.firstChild)}function d(){var a=t.elements;return"string"==typeof a?a.split(" "):a}function e(a,b){var c=t.elements;"string"!=typeof c&&(c=c.join(" ")),"string"!=typeof a&&(a=a.join(" ")),t.elements=c+" "+a,j(b)}function f(a){var b=s[a[q]];return b||(b={},r++,a[q]=r,s[r]=b),b}function g(a,c,d){if(c||(c=b),l)return c.createElement(a);d||(d=f(c));var e;return e=d.cache[a]?d.cache[a].cloneNode():p.test(a)?(d.cache[a]=d.createElem(a)).cloneNode():d.createElem(a),!e.canHaveChildren||o.test(a)||e.tagUrn?e:d.frag.appendChild(e)}function h(a,c){if(a||(a=b),l)return a.createDocumentFragment();c=c||f(a);for(var e=c.frag.cloneNode(),g=0,h=d(),i=h.length;i>g;g++)e.createElement(h[g]);return e}function i(a,b){b.cache||(b.cache={},b.createElem=a.createElement,b.createFrag=a.createDocumentFragment,b.frag=b.createFrag()),a.createElement=function(c){return t.shivMethods?g(c,a,b):b.createElem(c)},a.createDocumentFragment=Function("h,f","return function(){var n=f.cloneNode(),c=n.createElement;h.shivMethods&&("+d().join().replace(/[\w\-:]+/g,function(a){return b.createElem(a),b.frag.createElement(a),'c("'+a+'")'})+");return n}")(t,b.frag)}function j(a){a||(a=b);var d=f(a);return!t.shivCSS||k||d.hasCSS||(d.hasCSS=!!c(a,"article,aside,dialog,figcaption,figure,footer,header,hgroup,main,nav,section{display:block}mark{background:#FF0;color:#000}template{display:none}")),l||i(a,d),a}var k,l,m="3.7.2",n=a.html5||{},o=/^<|^(?:button|map|select|textarea|object|iframe|option|optgroup)$/i,p=/^(?:a|b|code|div|fieldset|h1|h2|h3|h4|h5|h6|i|label|li|ol|p|q|span|strong|style|table|tbody|td|th|tr|ul)$/i,q="_html5shiv",r=0,s={};!function(){try{var a=b.createElement("a");a.innerHTML="<xyz></xyz>",k="hidden"in a,l=1==a.childNodes.length||function(){b.createElement("a");var a=b.createDocumentFragment();return"undefined"==typeof a.cloneNode||"undefined"==typeof a.createDocumentFragment||"undefined"==typeof a.createElement}()}catch(c){k=!0,l=!0}}();var t={elements:n.elements||"abbr article aside audio bdi canvas data datalist details dialog figcaption figure footer header hgroup main mark meter nav output picture progress section summary template time video",version:m,shivCSS:n.shivCSS!==!1,supportsUnknownElements:l,shivMethods:n.shivMethods!==!1,type:"default",shivDocument:j,createElement:g,createDocumentFragment:h,addElements:e};a.html5=t,j(b)}(this,document);
};
</script>
<script>/*! Respond.js v1.4.2: min/max-width media query polyfill * Copyright 2013 Scott Jehl
 * Licensed under https://github.com/scottjehl/Respond/blob/master/LICENSE-MIT
 *  */

// Only run this code in IE 8
if (!!window.navigator.userAgent.match("MSIE 8")) {
!function(a){"use strict";a.matchMedia=a.matchMedia||function(a){var b,c=a.documentElement,d=c.firstElementChild||c.firstChild,e=a.createElement("body"),f=a.createElement("div");return f.id="mq-test-1",f.style.cssText="position:absolute;top:-100em",e.style.background="none",e.appendChild(f),function(a){return f.innerHTML='&shy;<style media="'+a+'"> #mq-test-1 { width: 42px; }</style>',c.insertBefore(e,d),b=42===f.offsetWidth,c.removeChild(e),{matches:b,media:a}}}(a.document)}(this),function(a){"use strict";function b(){u(!0)}var c={};a.respond=c,c.update=function(){};var d=[],e=function(){var b=!1;try{b=new a.XMLHttpRequest}catch(c){b=new a.ActiveXObject("Microsoft.XMLHTTP")}return function(){return b}}(),f=function(a,b){var c=e();c&&(c.open("GET",a,!0),c.onreadystatechange=function(){4!==c.readyState||200!==c.status&&304!==c.status||b(c.responseText)},4!==c.readyState&&c.send(null))};if(c.ajax=f,c.queue=d,c.regex={media:/@media[^\{]+\{([^\{\}]*\{[^\}\{]*\})+/gi,keyframes:/@(?:\-(?:o|moz|webkit)\-)?keyframes[^\{]+\{(?:[^\{\}]*\{[^\}\{]*\})+[^\}]*\}/gi,urls:/(url\()['"]?([^\/\)'"][^:\)'"]+)['"]?(\))/g,findStyles:/@media *([^\{]+)\{([\S\s]+?)$/,only:/(only\s+)?([a-zA-Z]+)\s?/,minw:/\([\s]*min\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/,maxw:/\([\s]*max\-width\s*:[\s]*([\s]*[0-9\.]+)(px|em)[\s]*\)/},c.mediaQueriesSupported=a.matchMedia&&null!==a.matchMedia("only all")&&a.matchMedia("only all").matches,!c.mediaQueriesSupported){var g,h,i,j=a.document,k=j.documentElement,l=[],m=[],n=[],o={},p=30,q=j.getElementsByTagName("head")[0]||k,r=j.getElementsByTagName("base")[0],s=q.getElementsByTagName("link"),t=function(){var a,b=j.createElement("div"),c=j.body,d=k.style.fontSize,e=c&&c.style.fontSize,f=!1;return b.style.cssText="position:absolute;font-size:1em;width:1em",c||(c=f=j.createElement("body"),c.style.background="none"),k.style.fontSize="100%",c.style.fontSize="100%",c.appendChild(b),f&&k.insertBefore(c,k.firstChild),a=b.offsetWidth,f?k.removeChild(c):c.removeChild(b),k.style.fontSize=d,e&&(c.style.fontSize=e),a=i=parseFloat(a)},u=function(b){var c="clientWidth",d=k[c],e="CSS1Compat"===j.compatMode&&d||j.body[c]||d,f={},o=s[s.length-1],r=(new Date).getTime();if(b&&g&&p>r-g)return a.clearTimeout(h),h=a.setTimeout(u,p),void 0;g=r;for(var v in l)if(l.hasOwnProperty(v)){var w=l[v],x=w.minw,y=w.maxw,z=null===x,A=null===y,B="em";x&&(x=parseFloat(x)*(x.indexOf(B)>-1?i||t():1)),y&&(y=parseFloat(y)*(y.indexOf(B)>-1?i||t():1)),w.hasquery&&(z&&A||!(z||e>=x)||!(A||y>=e))||(f[w.media]||(f[w.media]=[]),f[w.media].push(m[w.rules]))}for(var C in n)n.hasOwnProperty(C)&&n[C]&&n[C].parentNode===q&&q.removeChild(n[C]);n.length=0;for(var D in f)if(f.hasOwnProperty(D)){var E=j.createElement("style"),F=f[D].join("\n");E.type="text/css",E.media=D,q.insertBefore(E,o.nextSibling),E.styleSheet?E.styleSheet.cssText=F:E.appendChild(j.createTextNode(F)),n.push(E)}},v=function(a,b,d){var e=a.replace(c.regex.keyframes,"").match(c.regex.media),f=e&&e.length||0;b=b.substring(0,b.lastIndexOf("/"));var g=function(a){return a.replace(c.regex.urls,"$1"+b+"$2$3")},h=!f&&d;b.length&&(b+="/"),h&&(f=1);for(var i=0;f>i;i++){var j,k,n,o;h?(j=d,m.push(g(a))):(j=e[i].match(c.regex.findStyles)&&RegExp.$1,m.push(RegExp.$2&&g(RegExp.$2))),n=j.split(","),o=n.length;for(var p=0;o>p;p++)k=n[p],l.push({media:k.split("(")[0].match(c.regex.only)&&RegExp.$2||"all",rules:m.length-1,hasquery:k.indexOf("(")>-1,minw:k.match(c.regex.minw)&&parseFloat(RegExp.$1)+(RegExp.$2||""),maxw:k.match(c.regex.maxw)&&parseFloat(RegExp.$1)+(RegExp.$2||"")})}u()},w=function(){if(d.length){var b=d.shift();f(b.href,function(c){v(c,b.href,b.media),o[b.href]=!0,a.setTimeout(function(){w()},0)})}},x=function(){for(var b=0;b<s.length;b++){var c=s[b],e=c.href,f=c.media,g=c.rel&&"stylesheet"===c.rel.toLowerCase();e&&g&&!o[e]&&(c.styleSheet&&c.styleSheet.rawCssText?(v(c.styleSheet.rawCssText,e,f),o[e]=!0):(!/^([a-zA-Z:]*\/\/)/.test(e)&&!r||e.replace(RegExp.$1,"").split("/")[0]===a.location.host)&&("//"===e.substring(0,2)&&(e=a.location.protocol+e),d.push({href:e,media:f})))}w()};x(),c.update=x,c.getEmValue=t,a.addEventListener?a.addEventListener("resize",b,!1):a.attachEvent&&a.attachEvent("onresize",b)}}(this);
};
</script>
<style>h1 {font-size: 34px;}
h1.title {font-size: 38px;}
h2 {font-size: 30px;}
h3 {font-size: 24px;}
h4 {font-size: 18px;}
h5 {font-size: 16px;}
h6 {font-size: 12px;}
code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
pre:not([class]) { background-color: white }</style>
<style type="text/css">.pagedtable {
overflow: auto;
padding-left: 8px;
padding-right: 8px;
}
.pagedtable-wrapper {
border: 1px solid #ccc;
border-radius: 4px;
margin-bottom: 10px;
}
.pagedtable table {
width: 100%;
max-width: 100%;
margin: 0;
}
.pagedtable th {
padding: 0 5px 0 5px;
border: none;
border-bottom: 2px solid #dddddd;
min-width: 45px;
}
.pagedtable-empty th {
display: none;
}
.pagedtable td {
padding: 0 4px 0 4px;
}
.pagedtable .even {
background-color: rgba(140, 140, 140, 0.1);
}
.pagedtable-padding-col {
display: none;
}
.pagedtable a {
-webkit-touch-callout: none;
-webkit-user-select: none;
-khtml-user-select: none;
-moz-user-select: none;
-ms-user-select: none;
user-select: none;
}
.pagedtable-index-nav {
cursor: pointer;
padding: 0 5px 0 5px;
float: right;
border: 0;
}
.pagedtable-index-nav-disabled {
cursor: default;
text-decoration: none;
color: #999;
}
a.pagedtable-index-nav-disabled:hover {
text-decoration: none;
color: #999;
}
.pagedtable-indexes {
cursor: pointer;
float: right;
border: 0;
}
.pagedtable-index-current {
cursor: default;
text-decoration: none;
font-weight: bold;
color: #333;
border: 0;
}
a.pagedtable-index-current:hover {
text-decoration: none;
font-weight: bold;
color: #333;
}
.pagedtable-index {
width: 30px;
display: inline-block;
text-align: center;
border: 0;
}
.pagedtable-index-separator-left {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 0 0 0;
cursor: default;
}
.pagedtable-index-separator-right {
display: inline-block;
color: #333;
font-size: 9px;
padding: 0 4px 0 0;
cursor: default;
}
.pagedtable-footer {
padding-top: 4px;
padding-bottom: 5px;
}
.pagedtable-not-empty .pagedtable-footer {
border-top: 2px solid #dddddd;
}
.pagedtable-info {
overflow: hidden;
color: #999;
white-space: nowrap;
text-overflow: ellipsis;
}
.pagedtable-header-name {
overflow: hidden;
text-overflow: ellipsis;
}
.pagedtable-header-type {
color: #999;
font-weight: 400;
}
.pagedtable-na-cell {
font-style: italic;
opacity: 0.3;
}
</style>
<script>// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
</script>
<script>

/**
 * jQuery Plugin: Sticky Tabs
 *
 * @author Aidan Lister <aidan@php.net>
 * adapted by Ruben Arslan to activate parent tabs too
 * http://www.aidanlister.com/2014/03/persisting-the-tab-state-in-bootstrap/
 */
(function($) {
  "use strict";
  $.fn.rmarkdownStickyTabs = function() {
    var context = this;
    // Show the tab corresponding with the hash in the URL, or the first tab
    var showStuffFromHash = function() {
      var hash = window.location.hash;
      var selector = hash ? 'a[href="' + hash + '"]' : 'li.active > a';
      var $selector = $(selector, context);
      if($selector.data('toggle') === "tab") {
        $selector.tab('show');
        // walk up the ancestors of this element, show any hidden tabs
        $selector.parents('.section.tabset').each(function(i, elm) {
          var link = $('a[href="#' + $(elm).attr('id') + '"]');
          if(link.data('toggle') === "tab") {
            link.tab("show");
          }
        });
      }
    };


    // Set the correct tab when the page loads
    showStuffFromHash(context);

    // Set the correct tab when a user uses their back/forward button
    $(window).on('hashchange', function() {
      showStuffFromHash(context);
    });

    // Change the URL when tabs are clicked
    $('a', context).on('click', function(e) {
      history.pushState(null, null, this.href);
      showStuffFromHash(context);
    });

    return this;
  };
}(jQuery));

window.buildTabsets = function(tocID) {

  // build a tabset from a section div with the .tabset class
  function buildTabset(tabset) {

    // check for fade and pills options
    var fade = tabset.hasClass("tabset-fade");
    var pills = tabset.hasClass("tabset-pills");
    var navClass = pills ? "nav-pills" : "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    var activeTab = 0;
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // see if this is marked as the active tab
      if (tab.hasClass('active'))
        activeTab = i;

      // remove any table of contents entries associated with
      // this ID (since we'll be removing the heading element)
      $("div#" + tocID + " li a[href='#" + id + "']").parent().remove();

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it, grab it's text, then remove it
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();
      heading.remove();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      if (fade)
        tab.addClass('fade');

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // set active tab
    $(tabList.children('li')[activeTab]).addClass('active');
    var active = $(tabContent.children('div.section')[activeTab]);
    active.addClass('active');
    if (fade)
      active.addClass('in');

    if (tabset.hasClass("tabset-sticky"))
      tabset.rmarkdownStickyTabs();
  }

  // convert section divs with the .tabset class to tabsets
  var tabsets = $("div.section.tabset");
  tabsets.each(function(i) {
    buildTabset($(tabsets[i]));
  });
};

</script>
<script>
window.initializeCodeFolding = function(show) {

  // handlers for show-all and hide all
  $("#rmd-show-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('show');
    });
  });
  $("#rmd-hide-all-code").click(function() {
    $('div.r-code-collapse').each(function() {
      $(this).collapse('hide');
    });
  });

  // index for unique code element ids
  var currentIndex = 1;

  // select all R code blocks
  var rCodeBlocks = $('pre.r, pre.python, pre.bash, pre.sql, pre.cpp, pre.stan, pre.julia, pre.foldable');
  rCodeBlocks.each(function() {
    // skip if the block has fold-none class
    if ($(this).hasClass('fold-none')) return;

    // create a collapsable div to wrap the code in
    var div = $('<div class="collapse r-code-collapse"></div>');
    var showThis = (show || $(this).hasClass('fold-show')) && !$(this).hasClass('fold-hide');
    var id = 'rcode-643E0F36' + currentIndex++;
    div.attr('id', id);
    $(this).before(div);
    $(this).detach().appendTo(div);

    // add a show code button right above
    var showCodeText = $('<span>' + (showThis ? 'Hide' : 'Show') + '</span>');
    var showCodeButton = $('<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm code-folding-btn pull-right float-right"></button>');
    showCodeButton.append(showCodeText);
    showCodeButton
        .attr('data-toggle', 'collapse')
        .attr('data-bs-toggle', 'collapse') // BS5
        .attr('data-target', '#' + id)
        .attr('data-bs-target', '#' + id)   // BS5
        .attr('aria-expanded', showThis)
        .attr('aria-controls', id);

    var buttonRow = $('<div class="row"></div>');
    var buttonCol = $('<div class="col-md-12"></div>');

    buttonCol.append(showCodeButton);
    buttonRow.append(buttonCol);

    div.before(buttonRow);

    // show the div if necessary
    if (showThis) div.collapse('show');

    // update state of button on show/hide
    //   * Change text
    //   * add a class for intermediate states styling
    div.on('hide.bs.collapse', function () {
      showCodeText.text('Show');
      showCodeButton.addClass('btn-collapsing');
    });
    div.on('hidden.bs.collapse', function () {
      showCodeButton.removeClass('btn-collapsing');
    });
    div.on('show.bs.collapse', function () {
      showCodeText.text('Hide');
      showCodeButton.addClass('btn-expanding');
    });
    div.on('shown.bs.collapse', function () {
      showCodeButton.removeClass('btn-expanding');
    });

  });

}
</script>
<script>
window.initializeSourceEmbed = function(filename) {
  $("#rmd-download-source").click(function() {
    var src = $("#rmd-source-code").html();
    var a = document.createElement('a');
    a.href = "data:text/x-r-markdown;base64," + src;
    a.download = filename;
    document.body.appendChild(a);
    a.click();
    document.body.removeChild(a);
  });
};
</script>
<style type="text/css">.hljs-literal {
color: rgb(88, 72, 246);
}
.hljs-number {
color: rgb(0, 0, 205);
}
.hljs-comment {
color: rgb(76, 136, 107);
}
.hljs-keyword {
color: rgb(0, 0, 255);
}
.hljs-string {
color: rgb(3, 106, 7);
}
</style>
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
</style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>




<style type="text/css">
#rmd-source-code {
display: none;
}
</style>





<style type="text/css">
.main-container {
max-width: 940px;
margin-left: auto;
margin-right: auto;
}
img {
max-width:100%;
}
.tabbed-pane {
padding-top: 12px;
}
.html-widget {
margin-bottom: 20px;
}
button.code-folding-btn:focus {
outline: none;
}
summary {
display: list-item;
}
details > summary > p:only-child {
display: inline;
}
pre code {
padding: 0;
}
</style>

<style type="text/css">
.kable-table {
border: 1px solid #ccc;
border-radius: 4px;
overflow: auto;
padding-left: 8px;
padding-right: 8px;
margin-bottom: 20px;
max-height: 350px;
}
.kable-table table {
margin-bottom: 0px;
}
.kable-table table>thead>tr>th {
border: none;
border-bottom: 2px solid #dddddd;
}
.kable-table table>thead {
background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
display: inline-table;
max-height: 500px;
min-height: 44px;
overflow-y: auto;
border: 1px solid #ddd;
border-radius: 4px;
}
.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
content: "\e259";
font-family: 'Glyphicons Halflings';
display: inline-block;
padding: 10px;
border-right: 1px solid #ddd;
}
.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
content: "\e258";
font-family: 'Glyphicons Halflings';
border: none;
}
.tabset-dropdown > .nav-tabs > li.active {
display: block;
}
.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
border: none;
display: inline-block;
border-radius: 4px;
background-color: transparent;
}
.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
display: block;
float: none;
}
.tabset-dropdown > .nav-tabs > li {
display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>




</head>

<body>


<div class="container-fluid main-container">




<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
<li role="separator" class="divider"></li>
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">R Notebook</h1>

</div>


<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShwdXJycilcbmxpYnJhcnkocmVhZHhsKVxubGlicmFyeShkcGx5cilcbmBgYCJ9 -->
<pre class="r"><code>library(purrr)
library(readxl)
library(dplyr)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG5BdHRhY2hpbmcgcGFja2FnZTog4oCYZHBseXLigJlcblxuVGhlIGZvbGxvd2luZyBvYmplY3RzIGFyZSBtYXNrZWQgZnJvbSDigJhwYWNrYWdlOnN0YXRz4oCZOlxuXG4gICAgZmlsdGVyLCBsYWdcblxuVGhlIGZvbGxvd2luZyBvYmplY3RzIGFyZSBtYXNrZWQgZnJvbSDigJhwYWNrYWdlOmJhc2XigJk6XG5cbiAgICBpbnRlcnNlY3QsIHNldGRpZmYsIHNldGVxdWFsLCB1bmlvblxuIn0= -->
<pre><code>
Attaching package: dplyr

The following objects are masked from package:stats:

    filter, lag

The following objects are masked from package:base:

    intersect, setdiff, setequal, union</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeSh0aWR5dmVyc2UpXG5gYGAifQ== -->
<pre class="r"><code>library(tidyverse)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code> Attaching core tidyverse packages  tidyverse 2.0.0 
 forcats   1.0.0      stringr   1.5.1
 ggplot2   3.4.4      tibble    3.2.1
 lubridate 1.9.3      tidyr     1.3.0
 readr     2.1.4      Conflicts  tidyverse_conflicts() 
 dplyr::filter() masks stats::filter()
 dplyr::lag()    masks stats::lag()
 Use the ]8;;http://conflicted.r-lib.org/conflicted package]8;; to force all conflicts to become errors</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShqc29ubGl0ZSlcbmBgYCJ9 -->
<pre class="r"><code>library(jsonlite)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG5BdHRhY2hpbmcgcGFja2FnZTog4oCYanNvbmxpdGXigJlcblxuVGhlIGZvbGxvd2luZyBvYmplY3QgaXMgbWFza2VkIGZyb20g4oCYcGFja2FnZTpwdXJycuKAmTpcblxuICAgIGZsYXR0ZW5cbiJ9 -->
<pre><code>
Attaching package: jsonlite

The following object is masked from package:purrr:

    flatten</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeSh1dWlkKVxubGlicmFyeShkYXRhLnRhYmxlKVxuYGBgIn0= -->
<pre class="r"><code>library(uuid)
library(data.table)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiUmVnaXN0ZXJlZCBTMyBtZXRob2Qgb3ZlcndyaXR0ZW4gYnkgJ2RhdGEudGFibGUnOlxuICBtZXRob2QgICAgICAgICAgIGZyb21cbiAgcHJpbnQuZGF0YS50YWJsZSAgICAgXG5kYXRhLnRhYmxlIDEuMTQuMTAgdXNpbmcgMSB0aHJlYWRzIChzZWUgP2dldERUdGhyZWFkcykuICBMYXRlc3QgbmV3czogci1kYXRhdGFibGUuY29tXG4qKioqKioqKioqXG5UaGlzIGluc3RhbGxhdGlvbiBvZiBkYXRhLnRhYmxlIGhhcyBub3QgZGV0ZWN0ZWQgT3Blbk1QIHN1cHBvcnQuIEl0IHNob3VsZCBzdGlsbCB3b3JrIGJ1dCBpbiBzaW5nbGUtdGhyZWFkZWQgbW9kZS5cblRoaXMgaXMgYSBNYWMuIFBsZWFzZSByZWFkIGh0dHBzOi8vbWFjLnItcHJvamVjdC5vcmcvb3Blbm1wLy4gUGxlYXNlIGVuZ2FnZSB3aXRoIEFwcGxlIGFuZCBhc2sgdGhlbSBmb3Igc3VwcG9ydC4gQ2hlY2sgci1kYXRhdGFibGUuY29tIGZvciB1cGRhdGVzLCBhbmQgb3VyIE1hYyBpbnN0cnVjdGlvbnMgaGVyZTogaHR0cHM6Ly9naXRodWIuY29tL1JkYXRhdGFibGUvZGF0YS50YWJsZS93aWtpL0luc3RhbGxhdGlvbi4gQWZ0ZXIgc2V2ZXJhbCB5ZWFycyBvZiBtYW55IHJlcG9ydHMgb2YgaW5zdGFsbGF0aW9uIHByb2JsZW1zIG9uIE1hYywgaXQncyB0aW1lIHRvIGdpbmdlcmx5IHBvaW50IG91dCB0aGF0IHRoZXJlIGhhdmUgYmVlbiBubyBzaW1pbGFyIHByb2JsZW1zIG9uIFdpbmRvd3Mgb3IgTGludXguXG4qKioqKioqKioqXG5cbkF0dGFjaGluZyBwYWNrYWdlOiDigJhkYXRhLnRhYmxl4oCZXG5cblRoZSBmb2xsb3dpbmcgb2JqZWN0cyBhcmUgbWFza2VkIGZyb20g4oCYcGFja2FnZTpsdWJyaWRhdGXigJk6XG5cbiAgICBob3VyLCBpc293ZWVrLCBtZGF5LCBtaW51dGUsIG1vbnRoLCBxdWFydGVyLCBzZWNvbmQsIHdkYXksIHdlZWssIHlkYXksIHllYXJcblxuVGhlIGZvbGxvd2luZyBvYmplY3RzIGFyZSBtYXNrZWQgZnJvbSDigJhwYWNrYWdlOmRwbHly4oCZOlxuXG4gICAgYmV0d2VlbiwgZmlyc3QsIGxhc3RcblxuVGhlIGZvbGxvd2luZyBvYmplY3QgaXMgbWFza2VkIGZyb20g4oCYcGFja2FnZTpwdXJycuKAmTpcblxuICAgIHRyYW5zcG9zZVxuIn0= -->
<pre><code>Registered S3 method overwritten by &#39;data.table&#39;:
  method           from
  print.data.table     
data.table 1.14.10 using 1 threads (see ?getDTthreads).  Latest news: r-datatable.com
**********
This installation of data.table has not detected OpenMP support. It should still work but in single-threaded mode.
This is a Mac. Please read https://mac.r-project.org/openmp/. Please engage with Apple and ask them for support. Check r-datatable.com for updates, and our Mac instructions here: https://github.com/Rdatatable/data.table/wiki/Installation. After several years of many reports of installation problems on Mac, it&#39;s time to gingerly point out that there have been no similar problems on Windows or Linux.
**********

Attaching package: data.table

The following objects are masked from package:lubridate:

    hour, isoweek, mday, minute, month, quarter, second, wday, week, yday, year

The following objects are masked from package:dplyr:

    between, first, last

The following object is masked from package:purrr:

    transpose</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeSh4bWwyKVxuYGBgIn0= -->
<pre class="r"><code>library(xml2)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGYgPC0gcmVhZF9leGNlbChcIi4uLy4uLy4uLy4uL2FudGliaW90aWNzL1dITy1NSFAtSFBTLUVNTC0yMDIzLjA0LWVuZy54bHN4XCIsIHNoZWV0ID0gNCwgc2tpcCA9IDMpXG5gYGAifQ== -->
<pre class="r"><code>df &lt;- read_excel(&quot;../../../../antibiotics/WHO-MHP-HPS-EML-2023.04-eng.xlsx&quot;, sheet = 4, skip = 3)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiTmV3IG5hbWVzOlxuIn0= -->
<pre><code>New names:</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGZcbmBgYCJ9 -->
<pre class="r"><code>df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Antibiotic"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Class"],"name":[2],"type":["chr"],"align":["left"]},{"label":["ATC code"],"name":[3],"type":["chr"],"align":["left"]},{"label":["Category"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Listed on EML/EMLc 2023"],"name":[5],"type":["chr"],"align":["left"]},{"label":["...6"],"name":[6],"type":["lgl"],"align":["right"]},{"label":["...7"],"name":[7],"type":["lgl"],"align":["right"]},{"label":["...8"],"name":[8],"type":["lgl"],"align":["right"]}],"data":[{"1":"Amikacin","2":"Aminoglycosides","3":"J01GB06","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Amoxicillin","2":"Penicillins","3":"J01CA04","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Amoxicillin/clavulanic-acid","2":"Beta-lactam/beta-lactamase-inhibitor","3":"J01CR02","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Ampicillin","2":"Penicillins","3":"J01CA01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Ampicillin/sulbactam","2":"Beta-lactam/beta-lactamase-inhibitor","3":"J01CR01","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Arbekacin","2":"Aminoglycosides","3":"J01GB12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Aspoxicillin","2":"Penicillins","3":"J01CA19","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Azidocillin","2":"Penicillins","3":"J01CE04","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Azithromycin","2":"Macrolides","3":"J01FA10","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Azlocillin","2":"Penicillins","3":"J01CA09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Aztreonam","2":"Monobactams","3":"J01DF01","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Bacampicillin","2":"Penicillins","3":"J01CA06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Bekanamycin","2":"Aminoglycosides","3":"J01GB13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Benzathine-benzylpenicillin","2":"Penicillins","3":"J01CE08","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Benzylpenicillin","2":"Penicillins","3":"J01CE01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Biapenem","2":"Carbapenems","3":"J01DH05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Brodimoprim","2":"Trimethoprim-derivatives","3":"J01EA02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Carbenicillin","2":"Penicillins","3":"J01CA03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Carindacillin","2":"Penicillins","3":"J01CA05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Carumonam","2":"Monobactams","3":"J01DF02","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefacetrile","2":"First-generation-cephalosporins","3":"J01DB10","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefaclor","2":"Second-generation-cephalosporins","3":"J01DC04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefadroxil","2":"First-generation-cephalosporins","3":"J01DB05","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefalexin","2":"First-generation-cephalosporins","3":"J01DB01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefaloridine","2":"First-generation-cephalosporins","3":"J01DB02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefalotin","2":"First-generation-cephalosporins","3":"J01DB03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefamandole","2":"Second-generation-cephalosporins","3":"J01DC03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefapirin","2":"First-generation-cephalosporins","3":"J01DB08","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefatrizine","2":"First-generation-cephalosporins","3":"J01DB07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefazedone","2":"First-generation-cephalosporins","3":"J01DB06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefazolin","2":"First-generation-cephalosporins","3":"J01DB04","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefbuperazone","2":"Second-generation-cephalosporins","3":"J01DC13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefcapene-pivoxil","2":"Third-generation-cephalosporins","3":"J01DD17","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefdinir","2":"Third-generation-cephalosporins","3":"J01DD15","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefditoren-pivoxil","2":"Third-generation-cephalosporins","3":"J01DD16","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefepime","2":"Fourth-generation-cephalosporins","3":"J01DE01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefetamet-pivoxil","2":"Third-generation-cephalosporins","3":"J01DD10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefiderocol","2":"Other-cephalosporins","3":"J01DI04","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefixime","2":"Third-generation-cephalosporins","3":"J01DD08","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefmenoxime","2":"Third-generation-cephalosporins","3":"J01DD05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefmetazole","2":"Second-generation-cephalosporins","3":"J01DC09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefminox","2":"Second-generation-cephalosporins","3":"J01DC12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefodizime","2":"Third-generation-cephalosporins","3":"J01DD09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefonicid","2":"Second-generation-cephalosporins","3":"J01DC06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefoperazone","2":"Third-generation-cephalosporins","3":"J01DD12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceforanide","2":"Second-generation-cephalosporins","3":"J01DC11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefoselis","2":"Fourth-generation-cephalosporins","3":"to be assigned","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefotaxime","2":"Third-generation-cephalosporins","3":"J01DD01","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefotetan","2":"Second-generation-cephalosporins","3":"J01DC05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefotiam","2":"Second-generation-cephalosporins","3":"J01DC07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefoxitin","2":"Second-generation-cephalosporins","3":"J01DC01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefozopran","2":"Fourth-generation-cephalosporins","3":"J01DE03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefpiramide","2":"Third-generation-cephalosporins","3":"J01DD11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefpirome","2":"Fourth-generation-cephalosporins","3":"J01DE02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefpodoxime-proxetil","2":"Third-generation-cephalosporins","3":"J01DD13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefprozil","2":"Second-generation-cephalosporins","3":"J01DC10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefradine","2":"First-generation-cephalosporins","3":"J01DB09","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefroxadine","2":"First-generation-cephalosporins","3":"J01DB11","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cefsulodin","2":"Third-generation-cephalosporins","3":"J01DD03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftaroline-fosamil","2":"Fifth-generation cephalosporins","3":"J01DI02","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftazidime","2":"Third-generation-cephalosporins","3":"J01DD02","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Ceftazidime/avibactam","2":"Third-generation-cephalosporins","3":"J01DD52","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefteram-pivoxil","2":"Third-generation-cephalosporins","3":"J01DD18","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftezole","2":"First-generation-cephalosporins","3":"J01DB12","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftibuten","2":"Third-generation-cephalosporins","3":"J01DD14","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftizoxime","2":"Third-generation-cephalosporins","3":"J01DD07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftobiprole-medocaril","2":"Fifth-generation cephalosporins","3":"J01DI01","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ceftolozane/tazobactam","2":"Fifth-generation cephalosporins","3":"J01DI54","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Ceftriaxone","2":"Third-generation-cephalosporins","3":"J01DD04","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Cefuroxime","2":"Second-generation-cephalosporins","3":"J01DC02","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Chloramphenicol","2":"Amphenicols","3":"J01BA01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Chlortetracycline","2":"Tetracyclines","3":"J01AA03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cinoxacin","2":"Quinolones","3":"J01MB06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ciprofloxacin","2":"Fluoroquinolones","3":"J01MA02","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Clarithromycin","2":"Macrolides","3":"J01FA09","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Clindamycin","2":"Lincosamides","3":"J01FF01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Clofoctol","2":"Phenol derivatives","3":"J01XX03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Clometocillin","2":"Penicillins","3":"J01CE07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Clomocycline","2":"Tetracyclines","3":"J01AA11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Cloxacillin","2":"Penicillins","3":"J01CF02","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Colistin_IV","2":"Polymyxins","3":"J01XB01","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Colistin_oral","2":"Polymyxins","3":"A07AA10","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Dalbavancin","2":"Glycopeptides","3":"J01XA04","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Dalfopristin/quinupristin","2":"Streptogramins","3":"J01FG02","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Daptomycin","2":"Lipopeptides","3":"J01XX09","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Delafloxacin","2":"Fluoroquinolones","3":"J01MA23","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Demeclocycline","2":"Tetracyclines","3":"J01AA01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Dibekacin","2":"Aminoglycosides","3":"J01GB09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Dicloxacillin","2":"Penicillins","3":"J01CF01","4":"Access","5":"Yes (therapeutic alternative to cloxacillin)","6":"NA","7":"NA","8":"NA"},{"1":"Dirithromycin","2":"Macrolides","3":"J01FA13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Doripenem","2":"Carbapenems","3":"J01DH04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Doxycycline","2":"Tetracyclines","3":"J01AA02","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Enoxacin","2":"Fluoroquinolones","3":"J01MA04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Epicillin","2":"Penicillins","3":"J01CA07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Eravacycline","2":"Tetracyclines","3":"J01AA13","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ertapenem","2":"Carbapenems","3":"J01DH03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Erythromycin","2":"Macrolides","3":"J01FA01","4":"Watch","5":"Yes (therapeutic alternative to clarithromycin (EMLc))","6":"NA","7":"NA","8":"NA"},{"1":"Faropenem","2":"Penems","3":"J01DI03","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Fidaxomicin","2":"Macrolides","3":"A07AA12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Fleroxacin","2":"Fluoroquinolones","3":"J01MA08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Flomoxef","2":"Second-generation-cephalosporins","3":"J01DC14","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Flucloxacillin","2":"Penicillins","3":"J01CF05","4":"Access","5":"Yes (therapeutic alternative to cloxacillin)","6":"NA","7":"NA","8":"NA"},{"1":"Flumequine","2":"Quinolones","3":"J01MB07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Flurithromycin","2":"Macrolides","3":"J01FA14","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Fosfomycin_IV","2":"Phosphonics","3":"J01XX01","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Fosfomycin_oral","2":"Phosphonics","3":"J01XX01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Furazidin","2":"Nitrofuran derivatives","3":"J01XE03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Fusidic-acid","2":"Steroid antibacterials","3":"J01XC01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Garenoxacin","2":"Fluoroquinolones","3":"J01MA19","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Gatifloxacin","2":"Fluoroquinolones","3":"J01MA16","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Gemifloxacin","2":"Fluoroquinolones","3":"J01MA15","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Gentamicin","2":"Aminoglycosides","3":"J01GB03","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Grepafloxacin","2":"Fluoroquinolones","3":"J01MA11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Hetacillin","2":"Penicillins","3":"J01CA18","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Iclaprim","2":"Trimethoprim-derivatives","3":"J01EA03","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Imipenem/cilastatin","2":"Carbapenems","3":"J01DH51","4":"Watch","5":"Yes (therapeutic alternative to meropenem)","6":"NA","7":"NA","8":"NA"},{"1":"Imipenem/cilastatin/relebactam","2":"Carbapenems","3":"J01DH56","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Isepamicin","2":"Aminoglycosides","3":"J01GB11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Josamycin","2":"Macrolides","3":"J01FA07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Kanamycin_IV","2":"Aminoglycosides","3":"J01GB04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Kanamycin_oral","2":"Aminoglycosides","3":"A07AA08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Lascufloxacin","2":"Fluoroquinolones","3":"J01MA25","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Latamoxef","2":"Third-generation-cephalosporins","3":"J01DD06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Lefamulin","2":"Pleuromutilin","3":"J01XX12","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Levofloxacin","2":"Fluoroquinolones","3":"J01MA12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Levonadifloxacin","2":"Fluoroquinolones","3":"J01MA24","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Lincomycin","2":"Lincosamides","3":"J01FF02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Linezolid","2":"Oxazolidinones","3":"J01XX08","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Lomefloxacin","2":"Fluoroquinolones","3":"J01MA07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Loracarbef","2":"Second-generation-cephalosporins","3":"J01DC08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Lymecycline","2":"Tetracyclines","3":"J01AA04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Mecillinam","2":"Penicillins","3":"J01CA11","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Meropenem","2":"Carbapenems","3":"J01DH02","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Meropenem/vaborbactam","2":"Carbapenems","3":"J01DH52","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Metacycline","2":"Tetracyclines","3":"J01AA05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Metampicillin","2":"Penicillins","3":"J01CA14","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Meticillin","2":"Penicillins","3":"J01CF03","4":"Access","5":"Yes (therapeutic alternative to cloxacillin)","6":"NA","7":"NA","8":"NA"},{"1":"Metronidazole_IV","2":"Imidazoles","3":"J01XD01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Metronidazole_oral","2":"Imidazoles","3":"P01AB01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Mezlocillin","2":"Penicillins","3":"J01CA10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Micronomicin","2":"Aminoglycosides","3":"to be assigned","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Midecamycin","2":"Macrolides","3":"J01FA03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Minocycline_IV","2":"Tetracyclines","3":"J01AA08","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Minocycline_oral","2":"Tetracyclines","3":"J01AA08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Miocamycin","2":"Macrolides","3":"J01FA11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Moxifloxacin","2":"Fluoroquinolones","3":"J01MA14","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Nafcillin","2":"Penicillins","3":"J01CF06","4":"Access","5":"Yes (therapeutic alternative to cloxacillin)","6":"NA","7":"NA","8":"NA"},{"1":"Nemonoxacin","2":"Quinolones","3":"J01MB08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Neomycin_IV","2":"Aminoglycosides","3":"J01GB05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Neomycin_oral","2":"Aminoglycosides","3":"A07AA01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Netilmicin","2":"Aminoglycosides","3":"J01GB07","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Nifurtoinol","2":"Nitrofuran derivatives","3":"J01XE02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Nitrofurantoin","2":"Nitrofuran-derivatives","3":"J01XE01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Norfloxacin","2":"Fluoroquinolones","3":"J01MA06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ofloxacin","2":"Fluoroquinolones","3":"J01MA01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Oleandomycin","2":"Macrolides","3":"J01FA05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Omadacycline","2":"Tetracyclines","3":"J01AA15","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Oritavancin","2":"Glycopeptides","3":"J01XA05","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ornidazole_IV","2":"Imidazoles","3":"J01XD03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ornidazole_oral","2":"Imidazoles","3":"P01AB03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Oxacillin","2":"Penicillins","3":"J01CF04","4":"Access","5":"Yes (therapeutic alternative to cloxacillin)","6":"NA","7":"NA","8":"NA"},{"1":"Oxolinic-acid","2":"Quinolones","3":"J01MB05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Oxytetracycline","2":"Tetracyclines","3":"J01AA06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Panipenem","2":"Carbapenems","3":"J01DH55","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pazufloxacin","2":"Fluoroquinolones","3":"J01MA18","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pefloxacin","2":"Fluoroquinolones","3":"J01MA03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Penamecillin","2":"Penicillins","3":"J01CE06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Penimepicycline","2":"Tetracyclines","3":"J01AA10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pheneticillin","2":"Penicillins","3":"J01CE05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Phenoxymethylpenicillin","2":"Penicillins","3":"J01CE02","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Pipemidic-acid","2":"Quinolones","3":"J01MB04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Piperacillin","2":"Penicillins","3":"J01CA12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Piperacillin/tazobactam","2":"Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal","3":"J01CR05","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Piromidic-acid","2":"Quinolones","3":"J01MB03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pivampicillin","2":"Penicillins","3":"J01CA02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pivmecillinam","2":"Penicillins","3":"J01CA08","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Plazomicin","2":"Aminoglycosides","3":"J01GB14","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Polymyxin-B_IV","2":"Polymyxins","3":"J01XB02","4":"Reserve","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Polymyxin-B_oral","2":"Polymyxins","3":"A07AA05","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Pristinamycin","2":"Streptogramins","3":"J01FG01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Procaine-benzylpenicillin","2":"Penicillins","3":"J01CE09","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Propicillin","2":"Penicillins","3":"J01CE03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Prulifloxacin","2":"Fluoroquinolones","3":"J01MA17","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ribostamycin","2":"Aminoglycosides","3":"J01GB10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rifabutin","2":"Rifamycins","3":"J04AB04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rifampicin","2":"Rifamycins","3":"J04AB02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rifamycin_IV","2":"Rifamycins","3":"J04AB03","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rifamycin_oral","2":"Rifamycins","3":"A07AA13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rifaximin","2":"Rifamycins","3":"A07AA11","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rokitamycin","2":"Macrolides","3":"J01FA12","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rolitetracycline","2":"Tetracyclines","3":"J01AA09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rosoxacin","2":"Quinolones","3":"J01MB01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Roxithromycin","2":"Macrolides","3":"J01FA06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Rufloxacin","2":"Fluoroquinolones","3":"J01MA10","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sarecycline","2":"Tetracyclines","3":"J01AA14","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Secnidazole","2":"Imidazoles","3":"P01AB07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sisomicin","2":"Aminoglycosides","3":"J01GB08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sitafloxacin","2":"Fluoroquinolones","3":"J01MA21","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Solithromycin","2":"Macrolides","3":"J01FA16","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sparfloxacin","2":"Fluoroquinolones","3":"J01MA09","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Spectinomycin","2":"Aminocyclitols","3":"J01XX04","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Spiramycin","2":"Macrolides","3":"J01FA02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Streptoduocin","2":"Aminoglycosides","3":"J01GA02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Streptomycin_IV","2":"Aminoglycosides","3":"J01GA01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Streptomycin_oral","2":"Aminoglycosides","3":"A07AA04","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulbactam","2":"Beta-lactamase-inhibitors","3":"J01CG01","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulbenicillin","2":"Penicillins","3":"J01CA16","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadiazine","2":"Sulfonamides","3":"J01EC02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadiazine/tetroxoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadiazine/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadimethoxine","2":"Sulfonamides","3":"J01ED01","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadimidine","2":"Sulfonamides","3":"J01EB03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfadimidine/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE05","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfafurazole","2":"Sulfonamides","3":"J01EB05","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfaisodimidine","2":"Sulfonamides","3":"J01EB01","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfalene","2":"Sulfonamides","3":"J01ED02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamazone","2":"Sulfonamides","3":"J01ED09","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamerazine","2":"Sulfonamides","3":"J01ED07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamerazine/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamethizole","2":"Sulfonamides","3":"J01EB02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamethoxazole","2":"Sulfonamides","3":"J01EC01","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamethoxazole/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamethoxypyridazine","2":"Sulfonamides","3":"J01ED05","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfametomidine","2":"Sulfonamides","3":"J01ED03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfametoxydiazine","2":"Sulfonamides","3":"J01ED04","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfametrole/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamoxole","2":"Sulfonamides","3":"J01EC03","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfamoxole/trimethoprim","2":"Sulfonamide-trimethoprim-combinations","3":"J01EE04","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfanilamide","2":"Sulfonamides","3":"J01EB06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfaperin","2":"Sulfonamides","3":"J01ED06","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfaphenazole","2":"Sulfonamides","3":"J01ED08","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfapyridine","2":"Sulfonamides","3":"J01EB04","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfathiazole","2":"Sulfonamides","3":"J01EB07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sulfathiourea","2":"Sulfonamides","3":"J01EB08","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Sultamicillin","2":"Beta-lactam/beta-lactamase-inhibitor","3":"J01CR04","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Talampicillin","2":"Penicillins","3":"J01CA15","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tazobactam","2":"Beta-lactamase-inhibitors","3":"J01CG02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tebipenem","2":"Carbapenems","3":"J01DH06","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tedizolid","2":"Oxazolidinones","3":"J01XX11","4":"Reserve","5":"Yes (therapeutic alternative to linezolid (EML))","6":"NA","7":"NA","8":"NA"},{"1":"Teicoplanin","2":"Glycopeptides","3":"J01XA02","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Telavancin","2":"Glycopeptides","3":"J01XA03","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Telithromycin","2":"Macrolides","3":"J01FA15","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Temafloxacin","2":"Fluoroquinolones","3":"J01MA05","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Temocillin","2":"Penicillins","3":"J01CA17","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tetracycline","2":"Tetracyclines","3":"J01AA07","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Thiamphenicol","2":"Amphenicols","3":"J01BA02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Ticarcillin","2":"Penicillins","3":"J01CA13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tigecycline","2":"Glycylcyclines","3":"J01AA12","4":"Reserve","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tinidazole_IV","2":"Imidazoles","3":"J01XD02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tinidazole_oral","2":"Imidazoles","3":"P01AB02","4":"Access","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tobramycin","2":"Aminoglycosides","3":"J01GB01","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Tosufloxacin","2":"Fluoroquinolones","3":"J01MA22","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Trimethoprim","2":"Trimethoprim-derivatives","3":"J01EA01","4":"Access","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Troleandomycin","2":"Macrolides","3":"J01FA08","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Trovafloxacin","2":"Fluoroquinolones","3":"J01MA13","4":"Watch","5":"No","6":"NA","7":"NA","8":"NA"},{"1":"Vancomycin_IV","2":"Glycopeptides","3":"J01XA01","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"},{"1":"Vancomycin_oral","2":"Glycopeptides","3":"A07AA09","4":"Watch","5":"Yes","6":"NA","7":"NA","8":"NA"}],"options":{"columns":{"min":{},"max":[10],"total":[8]},"rows":{"min":[10],"max":[10],"total":[257]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGYgPC0gZGYgfD4gcmVuYW1lKEFUQ19jb2RlID0gJ0FUQyBjb2RlJywgRU1MID0gJ0xpc3RlZCBvbiBFTUwvRU1MYyAyMDIzJylcbmRmIDwtIGRmIHw+IHNlbGVjdChBbnRpYmlvdGljLCBDbGFzcywgQ2F0ZWdvcnksIEFUQ19jb2RlLCBFTUwpXG5gYGAifQ== -->
<pre class="r"><code>df &lt;- df |&gt; rename(ATC_code = &#39;ATC code&#39;, EML = &#39;Listed on EML/EMLc 2023&#39;)
df &lt;- df |&gt; select(Antibiotic, Class, Category, ATC_code, EML)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>
patterns_to_replace &lt;- c(&quot;generation&quot; = &quot;gen&quot;, &quot;First&quot; = &quot;1st&quot;, &quot;Second&quot; = &quot;2nd&quot;, &quot;Third&quot; = &quot;3rd&quot;, &quot;Fourth&quot; = &quot;4th&quot;, &quot;Fifth&quot; = &quot;5th&quot;, &quot;combinations&quot; = &quot;combos&quot;, &quot;Beta-lactam/beta-lactamase-inhibitor_anti-pseudomonal&quot; = &quot;Beta-lactam/beta-lactamase-inhibitor&quot; )

df$Class &lt;- str_replace_all(df$Class, patterns_to_replace)

beta_lactam_classes &lt;- c(&quot;Penicillins&quot;, &quot;Beta-lactam/beta-lactamase-inhibitor&quot;, 
                         &quot;Monobactams&quot;, &quot;Carbapenems&quot;, 
                         &quot;1st-gen-cephalosporins&quot;, &quot;2nd-gen-cephalosporins&quot;, 
                         &quot;3rd-gen-cephalosporins&quot;, &quot;4th-gen-cephalosporins&quot;, 
                         &quot;Other-cephalosporins&quot;, &quot;5th-gen cephalosporins&quot;, 
                         &quot;Penems&quot;, &quot;Beta-lactamase-inhibitors&quot;)

df &lt;- df %&gt;%
  mutate(Category_Beta_Lactam = ifelse(Class %in% beta_lactam_classes, &quot;Beta-Lactams&quot;, &quot;Other&quot;),
         value = ifelse(!duplicated(Class) &amp; !duplicated(Class, fromLast = TRUE), 2, 1))
df</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Antibiotic"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Class"],"name":[2],"type":["chr"],"align":["left"]},{"label":["Category"],"name":[3],"type":["chr"],"align":["left"]},{"label":["ATC_code"],"name":[4],"type":["chr"],"align":["left"]},{"label":["EML"],"name":[5],"type":["chr"],"align":["left"]},{"label":["Category_Beta_Lactam"],"name":[6],"type":["chr"],"align":["left"]},{"label":["value"],"name":[7],"type":["dbl"],"align":["right"]}],"data":[{"1":"Amikacin","2":"Aminoglycosides","3":"Access","4":"J01GB06","5":"Yes","6":"Other","7":"1"},{"1":"Amoxicillin","2":"Penicillins","3":"Access","4":"J01CA04","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Amoxicillin/clavulanic-acid","2":"Beta-lactam/beta-lactamase-inhibitor","3":"Access","4":"J01CR02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Ampicillin","2":"Penicillins","3":"Access","4":"J01CA01","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Ampicillin/sulbactam","2":"Beta-lactam/beta-lactamase-inhibitor","3":"Access","4":"J01CR01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Arbekacin","2":"Aminoglycosides","3":"Watch","4":"J01GB12","5":"No","6":"Other","7":"1"},{"1":"Aspoxicillin","2":"Penicillins","3":"Watch","4":"J01CA19","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Azidocillin","2":"Penicillins","3":"Access","4":"J01CE04","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Azithromycin","2":"Macrolides","3":"Watch","4":"J01FA10","5":"Yes","6":"Other","7":"1"},{"1":"Azlocillin","2":"Penicillins","3":"Watch","4":"J01CA09","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Aztreonam","2":"Monobactams","3":"Reserve","4":"J01DF01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Bacampicillin","2":"Penicillins","3":"Access","4":"J01CA06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Bekanamycin","2":"Aminoglycosides","3":"Watch","4":"J01GB13","5":"No","6":"Other","7":"1"},{"1":"Benzathine-benzylpenicillin","2":"Penicillins","3":"Access","4":"J01CE08","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Benzylpenicillin","2":"Penicillins","3":"Access","4":"J01CE01","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Biapenem","2":"Carbapenems","3":"Watch","4":"J01DH05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Brodimoprim","2":"Trimethoprim-derivatives","3":"Access","4":"J01EA02","5":"No","6":"Other","7":"1"},{"1":"Carbenicillin","2":"Penicillins","3":"Watch","4":"J01CA03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Carindacillin","2":"Penicillins","3":"Watch","4":"J01CA05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Carumonam","2":"Monobactams","3":"Reserve","4":"J01DF02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefacetrile","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB10","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefaclor","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC04","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefadroxil","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefalexin","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB01","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefaloridine","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefalotin","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefamandole","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefapirin","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB08","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefatrizine","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB07","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefazedone","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefazolin","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB04","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefbuperazone","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC13","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefcapene-pivoxil","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD17","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefdinir","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD15","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefditoren-pivoxil","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD16","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefepime","2":"4th-gen-cephalosporins","3":"Watch","4":"J01DE01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefetamet-pivoxil","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD10","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefiderocol","2":"Other-cephalosporins","3":"Reserve","4":"J01DI04","5":"Yes","6":"Beta-Lactams","7":"2"},{"1":"Cefixime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD08","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefmenoxime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefmetazole","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC09","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefminox","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC12","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefodizime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD09","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefonicid","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefoperazone","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD12","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceforanide","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC11","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefoselis","2":"4th-gen-cephalosporins","3":"Watch","4":"to be assigned","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefotaxime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD01","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefotetan","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefotiam","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC07","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefoxitin","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefozopran","2":"4th-gen-cephalosporins","3":"Watch","4":"J01DE03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefpiramide","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD11","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefpirome","2":"4th-gen-cephalosporins","3":"Watch","4":"J01DE02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefpodoxime-proxetil","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD13","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefprozil","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC10","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefradine","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB09","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefroxadine","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB11","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Cefsulodin","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftaroline-fosamil","2":"5th-gen cephalosporins","3":"Reserve","4":"J01DI02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftazidime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Ceftazidime/avibactam","2":"3rd-gen-cephalosporins","3":"Reserve","4":"J01DD52","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefteram-pivoxil","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD18","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftezole","2":"1st-gen-cephalosporins","3":"Access","4":"J01DB12","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftibuten","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD14","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftizoxime","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD07","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftobiprole-medocaril","2":"5th-gen cephalosporins","3":"Reserve","4":"J01DI01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Ceftolozane/tazobactam","2":"5th-gen cephalosporins","3":"Reserve","4":"J01DI54","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Ceftriaxone","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD04","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Cefuroxime","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Chloramphenicol","2":"Amphenicols","3":"Access","4":"J01BA01","5":"Yes","6":"Other","7":"1"},{"1":"Chlortetracycline","2":"Tetracyclines","3":"Watch","4":"J01AA03","5":"No","6":"Other","7":"1"},{"1":"Cinoxacin","2":"Quinolones","3":"Watch","4":"J01MB06","5":"No","6":"Other","7":"1"},{"1":"Ciprofloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA02","5":"Yes","6":"Other","7":"1"},{"1":"Clarithromycin","2":"Macrolides","3":"Watch","4":"J01FA09","5":"Yes","6":"Other","7":"1"},{"1":"Clindamycin","2":"Lincosamides","3":"Access","4":"J01FF01","5":"Yes","6":"Other","7":"1"},{"1":"Clofoctol","2":"Phenol derivatives","3":"Watch","4":"J01XX03","5":"No","6":"Other","7":"2"},{"1":"Clometocillin","2":"Penicillins","3":"Access","4":"J01CE07","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Clomocycline","2":"Tetracyclines","3":"Watch","4":"J01AA11","5":"No","6":"Other","7":"1"},{"1":"Cloxacillin","2":"Penicillins","3":"Access","4":"J01CF02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Colistin_IV","2":"Polymyxins","3":"Reserve","4":"J01XB01","5":"Yes","6":"Other","7":"1"},{"1":"Colistin_oral","2":"Polymyxins","3":"Reserve","4":"A07AA10","5":"No","6":"Other","7":"1"},{"1":"Dalbavancin","2":"Glycopeptides","3":"Reserve","4":"J01XA04","5":"No","6":"Other","7":"1"},{"1":"Dalfopristin/quinupristin","2":"Streptogramins","3":"Reserve","4":"J01FG02","5":"No","6":"Other","7":"1"},{"1":"Daptomycin","2":"Lipopeptides","3":"Reserve","4":"J01XX09","5":"No","6":"Other","7":"2"},{"1":"Delafloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA23","5":"No","6":"Other","7":"1"},{"1":"Demeclocycline","2":"Tetracyclines","3":"Watch","4":"J01AA01","5":"No","6":"Other","7":"1"},{"1":"Dibekacin","2":"Aminoglycosides","3":"Watch","4":"J01GB09","5":"No","6":"Other","7":"1"},{"1":"Dicloxacillin","2":"Penicillins","3":"Access","4":"J01CF01","5":"Yes (therapeutic alternative to cloxacillin)","6":"Beta-Lactams","7":"1"},{"1":"Dirithromycin","2":"Macrolides","3":"Watch","4":"J01FA13","5":"No","6":"Other","7":"1"},{"1":"Doripenem","2":"Carbapenems","3":"Watch","4":"J01DH04","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Doxycycline","2":"Tetracyclines","3":"Access","4":"J01AA02","5":"Yes","6":"Other","7":"1"},{"1":"Enoxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA04","5":"No","6":"Other","7":"1"},{"1":"Epicillin","2":"Penicillins","3":"Access","4":"J01CA07","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Eravacycline","2":"Tetracyclines","3":"Reserve","4":"J01AA13","5":"No","6":"Other","7":"1"},{"1":"Ertapenem","2":"Carbapenems","3":"Watch","4":"J01DH03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Erythromycin","2":"Macrolides","3":"Watch","4":"J01FA01","5":"Yes (therapeutic alternative to clarithromycin (EMLc))","6":"Other","7":"1"},{"1":"Faropenem","2":"Penems","3":"Reserve","4":"J01DI03","5":"No","6":"Beta-Lactams","7":"2"},{"1":"Fidaxomicin","2":"Macrolides","3":"Watch","4":"A07AA12","5":"No","6":"Other","7":"1"},{"1":"Fleroxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA08","5":"No","6":"Other","7":"1"},{"1":"Flomoxef","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC14","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Flucloxacillin","2":"Penicillins","3":"Access","4":"J01CF05","5":"Yes (therapeutic alternative to cloxacillin)","6":"Beta-Lactams","7":"1"},{"1":"Flumequine","2":"Quinolones","3":"Watch","4":"J01MB07","5":"No","6":"Other","7":"1"},{"1":"Flurithromycin","2":"Macrolides","3":"Watch","4":"J01FA14","5":"No","6":"Other","7":"1"},{"1":"Fosfomycin_IV","2":"Phosphonics","3":"Reserve","4":"J01XX01","5":"Yes","6":"Other","7":"1"},{"1":"Fosfomycin_oral","2":"Phosphonics","3":"Watch","4":"J01XX01","5":"No","6":"Other","7":"1"},{"1":"Furazidin","2":"Nitrofuran derivatives","3":"Access","4":"J01XE03","5":"No","6":"Other","7":"1"},{"1":"Fusidic-acid","2":"Steroid antibacterials","3":"Watch","4":"J01XC01","5":"No","6":"Other","7":"2"},{"1":"Garenoxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA19","5":"No","6":"Other","7":"1"},{"1":"Gatifloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA16","5":"No","6":"Other","7":"1"},{"1":"Gemifloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA15","5":"No","6":"Other","7":"1"},{"1":"Gentamicin","2":"Aminoglycosides","3":"Access","4":"J01GB03","5":"Yes","6":"Other","7":"1"},{"1":"Grepafloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA11","5":"No","6":"Other","7":"1"},{"1":"Hetacillin","2":"Penicillins","3":"Access","4":"J01CA18","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Iclaprim","2":"Trimethoprim-derivatives","3":"Reserve","4":"J01EA03","5":"No","6":"Other","7":"1"},{"1":"Imipenem/cilastatin","2":"Carbapenems","3":"Watch","4":"J01DH51","5":"Yes (therapeutic alternative to meropenem)","6":"Beta-Lactams","7":"1"},{"1":"Imipenem/cilastatin/relebactam","2":"Carbapenems","3":"Reserve","4":"J01DH56","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Isepamicin","2":"Aminoglycosides","3":"Watch","4":"J01GB11","5":"No","6":"Other","7":"1"},{"1":"Josamycin","2":"Macrolides","3":"Watch","4":"J01FA07","5":"No","6":"Other","7":"1"},{"1":"Kanamycin_IV","2":"Aminoglycosides","3":"Watch","4":"J01GB04","5":"No","6":"Other","7":"1"},{"1":"Kanamycin_oral","2":"Aminoglycosides","3":"Watch","4":"A07AA08","5":"No","6":"Other","7":"1"},{"1":"Lascufloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA25","5":"No","6":"Other","7":"1"},{"1":"Latamoxef","2":"3rd-gen-cephalosporins","3":"Watch","4":"J01DD06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Lefamulin","2":"Pleuromutilin","3":"Reserve","4":"J01XX12","5":"No","6":"Other","7":"2"},{"1":"Levofloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA12","5":"No","6":"Other","7":"1"},{"1":"Levonadifloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA24","5":"No","6":"Other","7":"1"},{"1":"Lincomycin","2":"Lincosamides","3":"Watch","4":"J01FF02","5":"No","6":"Other","7":"1"},{"1":"Linezolid","2":"Oxazolidinones","3":"Reserve","4":"J01XX08","5":"Yes","6":"Other","7":"1"},{"1":"Lomefloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA07","5":"No","6":"Other","7":"1"},{"1":"Loracarbef","2":"2nd-gen-cephalosporins","3":"Watch","4":"J01DC08","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Lymecycline","2":"Tetracyclines","3":"Watch","4":"J01AA04","5":"No","6":"Other","7":"1"},{"1":"Mecillinam","2":"Penicillins","3":"Access","4":"J01CA11","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Meropenem","2":"Carbapenems","3":"Watch","4":"J01DH02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Meropenem/vaborbactam","2":"Carbapenems","3":"Reserve","4":"J01DH52","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Metacycline","2":"Tetracyclines","3":"Watch","4":"J01AA05","5":"No","6":"Other","7":"1"},{"1":"Metampicillin","2":"Penicillins","3":"Access","4":"J01CA14","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Meticillin","2":"Penicillins","3":"Access","4":"J01CF03","5":"Yes (therapeutic alternative to cloxacillin)","6":"Beta-Lactams","7":"1"},{"1":"Metronidazole_IV","2":"Imidazoles","3":"Access","4":"J01XD01","5":"Yes","6":"Other","7":"1"},{"1":"Metronidazole_oral","2":"Imidazoles","3":"Access","4":"P01AB01","5":"Yes","6":"Other","7":"1"},{"1":"Mezlocillin","2":"Penicillins","3":"Watch","4":"J01CA10","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Micronomicin","2":"Aminoglycosides","3":"Watch","4":"to be assigned","5":"No","6":"Other","7":"1"},{"1":"Midecamycin","2":"Macrolides","3":"Watch","4":"J01FA03","5":"No","6":"Other","7":"1"},{"1":"Minocycline_IV","2":"Tetracyclines","3":"Reserve","4":"J01AA08","5":"No","6":"Other","7":"1"},{"1":"Minocycline_oral","2":"Tetracyclines","3":"Watch","4":"J01AA08","5":"No","6":"Other","7":"1"},{"1":"Miocamycin","2":"Macrolides","3":"Watch","4":"J01FA11","5":"No","6":"Other","7":"1"},{"1":"Moxifloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA14","5":"No","6":"Other","7":"1"},{"1":"Nafcillin","2":"Penicillins","3":"Access","4":"J01CF06","5":"Yes (therapeutic alternative to cloxacillin)","6":"Beta-Lactams","7":"1"},{"1":"Nemonoxacin","2":"Quinolones","3":"Watch","4":"J01MB08","5":"No","6":"Other","7":"1"},{"1":"Neomycin_IV","2":"Aminoglycosides","3":"Watch","4":"J01GB05","5":"No","6":"Other","7":"1"},{"1":"Neomycin_oral","2":"Aminoglycosides","3":"Watch","4":"A07AA01","5":"No","6":"Other","7":"1"},{"1":"Netilmicin","2":"Aminoglycosides","3":"Watch","4":"J01GB07","5":"No","6":"Other","7":"1"},{"1":"Nifurtoinol","2":"Nitrofuran derivatives","3":"Access","4":"J01XE02","5":"No","6":"Other","7":"1"},{"1":"Nitrofurantoin","2":"Nitrofuran-derivatives","3":"Access","4":"J01XE01","5":"Yes","6":"Other","7":"2"},{"1":"Norfloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA06","5":"No","6":"Other","7":"1"},{"1":"Ofloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA01","5":"No","6":"Other","7":"1"},{"1":"Oleandomycin","2":"Macrolides","3":"Watch","4":"J01FA05","5":"No","6":"Other","7":"1"},{"1":"Omadacycline","2":"Tetracyclines","3":"Reserve","4":"J01AA15","5":"No","6":"Other","7":"1"},{"1":"Oritavancin","2":"Glycopeptides","3":"Reserve","4":"J01XA05","5":"No","6":"Other","7":"1"},{"1":"Ornidazole_IV","2":"Imidazoles","3":"Access","4":"J01XD03","5":"No","6":"Other","7":"1"},{"1":"Ornidazole_oral","2":"Imidazoles","3":"Access","4":"P01AB03","5":"No","6":"Other","7":"1"},{"1":"Oxacillin","2":"Penicillins","3":"Access","4":"J01CF04","5":"Yes (therapeutic alternative to cloxacillin)","6":"Beta-Lactams","7":"1"},{"1":"Oxolinic-acid","2":"Quinolones","3":"Watch","4":"J01MB05","5":"No","6":"Other","7":"1"},{"1":"Oxytetracycline","2":"Tetracyclines","3":"Watch","4":"J01AA06","5":"No","6":"Other","7":"1"},{"1":"Panipenem","2":"Carbapenems","3":"Watch","4":"J01DH55","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Pazufloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA18","5":"No","6":"Other","7":"1"},{"1":"Pefloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA03","5":"No","6":"Other","7":"1"},{"1":"Penamecillin","2":"Penicillins","3":"Access","4":"J01CE06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Penimepicycline","2":"Tetracyclines","3":"Watch","4":"J01AA10","5":"No","6":"Other","7":"1"},{"1":"Pheneticillin","2":"Penicillins","3":"Watch","4":"J01CE05","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Phenoxymethylpenicillin","2":"Penicillins","3":"Access","4":"J01CE02","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Pipemidic-acid","2":"Quinolones","3":"Watch","4":"J01MB04","5":"No","6":"Other","7":"1"},{"1":"Piperacillin","2":"Penicillins","3":"Watch","4":"J01CA12","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Piperacillin/tazobactam","2":"Beta-lactam/beta-lactamase-inhibitor","3":"Watch","4":"J01CR05","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Piromidic-acid","2":"Quinolones","3":"Watch","4":"J01MB03","5":"No","6":"Other","7":"1"},{"1":"Pivampicillin","2":"Penicillins","3":"Access","4":"J01CA02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Pivmecillinam","2":"Penicillins","3":"Access","4":"J01CA08","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Plazomicin","2":"Aminoglycosides","3":"Reserve","4":"J01GB14","5":"Yes","6":"Other","7":"1"},{"1":"Polymyxin-B_IV","2":"Polymyxins","3":"Reserve","4":"J01XB02","5":"Yes","6":"Other","7":"1"},{"1":"Polymyxin-B_oral","2":"Polymyxins","3":"Reserve","4":"A07AA05","5":"No","6":"Other","7":"1"},{"1":"Pristinamycin","2":"Streptogramins","3":"Watch","4":"J01FG01","5":"No","6":"Other","7":"1"},{"1":"Procaine-benzylpenicillin","2":"Penicillins","3":"Access","4":"J01CE09","5":"Yes","6":"Beta-Lactams","7":"1"},{"1":"Propicillin","2":"Penicillins","3":"Access","4":"J01CE03","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Prulifloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA17","5":"No","6":"Other","7":"1"},{"1":"Ribostamycin","2":"Aminoglycosides","3":"Watch","4":"J01GB10","5":"No","6":"Other","7":"1"},{"1":"Rifabutin","2":"Rifamycins","3":"Watch","4":"J04AB04","5":"No","6":"Other","7":"1"},{"1":"Rifampicin","2":"Rifamycins","3":"Watch","4":"J04AB02","5":"No","6":"Other","7":"1"},{"1":"Rifamycin_IV","2":"Rifamycins","3":"Watch","4":"J04AB03","5":"No","6":"Other","7":"1"},{"1":"Rifamycin_oral","2":"Rifamycins","3":"Watch","4":"A07AA13","5":"No","6":"Other","7":"1"},{"1":"Rifaximin","2":"Rifamycins","3":"Watch","4":"A07AA11","5":"No","6":"Other","7":"1"},{"1":"Rokitamycin","2":"Macrolides","3":"Watch","4":"J01FA12","5":"No","6":"Other","7":"1"},{"1":"Rolitetracycline","2":"Tetracyclines","3":"Watch","4":"J01AA09","5":"No","6":"Other","7":"1"},{"1":"Rosoxacin","2":"Quinolones","3":"Watch","4":"J01MB01","5":"No","6":"Other","7":"1"},{"1":"Roxithromycin","2":"Macrolides","3":"Watch","4":"J01FA06","5":"No","6":"Other","7":"1"},{"1":"Rufloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA10","5":"No","6":"Other","7":"1"},{"1":"Sarecycline","2":"Tetracyclines","3":"Watch","4":"J01AA14","5":"No","6":"Other","7":"1"},{"1":"Secnidazole","2":"Imidazoles","3":"Access","4":"P01AB07","5":"No","6":"Other","7":"1"},{"1":"Sisomicin","2":"Aminoglycosides","3":"Watch","4":"J01GB08","5":"No","6":"Other","7":"1"},{"1":"Sitafloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA21","5":"No","6":"Other","7":"1"},{"1":"Solithromycin","2":"Macrolides","3":"Watch","4":"J01FA16","5":"No","6":"Other","7":"1"},{"1":"Sparfloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA09","5":"No","6":"Other","7":"1"},{"1":"Spectinomycin","2":"Aminocyclitols","3":"Access","4":"J01XX04","5":"Yes","6":"Other","7":"2"},{"1":"Spiramycin","2":"Macrolides","3":"Watch","4":"J01FA02","5":"No","6":"Other","7":"1"},{"1":"Streptoduocin","2":"Aminoglycosides","3":"Watch","4":"J01GA02","5":"No","6":"Other","7":"1"},{"1":"Streptomycin_IV","2":"Aminoglycosides","3":"Watch","4":"J01GA01","5":"No","6":"Other","7":"1"},{"1":"Streptomycin_oral","2":"Aminoglycosides","3":"Watch","4":"A07AA04","5":"No","6":"Other","7":"1"},{"1":"Sulbactam","2":"Beta-lactamase-inhibitors","3":"Access","4":"J01CG01","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Sulbenicillin","2":"Penicillins","3":"Watch","4":"J01CA16","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Sulfadiazine","2":"Sulfonamides","3":"Access","4":"J01EC02","5":"No","6":"Other","7":"1"},{"1":"Sulfadiazine/tetroxoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE06","5":"No","6":"Other","7":"1"},{"1":"Sulfadiazine/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE02","5":"No","6":"Other","7":"1"},{"1":"Sulfadimethoxine","2":"Sulfonamides","3":"Access","4":"J01ED01","5":"No","6":"Other","7":"1"},{"1":"Sulfadimidine","2":"Sulfonamides","3":"Access","4":"J01EB03","5":"No","6":"Other","7":"1"},{"1":"Sulfadimidine/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE05","5":"No","6":"Other","7":"1"},{"1":"Sulfafurazole","2":"Sulfonamides","3":"Access","4":"J01EB05","5":"No","6":"Other","7":"1"},{"1":"Sulfaisodimidine","2":"Sulfonamides","3":"Access","4":"J01EB01","5":"No","6":"Other","7":"1"},{"1":"Sulfalene","2":"Sulfonamides","3":"Access","4":"J01ED02","5":"No","6":"Other","7":"1"},{"1":"Sulfamazone","2":"Sulfonamides","3":"Access","4":"J01ED09","5":"No","6":"Other","7":"1"},{"1":"Sulfamerazine","2":"Sulfonamides","3":"Access","4":"J01ED07","5":"No","6":"Other","7":"1"},{"1":"Sulfamerazine/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE07","5":"No","6":"Other","7":"1"},{"1":"Sulfamethizole","2":"Sulfonamides","3":"Access","4":"J01EB02","5":"No","6":"Other","7":"1"},{"1":"Sulfamethoxazole","2":"Sulfonamides","3":"Access","4":"J01EC01","5":"No","6":"Other","7":"1"},{"1":"Sulfamethoxazole/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE01","5":"Yes","6":"Other","7":"1"},{"1":"Sulfamethoxypyridazine","2":"Sulfonamides","3":"Access","4":"J01ED05","5":"No","6":"Other","7":"1"},{"1":"Sulfametomidine","2":"Sulfonamides","3":"Access","4":"J01ED03","5":"No","6":"Other","7":"1"},{"1":"Sulfametoxydiazine","2":"Sulfonamides","3":"Access","4":"J01ED04","5":"No","6":"Other","7":"1"},{"1":"Sulfametrole/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE03","5":"No","6":"Other","7":"1"},{"1":"Sulfamoxole","2":"Sulfonamides","3":"Access","4":"J01EC03","5":"No","6":"Other","7":"1"},{"1":"Sulfamoxole/trimethoprim","2":"Sulfonamide-trimethoprim-combos","3":"Access","4":"J01EE04","5":"No","6":"Other","7":"1"},{"1":"Sulfanilamide","2":"Sulfonamides","3":"Access","4":"J01EB06","5":"No","6":"Other","7":"1"},{"1":"Sulfaperin","2":"Sulfonamides","3":"Access","4":"J01ED06","5":"No","6":"Other","7":"1"},{"1":"Sulfaphenazole","2":"Sulfonamides","3":"Access","4":"J01ED08","5":"No","6":"Other","7":"1"},{"1":"Sulfapyridine","2":"Sulfonamides","3":"Access","4":"J01EB04","5":"No","6":"Other","7":"1"},{"1":"Sulfathiazole","2":"Sulfonamides","3":"Access","4":"J01EB07","5":"No","6":"Other","7":"1"},{"1":"Sulfathiourea","2":"Sulfonamides","3":"Access","4":"J01EB08","5":"No","6":"Other","7":"1"},{"1":"Sultamicillin","2":"Beta-lactam/beta-lactamase-inhibitor","3":"Access","4":"J01CR04","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Talampicillin","2":"Penicillins","3":"Access","4":"J01CA15","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Tazobactam","2":"Beta-lactamase-inhibitors","3":"Watch","4":"J01CG02","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Tebipenem","2":"Carbapenems","3":"Watch","4":"J01DH06","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Tedizolid","2":"Oxazolidinones","3":"Reserve","4":"J01XX11","5":"Yes (therapeutic alternative to linezolid (EML))","6":"Other","7":"1"},{"1":"Teicoplanin","2":"Glycopeptides","3":"Watch","4":"J01XA02","5":"No","6":"Other","7":"1"},{"1":"Telavancin","2":"Glycopeptides","3":"Reserve","4":"J01XA03","5":"No","6":"Other","7":"1"},{"1":"Telithromycin","2":"Macrolides","3":"Watch","4":"J01FA15","5":"No","6":"Other","7":"1"},{"1":"Temafloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA05","5":"No","6":"Other","7":"1"},{"1":"Temocillin","2":"Penicillins","3":"Watch","4":"J01CA17","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Tetracycline","2":"Tetracyclines","3":"Access","4":"J01AA07","5":"No","6":"Other","7":"1"},{"1":"Thiamphenicol","2":"Amphenicols","3":"Access","4":"J01BA02","5":"No","6":"Other","7":"1"},{"1":"Ticarcillin","2":"Penicillins","3":"Watch","4":"J01CA13","5":"No","6":"Beta-Lactams","7":"1"},{"1":"Tigecycline","2":"Glycylcyclines","3":"Reserve","4":"J01AA12","5":"No","6":"Other","7":"2"},{"1":"Tinidazole_IV","2":"Imidazoles","3":"Access","4":"J01XD02","5":"No","6":"Other","7":"1"},{"1":"Tinidazole_oral","2":"Imidazoles","3":"Access","4":"P01AB02","5":"No","6":"Other","7":"1"},{"1":"Tobramycin","2":"Aminoglycosides","3":"Watch","4":"J01GB01","5":"No","6":"Other","7":"1"},{"1":"Tosufloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA22","5":"No","6":"Other","7":"1"},{"1":"Trimethoprim","2":"Trimethoprim-derivatives","3":"Access","4":"J01EA01","5":"Yes","6":"Other","7":"1"},{"1":"Troleandomycin","2":"Macrolides","3":"Watch","4":"J01FA08","5":"No","6":"Other","7":"1"},{"1":"Trovafloxacin","2":"Fluoroquinolones","3":"Watch","4":"J01MA13","5":"No","6":"Other","7":"1"},{"1":"Vancomycin_IV","2":"Glycopeptides","3":"Watch","4":"J01XA01","5":"Yes","6":"Other","7":"1"},{"1":"Vancomycin_oral","2":"Glycopeptides","3":"Watch","4":"A07AA09","5":"Yes","6":"Other","7":"1"}],"options":{"columns":{"min":{},"max":[10],"total":[7]},"rows":{"min":[10],"max":[10],"total":[257]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuXG5cbiMgUmVhZCB0aGUgWE1MIGZpbGVcbnhtbF9kYXRhIDwtIHJlYWRfeG1sKFwiLi4vLi4vLi4vLi4vYW50aWJpb3RpY3MvZnVsbF9kYXRhYmFzZS54bWxcIilcbm5zIDwtIHhtbF9ucyh4bWxfZGF0YSlcbmF0Y19jb2RlX3ZlY3RvciA8LSBkZiRBVENfY29kZVxuXG54cGF0aF9xdWVyeSA8LSBwYXN0ZTAoXCIuLy9kMTphdGMtY29kZXMvZDE6YXRjLWNvZGVbQGNvZGU9J1wiLCBwYXN0ZShhdGNfY29kZV92ZWN0b3IsIGNvbGxhcHNlPVwiJyBvciBAY29kZT0nXCIpLCBcIiddXCIpXG5cbmF0Y19jb2RlcyA8LSB4bWxfZmluZF9hbGwoeG1sX2RhdGEsIHhwYXRoX3F1ZXJ5LCBucylcblxuYGBgIn0= -->
<pre class="r"><code>

# Read the XML file
xml_data &lt;- read_xml(&quot;../../../../antibiotics/full_database.xml&quot;)
ns &lt;- xml_ns(xml_data)
atc_code_vector &lt;- df$ATC_code

xpath_query &lt;- paste0(&quot;.//d1:atc-codes/d1:atc-code[@code=&#39;&quot;, paste(atc_code_vector, collapse=&quot;&#39; or @code=&#39;&quot;), &quot;&#39;]&quot;)

atc_codes &lt;- xml_find_all(xml_data, xpath_query, ns)
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuXG5kcnVnX2luZm9fZHQgPC0gZGF0YS50YWJsZShBVENfY29kZSA9IGNoYXJhY3RlcigpLCBkZXNjcmlwdGlvbiA9IGNoYXJhY3RlcigpLCBnZW5lcmljX2Rlc2NyaXB0aW9uID0gY2hhcmFjdGVyKCkpXG5cbiMgSXRlcmF0ZSBvdmVyIHRoZSBmaWx0ZXJlZCBBVEMgY29kZXNcbmZvciAoYXRjX2NvZGUgaW4gYXRjX2NvZGVzKSB7XG4gICAgZHJ1ZyA8LSB4bWxfZmluZF9maXJzdChhdGNfY29kZSwgXCJhbmNlc3Rvcjo6ZDE6ZHJ1Z1wiKVxuXG4gICAgZGVzY3JpcHRpb24gPC0geG1sX2ZpbmRfZmlyc3QoZHJ1ZywgXCIuLy9kMTpkZXNjcmlwdGlvblwiLCBucykgJT4lIHhtbF90ZXh0KClcblxuICAgICAgZ2VuZXJpY19kZXNjcmlwdGlvbiA9IHhtbF9maW5kX2ZpcnN0KGF0Y19jb2RlLCBcIi4vL2QxOmxldmVsXCIsIG5zKSAlPiUgeG1sX3RleHQoKVxuXG4gICAgZHJ1Z19pbmZvX2R0IDwtIHJiaW5kbGlzdChsaXN0KGRydWdfaW5mb19kdCwgZGF0YS50YWJsZShBVENfY29kZSA9IHhtbF9hdHRyKGF0Y19jb2RlLCBcImNvZGVcIiksIGRlc2NyaXB0aW9uLCBnZW5lcmljX2Rlc2NyaXB0aW9uKSksIGZpbGwgPSBUUlVFKVxuXG59XG5cbmBgYCJ9 -->
<pre class="r"><code>
drug_info_dt &lt;- data.table(ATC_code = character(), description = character(), generic_description = character())

# Iterate over the filtered ATC codes
for (atc_code in atc_codes) {
    drug &lt;- xml_find_first(atc_code, &quot;ancestor::d1:drug&quot;)

    description &lt;- xml_find_first(drug, &quot;.//d1:description&quot;, ns) %&gt;% xml_text()

      generic_description = xml_find_first(atc_code, &quot;.//d1:level&quot;, ns) %&gt;% xml_text()

    drug_info_dt &lt;- rbindlist(list(drug_info_dt, data.table(ATC_code = xml_attr(atc_code, &quot;code&quot;), description, generic_description)), fill = TRUE)

}
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>unique_drug_info_dt &lt;- drug_info_dt[, .SD[.N == 1], by = ATC_code]

unique_drug_info_dt$description &lt;- if_else(unique_drug_info_dt$description == &quot;&quot;, unique_drug_info_dt$generic_description, unique_drug_info_dt$description)

unique_drug_info_dt &lt;- unique_drug_info_dt |&gt; select(-generic_description)

unique_drug_info_dt$description &lt;- gsub(&quot;\\[[A-Z0-9]+(,\\s*[A-Z0-9]+)*\\]&quot;, &quot;&quot;, unique_drug_info_dt$description)

unique_drug_info_dt$description &lt;- gsub(&quot;&lt;i&gt;|&lt;/i&gt;|\\[|\\]|\\_&quot;, &quot;&quot;, unique_drug_info_dt$description)

merged_df &lt;- left_join(df, unique_drug_info_dt, by = &quot;ATC_code&quot;)

print &lt;- merged_df |&gt; filter(is.na(merged_df$description))

extra_description = read_excel(&quot;../../../../antibiotics/extra_descriptions.xlsx&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiTmV3IG5hbWVzOlxuIn0= -->
<pre><code>New names:</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZXh0cmFfZGVzY3JpcHRpb24gPC0gZXh0cmFfZGVzY3JpcHRpb24gfD4gc2VsZWN0KEFudGliaW90aWMsIGRlc2NyaXB0aW9uKVxuXG5tZXJnZWRfZGZfYWxsIDwtIGxlZnRfam9pbihtZXJnZWRfZGYsIGV4dHJhX2Rlc2NyaXB0aW9uLCBieSA9IFwiQW50aWJpb3RpY1wiKVxuXG5tZXJnZWRfZGZfYWxsJGRlc2NyaXB0aW9uIDwtIGlmX2Vsc2UoaXMubmEobWVyZ2VkX2RmX2FsbCRkZXNjcmlwdGlvbi54KSwgbWVyZ2VkX2RmX2FsbCRkZXNjcmlwdGlvbi55LCBtZXJnZWRfZGZfYWxsJGRlc2NyaXB0aW9uLngpXG5cbm1lcmdlZF9kZl9hbGwgPC0gbWVyZ2VkX2RmX2FsbCB8PiBzZWxlY3QoLWRlc2NyaXB0aW9uLnksIGRlc2NyaXB0aW9uLngpXG5gYGAifQ== -->
<pre class="r"><code>extra_description &lt;- extra_description |&gt; select(Antibiotic, description)

merged_df_all &lt;- left_join(merged_df, extra_description, by = &quot;Antibiotic&quot;)

merged_df_all$description &lt;- if_else(is.na(merged_df_all$description.x), merged_df_all$description.y, merged_df_all$description.x)

merged_df_all &lt;- merged_df_all |&gt; select(-description.y, description.x)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBHcm91cCBieSBDYXRlZ29yeV9CZXRhX0xhY3RhbSBhbmQgbmVzdFxubmVzdGVkIDwtIG1lcmdlZF9kZl9hbGwgJT4lXG4gIGdyb3VwX2J5KENhdGVnb3J5X0JldGFfTGFjdGFtKSAlPiVcbiAgbmVzdCgua2V5ID0gXCJjaGlsZHJlblwiKVxuXG4jIENoZWNrIHRoZSBzdHJ1Y3R1cmUgb2YgJ25lc3RlZCdcbnByaW50KHN0cihuZXN0ZWQpKVxuYGBgIn0= -->
<pre class="r"><code># Group by Category_Beta_Lactam and nest
nested &lt;- merged_df_all %&gt;%
  group_by(Category_Beta_Lactam) %&gt;%
  nest(.key = &quot;children&quot;)

# Check the structure of &#39;nested&#39;
print(str(nested))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>gropd_df [2  2] (S3: grouped_df/tbl_df/tbl/data.frame)
 $ Category_Beta_Lactam: chr [1:2] &quot;Other&quot; &quot;Beta-Lactams&quot;
 $ children            :List of 2
  ..$ : tibble [152  8] (S3: tbl_df/tbl/data.frame)
  .. ..$ Antibiotic   : chr [1:152] &quot;Amikacin&quot; &quot;Arbekacin&quot; &quot;Azithromycin&quot; &quot;Bekanamycin&quot; ...
  .. ..$ Class        : chr [1:152] &quot;Aminoglycosides&quot; &quot;Aminoglycosides&quot; &quot;Macrolides&quot; &quot;Aminoglycosides&quot; ...
  .. ..$ Category     : chr [1:152] &quot;Access&quot; &quot;Watch&quot; &quot;Watch&quot; &quot;Watch&quot; ...
  .. ..$ ATC_code     : chr [1:152] &quot;J01GB06&quot; &quot;J01GB12&quot; &quot;J01FA10&quot; &quot;J01GB13&quot; ...
  .. ..$ EML          : chr [1:152] &quot;Yes&quot; &quot;No&quot; &quot;Yes&quot; &quot;No&quot; ...
  .. ..$ value        : num [1:152] 1 1 1 1 1 1 1 1 1 1 ...
  .. ..$ description.x: chr [1:152] &quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is s&quot;| __truncated__ &quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection suc&quot;| __truncated__ &quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetra&quot;| __truncated__ &quot;Other aminoglycosides&quot; ...
  .. ..$ description  : chr [1:152] &quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is s&quot;| __truncated__ &quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection suc&quot;| __truncated__ &quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetra&quot;| __truncated__ &quot;Other aminoglycosides&quot; ...
  ..$ : tibble [105  8] (S3: tbl_df/tbl/data.frame)
  .. ..$ Antibiotic   : chr [1:105] &quot;Amoxicillin&quot; &quot;Amoxicillin/clavulanic-acid&quot; &quot;Ampicillin&quot; &quot;Ampicillin/sulbactam&quot; ...
  .. ..$ Class        : chr [1:105] &quot;Penicillins&quot; &quot;Beta-lactam/beta-lactamase-inhibitor&quot; &quot;Penicillins&quot; &quot;Beta-lactam/beta-lactamase-inhibitor&quot; ...
  .. ..$ Category     : chr [1:105] &quot;Access&quot; &quot;Access&quot; &quot;Access&quot; &quot;Access&quot; ...
  .. ..$ ATC_code     : chr [1:105] &quot;J01CA04&quot; &quot;J01CR02&quot; &quot;J01CA01&quot; &quot;J01CR01&quot; ...
  .. ..$ EML          : chr [1:105] &quot;Yes&quot; &quot;Yes&quot; &quot;Yes&quot; &quot;No&quot; ...
  .. ..$ value        : num [1:105] 1 1 1 1 1 1 1 1 1 1 ...
  .. ..$ description.x: chr [1:105] &quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin h&quot;| __truncated__ NA NA NA ...
  .. ..$ description  : chr [1:105] &quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin h&quot;| __truncated__ &quot;Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for &quot;| __truncated__ &quot;Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It&#39;s used t&quot;| __truncated__ &quot;Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-&quot;| __truncated__ ...
 - attr(*, &quot;groups&quot;)= tibble [2  2] (S3: tbl_df/tbl/data.frame)
  ..$ Category_Beta_Lactam: chr [1:2] &quot;Beta-Lactams&quot; &quot;Other&quot;
  ..$ .rows               : list&lt;int&gt; [1:2] 
  .. ..$ : int 2
  .. ..$ : int 1
  .. ..@ ptype: int(0) 
  ..- attr(*, &quot;.drop&quot;)= logi TRUE
NULL</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBEZWZpbmUgYSBmdW5jdGlvbiBmb3IgZnVydGhlciBuZXN0aW5nXG5uZXN0X21vcmUgPC0gZnVuY3Rpb24oZGYpIHtcbiAgZGYgJT4lXG4gICAgZ3JvdXBfYnkoQ2xhc3MpICU+JVxuICAgIG5lc3QoKSAlPiVcbiAgICBtdXRhdGUoY2hpbGRyZW4gPSBtYXAoZGF0YSwgfiBncm91cF9ieSgueCwgQ2F0ZWdvcnkpICU+JSBuZXN0KC5rZXkgPSBcImNoaWxkcmVuXCIpKSlcbn1cblxuIyBBcHBseSB0aGUgZnVuY3Rpb24gdG8gZWFjaCBuZXN0ZWQgZGF0YSBmcmFtZVxubmVzdGVkIDwtIG5lc3RlZCAlPiVcbiAgbXV0YXRlKGNoaWxkcmVuID0gbWFwKGNoaWxkcmVuLCBuZXN0X21vcmUpKVxuXG5cbm5lc3RlZFxuYGBgIn0= -->
<pre class="r"><code># Define a function for further nesting
nest_more &lt;- function(df) {
  df %&gt;%
    group_by(Class) %&gt;%
    nest() %&gt;%
    mutate(children = map(data, ~ group_by(.x, Category) %&gt;% nest(.key = &quot;children&quot;)))
}

# Apply the function to each nested data frame
nested &lt;- nested %&gt;%
  mutate(children = map(children, nest_more))


nested</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["grouped_df","tbl_df","tbl","data.frame"],"nrow":2,"ncol":2,"summary":{"A tibble":["2 × 2"],"Groups":["Category_Beta_Lactam [2]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Category_Beta_Lactam"],"name":[1],"type":["chr"],"align":["left"]},{"label":["children"],"name":[2],"type":["list"],"align":["right"]}],"data":[{"1":"Other","2":"<S3: grouped_df>"},{"1":"Beta-Lactams","2":"<S3: grouped_df>"}],"options":{"columns":{"min":{},"max":[10],"total":[2]},"rows":{"min":[10],"max":[10],"total":[2]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>json &lt;- toJSON(nested)

updated_json_string &lt;- gsub(&quot;\&quot;Antibiotic\&quot;&quot;, &quot;\&quot;name\&quot;&quot;, json)

updated_json_string &lt;- gsub(&quot;\&quot;Class\&quot;&quot;, &quot;\&quot;name\&quot;&quot;, updated_json_string)

updated_json_string &lt;- gsub(&quot;\&quot;Category\&quot;&quot;, &quot;\&quot;name\&quot;&quot;, updated_json_string)

updated_json_string &lt;- gsub(&quot;\&quot;Category_Beta_Lactam\&quot;&quot;, &quot;\&quot;name\&quot;&quot;, updated_json_string)


existing_data &lt;- fromJSON(updated_json_string)

new_parent &lt;- new_parent &lt;- list(name = &quot;Antibiotics&quot;, children = existing_data)

new_json &lt;- toJSON(new_parent, auto_unbox = TRUE)

new_json</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin {"data":"{\"name\":\"Antibiotics\",\"children\":[{\"name\":\"Other\",\"children\":[{\"name\":\"Aminoglycosides\",\"data\":[{\"name\":\"Amikacin\",\"ATC_code\":\"J01GB06\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\\r\\n\\r\\nAmikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\\r\\n\\r\\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.\",\"description\":\"Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\\r\\n\\r\\nAmikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\\r\\n\\r\\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.\"},{\"name\":\"Arbekacin\",\"ATC_code\":\"J01GB12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).\",\"description\":\"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).\"},{\"name\":\"Bekanamycin\",\"ATC_code\":\"J01GB13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other aminoglycosides\",\"description\":\"Other aminoglycosides\"},{\"name\":\"Dibekacin\",\"ATC_code\":\"J01GB09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dibekacin is an aminoglycoside antibiotic marketed in Japan .\",\"description\":\"Dibekacin is an aminoglycoside antibiotic marketed in Japan .\"},{\"name\":\"Gentamicin\",\"ATC_code\":\"J01GB03\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\\r\\n\\r\\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.\",\"description\":\"Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\\r\\n\\r\\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.\"},{\"name\":\"Isepamicin\",\"ATC_code\":\"J01GB11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other aminoglycosides\",\"description\":\"Other aminoglycosides\"},{\"name\":\"Kanamycin_IV\",\"ATC_code\":\"J01GB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\",\"description\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\"},{\"name\":\"Kanamycin_oral\",\"ATC_code\":\"A07AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\",\"description\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\"},{\"name\":\"Micronomicin\",\"ATC_code\":\"to be assigned\",\"EML\":\"No\",\"value\":1,\"description\":\"Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia\"},{\"name\":\"Neomycin_IV\",\"ATC_code\":\"J01GB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\",\"description\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\"},{\"name\":\"Neomycin_oral\",\"ATC_code\":\"A07AA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\",\"description\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\"},{\"name\":\"Netilmicin\",\"ATC_code\":\"J01GB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.\",\"description\":\"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.\"},{\"name\":\"Plazomicin\",\"ATC_code\":\"J01GB14\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.\",\"description\":\"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.\"},{\"name\":\"Ribostamycin\",\"ATC_code\":\"J01GB10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.\",\"description\":\"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.\"},{\"name\":\"Sisomicin\",\"ATC_code\":\"J01GB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sisomicin has been used in trials studying the treatment of Pyoderma.\",\"description\":\"Sisomicin has been used in trials studying the treatment of Pyoderma.\"},{\"name\":\"Streptoduocin\",\"ATC_code\":\"J01GA02\",\"EML\":\"No\",\"value\":1,\"description\":\"Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia\"},{\"name\":\"Streptomycin_IV\",\"ATC_code\":\"J01GA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\",\"description\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\"},{\"name\":\"Streptomycin_oral\",\"ATC_code\":\"A07AA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\",\"description\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\"},{\"name\":\"Tobramycin\",\"ATC_code\":\"J01GB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\\r\\n\\r\\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).\",\"description\":\"Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\\r\\n\\r\\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Amikacin\",\"ATC_code\":\"J01GB06\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\\r\\n\\r\\nAmikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\\r\\n\\r\\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.\",\"description\":\"Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)-γ-amino-α-hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\\r\\n\\r\\nAmikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\\r\\n\\r\\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.\"},{\"name\":\"Gentamicin\",\"ATC_code\":\"J01GB03\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\\r\\n\\r\\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.\",\"description\":\"Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\\r\\n\\r\\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Arbekacin\",\"ATC_code\":\"J01GB12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).\",\"description\":\"An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).\"},{\"name\":\"Bekanamycin\",\"ATC_code\":\"J01GB13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other aminoglycosides\",\"description\":\"Other aminoglycosides\"},{\"name\":\"Dibekacin\",\"ATC_code\":\"J01GB09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dibekacin is an aminoglycoside antibiotic marketed in Japan .\",\"description\":\"Dibekacin is an aminoglycoside antibiotic marketed in Japan .\"},{\"name\":\"Isepamicin\",\"ATC_code\":\"J01GB11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other aminoglycosides\",\"description\":\"Other aminoglycosides\"},{\"name\":\"Kanamycin_IV\",\"ATC_code\":\"J01GB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\",\"description\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\"},{\"name\":\"Kanamycin_oral\",\"ATC_code\":\"A07AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\",\"description\":\"Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.\"},{\"name\":\"Micronomicin\",\"ATC_code\":\"to be assigned\",\"EML\":\"No\",\"value\":1,\"description\":\"Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia\"},{\"name\":\"Neomycin_IV\",\"ATC_code\":\"J01GB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\",\"description\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\"},{\"name\":\"Neomycin_oral\",\"ATC_code\":\"A07AA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\",\"description\":\"Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \\r\\n\\r\\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.\"},{\"name\":\"Netilmicin\",\"ATC_code\":\"J01GB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.\",\"description\":\"Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.\"},{\"name\":\"Ribostamycin\",\"ATC_code\":\"J01GB10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.\",\"description\":\"Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization's critically important antimicrobials.\"},{\"name\":\"Sisomicin\",\"ATC_code\":\"J01GB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sisomicin has been used in trials studying the treatment of Pyoderma.\",\"description\":\"Sisomicin has been used in trials studying the treatment of Pyoderma.\"},{\"name\":\"Streptoduocin\",\"ATC_code\":\"J01GA02\",\"EML\":\"No\",\"value\":1,\"description\":\"Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia\"},{\"name\":\"Streptomycin_IV\",\"ATC_code\":\"J01GA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\",\"description\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\"},{\"name\":\"Streptomycin_oral\",\"ATC_code\":\"A07AA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\",\"description\":\"Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.\"},{\"name\":\"Tobramycin\",\"ATC_code\":\"J01GB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\\r\\n\\r\\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).\",\"description\":\"Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as β-lactams and cephalosporins.\\r\\n\\r\\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).\"}]},{\"name\":\"Reserve\",\"children\":[{\"name\":\"Plazomicin\",\"ATC_code\":\"J01GB14\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.\",\"description\":\"Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.\"}]}]},{\"name\":\"Macrolides\",\"data\":[{\"name\":\"Azithromycin\",\"ATC_code\":\"J01FA10\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\\r\\n\\r\\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\\r\\n\\r\\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\\r\\n\\r\\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.\",\"description\":\"Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\\r\\n\\r\\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\\r\\n\\r\\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\\r\\n\\r\\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.\"},{\"name\":\"Clarithromycin\",\"ATC_code\":\"J01FA09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.\",\"description\":\"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.\"},{\"name\":\"Dirithromycin\",\"ATC_code\":\"J01FA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.\",\"description\":\"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.\"},{\"name\":\"Erythromycin\",\"ATC_code\":\"J01FA01\",\"EML\":\"Yes (therapeutic alternative to clarithromycin (EMLc))\",\"value\":1,\"description.x\":\"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.\",\"description\":\"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.\"},{\"name\":\"Fidaxomicin\",\"ATC_code\":\"A07AA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90<\\/sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\\r\\n\\r\\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.\",\"description\":\"Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90<\\/sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\\r\\n\\r\\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.\"},{\"name\":\"Flurithromycin\",\"ATC_code\":\"J01FA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Macrolides\",\"description\":\"Macrolides\"},{\"name\":\"Josamycin\",\"ATC_code\":\"J01FA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.\",\"description\":\"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.\"},{\"name\":\"Midecamycin\",\"ATC_code\":\"J01FA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.\",\"description\":\"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.\"},{\"name\":\"Miocamycin\",\"ATC_code\":\"J01FA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .\",\"description\":\"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .\"},{\"name\":\"Oleandomycin\",\"ATC_code\":\"J01FA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.\",\"description\":\"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.\"},{\"name\":\"Rokitamycin\",\"ATC_code\":\"J01FA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Macrolides\",\"description\":\"Macrolides\"},{\"name\":\"Roxithromycin\",\"ATC_code\":\"J01FA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.\",\"description\":\"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.\"},{\"name\":\"Solithromycin\",\"ATC_code\":\"J01FA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.\",\"description\":\"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.\"},{\"name\":\"Spiramycin\",\"ATC_code\":\"J01FA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\\r\\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.\",\"description\":\"Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\\r\\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.\"},{\"name\":\"Telithromycin\",\"ATC_code\":\"J01FA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.\",\"description\":\"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.\"},{\"name\":\"Troleandomycin\",\"ATC_code\":\"J01FA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A macrolide antibiotic that is similar to erythromycin.\",\"description\":\"A macrolide antibiotic that is similar to erythromycin.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Azithromycin\",\"ATC_code\":\"J01FA10\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\\r\\n\\r\\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\\r\\n\\r\\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\\r\\n\\r\\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.\",\"description\":\"Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\\r\\n\\r\\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\\r\\n\\r\\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\\r\\n\\r\\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.\"},{\"name\":\"Clarithromycin\",\"ATC_code\":\"J01FA09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.\",\"description\":\"Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.\"},{\"name\":\"Dirithromycin\",\"ATC_code\":\"J01FA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.\",\"description\":\"Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.\"},{\"name\":\"Erythromycin\",\"ATC_code\":\"J01FA01\",\"EML\":\"Yes (therapeutic alternative to clarithromycin (EMLc))\",\"value\":1,\"description.x\":\"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.\",\"description\":\"Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.\"},{\"name\":\"Fidaxomicin\",\"ATC_code\":\"A07AA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90<\\/sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\\r\\n\\r\\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.\",\"description\":\"Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC<sub>90<\\/sub>) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\\r\\n\\r\\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.\"},{\"name\":\"Flurithromycin\",\"ATC_code\":\"J01FA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Macrolides\",\"description\":\"Macrolides\"},{\"name\":\"Josamycin\",\"ATC_code\":\"J01FA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.\",\"description\":\"A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.\"},{\"name\":\"Midecamycin\",\"ATC_code\":\"J01FA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.\",\"description\":\"Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.\"},{\"name\":\"Miocamycin\",\"ATC_code\":\"J01FA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .\",\"description\":\"Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .\"},{\"name\":\"Oleandomycin\",\"ATC_code\":\"J01FA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.\",\"description\":\"Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.\"},{\"name\":\"Rokitamycin\",\"ATC_code\":\"J01FA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Macrolides\",\"description\":\"Macrolides\"},{\"name\":\"Roxithromycin\",\"ATC_code\":\"J01FA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.\",\"description\":\"Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.\"},{\"name\":\"Solithromycin\",\"ATC_code\":\"J01FA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.\",\"description\":\"Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.\"},{\"name\":\"Spiramycin\",\"ATC_code\":\"J01FA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\\r\\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.\",\"description\":\"Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\\r\\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.\"},{\"name\":\"Telithromycin\",\"ATC_code\":\"J01FA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.\",\"description\":\"Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.\"},{\"name\":\"Troleandomycin\",\"ATC_code\":\"J01FA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A macrolide antibiotic that is similar to erythromycin.\",\"description\":\"A macrolide antibiotic that is similar to erythromycin.\"}]}]},{\"name\":\"Trimethoprim-derivatives\",\"data\":[{\"name\":\"Brodimoprim\",\"ATC_code\":\"J01EA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trimethoprim and derivatives\",\"description\":\"Trimethoprim and derivatives\"},{\"name\":\"Iclaprim\",\"ATC_code\":\"J01EA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trimethoprim and derivatives\",\"description\":\"Trimethoprim and derivatives\"},{\"name\":\"Trimethoprim\",\"ATC_code\":\"J01EA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.\",\"description\":\"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Brodimoprim\",\"ATC_code\":\"J01EA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trimethoprim and derivatives\",\"description\":\"Trimethoprim and derivatives\"},{\"name\":\"Trimethoprim\",\"ATC_code\":\"J01EA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.\",\"description\":\"Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.\"}]},{\"name\":\"Reserve\",\"children\":[{\"name\":\"Iclaprim\",\"ATC_code\":\"J01EA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trimethoprim and derivatives\",\"description\":\"Trimethoprim and derivatives\"}]}]},{\"name\":\"Amphenicols\",\"data\":[{\"name\":\"Chloramphenicol\",\"ATC_code\":\"J01BA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\\r\\n\\r\\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.\",\"description\":\"An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\\r\\n\\r\\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.\"},{\"name\":\"Thiamphenicol\",\"ATC_code\":\"J01BA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Amphenicols\",\"description\":\"Amphenicols\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Chloramphenicol\",\"ATC_code\":\"J01BA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\\r\\n\\r\\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.\",\"description\":\"An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\\r\\n\\r\\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.\"},{\"name\":\"Thiamphenicol\",\"ATC_code\":\"J01BA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Amphenicols\",\"description\":\"Amphenicols\"}]}]},{\"name\":\"Tetracyclines\",\"data\":[{\"name\":\"Chlortetracycline\",\"ATC_code\":\"J01AA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.\",\"description\":\"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.\"},{\"name\":\"Clomocycline\",\"ATC_code\":\"J01AA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Clomocycline is a tetracycline used to treat bacterial infections.\",\"description\":\"Clomocycline is a tetracycline used to treat bacterial infections.\"},{\"name\":\"Demeclocycline\",\"ATC_code\":\"J01AA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.\",\"description\":\"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.\"},{\"name\":\"Doxycycline\",\"ATC_code\":\"J01AA02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.\",\"description\":\"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.\"},{\"name\":\"Eravacycline\",\"ATC_code\":\"J01AA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .\",\"description\":\"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .\"},{\"name\":\"Lymecycline\",\"ATC_code\":\"J01AA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.\",\"description\":\"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.\"},{\"name\":\"Metacycline\",\"ATC_code\":\"J01AA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.\",\"description\":\"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.\"},{\"name\":\"Minocycline_IV\",\"ATC_code\":\"J01AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\",\"description\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\"},{\"name\":\"Minocycline_oral\",\"ATC_code\":\"J01AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\",\"description\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\"},{\"name\":\"Omadacycline\",\"ATC_code\":\"J01AA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.\",\"description\":\"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.\"},{\"name\":\"Oxytetracycline\",\"ATC_code\":\"J01AA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.\",\"description\":\"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.\"},{\"name\":\"Penimepicycline\",\"ATC_code\":\"J01AA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .\",\"description\":\"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .\"},{\"name\":\"Rolitetracycline\",\"ATC_code\":\"J01AA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A pyrrolidinylmethyl tetracycline.\",\"description\":\"A pyrrolidinylmethyl tetracycline.\"},{\"name\":\"Sarecycline\",\"ATC_code\":\"J01AA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\\r\\n\\r\\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\\r\\n\\r\\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.\",\"description\":\"Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\\r\\n\\r\\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\\r\\n\\r\\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.\"},{\"name\":\"Tetracycline\",\"ATC_code\":\"J01AA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\\r\\n\\r\\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.\",\"description\":\"Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\\r\\n\\r\\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Chlortetracycline\",\"ATC_code\":\"J01AA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.\",\"description\":\"Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.\"},{\"name\":\"Clomocycline\",\"ATC_code\":\"J01AA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Clomocycline is a tetracycline used to treat bacterial infections.\",\"description\":\"Clomocycline is a tetracycline used to treat bacterial infections.\"},{\"name\":\"Demeclocycline\",\"ATC_code\":\"J01AA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.\",\"description\":\"A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.\"},{\"name\":\"Lymecycline\",\"ATC_code\":\"J01AA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.\",\"description\":\"Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.\"},{\"name\":\"Metacycline\",\"ATC_code\":\"J01AA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.\",\"description\":\"A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.\"},{\"name\":\"Minocycline_oral\",\"ATC_code\":\"J01AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\",\"description\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\"},{\"name\":\"Oxytetracycline\",\"ATC_code\":\"J01AA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.\",\"description\":\"A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.\"},{\"name\":\"Penimepicycline\",\"ATC_code\":\"J01AA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .\",\"description\":\"Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .\"},{\"name\":\"Rolitetracycline\",\"ATC_code\":\"J01AA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A pyrrolidinylmethyl tetracycline.\",\"description\":\"A pyrrolidinylmethyl tetracycline.\"},{\"name\":\"Sarecycline\",\"ATC_code\":\"J01AA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\\r\\n\\r\\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\\r\\n\\r\\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.\",\"description\":\"Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States .\\r\\n\\r\\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\\r\\n\\r\\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.\"}]},{\"name\":\"Access\",\"children\":[{\"name\":\"Doxycycline\",\"ATC_code\":\"J01AA02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.\",\"description\":\"Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.\"},{\"name\":\"Tetracycline\",\"ATC_code\":\"J01AA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\\r\\n\\r\\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.\",\"description\":\"Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\\r\\n\\r\\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.\"}]},{\"name\":\"Reserve\",\"children\":[{\"name\":\"Eravacycline\",\"ATC_code\":\"J01AA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .\",\"description\":\"Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, β-lactam/β-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .\"},{\"name\":\"Minocycline_IV\",\"ATC_code\":\"J01AA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\",\"description\":\"Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\\r\\n\\r\\nMinocycline was granted FDA approval on 30 June 1971.\"},{\"name\":\"Omadacycline\",\"ATC_code\":\"J01AA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.\",\"description\":\"Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.\"}]}]},{\"name\":\"Quinolones\",\"data\":[{\"name\":\"Cinoxacin\",\"ATC_code\":\"J01MB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.\",\"description\":\"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.\"},{\"name\":\"Flumequine\",\"ATC_code\":\"J01MB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.\",\"description\":\"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.\"},{\"name\":\"Nemonoxacin\",\"ATC_code\":\"J01MB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Oxolinic-acid\",\"ATC_code\":\"J01MB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Pipemidic-acid\",\"ATC_code\":\"J01MB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Piromidic-acid\",\"ATC_code\":\"J01MB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Rosoxacin\",\"ATC_code\":\"J01MB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.\",\"description\":\"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Cinoxacin\",\"ATC_code\":\"J01MB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.\",\"description\":\"Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.\"},{\"name\":\"Flumequine\",\"ATC_code\":\"J01MB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.\",\"description\":\"Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.\"},{\"name\":\"Nemonoxacin\",\"ATC_code\":\"J01MB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Oxolinic-acid\",\"ATC_code\":\"J01MB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Pipemidic-acid\",\"ATC_code\":\"J01MB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Piromidic-acid\",\"ATC_code\":\"J01MB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Other quinolones\",\"description\":\"Other quinolones\"},{\"name\":\"Rosoxacin\",\"ATC_code\":\"J01MB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.\",\"description\":\"Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.\"}]}]},{\"name\":\"Fluoroquinolones\",\"data\":[{\"name\":\"Ciprofloxacin\",\"ATC_code\":\"J01MA02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\\r\\n\\r\\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.\",\"description\":\"Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\\r\\n\\r\\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.\"},{\"name\":\"Delafloxacin\",\"ATC_code\":\"J01MA23\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.\",\"description\":\"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.\"},{\"name\":\"Enoxacin\",\"ATC_code\":\"J01MA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.\",\"description\":\"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.\"},{\"name\":\"Fleroxacin\",\"ATC_code\":\"J01MA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.\",\"description\":\"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.\"},{\"name\":\"Garenoxacin\",\"ATC_code\":\"J01MA19\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.\",\"description\":\"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.\"},{\"name\":\"Gatifloxacin\",\"ATC_code\":\"J01MA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\\r\\n\\r\\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.\",\"description\":\"Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\\r\\n\\r\\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.\"},{\"name\":\"Gemifloxacin\",\"ATC_code\":\"J01MA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.\",\"description\":\"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.\"},{\"name\":\"Grepafloxacin\",\"ATC_code\":\"J01MA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.\",\"description\":\"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.\"},{\"name\":\"Lascufloxacin\",\"ATC_code\":\"J01MA25\",\"EML\":\"No\",\"value\":1,\"description\":\"Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia\"},{\"name\":\"Levofloxacin\",\"ATC_code\":\"J01MA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \\\"respiratory quinolones\\\" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\\r\\n\\r\\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.\",\"description\":\"Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \\\"respiratory quinolones\\\" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\\r\\n\\r\\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.\"},{\"name\":\"Levonadifloxacin\",\"ATC_code\":\"J01MA24\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).\",\"description\":\"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).\"},{\"name\":\"Lomefloxacin\",\"ATC_code\":\"J01MA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.\",\"description\":\"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.\"},{\"name\":\"Moxifloxacin\",\"ATC_code\":\"J01MA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.\",\"description\":\"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.\"},{\"name\":\"Norfloxacin\",\"ATC_code\":\"J01MA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.\",\"description\":\"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.\"},{\"name\":\"Ofloxacin\",\"ATC_code\":\"J01MA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.\",\"description\":\"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.\"},{\"name\":\"Pazufloxacin\",\"ATC_code\":\"J01MA18\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).\",\"description\":\"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).\"},{\"name\":\"Pefloxacin\",\"ATC_code\":\"J01MA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.\",\"description\":\"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.\"},{\"name\":\"Prulifloxacin\",\"ATC_code\":\"J01MA17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.\",\"description\":\"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.\"},{\"name\":\"Rufloxacin\",\"ATC_code\":\"J01MA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rufloxacin is a quinolone antibiotic. \",\"description\":\"Rufloxacin is a quinolone antibiotic. \"},{\"name\":\"Sitafloxacin\",\"ATC_code\":\"J01MA21\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fluoroquinolones\",\"description\":\"Fluoroquinolones\"},{\"name\":\"Sparfloxacin\",\"ATC_code\":\"J01MA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.\",\"description\":\"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.\"},{\"name\":\"Temafloxacin\",\"ATC_code\":\"J01MA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.\",\"description\":\"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.\"},{\"name\":\"Tosufloxacin\",\"ATC_code\":\"J01MA22\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fluoroquinolones\",\"description\":\"Fluoroquinolones\"},{\"name\":\"Trovafloxacin\",\"ATC_code\":\"J01MA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.\",\"description\":\"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Ciprofloxacin\",\"ATC_code\":\"J01MA02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\\r\\n\\r\\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.\",\"description\":\"Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\\r\\n\\r\\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.\"},{\"name\":\"Delafloxacin\",\"ATC_code\":\"J01MA23\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.\",\"description\":\"Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.\"},{\"name\":\"Enoxacin\",\"ATC_code\":\"J01MA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.\",\"description\":\"A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.\"},{\"name\":\"Fleroxacin\",\"ATC_code\":\"J01MA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.\",\"description\":\"Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.\"},{\"name\":\"Garenoxacin\",\"ATC_code\":\"J01MA19\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.\",\"description\":\"Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.\"},{\"name\":\"Gatifloxacin\",\"ATC_code\":\"J01MA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\\r\\n\\r\\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.\",\"description\":\"Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan.\\r\\n\\r\\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.\"},{\"name\":\"Gemifloxacin\",\"ATC_code\":\"J01MA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.\",\"description\":\"Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.\"},{\"name\":\"Grepafloxacin\",\"ATC_code\":\"J01MA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.\",\"description\":\"Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.\"},{\"name\":\"Lascufloxacin\",\"ATC_code\":\"J01MA25\",\"EML\":\"No\",\"value\":1,\"description\":\"Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia\"},{\"name\":\"Levofloxacin\",\"ATC_code\":\"J01MA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \\\"respiratory quinolones\\\" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\\r\\n\\r\\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.\",\"description\":\"Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \\\"respiratory quinolones\\\" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\\r\\n\\r\\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.\"},{\"name\":\"Levonadifloxacin\",\"ATC_code\":\"J01MA24\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).\",\"description\":\"Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).\"},{\"name\":\"Lomefloxacin\",\"ATC_code\":\"J01MA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.\",\"description\":\"Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.\"},{\"name\":\"Moxifloxacin\",\"ATC_code\":\"J01MA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.\",\"description\":\"Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.\"},{\"name\":\"Norfloxacin\",\"ATC_code\":\"J01MA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.\",\"description\":\"A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.\"},{\"name\":\"Ofloxacin\",\"ATC_code\":\"J01MA01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.\",\"description\":\"A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.\"},{\"name\":\"Pazufloxacin\",\"ATC_code\":\"J01MA18\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).\",\"description\":\"Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).\"},{\"name\":\"Pefloxacin\",\"ATC_code\":\"J01MA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.\",\"description\":\"A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.\"},{\"name\":\"Prulifloxacin\",\"ATC_code\":\"J01MA17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.\",\"description\":\"Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.\"},{\"name\":\"Rufloxacin\",\"ATC_code\":\"J01MA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rufloxacin is a quinolone antibiotic. \",\"description\":\"Rufloxacin is a quinolone antibiotic. \"},{\"name\":\"Sitafloxacin\",\"ATC_code\":\"J01MA21\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fluoroquinolones\",\"description\":\"Fluoroquinolones\"},{\"name\":\"Sparfloxacin\",\"ATC_code\":\"J01MA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.\",\"description\":\"Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.\"},{\"name\":\"Temafloxacin\",\"ATC_code\":\"J01MA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.\",\"description\":\"Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.\"},{\"name\":\"Tosufloxacin\",\"ATC_code\":\"J01MA22\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fluoroquinolones\",\"description\":\"Fluoroquinolones\"},{\"name\":\"Trovafloxacin\",\"ATC_code\":\"J01MA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.\",\"description\":\"Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.\"}]}]},{\"name\":\"Lincosamides\",\"data\":[{\"name\":\"Clindamycin\",\"ATC_code\":\"J01FF01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\\r\\n\\r\\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.\",\"description\":\"Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\\r\\n\\r\\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.\"},{\"name\":\"Lincomycin\",\"ATC_code\":\"J01FF02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\\r\\n\\r\\nLincomycin was approved by the FDA on December 29, 1964.\",\"description\":\"Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\\r\\n\\r\\nLincomycin was approved by the FDA on December 29, 1964.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Clindamycin\",\"ATC_code\":\"J01FF01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\\r\\n\\r\\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.\",\"description\":\"Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\\r\\n\\r\\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Lincomycin\",\"ATC_code\":\"J01FF02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\\r\\n\\r\\nLincomycin was approved by the FDA on December 29, 1964.\",\"description\":\"Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\\r\\n\\r\\nLincomycin was approved by the FDA on December 29, 1964.\"}]}]},{\"name\":\"Phenol derivatives\",\"data\":[{\"name\":\"Clofoctol\",\"ATC_code\":\"J01XX03\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Other antibacterials\",\"description\":\"Other antibacterials\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Clofoctol\",\"ATC_code\":\"J01XX03\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Other antibacterials\",\"description\":\"Other antibacterials\"}]}]},{\"name\":\"Polymyxins\",\"data\":[{\"name\":\"Colistin_IV\",\"ATC_code\":\"J01XB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\",\"description\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\"},{\"name\":\"Colistin_oral\",\"ATC_code\":\"A07AA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\",\"description\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\"},{\"name\":\"Polymyxin-B_IV\",\"ATC_code\":\"J01XB02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\",\"description\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\"},{\"name\":\"Polymyxin-B_oral\",\"ATC_code\":\"A07AA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\",\"description\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Colistin_IV\",\"ATC_code\":\"J01XB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\",\"description\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\"},{\"name\":\"Colistin_oral\",\"ATC_code\":\"A07AA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\",\"description\":\"Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.\"},{\"name\":\"Polymyxin-B_IV\",\"ATC_code\":\"J01XB02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\",\"description\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\"},{\"name\":\"Polymyxin-B_oral\",\"ATC_code\":\"A07AA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\",\"description\":\"Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.\"}]}]},{\"name\":\"Glycopeptides\",\"data\":[{\"name\":\"Dalbavancin\",\"ATC_code\":\"J01XA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.\",\"description\":\"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.\"},{\"name\":\"Oritavancin\",\"ATC_code\":\"J01XA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\\r\\n\\r\\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.\",\"description\":\"Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\\r\\n\\r\\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.\"},{\"name\":\"Teicoplanin\",\"ATC_code\":\"J01XA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.\",\"description\":\"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.\"},{\"name\":\"Telavancin\",\"ATC_code\":\"J01XA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.\",\"description\":\"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.\"},{\"name\":\"Vancomycin_IV\",\"ATC_code\":\"J01XA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\",\"description\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\"},{\"name\":\"Vancomycin_oral\",\"ATC_code\":\"A07AA09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\",\"description\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Dalbavancin\",\"ATC_code\":\"J01XA04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.\",\"description\":\"Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.\"},{\"name\":\"Oritavancin\",\"ATC_code\":\"J01XA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\\r\\n\\r\\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.\",\"description\":\"Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\\r\\n\\r\\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.\"},{\"name\":\"Telavancin\",\"ATC_code\":\"J01XA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.\",\"description\":\"Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Teicoplanin\",\"ATC_code\":\"J01XA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.\",\"description\":\"Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.\"},{\"name\":\"Vancomycin_IV\",\"ATC_code\":\"J01XA01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\",\"description\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\"},{\"name\":\"Vancomycin_oral\",\"ATC_code\":\"A07AA09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\",\"description\":\"Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\\r\\n\\r\\nAs of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .\"}]}]},{\"name\":\"Streptogramins\",\"data\":[{\"name\":\"Dalfopristin/quinupristin\",\"ATC_code\":\"J01FG02\",\"EML\":\"No\",\"value\":1,\"description\":\"Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia\"},{\"name\":\"Pristinamycin\",\"ATC_code\":\"J01FG01\",\"EML\":\"No\",\"value\":1,\"description\":\"Streptogramins\",\"description.x\":\"Streptogramins\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Dalfopristin/quinupristin\",\"ATC_code\":\"J01FG02\",\"EML\":\"No\",\"value\":1,\"description\":\"Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Pristinamycin\",\"ATC_code\":\"J01FG01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Streptogramins\",\"description\":\"Streptogramins\"}]}]},{\"name\":\"Lipopeptides\",\"data\":[{\"name\":\"Daptomycin\",\"ATC_code\":\"J01XX09\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\\r\\n\\r\\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).\",\"description\":\"Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\\r\\n\\r\\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Daptomycin\",\"ATC_code\":\"J01XX09\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\\r\\n\\r\\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).\",\"description\":\"Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\\r\\n\\r\\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).\"}]}]},{\"name\":\"Phosphonics\",\"data\":[{\"name\":\"Fosfomycin_IV\",\"ATC_code\":\"J01XX01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\",\"description\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\"},{\"name\":\"Fosfomycin_oral\",\"ATC_code\":\"J01XX01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\",\"description\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Fosfomycin_IV\",\"ATC_code\":\"J01XX01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\",\"description\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Fosfomycin_oral\",\"ATC_code\":\"J01XX01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\",\"description\":\"Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\\r\\n\\r\\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.\"}]}]},{\"name\":\"Nitrofuran derivatives\",\"data\":[{\"name\":\"Furazidin\",\"ATC_code\":\"J01XE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Nitrofuran derivatives\",\"description\":\"Nitrofuran derivatives\"},{\"name\":\"Nifurtoinol\",\"ATC_code\":\"J01XE02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Nitrofuran derivatives\",\"description\":\"Nitrofuran derivatives\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Furazidin\",\"ATC_code\":\"J01XE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Nitrofuran derivatives\",\"description\":\"Nitrofuran derivatives\"},{\"name\":\"Nifurtoinol\",\"ATC_code\":\"J01XE02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Nitrofuran derivatives\",\"description\":\"Nitrofuran derivatives\"}]}]},{\"name\":\"Steroid antibacterials\",\"data\":[{\"name\":\"Fusidic-acid\",\"ATC_code\":\"J01XC01\",\"EML\":\"No\",\"value\":2,\"description.x\":\"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.\",\"description\":\"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Fusidic-acid\",\"ATC_code\":\"J01XC01\",\"EML\":\"No\",\"value\":2,\"description.x\":\"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.\",\"description\":\"An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.\"}]}]},{\"name\":\"Pleuromutilin\",\"data\":[{\"name\":\"Lefamulin\",\"ATC_code\":\"J01XX12\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.\",\"description\":\"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Lefamulin\",\"ATC_code\":\"J01XX12\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.\",\"description\":\"Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.\"}]}]},{\"name\":\"Oxazolidinones\",\"data\":[{\"name\":\"Linezolid\",\"ATC_code\":\"J01XX08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\\r\\n\\r\\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.\",\"description\":\"Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\\r\\n\\r\\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.\"},{\"name\":\"Tedizolid\",\"ATC_code\":\"J01XX11\",\"EML\":\"Yes (therapeutic alternative to linezolid (EML))\",\"value\":1,\"description.x\":\"Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\\r\\n\\r\\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.\",\"description\":\"Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\\r\\n\\r\\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Linezolid\",\"ATC_code\":\"J01XX08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\\r\\n\\r\\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.\",\"description\":\"Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\\r\\n\\r\\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.\"},{\"name\":\"Tedizolid\",\"ATC_code\":\"J01XX11\",\"EML\":\"Yes (therapeutic alternative to linezolid (EML))\",\"value\":1,\"description.x\":\"Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\\r\\n\\r\\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.\",\"description\":\"Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\\r\\n\\r\\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.\"}]}]},{\"name\":\"Imidazoles\",\"data\":[{\"name\":\"Metronidazole_IV\",\"ATC_code\":\"J01XD01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\",\"description\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\"},{\"name\":\"Metronidazole_oral\",\"ATC_code\":\"P01AB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\",\"description\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\"},{\"name\":\"Ornidazole_IV\",\"ATC_code\":\"J01XD03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\",\"description\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\"},{\"name\":\"Ornidazole_oral\",\"ATC_code\":\"P01AB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\",\"description\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\"},{\"name\":\"Secnidazole\",\"ATC_code\":\"P01AB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\\r\\n\\r\\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.\",\"description\":\"Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\\r\\n\\r\\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.\"},{\"name\":\"Tinidazole_IV\",\"ATC_code\":\"J01XD02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\",\"description\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\"},{\"name\":\"Tinidazole_oral\",\"ATC_code\":\"P01AB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\",\"description\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Metronidazole_IV\",\"ATC_code\":\"J01XD01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\",\"description\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\"},{\"name\":\"Metronidazole_oral\",\"ATC_code\":\"P01AB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\",\"description\":\"Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.\"},{\"name\":\"Ornidazole_IV\",\"ATC_code\":\"J01XD03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\",\"description\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\"},{\"name\":\"Ornidazole_oral\",\"ATC_code\":\"P01AB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\",\"description\":\"Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.\"},{\"name\":\"Secnidazole\",\"ATC_code\":\"P01AB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\\r\\n\\r\\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.\",\"description\":\"Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\\r\\n\\r\\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.\"},{\"name\":\"Tinidazole_IV\",\"ATC_code\":\"J01XD02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\",\"description\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\"},{\"name\":\"Tinidazole_oral\",\"ATC_code\":\"P01AB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\",\"description\":\"A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.\"}]}]},{\"name\":\"Nitrofuran-derivatives\",\"data\":[{\"name\":\"Nitrofurantoin\",\"ATC_code\":\"J01XE01\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\\r\\n\\r\\nNitrofurantoin was granted FDA approval on 6 February 1953.\",\"description\":\"Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\\r\\n\\r\\nNitrofurantoin was granted FDA approval on 6 February 1953.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Nitrofurantoin\",\"ATC_code\":\"J01XE01\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\\r\\n\\r\\nNitrofurantoin was granted FDA approval on 6 February 1953.\",\"description\":\"Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\\r\\n\\r\\nNitrofurantoin was granted FDA approval on 6 February 1953.\"}]}]},{\"name\":\"Rifamycins\",\"data\":[{\"name\":\"Rifabutin\",\"ATC_code\":\"J04AB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.\",\"description\":\"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.\"},{\"name\":\"Rifampicin\",\"ATC_code\":\"J04AB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)\",\"description\":\"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)\"},{\"name\":\"Rifamycin_IV\",\"ATC_code\":\"J04AB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\",\"description\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\"},{\"name\":\"Rifamycin_oral\",\"ATC_code\":\"A07AA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\",\"description\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\"},{\"name\":\"Rifaximin\",\"ATC_code\":\"A07AA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.\",\"description\":\"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Rifabutin\",\"ATC_code\":\"J04AB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.\",\"description\":\"A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.\"},{\"name\":\"Rifampicin\",\"ATC_code\":\"J04AB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)\",\"description\":\"A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)\"},{\"name\":\"Rifamycin_IV\",\"ATC_code\":\"J04AB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\",\"description\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\"},{\"name\":\"Rifamycin_oral\",\"ATC_code\":\"A07AA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\",\"description\":\"Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\\r\\n\\r\\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\\r\\n\\r\\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.\"},{\"name\":\"Rifaximin\",\"ATC_code\":\"A07AA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.\",\"description\":\"Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.\"}]}]},{\"name\":\"Aminocyclitols\",\"data\":[{\"name\":\"Spectinomycin\",\"ATC_code\":\"J01XX04\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.\",\"description\":\"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Spectinomycin\",\"ATC_code\":\"J01XX04\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.\",\"description\":\"An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.\"}]}]},{\"name\":\"Sulfonamides\",\"data\":[{\"name\":\"Sulfadiazine\",\"ATC_code\":\"J01EC02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.\",\"description\":\"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.\"},{\"name\":\"Sulfadimethoxine\",\"ATC_code\":\"J01ED01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\\r\\n\\r\\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.\",\"description\":\"Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\\r\\n\\r\\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.\"},{\"name\":\"Sulfadimidine\",\"ATC_code\":\"J01EB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.\",\"description\":\"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.\"},{\"name\":\"Sulfafurazole\",\"ATC_code\":\"J01EB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.\",\"description\":\"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.\"},{\"name\":\"Sulfaisodimidine\",\"ATC_code\":\"J01EB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .\",\"description\":\"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .\"},{\"name\":\"Sulfalene\",\"ATC_code\":\"J01ED02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.\",\"description\":\"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.\"},{\"name\":\"Sulfamazone\",\"ATC_code\":\"J01ED09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfamerazine\",\"ATC_code\":\"J01ED07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfanilamide that is used as an antibacterial agent.\",\"description\":\"A sulfanilamide that is used as an antibacterial agent.\"},{\"name\":\"Sulfamethizole\",\"ATC_code\":\"J01EB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfathiazole antibacterial agent.\",\"description\":\"A sulfathiazole antibacterial agent.\"},{\"name\":\"Sulfamethoxazole\",\"ATC_code\":\"J01EC01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.\",\"description\":\"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.\"},{\"name\":\"Sulfamethoxypyridazine\",\"ATC_code\":\"J01ED05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfametomidine\",\"ATC_code\":\"J01ED03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfametoxydiazine\",\"ATC_code\":\"J01ED04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.\",\"description\":\"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.\"},{\"name\":\"Sulfamoxole\",\"ATC_code\":\"J01EC03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfamoxole is an antibacterial in the sulfonamide class.\",\"description\":\"Sulfamoxole is an antibacterial in the sulfonamide class.\"},{\"name\":\"Sulfanilamide\",\"ATC_code\":\"J01EB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.\",\"description\":\"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.\"},{\"name\":\"Sulfaperin\",\"ATC_code\":\"J01ED06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfaphenazole\",\"ATC_code\":\"J01ED08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfaphenazole is a sulfonamide antibacterial.\",\"description\":\"Sulfaphenazole is a sulfonamide antibacterial.\"},{\"name\":\"Sulfapyridine\",\"ATC_code\":\"J01EB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.\",\"description\":\"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.\"},{\"name\":\"Sulfathiazole\",\"ATC_code\":\"J01EB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\\r\\n\\r\\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.\",\"description\":\"Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\\r\\n\\r\\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.\"},{\"name\":\"Sulfathiourea\",\"ATC_code\":\"J01EB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Short-acting sulfonamides\",\"description\":\"Short-acting sulfonamides\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Sulfadiazine\",\"ATC_code\":\"J01EC02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.\",\"description\":\"One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.\"},{\"name\":\"Sulfadimethoxine\",\"ATC_code\":\"J01ED01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\\r\\n\\r\\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.\",\"description\":\"Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\\r\\n\\r\\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.\"},{\"name\":\"Sulfadimidine\",\"ATC_code\":\"J01EB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.\",\"description\":\"A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.\"},{\"name\":\"Sulfafurazole\",\"ATC_code\":\"J01EB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.\",\"description\":\"A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.\"},{\"name\":\"Sulfaisodimidine\",\"ATC_code\":\"J01EB01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .\",\"description\":\"Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .\"},{\"name\":\"Sulfalene\",\"ATC_code\":\"J01ED02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.\",\"description\":\"Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.\"},{\"name\":\"Sulfamazone\",\"ATC_code\":\"J01ED09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfamerazine\",\"ATC_code\":\"J01ED07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfanilamide that is used as an antibacterial agent.\",\"description\":\"A sulfanilamide that is used as an antibacterial agent.\"},{\"name\":\"Sulfamethizole\",\"ATC_code\":\"J01EB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A sulfathiazole antibacterial agent.\",\"description\":\"A sulfathiazole antibacterial agent.\"},{\"name\":\"Sulfamethoxazole\",\"ATC_code\":\"J01EC01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.\",\"description\":\"Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.\"},{\"name\":\"Sulfamethoxypyridazine\",\"ATC_code\":\"J01ED05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfametomidine\",\"ATC_code\":\"J01ED03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfametoxydiazine\",\"ATC_code\":\"J01ED04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.\",\"description\":\"Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.\"},{\"name\":\"Sulfamoxole\",\"ATC_code\":\"J01EC03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfamoxole is an antibacterial in the sulfonamide class.\",\"description\":\"Sulfamoxole is an antibacterial in the sulfonamide class.\"},{\"name\":\"Sulfanilamide\",\"ATC_code\":\"J01EB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.\",\"description\":\"Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.\"},{\"name\":\"Sulfaperin\",\"ATC_code\":\"J01ED06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting sulfonamides\",\"description\":\"Long-acting sulfonamides\"},{\"name\":\"Sulfaphenazole\",\"ATC_code\":\"J01ED08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfaphenazole is a sulfonamide antibacterial.\",\"description\":\"Sulfaphenazole is a sulfonamide antibacterial.\"},{\"name\":\"Sulfapyridine\",\"ATC_code\":\"J01EB04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.\",\"description\":\"Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.\"},{\"name\":\"Sulfathiazole\",\"ATC_code\":\"J01EB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\\r\\n\\r\\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.\",\"description\":\"Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\\r\\n\\r\\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.\"},{\"name\":\"Sulfathiourea\",\"ATC_code\":\"J01EB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Short-acting sulfonamides\",\"description\":\"Short-acting sulfonamides\"}]}]},{\"name\":\"Sulfonamide-trimethoprim-combos\",\"data\":[{\"name\":\"Sulfadiazine/tetroxoprim\",\"ATC_code\":\"J01EE06\",\"EML\":\"No\",\"value\":1,\"description\":\"Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia\"},{\"name\":\"Sulfadiazine/trimethoprim\",\"ATC_code\":\"J01EE02\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses​. Source: Wikepedia\"},{\"name\":\"Sulfadimidine/trimethoprim\",\"ATC_code\":\"J01EE05\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia\"},{\"name\":\"Sulfamerazine/trimethoprim\",\"ATC_code\":\"J01EE07\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia\"},{\"name\":\"Sulfamethoxazole/trimethoprim\",\"ATC_code\":\"J01EE01\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, cholera, and more. It's also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia\"},{\"name\":\"Sulfametrole/trimethoprim\",\"ATC_code\":\"J01EE03\",\"EML\":\"No\",\"value\":1,\"description\":\"The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia\"},{\"name\":\"Sulfamoxole/trimethoprim\",\"ATC_code\":\"J01EE04\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Sulfadiazine/tetroxoprim\",\"ATC_code\":\"J01EE06\",\"EML\":\"No\",\"value\":1,\"description\":\"Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia\"},{\"name\":\"Sulfadiazine/trimethoprim\",\"ATC_code\":\"J01EE02\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses​. Source: Wikepedia\"},{\"name\":\"Sulfadimidine/trimethoprim\",\"ATC_code\":\"J01EE05\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia\"},{\"name\":\"Sulfamerazine/trimethoprim\",\"ATC_code\":\"J01EE07\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia\"},{\"name\":\"Sulfamethoxazole/trimethoprim\",\"ATC_code\":\"J01EE01\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers' diarrhea, respiratory tract infections, cholera, and more. It's also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia\"},{\"name\":\"Sulfametrole/trimethoprim\",\"ATC_code\":\"J01EE03\",\"EML\":\"No\",\"value\":1,\"description\":\"The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia\"},{\"name\":\"Sulfamoxole/trimethoprim\",\"ATC_code\":\"J01EE04\",\"EML\":\"No\",\"value\":1,\"description\":\"Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia\"}]}]},{\"name\":\"Glycylcyclines\",\"data\":[{\"name\":\"Tigecycline\",\"ATC_code\":\"J01AA12\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.\",\"description\":\"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Tigecycline\",\"ATC_code\":\"J01AA12\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.\",\"description\":\"Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.\"}]}]}]},{\"name\":\"Beta-Lactams\",\"children\":[{\"name\":\"Penicillins\",\"data\":[{\"name\":\"Amoxicillin\",\"ATC_code\":\"J01CA04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\\r\\n\\r\\nAmoxicillin was granted FDA approval on 18 January 1974.\",\"description\":\"Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\\r\\n\\r\\nAmoxicillin was granted FDA approval on 18 January 1974.\"},{\"name\":\"Ampicillin\",\"ATC_code\":\"J01CA01 \",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It's used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia\"},{\"name\":\"Aspoxicillin\",\"ATC_code\":\"J01CA19\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Azidocillin\",\"ATC_code\":\"J01CE04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Azidocillin is a penicillin antibiotic similir to ampicillin.\",\"description\":\"Azidocillin is a penicillin antibiotic similir to ampicillin.\"},{\"name\":\"Azlocillin\",\"ATC_code\":\"J01CA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.\",\"description\":\"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.\"},{\"name\":\"Bacampicillin\",\"ATC_code\":\"J01CA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.\",\"description\":\"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.\"},{\"name\":\"Benzathine-benzylpenicillin\",\"ATC_code\":\"J01CE08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\",\"description\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\"},{\"name\":\"Benzylpenicillin\",\"ATC_code\":\"J01CE01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\",\"description\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\"},{\"name\":\"Carbenicillin\",\"ATC_code\":\"J01CA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.\",\"description\":\"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.\"},{\"name\":\"Carindacillin\",\"ATC_code\":\"J01CA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.\",\"description\":\"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.\"},{\"name\":\"Clometocillin\",\"ATC_code\":\"J01CE07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Cloxacillin\",\"ATC_code\":\"J01CF02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.\",\"description\":\"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.\"},{\"name\":\"Dicloxacillin\",\"ATC_code\":\"J01CF01\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"One of the penicillins which is resistant to penicillinase.\",\"description\":\"One of the penicillins which is resistant to penicillinase.\"},{\"name\":\"Epicillin\",\"ATC_code\":\"J01CA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Flucloxacillin\",\"ATC_code\":\"J01CF05\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"Antibiotic analog of cloxacillin.\",\"description\":\"Antibiotic analog of cloxacillin.\"},{\"name\":\"Hetacillin\",\"ATC_code\":\"J01CA18\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \\\"penicillin\\\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.\",\"description\":\"Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \\\"penicillin\\\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.\"},{\"name\":\"Mecillinam\",\"ATC_code\":\"J01CA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.\",\"description\":\"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.\"},{\"name\":\"Metampicillin\",\"ATC_code\":\"J01CA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.\",\"description\":\"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.\"},{\"name\":\"Meticillin\",\"ATC_code\":\"J01CF03\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.\",\"description\":\"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.\"},{\"name\":\"Mezlocillin\",\"ATC_code\":\"J01CA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.\",\"description\":\"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.\"},{\"name\":\"Nafcillin\",\"ATC_code\":\"J01CF06\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .\",\"description\":\"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .\"},{\"name\":\"Oxacillin\",\"ATC_code\":\"J01CF04\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.\",\"description\":\"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.\"},{\"name\":\"Penamecillin\",\"ATC_code\":\"J01CE06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Pheneticillin\",\"ATC_code\":\"J01CE05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.\",\"description\":\"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.\"},{\"name\":\"Phenoxymethylpenicillin\",\"ATC_code\":\"J01CE02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label\",\"description\":\"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label\"},{\"name\":\"Piperacillin\",\"ATC_code\":\"J01CA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.\",\"description\":\"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.\"},{\"name\":\"Pivampicillin\",\"ATC_code\":\"J01CA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pivalate ester analog of ampicillin.\",\"description\":\"Pivalate ester analog of ampicillin.\"},{\"name\":\"Pivmecillinam\",\"ATC_code\":\"J01CA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem\",\"description\":\"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem\"},{\"name\":\"Procaine-benzylpenicillin\",\"ATC_code\":\"J01CE09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.\",\"description\":\"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.\"},{\"name\":\"Propicillin\",\"ATC_code\":\"J01CE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Sulbenicillin\",\"ATC_code\":\"J01CA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Talampicillin\",\"ATC_code\":\"J01CA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Temocillin\",\"ATC_code\":\"J01CA17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.\",\"description\":\"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.\"},{\"name\":\"Ticarcillin\",\"ATC_code\":\"J01CA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"An antibiotic derived from penicillin similar to carbenicillin in action.\",\"description\":\"An antibiotic derived from penicillin similar to carbenicillin in action.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Amoxicillin\",\"ATC_code\":\"J01CA04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\\r\\n\\r\\nAmoxicillin was granted FDA approval on 18 January 1974.\",\"description\":\"Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\\r\\n\\r\\nAmoxicillin was granted FDA approval on 18 January 1974.\"},{\"name\":\"Ampicillin\",\"ATC_code\":\"J01CA01 \",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It's used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia\"},{\"name\":\"Azidocillin\",\"ATC_code\":\"J01CE04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Azidocillin is a penicillin antibiotic similir to ampicillin.\",\"description\":\"Azidocillin is a penicillin antibiotic similir to ampicillin.\"},{\"name\":\"Bacampicillin\",\"ATC_code\":\"J01CA06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.\",\"description\":\"Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.\"},{\"name\":\"Benzathine-benzylpenicillin\",\"ATC_code\":\"J01CE08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\",\"description\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\"},{\"name\":\"Benzylpenicillin\",\"ATC_code\":\"J01CE01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\",\"description\":\"Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\\r\\n \\r\\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.\"},{\"name\":\"Clometocillin\",\"ATC_code\":\"J01CE07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Cloxacillin\",\"ATC_code\":\"J01CF02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.\",\"description\":\"A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.\"},{\"name\":\"Dicloxacillin\",\"ATC_code\":\"J01CF01\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"One of the penicillins which is resistant to penicillinase.\",\"description\":\"One of the penicillins which is resistant to penicillinase.\"},{\"name\":\"Epicillin\",\"ATC_code\":\"J01CA07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Flucloxacillin\",\"ATC_code\":\"J01CF05\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"Antibiotic analog of cloxacillin.\",\"description\":\"Antibiotic analog of cloxacillin.\"},{\"name\":\"Hetacillin\",\"ATC_code\":\"J01CA18\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \\\"penicillin\\\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.\",\"description\":\"Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \\\"penicillin\\\" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.\"},{\"name\":\"Mecillinam\",\"ATC_code\":\"J01CA11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.\",\"description\":\"Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.\"},{\"name\":\"Metampicillin\",\"ATC_code\":\"J01CA14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.\",\"description\":\"Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.\"},{\"name\":\"Meticillin\",\"ATC_code\":\"J01CF03\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.\",\"description\":\"One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.\"},{\"name\":\"Nafcillin\",\"ATC_code\":\"J01CF06\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .\",\"description\":\"A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .\"},{\"name\":\"Oxacillin\",\"ATC_code\":\"J01CF04\",\"EML\":\"Yes (therapeutic alternative to cloxacillin)\",\"value\":1,\"description.x\":\"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.\",\"description\":\"An antibiotic similar to flucloxacillin used in resistant staphylococci infections.\"},{\"name\":\"Penamecillin\",\"ATC_code\":\"J01CE06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Phenoxymethylpenicillin\",\"ATC_code\":\"J01CE02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label\",\"description\":\"Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G­-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label\"},{\"name\":\"Pivampicillin\",\"ATC_code\":\"J01CA02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pivalate ester analog of ampicillin.\",\"description\":\"Pivalate ester analog of ampicillin.\"},{\"name\":\"Pivmecillinam\",\"ATC_code\":\"J01CA08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem\",\"description\":\"Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem\"},{\"name\":\"Procaine-benzylpenicillin\",\"ATC_code\":\"J01CE09\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.\",\"description\":\"Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.\"},{\"name\":\"Propicillin\",\"ATC_code\":\"J01CE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Beta-lactamase sensitive penicillins\",\"description\":\"Beta-lactamase sensitive penicillins\"},{\"name\":\"Talampicillin\",\"ATC_code\":\"J01CA15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Aspoxicillin\",\"ATC_code\":\"J01CA19\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Azlocillin\",\"ATC_code\":\"J01CA09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.\",\"description\":\"Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.\"},{\"name\":\"Carbenicillin\",\"ATC_code\":\"J01CA03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.\",\"description\":\"Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.\"},{\"name\":\"Carindacillin\",\"ATC_code\":\"J01CA05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.\",\"description\":\"Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.\"},{\"name\":\"Mezlocillin\",\"ATC_code\":\"J01CA10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.\",\"description\":\"Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.\"},{\"name\":\"Pheneticillin\",\"ATC_code\":\"J01CE05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.\",\"description\":\"Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.\"},{\"name\":\"Piperacillin\",\"ATC_code\":\"J01CA12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.\",\"description\":\"Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.\"},{\"name\":\"Sulbenicillin\",\"ATC_code\":\"J01CA16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Penicillins with extended spectrum\",\"description\":\"Penicillins with extended spectrum\"},{\"name\":\"Temocillin\",\"ATC_code\":\"J01CA17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.\",\"description\":\"Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.\"},{\"name\":\"Ticarcillin\",\"ATC_code\":\"J01CA13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"An antibiotic derived from penicillin similar to carbenicillin in action.\",\"description\":\"An antibiotic derived from penicillin similar to carbenicillin in action.\"}]}]},{\"name\":\"Beta-lactam/beta-lactamase-inhibitor\",\"data\":[{\"name\":\"Amoxicillin/clavulanic-acid\",\"ATC_code\":\"J01CR02\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It's a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it's generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Ampicillin/sulbactam\",\"ATC_code\":\"J01CR01\",\"EML\":\"No\",\"value\":1,\"description\":\"Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia\"},{\"name\":\"Piperacillin/tazobactam\",\"ATC_code\":\"J01CR05\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It's commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It's generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Sultamicillin\",\"ATC_code\":\"J01CR04\",\"EML\":\"No\",\"value\":1,\"description\":\"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).\",\"description.x\":\"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Amoxicillin/clavulanic-acid\",\"ATC_code\":\"J01CR02\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It's a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it's generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Ampicillin/sulbactam\",\"ATC_code\":\"J01CR01\",\"EML\":\"No\",\"value\":1,\"description\":\"Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia\"},{\"name\":\"Sultamicillin\",\"ATC_code\":\"J01CR04\",\"EML\":\"No\",\"value\":1,\"description\":\"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).\",\"description.x\":\"Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Piperacillin/tazobactam\",\"ATC_code\":\"J01CR05\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the β-lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It's commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It's generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"}]}]},{\"name\":\"Monobactams\",\"data\":[{\"name\":\"Aztreonam\",\"ATC_code\":\"J01DF01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.\",\"description\":\"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.\"},{\"name\":\"Carumonam\",\"ATC_code\":\"J01DF02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Monobactams\",\"description\":\"Monobactams\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Aztreonam\",\"ATC_code\":\"J01DF01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.\",\"description\":\"A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.\"},{\"name\":\"Carumonam\",\"ATC_code\":\"J01DF02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Monobactams\",\"description\":\"Monobactams\"}]}]},{\"name\":\"Carbapenems\",\"data\":[{\"name\":\"Biapenem\",\"ATC_code\":\"J01DH05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Biapenem has been used in trials studying the treatment of Bacterial Infections.\",\"description\":\"Biapenem has been used in trials studying the treatment of Bacterial Infections.\"},{\"name\":\"Doripenem\",\"ATC_code\":\"J01DH04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.\",\"description\":\"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.\"},{\"name\":\"Ertapenem\",\"ATC_code\":\"J01DH03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.\",\"description\":\"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.\"},{\"name\":\"Imipenem/cilastatin\",\"ATC_code\":\"J01DH51\",\"EML\":\"Yes (therapeutic alternative to meropenem)\",\"value\":1,\"description\":\"Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria's cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Imipenem/cilastatin/relebactam\",\"ATC_code\":\"J01DH56\",\"EML\":\"No\",\"value\":1,\"description\":\"Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a β-lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia\"},{\"name\":\"Meropenem\",\"ATC_code\":\"J01DH02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\\r\\n\\r\\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.\",\"description\":\"Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\\r\\n\\r\\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.\"},{\"name\":\"Meropenem/vaborbactam\",\"ATC_code\":\"J01DH52\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce β-lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Panipenem\",\"ATC_code\":\"J01DH55\",\"EML\":\"No\",\"value\":1,\"description\":\"Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia\"},{\"name\":\"Tebipenem\",\"ATC_code\":\"J01DH06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Carbapenems\",\"description\":\"Carbapenems\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Biapenem\",\"ATC_code\":\"J01DH05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Biapenem has been used in trials studying the treatment of Bacterial Infections.\",\"description\":\"Biapenem has been used in trials studying the treatment of Bacterial Infections.\"},{\"name\":\"Doripenem\",\"ATC_code\":\"J01DH04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.\",\"description\":\"Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.\"},{\"name\":\"Ertapenem\",\"ATC_code\":\"J01DH03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.\",\"description\":\"Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.\"},{\"name\":\"Imipenem/cilastatin\",\"ATC_code\":\"J01DH51\",\"EML\":\"Yes (therapeutic alternative to meropenem)\",\"value\":1,\"description\":\"Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria's cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"},{\"name\":\"Meropenem\",\"ATC_code\":\"J01DH02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\\r\\n\\r\\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.\",\"description\":\"Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\\r\\n\\r\\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.\"},{\"name\":\"Panipenem\",\"ATC_code\":\"J01DH55\",\"EML\":\"No\",\"value\":1,\"description\":\"Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia\"},{\"name\":\"Tebipenem\",\"ATC_code\":\"J01DH06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Carbapenems\",\"description\":\"Carbapenems\"}]},{\"name\":\"Reserve\",\"children\":[{\"name\":\"Imipenem/cilastatin/relebactam\",\"ATC_code\":\"J01DH56\",\"EML\":\"No\",\"value\":1,\"description\":\"Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a β-lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia\"},{\"name\":\"Meropenem/vaborbactam\",\"ATC_code\":\"J01DH52\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a β-lactam antibiotic, and vaborbactam, a β-lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce β-lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization's List of Essential Medicines. Source: Wikepedia\"}]}]},{\"name\":\"1st-gen-cephalosporins\",\"data\":[{\"name\":\"Cefacetrile\",\"ATC_code\":\"J01DB10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A derivative of 7-aminocephalosporanic acid.\",\"description\":\"A derivative of 7-aminocephalosporanic acid.\"},{\"name\":\"Cefadroxil\",\"ATC_code\":\"J01DB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.\",\"description\":\"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.\"},{\"name\":\"Cefalexin\",\"ATC_code\":\"J01DB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.\",\"description\":\"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.\"},{\"name\":\"Cefaloridine\",\"ATC_code\":\"J01DB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.\",\"description\":\"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.\"},{\"name\":\"Cefalotin\",\"ATC_code\":\"J01DB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefalotin is a cephalosporin antibiotic.\",\"description\":\"Cefalotin is a cephalosporin antibiotic.\"},{\"name\":\"Cefapirin\",\"ATC_code\":\"J01DB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.\",\"description\":\"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.\"},{\"name\":\"Cefatrizine\",\"ATC_code\":\"J01DB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"},{\"name\":\"Cefazedone\",\"ATC_code\":\"J01DB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"},{\"name\":\"Cefazolin\",\"ATC_code\":\"J01DB04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.\",\"description\":\"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.\"},{\"name\":\"Cefradine\",\"ATC_code\":\"J01DB09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semi-synthetic cephalosporin antibiotic.\",\"description\":\"A semi-synthetic cephalosporin antibiotic.\"},{\"name\":\"Cefroxadine\",\"ATC_code\":\"J01DB11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.\",\"description\":\"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.\"},{\"name\":\"Ceftezole\",\"ATC_code\":\"J01DB12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Cefacetrile\",\"ATC_code\":\"J01DB10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A derivative of 7-aminocephalosporanic acid.\",\"description\":\"A derivative of 7-aminocephalosporanic acid.\"},{\"name\":\"Cefadroxil\",\"ATC_code\":\"J01DB05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.\",\"description\":\"Long-acting, broad-spectrum, water-soluble, cephalexin derivative.\"},{\"name\":\"Cefalexin\",\"ATC_code\":\"J01DB01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.\",\"description\":\"Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.\"},{\"name\":\"Cefaloridine\",\"ATC_code\":\"J01DB02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.\",\"description\":\"Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.\"},{\"name\":\"Cefalotin\",\"ATC_code\":\"J01DB03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefalotin is a cephalosporin antibiotic.\",\"description\":\"Cefalotin is a cephalosporin antibiotic.\"},{\"name\":\"Cefapirin\",\"ATC_code\":\"J01DB08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.\",\"description\":\"Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.\"},{\"name\":\"Cefatrizine\",\"ATC_code\":\"J01DB07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"},{\"name\":\"Cefazedone\",\"ATC_code\":\"J01DB06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"},{\"name\":\"Cefazolin\",\"ATC_code\":\"J01DB04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.\",\"description\":\"A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.\"},{\"name\":\"Cefradine\",\"ATC_code\":\"J01DB09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semi-synthetic cephalosporin antibiotic.\",\"description\":\"A semi-synthetic cephalosporin antibiotic.\"},{\"name\":\"Cefroxadine\",\"ATC_code\":\"J01DB11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.\",\"description\":\"Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.\"},{\"name\":\"Ceftezole\",\"ATC_code\":\"J01DB12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"First-generation cephalosporins\",\"description\":\"First-generation cephalosporins\"}]}]},{\"name\":\"2nd-gen-cephalosporins\",\"data\":[{\"name\":\"Cefaclor\",\"ATC_code\":\"J01DC04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.\",\"description\":\"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.\"},{\"name\":\"Cefamandole\",\"ATC_code\":\"J01DC03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.\",\"description\":\"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.\"},{\"name\":\"Cefbuperazone\",\"ATC_code\":\"J01DC13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Second-generation cephalosporins\",\"description\":\"Second-generation cephalosporins\"},{\"name\":\"Cefmetazole\",\"ATC_code\":\"J01DC09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.\",\"description\":\"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.\"},{\"name\":\"Cefminox\",\"ATC_code\":\"J01DC12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.\",\"description\":\"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.\"},{\"name\":\"Cefonicid\",\"ATC_code\":\"J01DC06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.\",\"description\":\"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.\"},{\"name\":\"Ceforanide\",\"ATC_code\":\"J01DC11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.\",\"description\":\"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.\"},{\"name\":\"Cefotetan\",\"ATC_code\":\"J01DC05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.\",\"description\":\"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.\"},{\"name\":\"Cefotiam\",\"ATC_code\":\"J01DC07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.\",\"description\":\"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.\"},{\"name\":\"Cefoxitin\",\"ATC_code\":\"J01DC01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.\",\"description\":\"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.\"},{\"name\":\"Cefprozil\",\"ATC_code\":\"J01DC10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.\",\"description\":\"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.\"},{\"name\":\"Cefuroxime\",\"ATC_code\":\"J01DC02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.\",\"description\":\"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.\"},{\"name\":\"Flomoxef\",\"ATC_code\":\"J01DC14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.\",\"description\":\"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.\"},{\"name\":\"Loracarbef\",\"ATC_code\":\"J01DC08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.\",\"description\":\"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Cefaclor\",\"ATC_code\":\"J01DC04\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.\",\"description\":\"Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.\"},{\"name\":\"Cefamandole\",\"ATC_code\":\"J01DC03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.\",\"description\":\"Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.\"},{\"name\":\"Cefbuperazone\",\"ATC_code\":\"J01DC13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Second-generation cephalosporins\",\"description\":\"Second-generation cephalosporins\"},{\"name\":\"Cefmetazole\",\"ATC_code\":\"J01DC09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.\",\"description\":\"A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.\"},{\"name\":\"Cefminox\",\"ATC_code\":\"J01DC12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.\",\"description\":\"Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.\"},{\"name\":\"Cefonicid\",\"ATC_code\":\"J01DC06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.\",\"description\":\"A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.\"},{\"name\":\"Ceforanide\",\"ATC_code\":\"J01DC11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.\",\"description\":\"Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.\"},{\"name\":\"Cefotetan\",\"ATC_code\":\"J01DC05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.\",\"description\":\"A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.\"},{\"name\":\"Cefotiam\",\"ATC_code\":\"J01DC07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.\",\"description\":\"One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.\"},{\"name\":\"Cefoxitin\",\"ATC_code\":\"J01DC01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.\",\"description\":\"Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.\"},{\"name\":\"Cefprozil\",\"ATC_code\":\"J01DC10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.\",\"description\":\"Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.\"},{\"name\":\"Cefuroxime\",\"ATC_code\":\"J01DC02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.\",\"description\":\"Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.\"},{\"name\":\"Flomoxef\",\"ATC_code\":\"J01DC14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.\",\"description\":\"Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.\"},{\"name\":\"Loracarbef\",\"ATC_code\":\"J01DC08\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.\",\"description\":\"Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.\"}]}]},{\"name\":\"3rd-gen-cephalosporins\",\"data\":[{\"name\":\"Cefcapene-pivoxil\",\"ATC_code\":\"J01DD17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefdinir\",\"ATC_code\":\"J01DD15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.\",\"description\":\"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.\"},{\"name\":\"Cefditoren-pivoxil\",\"ATC_code\":\"J01DD16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.\",\"description\":\"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.\"},{\"name\":\"Cefetamet-pivoxil\",\"ATC_code\":\"J01DD10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefixime\",\"ATC_code\":\"J01DD08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.\",\"description\":\"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.\"},{\"name\":\"Cefmenoxime\",\"ATC_code\":\"J01DD05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.\",\"description\":\"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.\"},{\"name\":\"Cefodizime\",\"ATC_code\":\"J01DD09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefoperazone\",\"ATC_code\":\"J01DD12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.\",\"description\":\"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.\"},{\"name\":\"Cefotaxime\",\"ATC_code\":\"J01DD01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).\",\"description\":\"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).\"},{\"name\":\"Cefpiramide\",\"ATC_code\":\"J01DD11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefpiramide is a third-generation cephalosporin antibiotic.\",\"description\":\"Cefpiramide is a third-generation cephalosporin antibiotic.\"},{\"name\":\"Cefpodoxime-proxetil\",\"ATC_code\":\"J01DD13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.\",\"description\":\"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.\"},{\"name\":\"Cefsulodin\",\"ATC_code\":\"J01DD03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Ceftazidime\",\"ATC_code\":\"J01DD02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \\\"penicillin-binding proteins\\\" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\\r\\n\\r\\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.\",\"description\":\"Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \\\"penicillin-binding proteins\\\" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\\r\\n\\r\\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.\"},{\"name\":\"Ceftazidime/avibactam\",\"ATC_code\":\"J01DD52\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization's List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia\"},{\"name\":\"Cefteram-pivoxil\",\"ATC_code\":\"J01DD18\",\"EML\":\"No\",\"value\":1,\"description\":\"Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It's designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It's commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia\"},{\"name\":\"Ceftibuten\",\"ATC_code\":\"J01DD14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.\",\"description\":\"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.\"},{\"name\":\"Ceftizoxime\",\"ATC_code\":\"J01DD07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.\",\"description\":\"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.\"},{\"name\":\"Ceftriaxone\",\"ATC_code\":\"J01DD04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.\",\"description\":\"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.\"},{\"name\":\"Latamoxef\",\"ATC_code\":\"J01DD06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.\",\"description\":\"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Cefcapene-pivoxil\",\"ATC_code\":\"J01DD17\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefdinir\",\"ATC_code\":\"J01DD15\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.\",\"description\":\"Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.\"},{\"name\":\"Cefditoren-pivoxil\",\"ATC_code\":\"J01DD16\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.\",\"description\":\"Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.\"},{\"name\":\"Cefetamet-pivoxil\",\"ATC_code\":\"J01DD10\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefixime\",\"ATC_code\":\"J01DD08\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.\",\"description\":\"Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.\"},{\"name\":\"Cefmenoxime\",\"ATC_code\":\"J01DD05\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.\",\"description\":\"Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.\"},{\"name\":\"Cefodizime\",\"ATC_code\":\"J01DD09\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Cefoperazone\",\"ATC_code\":\"J01DD12\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.\",\"description\":\"Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.\"},{\"name\":\"Cefotaxime\",\"ATC_code\":\"J01DD01\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).\",\"description\":\"Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).\"},{\"name\":\"Cefpiramide\",\"ATC_code\":\"J01DD11\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefpiramide is a third-generation cephalosporin antibiotic.\",\"description\":\"Cefpiramide is a third-generation cephalosporin antibiotic.\"},{\"name\":\"Cefpodoxime-proxetil\",\"ATC_code\":\"J01DD13\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.\",\"description\":\"Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.\"},{\"name\":\"Cefsulodin\",\"ATC_code\":\"J01DD03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Third-generation cephalosporins\",\"description\":\"Third-generation cephalosporins\"},{\"name\":\"Ceftazidime\",\"ATC_code\":\"J01DD02\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \\\"penicillin-binding proteins\\\" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\\r\\n\\r\\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.\",\"description\":\"Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \\\"penicillin-binding proteins\\\" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\\r\\n\\r\\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor avibactam to treat a variety of bacterial infections.\"},{\"name\":\"Cefteram-pivoxil\",\"ATC_code\":\"J01DD18\",\"EML\":\"No\",\"value\":1,\"description\":\"Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It's designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It's commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia\"},{\"name\":\"Ceftibuten\",\"ATC_code\":\"J01DD14\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.\",\"description\":\"Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.\"},{\"name\":\"Ceftizoxime\",\"ATC_code\":\"J01DD07\",\"EML\":\"No\",\"value\":1,\"description.x\":\"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.\",\"description\":\"A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.\"},{\"name\":\"Ceftriaxone\",\"ATC_code\":\"J01DD04\",\"EML\":\"Yes\",\"value\":1,\"description.x\":\"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.\",\"description\":\"Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.\"},{\"name\":\"Latamoxef\",\"ATC_code\":\"J01DD06\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.\",\"description\":\"Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.\"}]},{\"name\":\"Reserve\",\"children\":[{\"name\":\"Ceftazidime/avibactam\",\"ATC_code\":\"J01DD52\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a β-lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization's List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia\"}]}]},{\"name\":\"4th-gen-cephalosporins\",\"data\":[{\"name\":\"Cefepime\",\"ATC_code\":\"J01DE01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.\",\"description\":\"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.\"},{\"name\":\"Cefoselis\",\"ATC_code\":\"to be assigned\",\"EML\":\"No\",\"value\":1,\"description\":\"Cefoselis is a fourth-generation cephalosporin antibiotic. It's widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia\"},{\"name\":\"Cefozopran\",\"ATC_code\":\"J01DE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fourth-generation cephalosporins\",\"description\":\"Fourth-generation cephalosporins\"},{\"name\":\"Cefpirome\",\"ATC_code\":\"J01DE02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fourth-generation cephalosporins\",\"description\":\"Fourth-generation cephalosporins\"}],\"children\":[{\"name\":\"Watch\",\"children\":[{\"name\":\"Cefepime\",\"ATC_code\":\"J01DE01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.\",\"description\":\"Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.\"},{\"name\":\"Cefoselis\",\"ATC_code\":\"to be assigned\",\"EML\":\"No\",\"value\":1,\"description\":\"Cefoselis is a fourth-generation cephalosporin antibiotic. It's widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia\"},{\"name\":\"Cefozopran\",\"ATC_code\":\"J01DE03\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fourth-generation cephalosporins\",\"description\":\"Fourth-generation cephalosporins\"},{\"name\":\"Cefpirome\",\"ATC_code\":\"J01DE02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Fourth-generation cephalosporins\",\"description\":\"Fourth-generation cephalosporins\"}]}]},{\"name\":\"Other-cephalosporins\",\"data\":[{\"name\":\"Cefiderocol\",\"ATC_code\":\"J01DI04\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\\r\\n\\r\\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.\",\"description\":\"Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\\r\\n\\r\\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Cefiderocol\",\"ATC_code\":\"J01DI04\",\"EML\":\"Yes\",\"value\":2,\"description.x\":\"Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\\r\\n\\r\\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.\",\"description\":\"Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase producers and carbapenemase producing bacteria.\\r\\n\\r\\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.\"}]}]},{\"name\":\"5th-gen cephalosporins\",\"data\":[{\"name\":\"Ceftaroline-fosamil\",\"ATC_code\":\"J01DI02 \",\"EML\":\"No\",\"value\":1,\"description\":\"Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia\"},{\"name\":\"Ceftobiprole-medocaril\",\"ATC_code\":\"J01DI01\",\"EML\":\"No\",\"value\":1,\"description\":\"Ceftobiprole medocaril is a ceftobiprole prodrug.\",\"description.x\":\"Ceftobiprole medocaril is a ceftobiprole prodrug.\"},{\"name\":\"Ceftolozane/tazobactam\",\"ATC_code\":\"J01DI54\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a β-lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization's List of Essential Medicines. Source: Wikepedia\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Ceftaroline-fosamil\",\"ATC_code\":\"J01DI02 \",\"EML\":\"No\",\"value\":1,\"description\":\"Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia\"},{\"name\":\"Ceftobiprole-medocaril\",\"ATC_code\":\"J01DI01\",\"EML\":\"No\",\"value\":1,\"description\":\"Ceftobiprole medocaril is a ceftobiprole prodrug.\",\"description.x\":\"Ceftobiprole medocaril is a ceftobiprole prodrug.\"},{\"name\":\"Ceftolozane/tazobactam\",\"ATC_code\":\"J01DI54\",\"EML\":\"Yes\",\"value\":1,\"description\":\"Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a β-lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization's List of Essential Medicines. Source: Wikepedia\"}]}]},{\"name\":\"Penems\",\"data\":[{\"name\":\"Faropenem\",\"ATC_code\":\"J01DI03\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.\",\"description\":\"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.\"}],\"children\":[{\"name\":\"Reserve\",\"children\":[{\"name\":\"Faropenem\",\"ATC_code\":\"J01DI03\",\"EML\":\"No\",\"value\":2,\"description.x\":\"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.\",\"description\":\"Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.\"}]}]},{\"name\":\"Beta-lactamase-inhibitors\",\"data\":[{\"name\":\"Sulbactam\",\"ATC_code\":\"J01CG01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.\",\"description\":\"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.\"},{\"name\":\"Tazobactam\",\"ATC_code\":\"J01CG02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\\r\\n\\r\\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.\",\"description\":\"Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\\r\\n\\r\\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.\"}],\"children\":[{\"name\":\"Access\",\"children\":[{\"name\":\"Sulbactam\",\"ATC_code\":\"J01CG01\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.\",\"description\":\"Sulbactam is a β-lactamase inhibitor given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys antibiotic activity.\"}]},{\"name\":\"Watch\",\"children\":[{\"name\":\"Tazobactam\",\"ATC_code\":\"J01CG02\",\"EML\":\"No\",\"value\":1,\"description.x\":\"Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\\r\\n\\r\\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.\",\"description\":\"Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\\r\\n\\r\\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.\"}]}]}]}]} \n"} -->
<pre><code>{&quot;name&quot;:&quot;Antibiotics&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Other&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Aminoglycosides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Amikacin&quot;,&quot;ATC_code&quot;:&quot;J01GB06&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)--amino--hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r\n\r\nAmikacin&#39;s unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r\n\r\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.&quot;,&quot;description&quot;:&quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)--amino--hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r\n\r\nAmikacin&#39;s unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r\n\r\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.&quot;},{&quot;name&quot;:&quot;Arbekacin&quot;,&quot;ATC_code&quot;:&quot;J01GB12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).&quot;,&quot;description&quot;:&quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).&quot;},{&quot;name&quot;:&quot;Bekanamycin&quot;,&quot;ATC_code&quot;:&quot;J01GB13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other aminoglycosides&quot;,&quot;description&quot;:&quot;Other aminoglycosides&quot;},{&quot;name&quot;:&quot;Dibekacin&quot;,&quot;ATC_code&quot;:&quot;J01GB09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dibekacin is an aminoglycoside antibiotic marketed in Japan .&quot;,&quot;description&quot;:&quot;Dibekacin is an aminoglycoside antibiotic marketed in Japan .&quot;},{&quot;name&quot;:&quot;Gentamicin&quot;,&quot;ATC_code&quot;:&quot;J01GB03&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r\n\r\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.&quot;,&quot;description&quot;:&quot;Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r\n\r\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.&quot;},{&quot;name&quot;:&quot;Isepamicin&quot;,&quot;ATC_code&quot;:&quot;J01GB11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other aminoglycosides&quot;,&quot;description&quot;:&quot;Other aminoglycosides&quot;},{&quot;name&quot;:&quot;Kanamycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;,&quot;description&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;},{&quot;name&quot;:&quot;Kanamycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;,&quot;description&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;},{&quot;name&quot;:&quot;Micronomicin&quot;,&quot;ATC_code&quot;:&quot;to be assigned&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Neomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;,&quot;description&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;},{&quot;name&quot;:&quot;Neomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;,&quot;description&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;},{&quot;name&quot;:&quot;Netilmicin&quot;,&quot;ATC_code&quot;:&quot;J01GB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.&quot;,&quot;description&quot;:&quot;Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.&quot;},{&quot;name&quot;:&quot;Plazomicin&quot;,&quot;ATC_code&quot;:&quot;J01GB14&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6&#39; . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.&quot;,&quot;description&quot;:&quot;Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6&#39; . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.&quot;},{&quot;name&quot;:&quot;Ribostamycin&quot;,&quot;ATC_code&quot;:&quot;J01GB10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization&#39;s critically important antimicrobials.&quot;,&quot;description&quot;:&quot;Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization&#39;s critically important antimicrobials.&quot;},{&quot;name&quot;:&quot;Sisomicin&quot;,&quot;ATC_code&quot;:&quot;J01GB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sisomicin has been used in trials studying the treatment of Pyoderma.&quot;,&quot;description&quot;:&quot;Sisomicin has been used in trials studying the treatment of Pyoderma.&quot;},{&quot;name&quot;:&quot;Streptoduocin&quot;,&quot;ATC_code&quot;:&quot;J01GA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Streptomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;,&quot;description&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;},{&quot;name&quot;:&quot;Streptomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;,&quot;description&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;},{&quot;name&quot;:&quot;Tobramycin&quot;,&quot;ATC_code&quot;:&quot;J01GB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as -lactams and cephalosporins.\r\n\r\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).&quot;,&quot;description&quot;:&quot;Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as -lactams and cephalosporins.\r\n\r\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Amikacin&quot;,&quot;ATC_code&quot;:&quot;J01GB06&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)--amino--hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r\n\r\nAmikacin&#39;s unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r\n\r\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.&quot;,&quot;description&quot;:&quot;Amikacin is a semi-synthetic aminoglycoside antibiotic that is derived from kanamycin A.FDA label Amikacin is synthesized by acylation with the l-(-)--amino--hydroxybutyryl side chain at the C-1 amino group of the deoxystreptamine moiety of kanamycin A.\r\n\r\nAmikacin&#39;s unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. Amikacin also exerts excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia and some Mycobacterium (M. avium-intracellulare, M. chelonae, and M. fortuitum). M. avium-intracellulare (MAC) is a type of nontuberculous mycobacteria (NTM) found in water and soil. Symptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood.\r\n\r\nSeveral forms of amikacin are used currently, including an intravenous (IV) or intramuscular (IM) injection. In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population of patients with the disease who do not respond to traditional treatment.&quot;},{&quot;name&quot;:&quot;Gentamicin&quot;,&quot;ATC_code&quot;:&quot;J01GB03&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r\n\r\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.&quot;,&quot;description&quot;:&quot;Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from Micromonospora purpurea in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability. Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by Pseudomonas aeruginosa. There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams. This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.\r\n\r\nAlthough gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Arbekacin&quot;,&quot;ATC_code&quot;:&quot;J01GB12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).&quot;,&quot;description&quot;:&quot;An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant Staphylococcus aureus (MRSA).&quot;},{&quot;name&quot;:&quot;Bekanamycin&quot;,&quot;ATC_code&quot;:&quot;J01GB13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other aminoglycosides&quot;,&quot;description&quot;:&quot;Other aminoglycosides&quot;},{&quot;name&quot;:&quot;Dibekacin&quot;,&quot;ATC_code&quot;:&quot;J01GB09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dibekacin is an aminoglycoside antibiotic marketed in Japan .&quot;,&quot;description&quot;:&quot;Dibekacin is an aminoglycoside antibiotic marketed in Japan .&quot;},{&quot;name&quot;:&quot;Isepamicin&quot;,&quot;ATC_code&quot;:&quot;J01GB11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other aminoglycosides&quot;,&quot;description&quot;:&quot;Other aminoglycosides&quot;},{&quot;name&quot;:&quot;Kanamycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;,&quot;description&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;},{&quot;name&quot;:&quot;Kanamycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;,&quot;description&quot;:&quot;Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.&quot;},{&quot;name&quot;:&quot;Micronomicin&quot;,&quot;ATC_code&quot;:&quot;to be assigned&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Micronomicin is an aminoglycoside antibiotic primarily used for treating eye infections. It falls under the category of systemic antibiotics and is known for its effectiveness against specific bacterial infections. Micronomicin is administered either as eye drops or intravenously. It has been identified as a useful medication in ophthalmology due to its properties as an aminoglycoside antibiotic, a class known for treating various bacterial infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Neomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;,&quot;description&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;},{&quot;name&quot;:&quot;Neomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;,&quot;description&quot;:&quot;Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin. Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together. Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria. \r\n\r\nNeomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units. Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma. It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear. Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye. Neomycin is also available in over-the-counter topical products to prevent minor skin infections.&quot;},{&quot;name&quot;:&quot;Netilmicin&quot;,&quot;ATC_code&quot;:&quot;J01GB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.&quot;,&quot;description&quot;:&quot;Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site. The bactericidal effect of netilmiicin is not fully understood.&quot;},{&quot;name&quot;:&quot;Ribostamycin&quot;,&quot;ATC_code&quot;:&quot;J01GB10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization&#39;s critically important antimicrobials.&quot;,&quot;description&quot;:&quot;Ribostamycin is an aminoglycoside antibiotic isolated from Streptomyces ribosidificus listed as one of the World Health Organization&#39;s critically important antimicrobials.&quot;},{&quot;name&quot;:&quot;Sisomicin&quot;,&quot;ATC_code&quot;:&quot;J01GB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sisomicin has been used in trials studying the treatment of Pyoderma.&quot;,&quot;description&quot;:&quot;Sisomicin has been used in trials studying the treatment of Pyoderma.&quot;},{&quot;name&quot;:&quot;Streptoduocin&quot;,&quot;ATC_code&quot;:&quot;J01GA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Streptoduocin is an aminoglycoside antibiotic, which is a combination of streptomycin and dihydrostreptomycin. These components make it effective against a range of bacterial infections. Aminoglycoside antibiotics like streptoduocin work by interfering with bacterial protein synthesis, which is crucial for their growth and survival. This type of antibiotic is known for its effectiveness, particularly against certain types of bacteria. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Streptomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01GA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;,&quot;description&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;},{&quot;name&quot;:&quot;Streptomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;,&quot;description&quot;:&quot;Streptomycin, an antibiotic derived from Streptomyces griseus, was the first aminoglycoside to be discovered and used in practice in the 1940s. Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activity. Although streptomycin was the first antibiotic determined to be effective against mycobacterium tuberculosis, it has fallen out of favor due to resistance and is now primarily used as adjunctive treatment in cases of multi-drug resistant tuberculosis.&quot;},{&quot;name&quot;:&quot;Tobramycin&quot;,&quot;ATC_code&quot;:&quot;J01GB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as -lactams and cephalosporins.\r\n\r\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).&quot;,&quot;description&quot;:&quot;Aminoglycosides, many of which are derived directly from Streptomyces spp., are concentration-dependent bactericidal antibiotics with a broad spectrum of activity against Gram-positive and Gram-negative organisms. Inhaled tobramycin is notable for its use in treating chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, as P. aeruginosa is notoriously inherently resistant to many antibiotics. However, tobramycin can also be administered intravenously and topically to treat a variety of infections caused by susceptible bacteria. Its use is limited in some cases by characteristic toxicities such as nephrotoxicity and ototoxicity, yet it remains a valuable option in the face of growing resistance to front-line antibiotics such as -lactams and cephalosporins.\r\n\r\nTobramycin was approved by the FDA in 1975 and is currently available in a variety of forms for administration by inhalation, injection, and external application to the eye (ophthalmic).&quot;}]},{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Plazomicin&quot;,&quot;ATC_code&quot;:&quot;J01GB14&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6&#39; . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.&quot;,&quot;description&quot;:&quot;Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to  at position 1 and 2-hydroxyethyl group at position 6&#39; . It was designed to evade all clinically relevant aminoglycoside-modifying enzymes, which contribute to the main resistance mechanism for aminoglycoside therapy . However, acquired resistance of aminoglycosides may arise through over expression of efflux pumps and ribosomal modification by bacteria, which results from amino acid or rRNA sequence mutations . Like other aminoglycosides, plazomicin is ineffective against bacterial isolates that produce 16S rRNA methyltransferases FDA Label. Plazomicin mediates the antibacterial activity against pathogens including carbapenem-resistant (CRE) and extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis FDA Label. On June 28th, 2018, plazomicin sulfate was approved by the FDA for use in adult patients for the treatment of complicated urinary tract infections (cUTI) including Pyelonephritis. It is marketed as Zemdri and is administered via once-daily intravenous infusion.&quot;}]}]},{&quot;name&quot;:&quot;Macrolides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Azithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA10&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r\n\r\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r\n\r\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r\n\r\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.&quot;,&quot;description&quot;:&quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r\n\r\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r\n\r\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r\n\r\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.&quot;},{&quot;name&quot;:&quot;Clarithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.&quot;,&quot;description&quot;:&quot;Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.&quot;},{&quot;name&quot;:&quot;Dirithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.&quot;,&quot;description&quot;:&quot;Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.&quot;},{&quot;name&quot;:&quot;Erythromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA01&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to clarithromycin (EMLc))&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.&quot;,&quot;description&quot;:&quot;Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.&quot;},{&quot;name&quot;:&quot;Fidaxomicin&quot;,&quot;ATC_code&quot;:&quot;A07AA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC&lt;sub&gt;90&lt;\/sub&gt;) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r\n\r\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.&quot;,&quot;description&quot;:&quot;Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC&lt;sub&gt;90&lt;\/sub&gt;) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r\n\r\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.&quot;},{&quot;name&quot;:&quot;Flurithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Macrolides&quot;,&quot;description&quot;:&quot;Macrolides&quot;},{&quot;name&quot;:&quot;Josamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.&quot;,&quot;description&quot;:&quot;A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.&quot;},{&quot;name&quot;:&quot;Midecamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.&quot;,&quot;description&quot;:&quot;Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.&quot;},{&quot;name&quot;:&quot;Miocamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .&quot;,&quot;description&quot;:&quot;Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .&quot;},{&quot;name&quot;:&quot;Oleandomycin&quot;,&quot;ATC_code&quot;:&quot;J01FA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.&quot;,&quot;description&quot;:&quot;Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.&quot;},{&quot;name&quot;:&quot;Rokitamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Macrolides&quot;,&quot;description&quot;:&quot;Macrolides&quot;},{&quot;name&quot;:&quot;Roxithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.&quot;,&quot;description&quot;:&quot;Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.&quot;},{&quot;name&quot;:&quot;Solithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.&quot;,&quot;description&quot;:&quot;Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.&quot;},{&quot;name&quot;:&quot;Spiramycin&quot;,&quot;ATC_code&quot;:&quot;J01FA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.&quot;,&quot;description&quot;:&quot;Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.&quot;},{&quot;name&quot;:&quot;Telithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.&quot;,&quot;description&quot;:&quot;Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.&quot;},{&quot;name&quot;:&quot;Troleandomycin&quot;,&quot;ATC_code&quot;:&quot;J01FA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A macrolide antibiotic that is similar to erythromycin.&quot;,&quot;description&quot;:&quot;A macrolide antibiotic that is similar to erythromycin.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Azithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA10&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r\n\r\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r\n\r\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r\n\r\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.&quot;,&quot;description&quot;:&quot;Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .\r\n\r\nIt is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin .\r\n\r\nAzithromycin 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin is a part of the azalide subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides .\r\n\r\nIn March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug hydroxychloroquine. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.&quot;},{&quot;name&quot;:&quot;Clarithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.&quot;,&quot;description&quot;:&quot;Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration.&quot;},{&quot;name&quot;:&quot;Dirithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.&quot;,&quot;description&quot;:&quot;Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.&quot;},{&quot;name&quot;:&quot;Erythromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA01&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to clarithromycin (EMLc))&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.&quot;,&quot;description&quot;:&quot;Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists of Azithromycin, Clarithromycin, Spiramycin and others. It was originally discovered in 1952. Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. It is available for administration in various forms, including intravenous, topical, and eye drop preparations.&quot;},{&quot;name&quot;:&quot;Fidaxomicin&quot;,&quot;ATC_code&quot;:&quot;A07AA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC&lt;sub&gt;90&lt;\/sub&gt;) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r\n\r\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.&quot;,&quot;description&quot;:&quot;Fidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by Clostridioides (formerly Clostridium) difficile in adult and pediatric patients over the age of 6 months. Fidaxomicin is a naturally-occurring 18-member macrocycle derived from fermentation. Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent. Fidaxomicin was the first macrocyclic lactone antibiotic with activity against C. difficile, and it displays a narrow spectrum of activity against gram-positive anaerobes. It mediates its potent bactericidal action on the bacteria by inhibiting the bacterial RNA synthase, thereby disrupting bacterial transcription. The minimum inhibitory concentration (MIC&lt;sub&gt;90&lt;\/sub&gt;) for fidaxomicin is four times less than that of vancomycin, which was the primary drug of choice for C. difficile infection before the approval of fidaxomicin. Unlike vancomycin, however, fidaxomicin has a negligible effect on normal colonic microflora.\r\n\r\nThe FDA initially approved fidaxomicin in May 2011 for the treatment of C. difficile-associated diarrhea in adult patients over the age of 18. Later that year in December, the drug was also approved by the European Medicine Agency. In June 2012, fidaxomicin was also granted approval by Health Canada. The approved indication of fidaxomicin was expanded by the FDA in January 2020 to include pediatric patients over the age of 6 months in the treatment population.&quot;},{&quot;name&quot;:&quot;Flurithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Macrolides&quot;,&quot;description&quot;:&quot;Macrolides&quot;},{&quot;name&quot;:&quot;Josamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.&quot;,&quot;description&quot;:&quot;A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.&quot;},{&quot;name&quot;:&quot;Midecamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.&quot;,&quot;description&quot;:&quot;Midecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on position 4 of the terminal sugar. Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.&quot;},{&quot;name&quot;:&quot;Miocamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .&quot;,&quot;description&quot;:&quot;Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and may be useful in the treatment of upper and lower respiratory tract infections, and urogenital tract infections or as an alternative to erythromycin treatment .&quot;},{&quot;name&quot;:&quot;Oleandomycin&quot;,&quot;ATC_code&quot;:&quot;J01FA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.&quot;,&quot;description&quot;:&quot;Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.&quot;},{&quot;name&quot;:&quot;Rokitamycin&quot;,&quot;ATC_code&quot;:&quot;J01FA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Macrolides&quot;,&quot;description&quot;:&quot;Macrolides&quot;},{&quot;name&quot;:&quot;Roxithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.&quot;,&quot;description&quot;:&quot;Roxithromycin is a semi-synthethic macrolide antibiotic that is structurally and pharmacologically similar to erythromycin, azithromycin, or clarithromycin. It was shown to be more effective against certain Gram-negative bacteria, particularly Legionella pneumophila. Roxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. It is marketed in Australia as a treatment for respiratory tract, urinary and soft tissue infections.&quot;},{&quot;name&quot;:&quot;Solithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.&quot;,&quot;description&quot;:&quot;Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.&quot;},{&quot;name&quot;:&quot;Spiramycin&quot;,&quot;ATC_code&quot;:&quot;J01FA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.&quot;,&quot;description&quot;:&quot;Spiramycin is a primarily bacteriostatic macrolide antimicrobial agent with activity against Gram-positive cocci and rods, Gram-negative cocci and also Legionellae, mycoplasmas, chlamydiae, some types of spirochetes, Toxoplasma gondii and Cryptosporidium.\r\nSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987. Resistant organisms include Enterobacteria, pseudomonads, and moulds.&quot;},{&quot;name&quot;:&quot;Telithromycin&quot;,&quot;ATC_code&quot;:&quot;J01FA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.&quot;,&quot;description&quot;:&quot;Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.&quot;},{&quot;name&quot;:&quot;Troleandomycin&quot;,&quot;ATC_code&quot;:&quot;J01FA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A macrolide antibiotic that is similar to erythromycin.&quot;,&quot;description&quot;:&quot;A macrolide antibiotic that is similar to erythromycin.&quot;}]}]},{&quot;name&quot;:&quot;Trimethoprim-derivatives&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Brodimoprim&quot;,&quot;ATC_code&quot;:&quot;J01EA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim and derivatives&quot;,&quot;description&quot;:&quot;Trimethoprim and derivatives&quot;},{&quot;name&quot;:&quot;Iclaprim&quot;,&quot;ATC_code&quot;:&quot;J01EA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim and derivatives&quot;,&quot;description&quot;:&quot;Trimethoprim and derivatives&quot;},{&quot;name&quot;:&quot;Trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.&quot;,&quot;description&quot;:&quot;Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Brodimoprim&quot;,&quot;ATC_code&quot;:&quot;J01EA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim and derivatives&quot;,&quot;description&quot;:&quot;Trimethoprim and derivatives&quot;},{&quot;name&quot;:&quot;Trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.&quot;,&quot;description&quot;:&quot;Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in combination with sulfamethoxazole due to their complementary and synergistic mechanisms but may be used as a monotherapy in the treatment and/or prophylaxis of urinary tract infections. It is structurally and chemically related to pyrimethamine, another antifolate antimicrobial used in the treatment of plasmodial infections.&quot;}]},{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Iclaprim&quot;,&quot;ATC_code&quot;:&quot;J01EA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trimethoprim and derivatives&quot;,&quot;description&quot;:&quot;Trimethoprim and derivatives&quot;}]}]},{&quot;name&quot;:&quot;Amphenicols&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Chloramphenicol&quot;,&quot;ATC_code&quot;:&quot;J01BA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r\n\r\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.&quot;,&quot;description&quot;:&quot;An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r\n\r\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.&quot;},{&quot;name&quot;:&quot;Thiamphenicol&quot;,&quot;ATC_code&quot;:&quot;J01BA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amphenicols&quot;,&quot;description&quot;:&quot;Amphenicols&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Chloramphenicol&quot;,&quot;ATC_code&quot;:&quot;J01BA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r\n\r\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.&quot;,&quot;description&quot;:&quot;An antibiotic first isolated from cultures of Streptomyces venequelae in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)\r\n\r\nThe FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.&quot;},{&quot;name&quot;:&quot;Thiamphenicol&quot;,&quot;ATC_code&quot;:&quot;J01BA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amphenicols&quot;,&quot;description&quot;:&quot;Amphenicols&quot;}]}]},{&quot;name&quot;:&quot;Tetracyclines&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Chlortetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.&quot;,&quot;description&quot;:&quot;Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.&quot;},{&quot;name&quot;:&quot;Clomocycline&quot;,&quot;ATC_code&quot;:&quot;J01AA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clomocycline is a tetracycline used to treat bacterial infections.&quot;,&quot;description&quot;:&quot;Clomocycline is a tetracycline used to treat bacterial infections.&quot;},{&quot;name&quot;:&quot;Demeclocycline&quot;,&quot;ATC_code&quot;:&quot;J01AA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.&quot;,&quot;description&quot;:&quot;A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.&quot;},{&quot;name&quot;:&quot;Doxycycline&quot;,&quot;ATC_code&quot;:&quot;J01AA02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.&quot;,&quot;description&quot;:&quot;Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.&quot;},{&quot;name&quot;:&quot;Eravacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, -lactam/-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .&quot;,&quot;description&quot;:&quot;Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, -lactam/-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .&quot;},{&quot;name&quot;:&quot;Lymecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.&quot;,&quot;description&quot;:&quot;Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.&quot;},{&quot;name&quot;:&quot;Metacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.&quot;,&quot;description&quot;:&quot;A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.&quot;},{&quot;name&quot;:&quot;Minocycline_IV&quot;,&quot;ATC_code&quot;:&quot;J01AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;,&quot;description&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;},{&quot;name&quot;:&quot;Minocycline_oral&quot;,&quot;ATC_code&quot;:&quot;J01AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;,&quot;description&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;},{&quot;name&quot;:&quot;Omadacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.&quot;,&quot;description&quot;:&quot;Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.&quot;},{&quot;name&quot;:&quot;Oxytetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.&quot;,&quot;description&quot;:&quot;A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.&quot;},{&quot;name&quot;:&quot;Penimepicycline&quot;,&quot;ATC_code&quot;:&quot;J01AA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .&quot;,&quot;description&quot;:&quot;Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .&quot;},{&quot;name&quot;:&quot;Rolitetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A pyrrolidinylmethyl tetracycline.&quot;,&quot;description&quot;:&quot;A pyrrolidinylmethyl tetracycline.&quot;},{&quot;name&quot;:&quot;Sarecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.&#39;s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan&#39;s US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company&#39;s presence in the United States .\r\n\r\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r\n\r\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.&quot;,&quot;description&quot;:&quot;Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.&#39;s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan&#39;s US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company&#39;s presence in the United States .\r\n\r\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r\n\r\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.&quot;},{&quot;name&quot;:&quot;Tetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r\n\r\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.&quot;,&quot;description&quot;:&quot;Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r\n\r\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Chlortetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.&quot;,&quot;description&quot;:&quot;Chlortetracycline is a tetracycline antibiotic, and historically the first member of this class to be identified. It was discovered in 1945 by the scientist, Benjamin Minge Duggar, working at Lederle Laboratories under the supervision of Yellapragada Subbarow. He discovered that this antibiotic was the product of an actinomycete strain he cultured and obtained from a soil sample from a field in Missouri. The organism was named Streptomyces aureofaciens due to its gold-hued color.&quot;},{&quot;name&quot;:&quot;Clomocycline&quot;,&quot;ATC_code&quot;:&quot;J01AA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clomocycline is a tetracycline used to treat bacterial infections.&quot;,&quot;description&quot;:&quot;Clomocycline is a tetracycline used to treat bacterial infections.&quot;},{&quot;name&quot;:&quot;Demeclocycline&quot;,&quot;ATC_code&quot;:&quot;J01AA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.&quot;,&quot;description&quot;:&quot;A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.&quot;},{&quot;name&quot;:&quot;Lymecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.&quot;,&quot;description&quot;:&quot;Lymecycline is a broad-spectrum second-generation tetracycline antibiotic used for the treatment of acne and other susceptible bacterial infections. It has been proven a cost-effective alternative to treatment with minocycline with comparable safety and efficacy. Lymecycline was initially discovered in 1961. It is marketed by Galderma and used in the UK as well as New Zealand in addition to other countries. Lymecycline is not marketed in the USA, however, equivalent drugs are available, such as minocycline and tetracycline.&quot;},{&quot;name&quot;:&quot;Metacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.&quot;,&quot;description&quot;:&quot;A broad-spectrum semisynthetic antibiotic related to tetracycline but excreted more slowly and maintaining effective blood levels for a more extended period.&quot;},{&quot;name&quot;:&quot;Minocycline_oral&quot;,&quot;ATC_code&quot;:&quot;J01AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;,&quot;description&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;},{&quot;name&quot;:&quot;Oxytetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.&quot;,&quot;description&quot;:&quot;A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions.&quot;},{&quot;name&quot;:&quot;Penimepicycline&quot;,&quot;ATC_code&quot;:&quot;J01AA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .&quot;,&quot;description&quot;:&quot;Penimepicycline is a tetracycline-class antibiotic. It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients . In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans .&quot;},{&quot;name&quot;:&quot;Rolitetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A pyrrolidinylmethyl tetracycline.&quot;,&quot;description&quot;:&quot;A pyrrolidinylmethyl tetracycline.&quot;},{&quot;name&quot;:&quot;Sarecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.&#39;s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan&#39;s US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company&#39;s presence in the United States .\r\n\r\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r\n\r\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.&quot;,&quot;description&quot;:&quot;Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris  the US Food and Drug Administration approved Barcelona based Almirall, S.A.&#39;s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan&#39;s US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company&#39;s presence in the United States .\r\n\r\nAcne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne .\r\n\r\nSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc.&quot;}]},{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Doxycycline&quot;,&quot;ATC_code&quot;:&quot;J01AA02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.&quot;,&quot;description&quot;:&quot;Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.&quot;},{&quot;name&quot;:&quot;Tetracycline&quot;,&quot;ATC_code&quot;:&quot;J01AA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r\n\r\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.&quot;,&quot;description&quot;:&quot;Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.\r\n\r\nThe FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used.&quot;}]},{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Eravacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, -lactam/-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .&quot;,&quot;description&quot;:&quot;Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquinolones, -lactam/-lactamase inhibitors, multidrug-resistant strains, and carbapenem-resistant Enterobacteriaceae, and the majority of anaerobic pathogens . It was first approved by the FDA on August 27, 2018 . Eravacycline has demonstrated superior potency to that of antibiotics that are currently being marketed for intraabdominal infections .&quot;},{&quot;name&quot;:&quot;Minocycline_IV&quot;,&quot;ATC_code&quot;:&quot;J01AA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;,&quot;description&quot;:&quot;Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.\r\n\r\nMinocycline was granted FDA approval on 30 June 1971.&quot;},{&quot;name&quot;:&quot;Omadacycline&quot;,&quot;ATC_code&quot;:&quot;J01AA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.&quot;,&quot;description&quot;:&quot;Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent infections caused by gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), and by gram-negative, atypical and anaerobic bacteria, including those resistant to currently available classes of antibiotics and known to cause diseases such as pneumonias, urinary tract infections, skin diseases and blood-borne infections in both the hospital and community settings.&quot;}]}]},{&quot;name&quot;:&quot;Quinolones&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cinoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.&quot;,&quot;description&quot;:&quot;Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.&quot;},{&quot;name&quot;:&quot;Flumequine&quot;,&quot;ATC_code&quot;:&quot;J01MB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.&quot;,&quot;description&quot;:&quot;Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.&quot;},{&quot;name&quot;:&quot;Nemonoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Oxolinic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Pipemidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Piromidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Rosoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.&quot;,&quot;description&quot;:&quot;Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cinoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.&quot;,&quot;description&quot;:&quot;Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.&quot;},{&quot;name&quot;:&quot;Flumequine&quot;,&quot;ATC_code&quot;:&quot;J01MB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.&quot;,&quot;description&quot;:&quot;Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.&quot;},{&quot;name&quot;:&quot;Nemonoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Oxolinic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Pipemidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Piromidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01MB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Other quinolones&quot;,&quot;description&quot;:&quot;Other quinolones&quot;},{&quot;name&quot;:&quot;Rosoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.&quot;,&quot;description&quot;:&quot;Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.&quot;}]}]},{&quot;name&quot;:&quot;Fluoroquinolones&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Ciprofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r\n\r\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.&quot;,&quot;description&quot;:&quot;Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r\n\r\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.&quot;},{&quot;name&quot;:&quot;Delafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA23&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.&quot;,&quot;description&quot;:&quot;Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.&quot;},{&quot;name&quot;:&quot;Enoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.&quot;,&quot;description&quot;:&quot;A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.&quot;},{&quot;name&quot;:&quot;Fleroxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.&quot;,&quot;description&quot;:&quot;Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.&quot;},{&quot;name&quot;:&quot;Garenoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA19&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.&quot;,&quot;description&quot;:&quot;Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.&quot;},{&quot;name&quot;:&quot;Gatifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar marketed by Allergan.\r\n\r\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.&quot;,&quot;description&quot;:&quot;Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar marketed by Allergan.\r\n\r\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.&quot;},{&quot;name&quot;:&quot;Gemifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.&quot;,&quot;description&quot;:&quot;Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.&quot;},{&quot;name&quot;:&quot;Grepafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.&quot;,&quot;description&quot;:&quot;Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.&quot;},{&quot;name&quot;:&quot;Lascufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA25&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Levofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \&quot;respiratory quinolones\&quot; due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r\n\r\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.&quot;,&quot;description&quot;:&quot;Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \&quot;respiratory quinolones\&quot; due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r\n\r\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.&quot;},{&quot;name&quot;:&quot;Levonadifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA24&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).&quot;,&quot;description&quot;:&quot;Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).&quot;},{&quot;name&quot;:&quot;Lomefloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.&quot;,&quot;description&quot;:&quot;Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.&quot;},{&quot;name&quot;:&quot;Moxifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.&quot;,&quot;description&quot;:&quot;Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.&quot;},{&quot;name&quot;:&quot;Norfloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.&quot;,&quot;description&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.&quot;},{&quot;name&quot;:&quot;Ofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.&quot;,&quot;description&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.&quot;},{&quot;name&quot;:&quot;Pazufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).&quot;,&quot;description&quot;:&quot;Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).&quot;},{&quot;name&quot;:&quot;Pefloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.&quot;,&quot;description&quot;:&quot;A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.&quot;},{&quot;name&quot;:&quot;Prulifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Rufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rufloxacin is a quinolone antibiotic. &quot;,&quot;description&quot;:&quot;Rufloxacin is a quinolone antibiotic. &quot;},{&quot;name&quot;:&quot;Sitafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA21&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fluoroquinolones&quot;,&quot;description&quot;:&quot;Fluoroquinolones&quot;},{&quot;name&quot;:&quot;Sparfloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.&quot;,&quot;description&quot;:&quot;Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.&quot;},{&quot;name&quot;:&quot;Temafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.&quot;,&quot;description&quot;:&quot;Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.&quot;},{&quot;name&quot;:&quot;Tosufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA22&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fluoroquinolones&quot;,&quot;description&quot;:&quot;Fluoroquinolones&quot;},{&quot;name&quot;:&quot;Trovafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.&quot;,&quot;description&quot;:&quot;Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Ciprofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r\n\r\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.&quot;,&quot;description&quot;:&quot;Ciprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.\r\n\r\nThe first ciprofloxacin containing product was FDA approved on 22 October 1987.&quot;},{&quot;name&quot;:&quot;Delafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA23&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.&quot;,&quot;description&quot;:&quot;Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections.&quot;},{&quot;name&quot;:&quot;Enoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.&quot;,&quot;description&quot;:&quot;A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.&quot;},{&quot;name&quot;:&quot;Fleroxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.&quot;,&quot;description&quot;:&quot;Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.&quot;},{&quot;name&quot;:&quot;Garenoxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA19&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.&quot;,&quot;description&quot;:&quot;Garenoxacin, a quinolone antibiotic, is being investigated for the treatment of gram-positive and gram-negative bacterial infections.&quot;},{&quot;name&quot;:&quot;Gatifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar marketed by Allergan.\r\n\r\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.&quot;,&quot;description&quot;:&quot;Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar marketed by Allergan.\r\n\r\nThe FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.&quot;},{&quot;name&quot;:&quot;Gemifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.&quot;,&quot;description&quot;:&quot;Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.&quot;},{&quot;name&quot;:&quot;Grepafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.&quot;,&quot;description&quot;:&quot;Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.&quot;},{&quot;name&quot;:&quot;Lascufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA25&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Lascufloxacin, marketed under the trade name Lasvic, is a fluoroquinolone antibiotic drug. It was approved in Japan in 2019 for the treatment of various bacterial infections such as community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. Lascufloxacin is effective against several Gram-positive bacteria, including Streptococcus pneumoniae and Streptococcus anginosus. This antibiotic provides a treatment option for specific bacterial infections, particularly those affecting the respiratory tract. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Levofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \&quot;respiratory quinolones\&quot; due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r\n\r\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.&quot;,&quot;description&quot;:&quot;Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin, is a member of the third generation of fluoroquinolones, colloquially referred to as the \&quot;respiratory quinolones\&quot; due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.\r\n\r\nLevofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.&quot;},{&quot;name&quot;:&quot;Levonadifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA24&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).&quot;,&quot;description&quot;:&quot;Levonadifloxacin is under investigation in clinical trial NCT03405064 (Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)).&quot;},{&quot;name&quot;:&quot;Lomefloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.&quot;,&quot;description&quot;:&quot;Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.&quot;},{&quot;name&quot;:&quot;Moxifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.&quot;,&quot;description&quot;:&quot;Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.&quot;},{&quot;name&quot;:&quot;Norfloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.&quot;,&quot;description&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase.&quot;},{&quot;name&quot;:&quot;Ofloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.&quot;,&quot;description&quot;:&quot;A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.&quot;},{&quot;name&quot;:&quot;Pazufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).&quot;,&quot;description&quot;:&quot;Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).&quot;},{&quot;name&quot;:&quot;Pefloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.&quot;,&quot;description&quot;:&quot;A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.&quot;},{&quot;name&quot;:&quot;Prulifloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Rufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rufloxacin is a quinolone antibiotic. &quot;,&quot;description&quot;:&quot;Rufloxacin is a quinolone antibiotic. &quot;},{&quot;name&quot;:&quot;Sitafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA21&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fluoroquinolones&quot;,&quot;description&quot;:&quot;Fluoroquinolones&quot;},{&quot;name&quot;:&quot;Sparfloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.&quot;,&quot;description&quot;:&quot;Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.&quot;},{&quot;name&quot;:&quot;Temafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.&quot;,&quot;description&quot;:&quot;Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.&quot;},{&quot;name&quot;:&quot;Tosufloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA22&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fluoroquinolones&quot;,&quot;description&quot;:&quot;Fluoroquinolones&quot;},{&quot;name&quot;:&quot;Trovafloxacin&quot;,&quot;ATC_code&quot;:&quot;J01MA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.&quot;,&quot;description&quot;:&quot;Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones. Due to its hepatotoxic potential, trovafloxacin was withdrawn from the market.&quot;}]}]},{&quot;name&quot;:&quot;Lincosamides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Clindamycin&quot;,&quot;ATC_code&quot;:&quot;J01FF01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r\n\r\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.&quot;,&quot;description&quot;:&quot;Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r\n\r\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.&quot;},{&quot;name&quot;:&quot;Lincomycin&quot;,&quot;ATC_code&quot;:&quot;J01FF02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r\n\r\nLincomycin was approved by the FDA on December 29, 1964.&quot;,&quot;description&quot;:&quot;Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r\n\r\nLincomycin was approved by the FDA on December 29, 1964.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Clindamycin&quot;,&quot;ATC_code&quot;:&quot;J01FF01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r\n\r\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.&quot;,&quot;description&quot;:&quot;Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamycin appears to carry some activity against protozoans, and has been used off-label in the treatment of toxoplasmosis, malaria, and babesiosis.\r\n\r\nClindamycin is derived from, and has largely replaced, lincomycin, a naturally occurring lincosamide and the eponymous member of this antibiotic class, due to its improved properties over the parent compound. The name lincomycin is derived from Lincoln, Nebraska, where it was first isolated from Streptomyces lincolnensis found in a soil sample.&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Lincomycin&quot;,&quot;ATC_code&quot;:&quot;J01FF02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r\n\r\nLincomycin was approved by the FDA on December 29, 1964.&quot;,&quot;description&quot;:&quot;Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium Streptomyces lincolnensis in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.\r\n\r\nLincomycin was approved by the FDA on December 29, 1964.&quot;}]}]},{&quot;name&quot;:&quot;Phenol derivatives&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Clofoctol&quot;,&quot;ATC_code&quot;:&quot;J01XX03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Other antibacterials&quot;,&quot;description&quot;:&quot;Other antibacterials&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Clofoctol&quot;,&quot;ATC_code&quot;:&quot;J01XX03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Other antibacterials&quot;,&quot;description&quot;:&quot;Other antibacterials&quot;}]}]},{&quot;name&quot;:&quot;Polymyxins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Colistin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;,&quot;description&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;},{&quot;name&quot;:&quot;Colistin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;,&quot;description&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;},{&quot;name&quot;:&quot;Polymyxin-B_IV&quot;,&quot;ATC_code&quot;:&quot;J01XB02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;,&quot;description&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;},{&quot;name&quot;:&quot;Polymyxin-B_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;,&quot;description&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Colistin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;,&quot;description&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;},{&quot;name&quot;:&quot;Colistin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;,&quot;description&quot;:&quot;Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.&quot;},{&quot;name&quot;:&quot;Polymyxin-B_IV&quot;,&quot;ATC_code&quot;:&quot;J01XB02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;,&quot;description&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;},{&quot;name&quot;:&quot;Polymyxin-B_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;,&quot;description&quot;:&quot;Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxicA176426,FDA Label. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosaFDA Label. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line.&quot;}]}]},{&quot;name&quot;:&quot;Glycopeptides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Dalbavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.&quot;,&quot;description&quot;:&quot;Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.&quot;},{&quot;name&quot;:&quot;Oritavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r\n\r\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.&quot;,&quot;description&quot;:&quot;Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r\n\r\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.&quot;},{&quot;name&quot;:&quot;Teicoplanin&quot;,&quot;ATC_code&quot;:&quot;J01XA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their -D-glucosamine moiety.&quot;,&quot;description&quot;:&quot;Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their -D-glucosamine moiety.&quot;},{&quot;name&quot;:&quot;Telavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.&quot;,&quot;description&quot;:&quot;Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.&quot;},{&quot;name&quot;:&quot;Vancomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;,&quot;description&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;},{&quot;name&quot;:&quot;Vancomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;,&quot;description&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Dalbavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.&quot;,&quot;description&quot;:&quot;Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin . Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing FDA Label, F2356, A4072, A4073. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) FDA Label, F2356. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking FDA Label, F2356, A4072, A4073.&quot;},{&quot;name&quot;:&quot;Oritavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r\n\r\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.&quot;,&quot;description&quot;:&quot;Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of vancomycin therapy.\r\n\r\nOn March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.&quot;},{&quot;name&quot;:&quot;Telavancin&quot;,&quot;ATC_code&quot;:&quot;J01XA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.&quot;,&quot;description&quot;:&quot;Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.  MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and subcutaneous tissue infections among others.&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Teicoplanin&quot;,&quot;ATC_code&quot;:&quot;J01XA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their -D-glucosamine moiety.&quot;,&quot;description&quot;:&quot;Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their -D-glucosamine moiety.&quot;},{&quot;name&quot;:&quot;Vancomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;,&quot;description&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;},{&quot;name&quot;:&quot;Vancomycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;,&quot;description&quot;:&quot;Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.\r\n\r\nAs of January 29 2018, CutisPharma&#39;s Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains . Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products .&quot;}]}]},{&quot;name&quot;:&quot;Streptogramins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Dalfopristin/quinupristin&quot;,&quot;ATC_code&quot;:&quot;J01FG02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Pristinamycin&quot;,&quot;ATC_code&quot;:&quot;J01FG01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Streptogramins&quot;,&quot;description.x&quot;:&quot;Streptogramins&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Dalfopristin/quinupristin&quot;,&quot;ATC_code&quot;:&quot;J01FG02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Quinupristin/dalfopristin, sold under the trade name Synercid, is a combination of two antibiotics used to treat infections caused by staphylococci and vancomycin-resistant Enterococcus faecium. Both quinupristin and dalfopristin are streptogramin antibiotics derived from pristinamycin. They are combined in a ratio of 30% quinupristin to 70% dalfopristin. This combination functions by inhibiting protein synthesis in bacteria in a synergistic manner, exhibiting bactericidal activity when used together. The drug is administered intravenously and is known to inhibit liver enzyme P450, affecting the metabolism of various other drugs. Source: Wikepedia&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Pristinamycin&quot;,&quot;ATC_code&quot;:&quot;J01FG01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Streptogramins&quot;,&quot;description&quot;:&quot;Streptogramins&quot;}]}]},{&quot;name&quot;:&quot;Lipopeptides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Daptomycin&quot;,&quot;ATC_code&quot;:&quot;J01XX09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r\n\r\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN by Cubist Pharmaceuticals LLC (Merck &amp; Co.).&quot;,&quot;description&quot;:&quot;Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r\n\r\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN by Cubist Pharmaceuticals LLC (Merck &amp; Co.).&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Daptomycin&quot;,&quot;ATC_code&quot;:&quot;J01XX09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r\n\r\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN by Cubist Pharmaceuticals LLC (Merck &amp; Co.).&quot;,&quot;description&quot;:&quot;Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid. Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey. Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.\r\n\r\nDaptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN by Cubist Pharmaceuticals LLC (Merck &amp; Co.).&quot;}]}]},{&quot;name&quot;:&quot;Phosphonics&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Fosfomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XX01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;,&quot;description&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;},{&quot;name&quot;:&quot;Fosfomycin_oral&quot;,&quot;ATC_code&quot;:&quot;J01XX01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;,&quot;description&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Fosfomycin_IV&quot;,&quot;ATC_code&quot;:&quot;J01XX01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;,&quot;description&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Fosfomycin_oral&quot;,&quot;ATC_code&quot;:&quot;J01XX01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;,&quot;description&quot;:&quot;Fosfomycin was discovered in 1969 by scientists at the Spanish Penicillin and Antibiotics Company and is produced by Streptomyces fradiae. It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. In terms of chemical structure, fosfomycin is a phosphoenolpyruvate analog and contains a phosphonic group and an epoxide ring.\r\n\r\nDue to its ease of administration as a single 3-gram oral dose and desirable safety profile, fosfomycin has largely become a first-line therapeutic option for the treatment of uncomplicated urinary tract infections (UTIs) in females. Despite being FDA approved only for urinary tract infections, fosfomycin actually has a broad spectrum of activity and is active against both gram-positive and gram-negative bacteria. As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.&quot;}]}]},{&quot;name&quot;:&quot;Nitrofuran derivatives&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Furazidin&quot;,&quot;ATC_code&quot;:&quot;J01XE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Nitrofuran derivatives&quot;,&quot;description&quot;:&quot;Nitrofuran derivatives&quot;},{&quot;name&quot;:&quot;Nifurtoinol&quot;,&quot;ATC_code&quot;:&quot;J01XE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Nitrofuran derivatives&quot;,&quot;description&quot;:&quot;Nitrofuran derivatives&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Furazidin&quot;,&quot;ATC_code&quot;:&quot;J01XE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Nitrofuran derivatives&quot;,&quot;description&quot;:&quot;Nitrofuran derivatives&quot;},{&quot;name&quot;:&quot;Nifurtoinol&quot;,&quot;ATC_code&quot;:&quot;J01XE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Nitrofuran derivatives&quot;,&quot;description&quot;:&quot;Nitrofuran derivatives&quot;}]}]},{&quot;name&quot;:&quot;Steroid antibacterials&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Fusidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01XC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.&quot;,&quot;description&quot;:&quot;An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Fusidic-acid&quot;,&quot;ATC_code&quot;:&quot;J01XC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.&quot;,&quot;description&quot;:&quot;An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed) It acts by inhibiting translocation during protein synthesis. It is often used topically in creams and eyedrops but is available in systemic formulations including tablets and injections.&quot;}]}]},{&quot;name&quot;:&quot;Pleuromutilin&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Lefamulin&quot;,&quot;ATC_code&quot;:&quot;J01XX12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.&quot;,&quot;description&quot;:&quot;Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Lefamulin&quot;,&quot;ATC_code&quot;:&quot;J01XX12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.&quot;,&quot;description&quot;:&quot;Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019.  This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.&quot;}]}]},{&quot;name&quot;:&quot;Oxazolidinones&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Linezolid&quot;,&quot;ATC_code&quot;:&quot;J01XX08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r\n\r\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.&quot;,&quot;description&quot;:&quot;Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r\n\r\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.&quot;},{&quot;name&quot;:&quot;Tedizolid&quot;,&quot;ATC_code&quot;:&quot;J01XX11&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to linezolid (EML))&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r\n\r\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO). This product is currently available as both an oral tablet and as a powder for intravenous injection.&quot;,&quot;description&quot;:&quot;Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r\n\r\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO). This product is currently available as both an oral tablet and as a powder for intravenous injection.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Linezolid&quot;,&quot;ATC_code&quot;:&quot;J01XX08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r\n\r\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.&quot;,&quot;description&quot;:&quot;Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction.\r\n\r\nLinezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, tedizolid, was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor.&quot;},{&quot;name&quot;:&quot;Tedizolid&quot;,&quot;ATC_code&quot;:&quot;J01XX11&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to linezolid (EML))&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r\n\r\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO). This product is currently available as both an oral tablet and as a powder for intravenous injection.&quot;,&quot;description&quot;:&quot;Drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and penicillin-resistant Streptococcus penumoniae, represent a massive public health threat. Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved linezolid and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than linezolid.\r\n\r\nTedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO). This product is currently available as both an oral tablet and as a powder for intravenous injection.&quot;}]}]},{&quot;name&quot;:&quot;Imidazoles&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Metronidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;,&quot;description&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;},{&quot;name&quot;:&quot;Metronidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;,&quot;description&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;},{&quot;name&quot;:&quot;Ornidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;,&quot;description&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;},{&quot;name&quot;:&quot;Ornidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;,&quot;description&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;},{&quot;name&quot;:&quot;Secnidazole&quot;,&quot;ATC_code&quot;:&quot;P01AB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r\n\r\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.&quot;,&quot;description&quot;:&quot;Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r\n\r\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.&quot;},{&quot;name&quot;:&quot;Tinidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;,&quot;description&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;},{&quot;name&quot;:&quot;Tinidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;,&quot;description&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Metronidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;,&quot;description&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;},{&quot;name&quot;:&quot;Metronidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;,&quot;description&quot;:&quot;Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections. Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.&quot;},{&quot;name&quot;:&quot;Ornidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;,&quot;description&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;},{&quot;name&quot;:&quot;Ornidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;,&quot;description&quot;:&quot;Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.&quot;},{&quot;name&quot;:&quot;Secnidazole&quot;,&quot;ATC_code&quot;:&quot;P01AB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r\n\r\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.&quot;,&quot;description&quot;:&quot;Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including  and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once it enters bacteria and parasites, secnidazole is activated by bacterial or parasitic enzymes to form a radical anion, thereby damaging and killing the target pathogen.\r\n\r\nSecnidazole has been available in many other countries in Europe, Asia, South America, and Africa for decades. In September 2017, FDA approved secnidazole under the market name Solosec for the treatment of trichomoniasis and bacterial vaginosis.&quot;},{&quot;name&quot;:&quot;Tinidazole_IV&quot;,&quot;ATC_code&quot;:&quot;J01XD02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;,&quot;description&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;},{&quot;name&quot;:&quot;Tinidazole_oral&quot;,&quot;ATC_code&quot;:&quot;P01AB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;,&quot;description&quot;:&quot;A nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.&quot;}]}]},{&quot;name&quot;:&quot;Nitrofuran-derivatives&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Nitrofurantoin&quot;,&quot;ATC_code&quot;:&quot;J01XE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r\n\r\nNitrofurantoin was granted FDA approval on 6 February 1953.&quot;,&quot;description&quot;:&quot;Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r\n\r\nNitrofurantoin was granted FDA approval on 6 February 1953.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Nitrofurantoin&quot;,&quot;ATC_code&quot;:&quot;J01XE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r\n\r\nNitrofurantoin was granted FDA approval on 6 February 1953.&quot;,&quot;description&quot;:&quot;Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.\r\n\r\nNitrofurantoin was granted FDA approval on 6 February 1953.&quot;}]}]},{&quot;name&quot;:&quot;Rifamycins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Rifabutin&quot;,&quot;ATC_code&quot;:&quot;J04AB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.&quot;,&quot;description&quot;:&quot;A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.&quot;},{&quot;name&quot;:&quot;Rifampicin&quot;,&quot;ATC_code&quot;:&quot;J04AB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th ed, p1160)&quot;,&quot;description&quot;:&quot;A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th ed, p1160)&quot;},{&quot;name&quot;:&quot;Rifamycin_IV&quot;,&quot;ATC_code&quot;:&quot;J04AB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;,&quot;description&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;},{&quot;name&quot;:&quot;Rifamycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;,&quot;description&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;},{&quot;name&quot;:&quot;Rifaximin&quot;,&quot;ATC_code&quot;:&quot;A07AA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller&#39;s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.&quot;,&quot;description&quot;:&quot;Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller&#39;s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Rifabutin&quot;,&quot;ATC_code&quot;:&quot;J04AB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.&quot;,&quot;description&quot;:&quot;A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.&quot;},{&quot;name&quot;:&quot;Rifampicin&quot;,&quot;ATC_code&quot;:&quot;J04AB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th ed, p1160)&quot;,&quot;description&quot;:&quot;A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th ed, p1160)&quot;},{&quot;name&quot;:&quot;Rifamycin_IV&quot;,&quot;ATC_code&quot;:&quot;J04AB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;,&quot;description&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;},{&quot;name&quot;:&quot;Rifamycin_oral&quot;,&quot;ATC_code&quot;:&quot;A07AA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;,&quot;description&quot;:&quot;Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent compound of rifamycin was rifamycin B which was originally obtained as a main product in the presence of diethylbarburitic acid. Some small modifications where performed in this inactive compound and with the creation of rifamycin SV there was the first antibiotic used intravenously for the treatment of tuberculosis.\r\n\r\nRifamycin has had several direct derivative products such as rifamycin SV, rifaximin, rifampin and rifamycin CV. All of the derivatives have slight different physicochemical properties when compared to the parent structure.\r\n\r\nRifamycin was further developed by Cosmo Technologies Ltd and approved in November 16, 2018 by the FDA as a prescription drug after being granted the designation of Qualified Infectious Disease Product which allowed it to have a status a priority review. This drug was also sent for review to the EMA in 2015 by Dr. Falk Pharma Gmbh and it was granted a waiver for the tested conditions.&quot;},{&quot;name&quot;:&quot;Rifaximin&quot;,&quot;ATC_code&quot;:&quot;A07AA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller&#39;s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.&quot;,&quot;description&quot;:&quot;Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller&#39;s diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.&quot;}]}]},{&quot;name&quot;:&quot;Aminocyclitols&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Spectinomycin&quot;,&quot;ATC_code&quot;:&quot;J01XX04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.&quot;,&quot;description&quot;:&quot;An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Spectinomycin&quot;,&quot;ATC_code&quot;:&quot;J01XX04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.&quot;,&quot;description&quot;:&quot;An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.&quot;}]}]},{&quot;name&quot;:&quot;Sulfonamides&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Sulfadiazine&quot;,&quot;ATC_code&quot;:&quot;J01EC02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.&quot;,&quot;description&quot;:&quot;One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.&quot;},{&quot;name&quot;:&quot;Sulfadimethoxine&quot;,&quot;ATC_code&quot;:&quot;J01ED01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r\n\r\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.&quot;,&quot;description&quot;:&quot;Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r\n\r\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.&quot;},{&quot;name&quot;:&quot;Sulfadimidine&quot;,&quot;ATC_code&quot;:&quot;J01EB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.&quot;,&quot;description&quot;:&quot;A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.&quot;},{&quot;name&quot;:&quot;Sulfafurazole&quot;,&quot;ATC_code&quot;:&quot;J01EB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.&quot;,&quot;description&quot;:&quot;A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Sulfaisodimidine&quot;,&quot;ATC_code&quot;:&quot;J01EB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .&quot;,&quot;description&quot;:&quot;Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .&quot;},{&quot;name&quot;:&quot;Sulfalene&quot;,&quot;ATC_code&quot;:&quot;J01ED02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.&quot;,&quot;description&quot;:&quot;Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.&quot;},{&quot;name&quot;:&quot;Sulfamazone&quot;,&quot;ATC_code&quot;:&quot;J01ED09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfamerazine&quot;,&quot;ATC_code&quot;:&quot;J01ED07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfanilamide that is used as an antibacterial agent.&quot;,&quot;description&quot;:&quot;A sulfanilamide that is used as an antibacterial agent.&quot;},{&quot;name&quot;:&quot;Sulfamethizole&quot;,&quot;ATC_code&quot;:&quot;J01EB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfathiazole antibacterial agent.&quot;,&quot;description&quot;:&quot;A sulfathiazole antibacterial agent.&quot;},{&quot;name&quot;:&quot;Sulfamethoxazole&quot;,&quot;ATC_code&quot;:&quot;J01EC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.&quot;,&quot;description&quot;:&quot;Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.&quot;},{&quot;name&quot;:&quot;Sulfamethoxypyridazine&quot;,&quot;ATC_code&quot;:&quot;J01ED05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfametomidine&quot;,&quot;ATC_code&quot;:&quot;J01ED03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfametoxydiazine&quot;,&quot;ATC_code&quot;:&quot;J01ED04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.&quot;,&quot;description&quot;:&quot;Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.&quot;},{&quot;name&quot;:&quot;Sulfamoxole&quot;,&quot;ATC_code&quot;:&quot;J01EC03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfamoxole is an antibacterial in the sulfonamide class.&quot;,&quot;description&quot;:&quot;Sulfamoxole is an antibacterial in the sulfonamide class.&quot;},{&quot;name&quot;:&quot;Sulfanilamide&quot;,&quot;ATC_code&quot;:&quot;J01EB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.&quot;,&quot;description&quot;:&quot;Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.&quot;},{&quot;name&quot;:&quot;Sulfaperin&quot;,&quot;ATC_code&quot;:&quot;J01ED06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfaphenazole&quot;,&quot;ATC_code&quot;:&quot;J01ED08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfaphenazole is a sulfonamide antibacterial.&quot;,&quot;description&quot;:&quot;Sulfaphenazole is a sulfonamide antibacterial.&quot;},{&quot;name&quot;:&quot;Sulfapyridine&quot;,&quot;ATC_code&quot;:&quot;J01EB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.&quot;,&quot;description&quot;:&quot;Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.&quot;},{&quot;name&quot;:&quot;Sulfathiazole&quot;,&quot;ATC_code&quot;:&quot;J01EB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r\n\r\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.&quot;,&quot;description&quot;:&quot;Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r\n\r\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.&quot;},{&quot;name&quot;:&quot;Sulfathiourea&quot;,&quot;ATC_code&quot;:&quot;J01EB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Short-acting sulfonamides&quot;,&quot;description&quot;:&quot;Short-acting sulfonamides&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Sulfadiazine&quot;,&quot;ATC_code&quot;:&quot;J01EC02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.&quot;,&quot;description&quot;:&quot;One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.&quot;},{&quot;name&quot;:&quot;Sulfadimethoxine&quot;,&quot;ATC_code&quot;:&quot;J01ED01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r\n\r\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.&quot;,&quot;description&quot;:&quot;Sulfadimethoxine is a sulfonamide antibiotic. Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. It is most frequently used in veterinary medicine, although it is approved in some countries for use in humans. Sulfadimethoxine inhibits bacterial synthesis of folic acid (pteroylglutamic acid) from para-aminobenzoic acid. Sulfadimethoxine is approved in Russia for use in humans, including children, and has been successfully used there for more than 35 years. It is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.\r\n\r\nIn the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.&quot;},{&quot;name&quot;:&quot;Sulfadimidine&quot;,&quot;ATC_code&quot;:&quot;J01EB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.&quot;,&quot;description&quot;:&quot;A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.&quot;},{&quot;name&quot;:&quot;Sulfafurazole&quot;,&quot;ATC_code&quot;:&quot;J01EB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.&quot;,&quot;description&quot;:&quot;A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Sulfaisodimidine&quot;,&quot;ATC_code&quot;:&quot;J01EB01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .&quot;,&quot;description&quot;:&quot;Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been officially approved for use anywhere .&quot;},{&quot;name&quot;:&quot;Sulfalene&quot;,&quot;ATC_code&quot;:&quot;J01ED02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.&quot;,&quot;description&quot;:&quot;Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.&quot;},{&quot;name&quot;:&quot;Sulfamazone&quot;,&quot;ATC_code&quot;:&quot;J01ED09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfamerazine&quot;,&quot;ATC_code&quot;:&quot;J01ED07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfanilamide that is used as an antibacterial agent.&quot;,&quot;description&quot;:&quot;A sulfanilamide that is used as an antibacterial agent.&quot;},{&quot;name&quot;:&quot;Sulfamethizole&quot;,&quot;ATC_code&quot;:&quot;J01EB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A sulfathiazole antibacterial agent.&quot;,&quot;description&quot;:&quot;A sulfathiazole antibacterial agent.&quot;},{&quot;name&quot;:&quot;Sulfamethoxazole&quot;,&quot;ATC_code&quot;:&quot;J01EC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.&quot;,&quot;description&quot;:&quot;Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with trimethoprim, which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps in the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. In this combination, sulfamethoxazole is useful for the treatment of a variety of bacterial infections, including those of the urinary, respiratory, and gastrointestinal tracts.&quot;},{&quot;name&quot;:&quot;Sulfamethoxypyridazine&quot;,&quot;ATC_code&quot;:&quot;J01ED05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfametomidine&quot;,&quot;ATC_code&quot;:&quot;J01ED03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfametoxydiazine&quot;,&quot;ATC_code&quot;:&quot;J01ED04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.&quot;,&quot;description&quot;:&quot;Long acting sulfonamide used in leprosy, urinary, and respiratory tract infections.&quot;},{&quot;name&quot;:&quot;Sulfamoxole&quot;,&quot;ATC_code&quot;:&quot;J01EC03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfamoxole is an antibacterial in the sulfonamide class.&quot;,&quot;description&quot;:&quot;Sulfamoxole is an antibacterial in the sulfonamide class.&quot;},{&quot;name&quot;:&quot;Sulfanilamide&quot;,&quot;ATC_code&quot;:&quot;J01EB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.&quot;,&quot;description&quot;:&quot;Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.&quot;},{&quot;name&quot;:&quot;Sulfaperin&quot;,&quot;ATC_code&quot;:&quot;J01ED06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting sulfonamides&quot;,&quot;description&quot;:&quot;Long-acting sulfonamides&quot;},{&quot;name&quot;:&quot;Sulfaphenazole&quot;,&quot;ATC_code&quot;:&quot;J01ED08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfaphenazole is a sulfonamide antibacterial.&quot;,&quot;description&quot;:&quot;Sulfaphenazole is a sulfonamide antibacterial.&quot;},{&quot;name&quot;:&quot;Sulfapyridine&quot;,&quot;ATC_code&quot;:&quot;J01EB04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.&quot;,&quot;description&quot;:&quot;Antibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.&quot;},{&quot;name&quot;:&quot;Sulfathiazole&quot;,&quot;ATC_code&quot;:&quot;J01EB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r\n\r\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.&quot;,&quot;description&quot;:&quot;Sulfathiazole is a short-acting sulfa drug. It used to be a common oral and topical antimicrobial until less toxic alternatives were discovered. It is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.\r\n\r\nExcept for those formulated for vaginal use, the FDA withdrew its approval for the use of all drug products containing sulfathiazole.&quot;},{&quot;name&quot;:&quot;Sulfathiourea&quot;,&quot;ATC_code&quot;:&quot;J01EB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Short-acting sulfonamides&quot;,&quot;description&quot;:&quot;Short-acting sulfonamides&quot;}]}]},{&quot;name&quot;:&quot;Sulfonamide-trimethoprim-combos&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Sulfadiazine/tetroxoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfadiazine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfadimidine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamerazine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamethoxazole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers&#39; diarrhea, respiratory tract infections, cholera, and more. It&#39;s also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfametrole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamoxole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Sulfadiazine/tetroxoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Tetroxoprim is a derivative of trimethoprim, first described in 1979. It is used in combination with sulfadiazine, an antibiotic, and this combination is coded under ATC code J01EE06 by the WHO. Tetroxoprim acts as an inhibitor of bacterial dihydrofolate reductase, contributing to its antibacterial effects. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfadiazine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfadiazine/trimethoprim, marketed under trade names like Tucoprim and Tribrissen, is a combination drug consisting of sulfadiazine and trimethoprim. This medication is primarily used in the treatment of bacterial infections in animals, particularly horses. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfadimidine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfadimidine is a sulfonamide antibiotic that inhibits bacterial synthesis of dihydrofolic acid, while trimethoprim further blocks the production of tetrahydrofolic acid, a form of folic acid bacteria use for growth and multiplication. This combination results in a synergistic effect, enhancing the overall antibacterial efficacy. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamerazine/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfamerazine is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamerazine are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamethoxazole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Trimethoprim/sulfamethoxazole, commonly known as Bactrim, is a combination antibiotic used to treat a variety of bacterial infections. It includes one part trimethoprim and five parts sulfamethoxazole. This medication is effective against urinary tract infections, methicillin-resistant Staphylococcus aureus (MRSA) skin infections, travelers&#39; diarrhea, respiratory tract infections, cholera, and more. It&#39;s also used for both treating and preventing pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and others with weakened immune systems. It can be administered orally or through intravenous infusion. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfametrole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;The combination of trimethoprim and sulfametrole, used as an alternative to the more common combination of trimethoprim/sulfamethoxazole, has been studied for its effectiveness and safety in treating various infections. It has shown promise in treating difficult-to-treat infections, particularly when administered intravenously. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sulfamoxole/trimethoprim&quot;,&quot;ATC_code&quot;:&quot;J01EE04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sulfamoxole is a sulfonamide antibacterial agent. This type of medication is part of a class of antibiotics known for their effectiveness against bacterial infections by inhibiting certain processes necessary for bacterial growth. Sulfonamides like Sulfamoxole are generally used in combination with Trimethoprim to enhance their antibacterial effectiveness. Source: Wikepedia&quot;}]}]},{&quot;name&quot;:&quot;Glycylcyclines&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Tigecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.&quot;,&quot;description&quot;:&quot;Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Tigecycline&quot;,&quot;ATC_code&quot;:&quot;J01AA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.&quot;,&quot;description&quot;:&quot;Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.&quot;}]}]}]},{&quot;name&quot;:&quot;Beta-Lactams&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Penicillins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Amoxicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r\n\r\nAmoxicillin was granted FDA approval on 18 January 1974.&quot;,&quot;description&quot;:&quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r\n\r\nAmoxicillin was granted FDA approval on 18 January 1974.&quot;},{&quot;name&quot;:&quot;Ampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It&#39;s used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Aspoxicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA19&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Azidocillin&quot;,&quot;ATC_code&quot;:&quot;J01CE04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azidocillin is a penicillin antibiotic similir to ampicillin.&quot;,&quot;description&quot;:&quot;Azidocillin is a penicillin antibiotic similir to ampicillin.&quot;},{&quot;name&quot;:&quot;Azlocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.&quot;,&quot;description&quot;:&quot;Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.&quot;},{&quot;name&quot;:&quot;Bacampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.&quot;,&quot;description&quot;:&quot;Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.&quot;},{&quot;name&quot;:&quot;Benzathine-benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;,&quot;description&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;},{&quot;name&quot;:&quot;Benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;,&quot;description&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;},{&quot;name&quot;:&quot;Carbenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.&quot;,&quot;description&quot;:&quot;Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.&quot;},{&quot;name&quot;:&quot;Carindacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.&quot;,&quot;description&quot;:&quot;Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.&quot;},{&quot;name&quot;:&quot;Clometocillin&quot;,&quot;ATC_code&quot;:&quot;J01CE07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Cloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.&quot;,&quot;description&quot;:&quot;A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.&quot;},{&quot;name&quot;:&quot;Dicloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF01&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the penicillins which is resistant to penicillinase.&quot;,&quot;description&quot;:&quot;One of the penicillins which is resistant to penicillinase.&quot;},{&quot;name&quot;:&quot;Epicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Flucloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF05&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibiotic analog of cloxacillin.&quot;,&quot;description&quot;:&quot;Antibiotic analog of cloxacillin.&quot;},{&quot;name&quot;:&quot;Hetacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \&quot;penicillin\&quot; can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.&quot;,&quot;description&quot;:&quot;Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \&quot;penicillin\&quot; can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.&quot;},{&quot;name&quot;:&quot;Mecillinam&quot;,&quot;ATC_code&quot;:&quot;J01CA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.&quot;,&quot;description&quot;:&quot;Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.&quot;},{&quot;name&quot;:&quot;Metampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.&quot;,&quot;description&quot;:&quot;Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.&quot;},{&quot;name&quot;:&quot;Meticillin&quot;,&quot;ATC_code&quot;:&quot;J01CF03&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.&quot;,&quot;description&quot;:&quot;One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.&quot;},{&quot;name&quot;:&quot;Mezlocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.&quot;,&quot;description&quot;:&quot;Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.&quot;},{&quot;name&quot;:&quot;Nafcillin&quot;,&quot;ATC_code&quot;:&quot;J01CF06&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .&quot;,&quot;description&quot;:&quot;A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .&quot;},{&quot;name&quot;:&quot;Oxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF04&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic similar to flucloxacillin used in resistant staphylococci infections.&quot;,&quot;description&quot;:&quot;An antibiotic similar to flucloxacillin used in resistant staphylococci infections.&quot;},{&quot;name&quot;:&quot;Penamecillin&quot;,&quot;ATC_code&quot;:&quot;J01CE06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Pheneticillin&quot;,&quot;ATC_code&quot;:&quot;J01CE05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.&quot;,&quot;description&quot;:&quot;Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.&quot;},{&quot;name&quot;:&quot;Phenoxymethylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label&quot;,&quot;description&quot;:&quot;Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label&quot;},{&quot;name&quot;:&quot;Piperacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.&quot;,&quot;description&quot;:&quot;Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.&quot;},{&quot;name&quot;:&quot;Pivampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pivalate ester analog of ampicillin.&quot;,&quot;description&quot;:&quot;Pivalate ester analog of ampicillin.&quot;},{&quot;name&quot;:&quot;Pivmecillinam&quot;,&quot;ATC_code&quot;:&quot;J01CA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem&quot;,&quot;description&quot;:&quot;Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem&quot;},{&quot;name&quot;:&quot;Procaine-benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.&quot;,&quot;description&quot;:&quot;Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.&quot;},{&quot;name&quot;:&quot;Propicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Sulbenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Talampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Temocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Ticarcillin&quot;,&quot;ATC_code&quot;:&quot;J01CA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic derived from penicillin similar to carbenicillin in action.&quot;,&quot;description&quot;:&quot;An antibiotic derived from penicillin similar to carbenicillin in action.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Amoxicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r\n\r\nAmoxicillin was granted FDA approval on 18 January 1974.&quot;,&quot;description&quot;:&quot;Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.\r\n\r\nAmoxicillin was granted FDA approval on 18 January 1974.&quot;},{&quot;name&quot;:&quot;Ampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ampicillin is an antibiotic that belongs to the aminopenicillin class within the penicillin family. It&#39;s used to prevent and treat various bacterial infections such as respiratory and urinary tract infections, meningitis, salmonellosis, and endocarditis. Ampicillin can also be used to prevent group B streptococcal infection in newborns. It can be administered orally, by intramuscular injection, or intravenously. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Azidocillin&quot;,&quot;ATC_code&quot;:&quot;J01CE04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azidocillin is a penicillin antibiotic similir to ampicillin.&quot;,&quot;description&quot;:&quot;Azidocillin is a penicillin antibiotic similir to ampicillin.&quot;},{&quot;name&quot;:&quot;Bacampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.&quot;,&quot;description&quot;:&quot;Bacampicillin is a prodrug of ampicillin and is microbiologically inactive. It is absorbed following oral administration. During absorption from the gastrointestinal tract, bacampicillin is hydrolyzed by esterases present in the intestinal wall. It is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.  It is used to cure infection of upper and lower respiratory tract; skin and soft tissue; urinary tract and acute uncomplicated gonococcal urethritis etc.&quot;},{&quot;name&quot;:&quot;Benzathine-benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;,&quot;description&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;},{&quot;name&quot;:&quot;Benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;,&quot;description&quot;:&quot;Benzylpenicillin (Penicillin G) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. It is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. Penicillin G may also be used in some cases as prophylaxis against susceptible organisms.\r\n \r\nNatural penicillins are considered the drugs of choice for several infections caused by susceptible gram positive aerobic organisms, such as *Streptococcus pneumoniae*, groups A, B, C and G streptococci, nonenterococcal group D streptococci, viridans group streptococci, and non-penicillinase producing staphylococcus. Aminoglycosides may be added for synergy against group B streptococcus (*S. agalactiae*), *S. viridans*, and *Enterococcus faecalis*. The natural penicillins may also be used as first or second line agents against susceptible gram positive aerobic bacilli such as *Bacillus anthracis*, *Corynebacterium diphtheriae*, and *Erysipelothrix rhusiopathiae*. Natural penicillins have limited activity against gram negative organisms; however, they may be used in some cases to treat infections caused by *Neisseria meningitidis* and *Pasteurella*. They are not generally used to treat anaerobic infections. Resistance patterns, susceptibility and treatment guidelines vary across regions.&quot;},{&quot;name&quot;:&quot;Clometocillin&quot;,&quot;ATC_code&quot;:&quot;J01CE07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Cloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.&quot;,&quot;description&quot;:&quot;A semi-synthetic penicillin antibiotic which is a chlorinated derivative of oxacillin.&quot;},{&quot;name&quot;:&quot;Dicloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF01&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the penicillins which is resistant to penicillinase.&quot;,&quot;description&quot;:&quot;One of the penicillins which is resistant to penicillinase.&quot;},{&quot;name&quot;:&quot;Epicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Flucloxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF05&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Antibiotic analog of cloxacillin.&quot;,&quot;description&quot;:&quot;Antibiotic analog of cloxacillin.&quot;},{&quot;name&quot;:&quot;Hetacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \&quot;penicillin\&quot; can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.&quot;,&quot;description&quot;:&quot;Hetacillin is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name \&quot;penicillin\&quot; can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Hetacillin has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Hetacillin results from the inhibition of cell wall synthesis and is mediated through Hetacillin binding to penicillin binding proteins (PBPs). Hetacillin has been withdrawn from the market since it has been discovered that it has no therapeutic advantage compared to non-ester derivatives like ampicillin.&quot;},{&quot;name&quot;:&quot;Mecillinam&quot;,&quot;ATC_code&quot;:&quot;J01CA11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.&quot;,&quot;description&quot;:&quot;Amidinopenicillanic acid derivative with broad spectrum antibacterial action. It is poorly absorbed if given orally and is used in urinary infections and typhus. Amdinocillin is not available in the United States.&quot;},{&quot;name&quot;:&quot;Metampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.&quot;,&quot;description&quot;:&quot;Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.&quot;},{&quot;name&quot;:&quot;Meticillin&quot;,&quot;ATC_code&quot;:&quot;J01CF03&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.&quot;,&quot;description&quot;:&quot;One of the penicillins which is resistant to penicillinase but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.&quot;},{&quot;name&quot;:&quot;Nafcillin&quot;,&quot;ATC_code&quot;:&quot;J01CF06&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .&quot;,&quot;description&quot;:&quot;A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections .&quot;},{&quot;name&quot;:&quot;Oxacillin&quot;,&quot;ATC_code&quot;:&quot;J01CF04&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to cloxacillin)&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic similar to flucloxacillin used in resistant staphylococci infections.&quot;,&quot;description&quot;:&quot;An antibiotic similar to flucloxacillin used in resistant staphylococci infections.&quot;},{&quot;name&quot;:&quot;Penamecillin&quot;,&quot;ATC_code&quot;:&quot;J01CE06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Phenoxymethylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label&quot;,&quot;description&quot;:&quot;Phenoxymethylpenicillin is a narrow spectrum antibiotic also commonly referred to as Penicillin V or Penicillin VK. It is a phenoxymethyl analog of Penicillin G, or benzylpenicillin. An orally active naturally penicillin, phenoxymethylpenicillin is used to treat mild to moderate infections in the respiratory tract, skin, and soft tissues caused by penicillin G-sensitive microorganisms. Phenoxymethylpenicillin has also be used in some cases as prophylaxis against susceptible organisms. While there have been no controlled clinical efficacy studies that were conducted, phenoxymethylpenicillin has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract, except for those who are at an elevated risk for endocarditis.label&quot;},{&quot;name&quot;:&quot;Pivampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pivalate ester analog of ampicillin.&quot;,&quot;description&quot;:&quot;Pivalate ester analog of ampicillin.&quot;},{&quot;name&quot;:&quot;Pivmecillinam&quot;,&quot;ATC_code&quot;:&quot;J01CA08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem&quot;,&quot;description&quot;:&quot;Pivmecillinam is a mecillinam prodrug, a pivaloyloxymethyl ester of amdinocillin that is well absorbed orally, but broken down to amdinocillin in the intestinal mucosa. It is active against gram-negative organisms and used as for amdinocillin. PubChem&quot;},{&quot;name&quot;:&quot;Procaine-benzylpenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE09&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.&quot;,&quot;description&quot;:&quot;Procaine benzylpenicillin (INN), also known as procaine G penicillin, is an injectable antiobiotic. It is a poorly soluble salt form of penicillin which is a combination of naturally occuring benzylpenicillin (penicillin G) and the local anaesthetic agent procaine in equimolar amounts. Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required. This combination is aimed at reducing the pain and discomfort associated with a large intramuscular injection of penicillin. It is widely used in veterinary settings. Benzylpenicillin is active against a wide range of organisms and is the drug of first choice for many infections.&quot;},{&quot;name&quot;:&quot;Propicillin&quot;,&quot;ATC_code&quot;:&quot;J01CE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Beta-lactamase sensitive penicillins&quot;,&quot;description&quot;:&quot;Beta-lactamase sensitive penicillins&quot;},{&quot;name&quot;:&quot;Talampicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Aspoxicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA19&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Azlocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.&quot;,&quot;description&quot;:&quot;Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.&quot;},{&quot;name&quot;:&quot;Carbenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.&quot;,&quot;description&quot;:&quot;Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.&quot;},{&quot;name&quot;:&quot;Carindacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.&quot;,&quot;description&quot;:&quot;Carindacillin or Carbenicillin isdanyl was an oral penicillin prodrug of carbenicillin marketed by Pfizer as Geocillin. It is no longer marketed in the United States.&quot;},{&quot;name&quot;:&quot;Mezlocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.&quot;,&quot;description&quot;:&quot;Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.&quot;},{&quot;name&quot;:&quot;Pheneticillin&quot;,&quot;ATC_code&quot;:&quot;J01CE05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.&quot;,&quot;description&quot;:&quot;Pheneticillin (or phenethicillin) is a penicillin antibiotic which is approved for use internationally.&quot;},{&quot;name&quot;:&quot;Piperacillin&quot;,&quot;ATC_code&quot;:&quot;J01CA12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.&quot;,&quot;description&quot;:&quot;Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.&quot;},{&quot;name&quot;:&quot;Sulbenicillin&quot;,&quot;ATC_code&quot;:&quot;J01CA16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Penicillins with extended spectrum&quot;,&quot;description&quot;:&quot;Penicillins with extended spectrum&quot;},{&quot;name&quot;:&quot;Temocillin&quot;,&quot;ATC_code&quot;:&quot;J01CA17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Temocillin has been investigated in Infection, Liver Dysfunction, and Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Ticarcillin&quot;,&quot;ATC_code&quot;:&quot;J01CA13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;An antibiotic derived from penicillin similar to carbenicillin in action.&quot;,&quot;description&quot;:&quot;An antibiotic derived from penicillin similar to carbenicillin in action.&quot;}]}]},{&quot;name&quot;:&quot;Beta-lactam/beta-lactamase-inhibitor&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Amoxicillin/clavulanic-acid&quot;,&quot;ATC_code&quot;:&quot;J01CR02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It&#39;s a combination of amoxicillin, a -lactam antibiotic, and potassium clavulanate, a -lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it&#39;s generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ampicillin/sulbactam&quot;,&quot;ATC_code&quot;:&quot;J01CR01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Piperacillin/tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01CR05&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the -lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It&#39;s commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It&#39;s generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sultamicillin&quot;,&quot;ATC_code&quot;:&quot;J01CR04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).&quot;,&quot;description.x&quot;:&quot;Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Amoxicillin/clavulanic-acid&quot;,&quot;ATC_code&quot;:&quot;J01CR02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Amoxicillin/clavulanic acid, commonly known as co-amoxiclav or amox-clav, is an antibiotic medication used for treating various bacterial infections. It&#39;s a combination of amoxicillin, a -lactam antibiotic, and potassium clavulanate, a -lactamase inhibitor. This combination is effective against a range of infections including otitis media, streptococcal pharyngitis, pneumonia, cellulitis, urinary tract infections, and animal bites. It is administered orally or by injection. Common side effects can include diarrhea, vomiting, and allergic reactions, and it&#39;s generally considered safe during pregnancy. This medication was approved for medical use in the United States in 1984 and is listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ampicillin/sulbactam&quot;,&quot;ATC_code&quot;:&quot;J01CR01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ampicillin/sulbactam is a combination medication consisting of the antibiotic ampicillin and sulbactam, a beta-lactamase inhibitor. This combination is used to treat various infections, particularly those caused by bacteria resistant to beta-lactam antibiotics. Sulbactam enhances the effect of ampicillin by inhibiting the enzyme that breaks down ampicillin, allowing it to effectively kill the bacteria. Ampicillin/sulbactam is effective against a range of gram-positive and gram-negative bacteria, as well as anaerobes. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Sultamicillin&quot;,&quot;ATC_code&quot;:&quot;J01CR04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).&quot;,&quot;description.x&quot;:&quot;Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Piperacillin/tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01CR05&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Piperacillin/tazobactam, marketed under names like Tazocin and Zosyn, is a combination medication that includes the antibiotic piperacillin and the -lactamase inhibitor tazobactam. This combination is effective against many Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It&#39;s commonly used for treating infections like pelvic inflammatory disease, intra-abdominal infections, pneumonia, cellulitis, and sepsis, and is administered via intravenous injection. Some common side effects are headaches, sleep disturbances, rashes, nausea, constipation, and diarrhea. It&#39;s generally considered safe for use during pregnancy and breastfeeding. Piperacillin/tazobactam was approved for medical use in the United States in 1993 and is on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;}]}]},{&quot;name&quot;:&quot;Monobactams&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Aztreonam&quot;,&quot;ATC_code&quot;:&quot;J01DF01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.&quot;,&quot;description&quot;:&quot;A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Carumonam&quot;,&quot;ATC_code&quot;:&quot;J01DF02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Monobactams&quot;,&quot;description&quot;:&quot;Monobactams&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Aztreonam&quot;,&quot;ATC_code&quot;:&quot;J01DF01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.&quot;,&quot;description&quot;:&quot;A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Carumonam&quot;,&quot;ATC_code&quot;:&quot;J01DF02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Monobactams&quot;,&quot;description&quot;:&quot;Monobactams&quot;}]}]},{&quot;name&quot;:&quot;Carbapenems&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Biapenem&quot;,&quot;ATC_code&quot;:&quot;J01DH05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Biapenem has been used in trials studying the treatment of Bacterial Infections.&quot;,&quot;description&quot;:&quot;Biapenem has been used in trials studying the treatment of Bacterial Infections.&quot;},{&quot;name&quot;:&quot;Doripenem&quot;,&quot;ATC_code&quot;:&quot;J01DH04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.&quot;,&quot;description&quot;:&quot;Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.&quot;},{&quot;name&quot;:&quot;Ertapenem&quot;,&quot;ATC_code&quot;:&quot;J01DH03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ertapenem is a 1- methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.&quot;,&quot;description&quot;:&quot;Ertapenem is a 1- methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.&quot;},{&quot;name&quot;:&quot;Imipenem/cilastatin&quot;,&quot;ATC_code&quot;:&quot;J01DH51&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to meropenem)&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria&#39;s cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Imipenem/cilastatin/relebactam&quot;,&quot;ATC_code&quot;:&quot;J01DH56&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a -lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Meropenem&quot;,&quot;ATC_code&quot;:&quot;J01DH02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r\n\r\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.&quot;,&quot;description&quot;:&quot;Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r\n\r\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.&quot;},{&quot;name&quot;:&quot;Meropenem/vaborbactam&quot;,&quot;ATC_code&quot;:&quot;J01DH52&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a -lactam antibiotic, and vaborbactam, a -lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce -lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Panipenem&quot;,&quot;ATC_code&quot;:&quot;J01DH55&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Tebipenem&quot;,&quot;ATC_code&quot;:&quot;J01DH06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Carbapenems&quot;,&quot;description&quot;:&quot;Carbapenems&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Biapenem&quot;,&quot;ATC_code&quot;:&quot;J01DH05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Biapenem has been used in trials studying the treatment of Bacterial Infections.&quot;,&quot;description&quot;:&quot;Biapenem has been used in trials studying the treatment of Bacterial Infections.&quot;},{&quot;name&quot;:&quot;Doripenem&quot;,&quot;ATC_code&quot;:&quot;J01DH04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.&quot;,&quot;description&quot;:&quot;Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen. Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections. In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates, resulting in a premature termination of the trial. The FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications.&quot;},{&quot;name&quot;:&quot;Ertapenem&quot;,&quot;ATC_code&quot;:&quot;J01DH03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ertapenem is a 1- methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.&quot;,&quot;description&quot;:&quot;Ertapenem is a 1- methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.&quot;},{&quot;name&quot;:&quot;Imipenem/cilastatin&quot;,&quot;ATC_code&quot;:&quot;J01DH51&quot;,&quot;EML&quot;:&quot;Yes (therapeutic alternative to meropenem)&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Imipenem/cilastatin, marketed under the name Primaxin, is an antibiotic used to treat a variety of bacterial infections, including pneumonia, sepsis, endocarditis, joint infections, intra-abdominal infections, and urinary tract infections. It is administered via injection into a vein or muscle. Common side effects include nausea, diarrhea, and pain at the injection site, along with potential allergic reactions such as anaphylaxis. It works by interfering with bacteria&#39;s cell wall formation and is included in the carbapenem family of medications. Cilastatin prevents the breakdown of imipenem, enhancing its effectiveness. This drug combination was first sold in 1987 and is listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Meropenem&quot;,&quot;ATC_code&quot;:&quot;J01DH02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r\n\r\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.&quot;,&quot;description&quot;:&quot;Meropenem is a broad-spectrum carbapenem antibiotic. It is active against Gram-positive and Gram-negative bacteria. Meropenem exerts its action by penetrating bacterial cells readily and interfering with the synthesis of vital cell wall components, which leads to cell death.\r\n\r\nIn August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and  and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.&quot;},{&quot;name&quot;:&quot;Panipenem&quot;,&quot;ATC_code&quot;:&quot;J01DH55&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Panipenem is a carbapenem antibiotic typically used in combination with betamipron. It is known for its effectiveness against a variety of bacterial infections but is notably not used in the United States. This antibiotic forms part of a class known for their broad-spectrum activity, particularly against Gram-negative and Gram-positive aerobic and anaerobic bacteria. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Tebipenem&quot;,&quot;ATC_code&quot;:&quot;J01DH06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Carbapenems&quot;,&quot;description&quot;:&quot;Carbapenems&quot;}]},{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Imipenem/cilastatin/relebactam&quot;,&quot;ATC_code&quot;:&quot;J01DH56&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio, is a combination antibiotic used for treating complicated urinary tract infections, complicated intra-abdominal infections, and hospital-acquired and ventilator-associated bacterial pneumonia in adults. It is administered via intravenous injection. Common adverse reactions include nausea, diarrhea, headache, fever, increased liver enzymes, anemia, hypokalemia (low potassium), and hyponatremia (low sodium). This combination enhances the activity of imipenem against certain bacteria by incorporating relebactam, a -lactamase inhibitor. The FDA approved Recarbrio in 2019 for its current uses. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Meropenem/vaborbactam&quot;,&quot;ATC_code&quot;:&quot;J01DH52&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Meropenem/vaborbactam, marketed under brand names like Vabomere, is a combination medication used for treating complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. It comprises meropenem, a -lactam antibiotic, and vaborbactam, a -lactamase inhibitor. Administered through intravenous injection, it is effective against certain types of bacteria, including those that produce -lactamases. Common side effects may include headache, injection site inflammation, nausea, diarrhea, liver inflammation, and low blood potassium. Approved for use in the United States in 2017 and Europe in 2018, it is also listed on the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;}]}]},{&quot;name&quot;:&quot;1st-gen-cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cefacetrile&quot;,&quot;ATC_code&quot;:&quot;J01DB10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A derivative of 7-aminocephalosporanic acid.&quot;,&quot;description&quot;:&quot;A derivative of 7-aminocephalosporanic acid.&quot;},{&quot;name&quot;:&quot;Cefadroxil&quot;,&quot;ATC_code&quot;:&quot;J01DB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting, broad-spectrum, water-soluble, cephalexin derivative.&quot;,&quot;description&quot;:&quot;Long-acting, broad-spectrum, water-soluble, cephalexin derivative.&quot;},{&quot;name&quot;:&quot;Cefalexin&quot;,&quot;ATC_code&quot;:&quot;J01DB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.&quot;,&quot;description&quot;:&quot;Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.&quot;},{&quot;name&quot;:&quot;Cefaloridine&quot;,&quot;ATC_code&quot;:&quot;J01DB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.&quot;,&quot;description&quot;:&quot;Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.&quot;},{&quot;name&quot;:&quot;Cefalotin&quot;,&quot;ATC_code&quot;:&quot;J01DB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefalotin is a cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;Cefalotin is a cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefapirin&quot;,&quot;ATC_code&quot;:&quot;J01DB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.&quot;,&quot;description&quot;:&quot;Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Cefatrizine&quot;,&quot;ATC_code&quot;:&quot;J01DB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefazedone&quot;,&quot;ATC_code&quot;:&quot;J01DB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefazolin&quot;,&quot;ATC_code&quot;:&quot;J01DB04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.&quot;,&quot;description&quot;:&quot;A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.&quot;},{&quot;name&quot;:&quot;Cefradine&quot;,&quot;ATC_code&quot;:&quot;J01DB09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;A semi-synthetic cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefroxadine&quot;,&quot;ATC_code&quot;:&quot;J01DB11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.&quot;,&quot;description&quot;:&quot;Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.&quot;},{&quot;name&quot;:&quot;Ceftezole&quot;,&quot;ATC_code&quot;:&quot;J01DB12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cefacetrile&quot;,&quot;ATC_code&quot;:&quot;J01DB10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A derivative of 7-aminocephalosporanic acid.&quot;,&quot;description&quot;:&quot;A derivative of 7-aminocephalosporanic acid.&quot;},{&quot;name&quot;:&quot;Cefadroxil&quot;,&quot;ATC_code&quot;:&quot;J01DB05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Long-acting, broad-spectrum, water-soluble, cephalexin derivative.&quot;,&quot;description&quot;:&quot;Long-acting, broad-spectrum, water-soluble, cephalexin derivative.&quot;},{&quot;name&quot;:&quot;Cefalexin&quot;,&quot;ATC_code&quot;:&quot;J01DB01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.&quot;,&quot;description&quot;:&quot;Cephalexin is the first of the first generation cephalosporins. This antibiotic contains a  beta lactam and a dihydrothiazide. Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.A179083,Label Cephalexin was approved by the FDA on 4 January 1971.&quot;},{&quot;name&quot;:&quot;Cefaloridine&quot;,&quot;ATC_code&quot;:&quot;J01DB02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.&quot;,&quot;description&quot;:&quot;Cephaloridine or cefaloridine is a first generation semisynthetic cephalosporin. It is derived from cephalosporin C and is a zwitterion at physiological pH.&quot;},{&quot;name&quot;:&quot;Cefalotin&quot;,&quot;ATC_code&quot;:&quot;J01DB03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefalotin is a cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;Cefalotin is a cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefapirin&quot;,&quot;ATC_code&quot;:&quot;J01DB08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.&quot;,&quot;description&quot;:&quot;Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.&quot;},{&quot;name&quot;:&quot;Cefatrizine&quot;,&quot;ATC_code&quot;:&quot;J01DB07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefazedone&quot;,&quot;ATC_code&quot;:&quot;J01DB06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefazolin&quot;,&quot;ATC_code&quot;:&quot;J01DB04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.&quot;,&quot;description&quot;:&quot;A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.&quot;},{&quot;name&quot;:&quot;Cefradine&quot;,&quot;ATC_code&quot;:&quot;J01DB09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semi-synthetic cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;A semi-synthetic cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefroxadine&quot;,&quot;ATC_code&quot;:&quot;J01DB11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.&quot;,&quot;description&quot;:&quot;Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.&quot;},{&quot;name&quot;:&quot;Ceftezole&quot;,&quot;ATC_code&quot;:&quot;J01DB12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;First-generation cephalosporins&quot;,&quot;description&quot;:&quot;First-generation cephalosporins&quot;}]}]},{&quot;name&quot;:&quot;2nd-gen-cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cefaclor&quot;,&quot;ATC_code&quot;:&quot;J01DC04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.&quot;,&quot;description&quot;:&quot;Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.&quot;},{&quot;name&quot;:&quot;Cefamandole&quot;,&quot;ATC_code&quot;:&quot;J01DC03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.&quot;,&quot;description&quot;:&quot;Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.&quot;},{&quot;name&quot;:&quot;Cefbuperazone&quot;,&quot;ATC_code&quot;:&quot;J01DC13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Second-generation cephalosporins&quot;,&quot;description&quot;:&quot;Second-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefmetazole&quot;,&quot;ATC_code&quot;:&quot;J01DC09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.&quot;,&quot;description&quot;:&quot;A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.&quot;},{&quot;name&quot;:&quot;Cefminox&quot;,&quot;ATC_code&quot;:&quot;J01DC12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.&quot;,&quot;description&quot;:&quot;Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.&quot;},{&quot;name&quot;:&quot;Cefonicid&quot;,&quot;ATC_code&quot;:&quot;J01DC06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.&quot;,&quot;description&quot;:&quot;A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.&quot;},{&quot;name&quot;:&quot;Ceforanide&quot;,&quot;ATC_code&quot;:&quot;J01DC11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.&quot;,&quot;description&quot;:&quot;Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.&quot;},{&quot;name&quot;:&quot;Cefotetan&quot;,&quot;ATC_code&quot;:&quot;J01DC05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.&quot;,&quot;description&quot;:&quot;A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.&quot;},{&quot;name&quot;:&quot;Cefotiam&quot;,&quot;ATC_code&quot;:&quot;J01DC07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.&quot;,&quot;description&quot;:&quot;One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.&quot;},{&quot;name&quot;:&quot;Cefoxitin&quot;,&quot;ATC_code&quot;:&quot;J01DC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.&quot;,&quot;description&quot;:&quot;Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.&quot;},{&quot;name&quot;:&quot;Cefprozil&quot;,&quot;ATC_code&quot;:&quot;J01DC10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.&quot;,&quot;description&quot;:&quot;Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.&quot;},{&quot;name&quot;:&quot;Cefuroxime&quot;,&quot;ATC_code&quot;:&quot;J01DC02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.&quot;,&quot;description&quot;:&quot;Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.&quot;},{&quot;name&quot;:&quot;Flomoxef&quot;,&quot;ATC_code&quot;:&quot;J01DC14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Loracarbef&quot;,&quot;ATC_code&quot;:&quot;J01DC08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.&quot;,&quot;description&quot;:&quot;Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cefaclor&quot;,&quot;ATC_code&quot;:&quot;J01DC04&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.&quot;,&quot;description&quot;:&quot;Semisynthetic, broad-spectrum antibiotic derivative of cephalexin.&quot;},{&quot;name&quot;:&quot;Cefamandole&quot;,&quot;ATC_code&quot;:&quot;J01DC03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.&quot;,&quot;description&quot;:&quot;Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.&quot;},{&quot;name&quot;:&quot;Cefbuperazone&quot;,&quot;ATC_code&quot;:&quot;J01DC13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Second-generation cephalosporins&quot;,&quot;description&quot;:&quot;Second-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefmetazole&quot;,&quot;ATC_code&quot;:&quot;J01DC09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.&quot;,&quot;description&quot;:&quot;A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.&quot;},{&quot;name&quot;:&quot;Cefminox&quot;,&quot;ATC_code&quot;:&quot;J01DC12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.&quot;,&quot;description&quot;:&quot;Cefminox (INN) is a second generation cephalosporin antibiotic. It is approved for use in Japan.&quot;},{&quot;name&quot;:&quot;Cefonicid&quot;,&quot;ATC_code&quot;:&quot;J01DC06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.&quot;,&quot;description&quot;:&quot;A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.&quot;},{&quot;name&quot;:&quot;Ceforanide&quot;,&quot;ATC_code&quot;:&quot;J01DC11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.&quot;,&quot;description&quot;:&quot;Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except that ceforanide is less active against most gram-positive organisms. Many coliforms, including Escherichia coli, Klebsiella, Enterobacter, and Proteus, are susceptible to ceforanide, as are most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.&quot;},{&quot;name&quot;:&quot;Cefotetan&quot;,&quot;ATC_code&quot;:&quot;J01DC05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.&quot;,&quot;description&quot;:&quot;A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.&quot;},{&quot;name&quot;:&quot;Cefotiam&quot;,&quot;ATC_code&quot;:&quot;J01DC07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.&quot;,&quot;description&quot;:&quot;One of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.&quot;},{&quot;name&quot;:&quot;Cefoxitin&quot;,&quot;ATC_code&quot;:&quot;J01DC01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.&quot;,&quot;description&quot;:&quot;Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.&quot;},{&quot;name&quot;:&quot;Cefprozil&quot;,&quot;ATC_code&quot;:&quot;J01DC10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.&quot;,&quot;description&quot;:&quot;Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.&quot;},{&quot;name&quot;:&quot;Cefuroxime&quot;,&quot;ATC_code&quot;:&quot;J01DC02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.&quot;,&quot;description&quot;:&quot;Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.&quot;},{&quot;name&quot;:&quot;Flomoxef&quot;,&quot;ATC_code&quot;:&quot;J01DC14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.&quot;,&quot;description&quot;:&quot;Flomoxef has been used in trials studying the treatment of Urinary Tract Infection.&quot;},{&quot;name&quot;:&quot;Loracarbef&quot;,&quot;ATC_code&quot;:&quot;J01DC08&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.&quot;,&quot;description&quot;:&quot;Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.&quot;}]}]},{&quot;name&quot;:&quot;3rd-gen-cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cefcapene-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefdinir&quot;,&quot;ATC_code&quot;:&quot;J01DD15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.&quot;,&quot;description&quot;:&quot;Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.&quot;},{&quot;name&quot;:&quot;Cefditoren-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.&quot;,&quot;description&quot;:&quot;Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.&quot;},{&quot;name&quot;:&quot;Cefetamet-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefixime&quot;,&quot;ATC_code&quot;:&quot;J01DD08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.&quot;,&quot;description&quot;:&quot;Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.&quot;},{&quot;name&quot;:&quot;Cefmenoxime&quot;,&quot;ATC_code&quot;:&quot;J01DD05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.&quot;,&quot;description&quot;:&quot;Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.&quot;},{&quot;name&quot;:&quot;Cefodizime&quot;,&quot;ATC_code&quot;:&quot;J01DD09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefoperazone&quot;,&quot;ATC_code&quot;:&quot;J01DD12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.&quot;,&quot;description&quot;:&quot;Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.&quot;},{&quot;name&quot;:&quot;Cefotaxime&quot;,&quot;ATC_code&quot;:&quot;J01DD01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).&quot;,&quot;description&quot;:&quot;Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).&quot;},{&quot;name&quot;:&quot;Cefpiramide&quot;,&quot;ATC_code&quot;:&quot;J01DD11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefpiramide is a third-generation cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;Cefpiramide is a third-generation cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefpodoxime-proxetil&quot;,&quot;ATC_code&quot;:&quot;J01DD13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.&quot;,&quot;description&quot;:&quot;Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.&quot;},{&quot;name&quot;:&quot;Cefsulodin&quot;,&quot;ATC_code&quot;:&quot;J01DD03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Ceftazidime&quot;,&quot;ATC_code&quot;:&quot;J01DD02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \&quot;penicillin-binding proteins\&quot; (PBPs). -lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r\n\r\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non--lactam -lactamase inhibitor avibactam to treat a variety of bacterial infections.&quot;,&quot;description&quot;:&quot;Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \&quot;penicillin-binding proteins\&quot; (PBPs). -lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r\n\r\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non--lactam -lactamase inhibitor avibactam to treat a variety of bacterial infections.&quot;},{&quot;name&quot;:&quot;Ceftazidime/avibactam&quot;,&quot;ATC_code&quot;:&quot;J01DD52&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a -lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization&#39;s List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Cefteram-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It&#39;s designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It&#39;s commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ceftibuten&quot;,&quot;ATC_code&quot;:&quot;J01DD14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.&quot;,&quot;description&quot;:&quot;Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.&quot;},{&quot;name&quot;:&quot;Ceftizoxime&quot;,&quot;ATC_code&quot;:&quot;J01DD07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.&quot;,&quot;description&quot;:&quot;A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.&quot;},{&quot;name&quot;:&quot;Ceftriaxone&quot;,&quot;ATC_code&quot;:&quot;J01DD04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.&quot;,&quot;description&quot;:&quot;Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.&quot;},{&quot;name&quot;:&quot;Latamoxef&quot;,&quot;ATC_code&quot;:&quot;J01DD06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.&quot;,&quot;description&quot;:&quot;Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cefcapene-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD17&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefdinir&quot;,&quot;ATC_code&quot;:&quot;J01DD15&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.&quot;,&quot;description&quot;:&quot;Cefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class. It has been proven to be effective for the treatment of common bacterial infections in the ear, sinus, throat, lungs, and skin. Cefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.&quot;},{&quot;name&quot;:&quot;Cefditoren-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD16&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.&quot;,&quot;description&quot;:&quot;Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.&quot;},{&quot;name&quot;:&quot;Cefetamet-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD10&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefixime&quot;,&quot;ATC_code&quot;:&quot;J01DD08&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.&quot;,&quot;description&quot;:&quot;Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results from inhibition of mucopeptide synthesis in the bacterial cell wall.&quot;},{&quot;name&quot;:&quot;Cefmenoxime&quot;,&quot;ATC_code&quot;:&quot;J01DD05&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.&quot;,&quot;description&quot;:&quot;Cefmenoxime is a novel broad-spectrum and third-generation cephalosporin antibiotic that is typically used in the treatment of female gynecologic and obstetric infections. It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.&quot;},{&quot;name&quot;:&quot;Cefodizime&quot;,&quot;ATC_code&quot;:&quot;J01DD09&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefoperazone&quot;,&quot;ATC_code&quot;:&quot;J01DD12&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.&quot;,&quot;description&quot;:&quot;Cefoperazone is a semisynthetic broad-spectrum cephalosporin proposed to be effective against Pseudomonas infections. It is a third-generation antiobiotic agent and it is used in the treatment of various bacterial infections caused by susceptible organisms in the body, including respiratory tract infections, peritonitis, skin infections, endometritis, and bacterial septicemia. While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.&quot;},{&quot;name&quot;:&quot;Cefotaxime&quot;,&quot;ATC_code&quot;:&quot;J01DD01&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).&quot;,&quot;description&quot;:&quot;Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).&quot;},{&quot;name&quot;:&quot;Cefpiramide&quot;,&quot;ATC_code&quot;:&quot;J01DD11&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefpiramide is a third-generation cephalosporin antibiotic.&quot;,&quot;description&quot;:&quot;Cefpiramide is a third-generation cephalosporin antibiotic.&quot;},{&quot;name&quot;:&quot;Cefpodoxime-proxetil&quot;,&quot;ATC_code&quot;:&quot;J01DD13&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.&quot;,&quot;description&quot;:&quot;Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria. Commonly used to treat acute otitis media, pharyngitis, and sinusitis, cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.&quot;},{&quot;name&quot;:&quot;Cefsulodin&quot;,&quot;ATC_code&quot;:&quot;J01DD03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Third-generation cephalosporins&quot;,&quot;description&quot;:&quot;Third-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Ceftazidime&quot;,&quot;ATC_code&quot;:&quot;J01DD02&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \&quot;penicillin-binding proteins\&quot; (PBPs). -lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r\n\r\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non--lactam -lactamase inhibitor avibactam to treat a variety of bacterial infections.&quot;,&quot;description&quot;:&quot;Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as \&quot;penicillin-binding proteins\&quot; (PBPs). -lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of essential PBPs, result in impaired cell wall homeostasis, loss of cell integrity, and ultimately bacterial cell death. Ceftazidime is a third-generation cephalosporin with broad-spectrum antibacterial activity, including against some treatment-resistant bacteria such as Pseudomonas aeruginosa.\r\n\r\nCeftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non--lactam -lactamase inhibitor avibactam to treat a variety of bacterial infections.&quot;},{&quot;name&quot;:&quot;Cefteram-pivoxil&quot;,&quot;ATC_code&quot;:&quot;J01DD18&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Cefteram-pivoxil is an orally administered prodrug of cefteram, a third-generation cephalosporin antibiotic. It&#39;s designed to be absorbed from the gastrointestinal tract and then converted into its active form, cefteram, in the body. This antibiotic is effective against a wide range of Gram-positive and Gram-negative bacteria, making it useful for treating various bacterial infections. Cefteram-pivoxil is particularly noted for its effectiveness against certain types of bacteria that are resistant to other cephalosporins. It&#39;s commonly used in the treatment of respiratory tract infections and other bacterial infections where oral administration is preferred or necessary. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ceftibuten&quot;,&quot;ATC_code&quot;:&quot;J01DD14&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.&quot;,&quot;description&quot;:&quot;Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.&quot;},{&quot;name&quot;:&quot;Ceftizoxime&quot;,&quot;ATC_code&quot;:&quot;J01DD07&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.&quot;,&quot;description&quot;:&quot;A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to be safe and effective in aged patients and in patients with hematologic disorders.&quot;},{&quot;name&quot;:&quot;Ceftriaxone&quot;,&quot;ATC_code&quot;:&quot;J01DD04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.&quot;,&quot;description&quot;:&quot;Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone is a commonly used antimicrobial due to its good activity against multi-drug resistant Enterobacteriaceae, its relatively safe adverse effect profile, and its long half-life which allows for the convenience of daily or twice-daily dosing.&quot;},{&quot;name&quot;:&quot;Latamoxef&quot;,&quot;ATC_code&quot;:&quot;J01DD06&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.&quot;,&quot;description&quot;:&quot;Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.&quot;}]},{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Ceftazidime/avibactam&quot;,&quot;ATC_code&quot;:&quot;J01DD52&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftazidime/avibactam, marketed as Avycaz among other names, is a combination medication consisting of ceftazidime, a cephalosporin antibiotic, and avibactam, a -lactamase inhibitor. This medication is primarily used to treat complicated intra-abdominal infections, urinary tract infections, and pneumonia, especially when other options are not suitable. Administered through intravenous injection, it can cause side effects such as nausea, fever, liver problems, and pain at the injection site. Approved for medical use in the United States and the European Union in 2015, it is included in the World Health Organization&#39;s List of Essential Medicines. However, increasing cases of resistance to this medication have been reported. Source: Wikepedia&quot;}]}]},{&quot;name&quot;:&quot;4th-gen-cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cefepime&quot;,&quot;ATC_code&quot;:&quot;J01DE01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.&quot;,&quot;description&quot;:&quot;Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.&quot;},{&quot;name&quot;:&quot;Cefoselis&quot;,&quot;ATC_code&quot;:&quot;to be assigned&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Cefoselis is a fourth-generation cephalosporin antibiotic. It&#39;s widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Cefozopran&quot;,&quot;ATC_code&quot;:&quot;J01DE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fourth-generation cephalosporins&quot;,&quot;description&quot;:&quot;Fourth-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefpirome&quot;,&quot;ATC_code&quot;:&quot;J01DE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fourth-generation cephalosporins&quot;,&quot;description&quot;:&quot;Fourth-generation cephalosporins&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cefepime&quot;,&quot;ATC_code&quot;:&quot;J01DE01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.&quot;,&quot;description&quot;:&quot;Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomonas aeruginosa, and is also indicated for the empirical treatment of febrile neutropenia. The popularity of its third-generation predecessors, its clinical efficacy, and the high prevalence of multidrug-resistant bacteria might be some of the factors leading to an increase in the use of cefepime. The activity of cefepime against Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus is due to its high stability toward beta-lactamases. In general, cefepime seems to be well tolerated; however, patients treated with this antibiotic, especially those with renal impairment, may develop neurotoxicity.&quot;},{&quot;name&quot;:&quot;Cefoselis&quot;,&quot;ATC_code&quot;:&quot;to be assigned&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Cefoselis is a fourth-generation cephalosporin antibiotic. It&#39;s widely used in Japan and China for treating various gram-positive and gram-negative infections. Clinical studies have shown its effectiveness in treating respiratory and urinary tract infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Cefozopran&quot;,&quot;ATC_code&quot;:&quot;J01DE03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fourth-generation cephalosporins&quot;,&quot;description&quot;:&quot;Fourth-generation cephalosporins&quot;},{&quot;name&quot;:&quot;Cefpirome&quot;,&quot;ATC_code&quot;:&quot;J01DE02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Fourth-generation cephalosporins&quot;,&quot;description&quot;:&quot;Fourth-generation cephalosporins&quot;}]}]},{&quot;name&quot;:&quot;Other-cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Cefiderocol&quot;,&quot;ATC_code&quot;:&quot;J01DI04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other -lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum -lactamase producers and carbapenemase producing bacteria.\r\n\r\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.&quot;,&quot;description&quot;:&quot;Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other -lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum -lactamase producers and carbapenemase producing bacteria.\r\n\r\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Cefiderocol&quot;,&quot;ATC_code&quot;:&quot;J01DI04&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other -lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum -lactamase producers and carbapenemase producing bacteria.\r\n\r\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.&quot;,&quot;description&quot;:&quot;Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other -lactam antibiotics.FDA Label Unlike other agents in this category, cefiderocol is a siderophore able to undergo active transport into the bacterial cell through iron channels. It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum -lactamase producers and carbapenemase producing bacteria.\r\n\r\nCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.FDA Label This indication was supported by a positive clinical trial composed of 448 patients with complicated urinary tract infections which demonstrated a 72.6% rate of symptom resolution and bacterial eradication with cefiderocol compared to 54.6% with the comparator, imipenem/cilastatin. A concern noted in the trial was a 0.3% higher rate of all cause mortality, the cause of which has not been determined.&quot;}]}]},{&quot;name&quot;:&quot;5th-gen cephalosporins&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Ceftaroline-fosamil&quot;,&quot;ATC_code&quot;:&quot;J01DI02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ceftobiprole-medocaril&quot;,&quot;ATC_code&quot;:&quot;J01DI01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftobiprole medocaril is a ceftobiprole prodrug.&quot;,&quot;description.x&quot;:&quot;Ceftobiprole medocaril is a ceftobiprole prodrug.&quot;},{&quot;name&quot;:&quot;Ceftolozane/tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01DI54&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a -lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Ceftaroline-fosamil&quot;,&quot;ATC_code&quot;:&quot;J01DI02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftaroline fosamil, known under the brand names Teflaro in the US and Zinforo in Europe, is a cephalosporin antibiotic with anti-MRSA activity. It is a prodrug of ceftaroline and is effective against methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive bacteria. While it retains broad-spectrum activity against Gram-negative bacteria, its effectiveness in this regard is relatively weaker. Ceftaroline fosamil is currently being investigated for treating community-acquired pneumonia and complicated skin and skin structure infection. It was developed by Forest Laboratories under a license from Takeda and received FDA approval in 2010 for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. Source: Wikepedia&quot;},{&quot;name&quot;:&quot;Ceftobiprole-medocaril&quot;,&quot;ATC_code&quot;:&quot;J01DI01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftobiprole medocaril is a ceftobiprole prodrug.&quot;,&quot;description.x&quot;:&quot;Ceftobiprole medocaril is a ceftobiprole prodrug.&quot;},{&quot;name&quot;:&quot;Ceftolozane/tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01DI54&quot;,&quot;EML&quot;:&quot;Yes&quot;,&quot;value&quot;:1,&quot;description&quot;:&quot;Ceftolozane/tazobactam, marketed under the brand name Zerbaxa, is a combination antibiotic used for treating complicated urinary tract and intra-abdominal infections in adults. It consists of ceftolozane, a cephalosporin antibiotic, and tazobactam, a -lactamase inhibitor. This combination is effective against gram-negative bacteria that are resistant to conventional antibiotics. Common side effects include nausea, headache, constipation, diarrhea, and fever. It was approved for medical use in the United States in 2014 and the European Union in 2015 and is included in the World Health Organization&#39;s List of Essential Medicines. Source: Wikepedia&quot;}]}]},{&quot;name&quot;:&quot;Penems&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Faropenem&quot;,&quot;ATC_code&quot;:&quot;J01DI03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.&quot;,&quot;description&quot;:&quot;Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Reserve&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Faropenem&quot;,&quot;ATC_code&quot;:&quot;J01DI03&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:2,&quot;description.x&quot;:&quot;Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.&quot;,&quot;description&quot;:&quot;Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.&quot;}]}]},{&quot;name&quot;:&quot;Beta-lactamase-inhibitors&quot;,&quot;data&quot;:[{&quot;name&quot;:&quot;Sulbactam&quot;,&quot;ATC_code&quot;:&quot;J01CG01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulbactam is a -lactamase inhibitor given in combination with -lactam antibiotics to inhibit -lactamase, an enzyme produced by bacteria that destroys antibiotic activity.&quot;,&quot;description&quot;:&quot;Sulbactam is a -lactamase inhibitor given in combination with -lactam antibiotics to inhibit -lactamase, an enzyme produced by bacteria that destroys antibiotic activity.&quot;},{&quot;name&quot;:&quot;Tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01CG02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r\n\r\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.&quot;,&quot;description&quot;:&quot;Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r\n\r\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.&quot;}],&quot;children&quot;:[{&quot;name&quot;:&quot;Access&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Sulbactam&quot;,&quot;ATC_code&quot;:&quot;J01CG01&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Sulbactam is a -lactamase inhibitor given in combination with -lactam antibiotics to inhibit -lactamase, an enzyme produced by bacteria that destroys antibiotic activity.&quot;,&quot;description&quot;:&quot;Sulbactam is a -lactamase inhibitor given in combination with -lactam antibiotics to inhibit -lactamase, an enzyme produced by bacteria that destroys antibiotic activity.&quot;}]},{&quot;name&quot;:&quot;Watch&quot;,&quot;children&quot;:[{&quot;name&quot;:&quot;Tazobactam&quot;,&quot;ATC_code&quot;:&quot;J01CG02&quot;,&quot;EML&quot;:&quot;No&quot;,&quot;value&quot;:1,&quot;description.x&quot;:&quot;Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r\n\r\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.&quot;,&quot;description&quot;:&quot;Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.\r\n\r\nPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014FDA label, providing wider antibacterial coverage for gram-negative infections. In June 2019, ceftolozane-tazobactam was approved by the FDA for treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, which are significant causes of morbidity and mortality in hospitalized patients.&quot;}]}]}]}]} </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->

<div id="rmd-source-code">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</div>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("antibiotics_analysis.Rmd");
  window.initializeCodeFolding("show" === "show");
});
</script>


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
